0001628280-24-019046.txt : 20240429 0001628280-24-019046.hdr.sgml : 20240429 20240429165135 ACCESSION NUMBER: 0001628280-24-019046 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 54 CONFORMED PERIOD OF REPORT: 20240331 FILED AS OF DATE: 20240429 DATE AS OF CHANGE: 20240429 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MEDIFAST INC CENTRAL INDEX KEY: 0000910329 STANDARD INDUSTRIAL CLASSIFICATION: MISCELLANEOUS FOOD PREPARATIONS & KINDRED PRODUCTS [2090] ORGANIZATION NAME: 04 Manufacturing IRS NUMBER: 133714405 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-31573 FILM NUMBER: 24892079 BUSINESS ADDRESS: STREET 1: 11445 CRONHILL DRIVE CITY: OWINGS MILLS STATE: MD ZIP: 21117 BUSINESS PHONE: 7327640619 MAIL ADDRESS: STREET 1: 11445 CRONHILL DRIVE CITY: OWINGS MILLS STATE: MD ZIP: 21117 FORMER COMPANY: FORMER CONFORMED NAME: HEALTHRITE INC DATE OF NAME CHANGE: 19951120 FORMER COMPANY: FORMER CONFORMED NAME: XX DATE OF NAME CHANGE: 19950619 FORMER COMPANY: FORMER CONFORMED NAME: 00 DATE OF NAME CHANGE: 19950619 10-Q 1 med-20240331.htm 10-Q med-20240331
000091032912-312024Q1FALSE00009103292024-01-012024-03-3100009103292024-04-22xbrli:sharesiso4217:USD00009103292023-01-012023-03-31iso4217:USDxbrli:shares00009103292024-03-3100009103292023-12-3100009103292022-12-3100009103292023-03-310000910329us-gaap:CommonStockMember2023-12-310000910329us-gaap:AdditionalPaidInCapitalMember2023-12-310000910329us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310000910329us-gaap:RetainedEarningsMember2023-12-310000910329us-gaap:TreasuryStockCommonMember2023-12-310000910329us-gaap:RetainedEarningsMember2024-01-012024-03-310000910329us-gaap:CommonStockMember2024-01-012024-03-310000910329us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310000910329us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310000910329us-gaap:CommonStockMember2024-03-310000910329us-gaap:AdditionalPaidInCapitalMember2024-03-310000910329us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310000910329us-gaap:RetainedEarningsMember2024-03-310000910329us-gaap:TreasuryStockCommonMember2024-03-310000910329us-gaap:CommonStockMember2022-12-310000910329us-gaap:AdditionalPaidInCapitalMember2022-12-310000910329us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000910329us-gaap:RetainedEarningsMember2022-12-310000910329us-gaap:TreasuryStockCommonMember2022-12-310000910329us-gaap:RetainedEarningsMember2023-01-012023-03-310000910329us-gaap:CommonStockMember2023-01-012023-03-310000910329us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310000910329us-gaap:TreasuryStockCommonMember2023-01-012023-03-310000910329us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310000910329us-gaap:CommonStockMember2023-03-310000910329us-gaap:AdditionalPaidInCapitalMember2023-03-310000910329us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310000910329us-gaap:RetainedEarningsMember2023-03-310000910329us-gaap:TreasuryStockCommonMember2023-03-310000910329us-gaap:RestrictedStockMember2024-01-012024-03-310000910329us-gaap:RestrictedStockMember2023-01-012023-03-310000910329us-gaap:EmployeeStockOptionMember2024-01-012024-03-310000910329us-gaap:RestrictedStockMember2024-01-012024-03-310000910329us-gaap:RestrictedStockMember2023-12-310000910329us-gaap:RestrictedStockMember2022-12-310000910329us-gaap:RestrictedStockMember2023-01-012023-03-310000910329us-gaap:RestrictedStockMember2024-03-310000910329us-gaap:RestrictedStockMember2023-03-310000910329med:MarketAndPerformanceBasedShareMembersrt:MinimumMember2024-01-012024-03-31xbrli:pure0000910329srt:MaximumMembermed:MarketAndPerformanceBasedShareMember2024-01-012024-03-310000910329med:MarketAndPerformanceBasedShareMember2024-01-012024-03-310000910329med:MarketAndPerformanceBasedShareMembermed:GrantedIn2022Member2023-01-012023-03-310000910329med:MarketAndPerformanceBasedShareMember2023-01-012023-03-310000910329us-gaap:PerformanceSharesMember2024-01-012024-03-310000910329med:OptionsAndRestrictedStockMember2024-01-012024-03-310000910329med:OptionsAndRestrictedStockMember2023-01-012023-03-310000910329med:GrantedIn2024Memberus-gaap:PerformanceSharesMember2024-01-012024-03-310000910329med:MarketAndPerformanceBasedShareMembermed:GrantedIn2023Member2024-01-012024-03-310000910329med:MarketAndPerformanceBasedShareMembermed:GrantedIn2023Member2023-01-012023-03-310000910329med:MarketAndPerformanceBasedShareMembermed:GrantedIn2022Member2024-01-012024-03-310000910329med:GrantedIn2021Memberus-gaap:PerformanceSharesMember2024-01-012024-03-310000910329med:GrantedIn2021Memberus-gaap:PerformanceSharesMember2023-01-012023-03-310000910329us-gaap:PerformanceSharesMembermed:GrantedIn2020Member2024-01-012024-03-310000910329us-gaap:PerformanceSharesMembermed:GrantedIn2020Member2023-01-012023-03-310000910329med:MarketAndPerformanceBasedShareMember2024-03-310000910329srt:MinimumMembermed:OperatingLeaseArrangementForRealEstateMember2024-03-310000910329srt:MaximumMembermed:OperatingLeaseArrangementForRealEstateMember2024-03-310000910329srt:MinimumMembermed:OperatingLeaseArrangementForEquipmentMember2024-03-310000910329us-gaap:CashAndCashEquivalentsMember2024-03-310000910329us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2024-03-310000910329us-gaap:FairValueInputsLevel1Memberus-gaap:CashAndCashEquivalentsMemberus-gaap:MoneyMarketFundsMember2024-03-310000910329us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMemberus-gaap:SecuritiesInvestmentMember2024-03-310000910329us-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember2024-03-310000910329us-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMembermed:DebtSecuritiesGainsLossesMember2024-03-310000910329us-gaap:FairValueInputsLevel1Membermed:DebtSecuritiesAccruedInterestMemberus-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember2024-03-310000910329us-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMemberus-gaap:CashAndCashEquivalentsMember2024-03-310000910329us-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMemberus-gaap:SecuritiesInvestmentMember2024-03-310000910329us-gaap:FairValueInputsLevel1Member2024-03-310000910329us-gaap:FairValueInputsLevel1Memberus-gaap:CashAndCashEquivalentsMember2024-03-310000910329us-gaap:FairValueInputsLevel1Memberus-gaap:SecuritiesInvestmentMember2024-03-310000910329us-gaap:MunicipalBondsMemberus-gaap:FairValueInputsLevel2Member2024-03-310000910329us-gaap:MunicipalBondsMemberus-gaap:FairValueInputsLevel2Membermed:DebtSecuritiesGainsLossesMember2024-03-310000910329us-gaap:MunicipalBondsMemberus-gaap:FairValueInputsLevel2Membermed:DebtSecuritiesAccruedInterestMember2024-03-310000910329us-gaap:MunicipalBondsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CashAndCashEquivalentsMember2024-03-310000910329us-gaap:MunicipalBondsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:SecuritiesInvestmentMember2024-03-310000910329us-gaap:SecuritiesInvestmentMember2024-03-310000910329us-gaap:CashAndCashEquivalentsMember2023-12-310000910329us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2023-12-310000910329us-gaap:FairValueInputsLevel1Memberus-gaap:CashAndCashEquivalentsMemberus-gaap:MoneyMarketFundsMember2023-12-310000910329us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMemberus-gaap:SecuritiesInvestmentMember2023-12-310000910329us-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember2023-12-310000910329us-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMembermed:DebtSecuritiesGainsLossesMember2023-12-310000910329us-gaap:FairValueInputsLevel1Membermed:DebtSecuritiesAccruedInterestMemberus-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember2023-12-310000910329us-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMemberus-gaap:CashAndCashEquivalentsMember2023-12-310000910329us-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMemberus-gaap:SecuritiesInvestmentMember2023-12-310000910329us-gaap:FairValueInputsLevel1Member2023-12-310000910329us-gaap:FairValueInputsLevel1Memberus-gaap:CashAndCashEquivalentsMember2023-12-310000910329us-gaap:FairValueInputsLevel1Memberus-gaap:SecuritiesInvestmentMember2023-12-310000910329us-gaap:MunicipalBondsMemberus-gaap:FairValueInputsLevel2Member2023-12-310000910329us-gaap:MunicipalBondsMemberus-gaap:FairValueInputsLevel2Membermed:DebtSecuritiesGainsLossesMember2023-12-310000910329us-gaap:MunicipalBondsMemberus-gaap:FairValueInputsLevel2Membermed:DebtSecuritiesAccruedInterestMember2023-12-310000910329us-gaap:MunicipalBondsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CashAndCashEquivalentsMember2023-12-310000910329us-gaap:MunicipalBondsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:SecuritiesInvestmentMember2023-12-310000910329us-gaap:SecuritiesInvestmentMember2023-12-310000910329med:LifeMDMember2023-10-012023-12-310000910329us-gaap:CollaborativeArrangementMembermed:LifeMDMember2023-01-012023-12-310000910329us-gaap:CollaborativeArrangementMembermed:LifeMDMember2024-03-182024-03-180000910329us-gaap:CollaborativeArrangementMembermed:LifeMDMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2024-01-012024-03-310000910329us-gaap:CollaborativeArrangementMembermed:LifeMDMemberus-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:SubsequentEventMembersrt:ScenarioForecastMember2024-04-012024-06-300000910329us-gaap:RevolvingCreditFacilityMembermed:AmendedCreditAgreementMember2021-04-130000910329us-gaap:LetterOfCreditMembermed:AmendedCreditAgreementMember2021-04-130000910329med:UncommittedIncrementalFacilityMembermed:AmendedCreditAgreementMember2021-04-130000910329srt:MinimumMembermed:AmendedCreditAgreementMember2021-04-132021-04-130000910329srt:MaximumMembermed:AmendedCreditAgreementMember2021-04-132021-04-130000910329med:SecuredOvernightFinancingRateSOFRMembermed:AmendedCreditAgreementMember2024-01-012024-03-310000910329us-gaap:BaseRateMembermed:AmendedCreditAgreementMember2024-01-012024-03-310000910329med:AmendedCreditAgreementMember2021-04-130000910329med:AmendedCreditAgreementMember2024-03-31
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2024
OR
o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from________ to ________.
Commission File Number: 001-31573
Medifast, Inc.
(Exact name of registrant as specified in its charter)
Delaware13-3714405
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)
100 International Drive
Baltimore, Maryland 21202
Telephone Number: (410) 581-8042
(Address of Principal Executive Offices, Zip Code and Telephone Number, Including Area Code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of each exchange on which registered
Common Stock, par value $0.001 per shareMEDNew York Stock Exchange
Indicate by checkmark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes x No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Yes x No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer ☒Accelerated filer☐
Non-accelerated filer ☐Smaller reporting company☐
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by checkmark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes o No x
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.
The number of shares of the registrant’s common stock outstanding at April 22, 2024 was 10,937,245.
Medifast, Inc. and Subsidiaries
Index
1
MEDIFAST, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)
(U.S. dollars in thousands, except per share amounts & dividend data)
Three months ended March 31,
20242023
Revenue$174,739 $348,983 
Cost of sales47,447 102,593 
Gross profit127,292 246,390 
Selling, general, and administrative119,352 192,879 
Income from operations7,940 53,511 
Other income (expense)
Interest income (expense)1,223 (181)
Other income (expense)2,422 (1)
3,645 (182)
Income from operations before income taxes11,585 53,329 
Provision for income taxes3,269 13,361 
Net income$8,316 $39,968 
Earnings per share - basic$0.76 $3.68 
Earnings per share - diluted$0.76 $3.67 
Weighted average shares outstanding
Basic10,909 10,864 
Diluted10,958 10,899 
Cash dividends declared per share$— $1.65 
The accompanying notes are an integral part of these condensed consolidated financial statements.
2
MEDIFAST, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)
(U.S. dollars in thousands)
Three months ended March 31,
20242023
Net income$8,316 $39,968 
Other comprehensive income, net of tax:
Foreign currency translation15 9 
Unrealized losses on investment securities(241)— 
(226)9 
Comprehensive income$8,090 $39,977 
The accompanying notes are an integral part of these condensed consolidated financial statements.
3
MEDIFAST, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
(U.S. dollars in thousands, except par value)
March 31,
2024		December 31,
2023
ASSETS
Current Assets
Cash and cash equivalents$97,471 $94,440 
Inventories46,273 54,591 
Investments
58,957 55,601 
Income taxes, prepaid5,471 8,727 
Prepaid expenses and other current assets11,412 10,670 
Total current assets219,584 224,029 
Property, plant and equipment - net of accumulated depreciation50,986 51,467 
Right-of-use assets14,536 15,645 
Other assets13,648 14,650 
Deferred tax assets4,005 4,117 
TOTAL ASSETS$302,759 $309,908 
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities
 Accounts payable and accrued expenses$71,229 $86,415 
 Current lease obligations5,958 5,885 
Total current liabilities77,187 92,300 
 Lease obligations, net of current lease obligations14,611 16,127 
Total liabilities91,798 108,427 
Stockholders' Equity
Common stock, par value $0.001 per share: 20,000 shares authorized;
10,937 and 10,896 issued and outstanding
at March 31, 2024 and December 31, 2023, respectively
11 11 
Additional paid-in capital27,963 26,573 
Accumulated other comprehensive income22 248 
Retained earnings 182,965 174,649 
Total stockholders' equity210,961 201,481 
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY$302,759 $309,908 
The accompanying notes are an integral part of these condensed consolidated financial statements.
4
MEDIFAST, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
(U.S. dollar in thousands)
Three months ended March 31,
20242023
Operating Activities
Net income$8,316 $39,968 
Adjustments to reconcile net income to cash provided by operating activities
Depreciation and amortization 3,261 2,974 
Non-cash lease expense1,1081,369 
Share-based compensation2,171606 
Loss on sale or disposal of property, plant and equipment
13 — 
Realized gain on sale of investment securities
(9)— 
Amortization of premium on investment securities(191)— 
Deferred income taxes112 800 
Unrealized gain on equity investment securities(2,437)— 
Change in operating assets and liabilities:
Inventories8,318 21,960 
Prepaid expenses and other current assets(742)6,563 
Other assets24 (887)
Accounts payable and accrued expenses (15,918)(21,897)
Prepaid income taxes
3,256 12,603 
Net cash flow provided by operating activities7,282 64,059 
Investing Activities
Purchase of investment securities(9,169)— 
Proceeds from sale and maturities of investment securities
8,235 — 
Purchase of property and equipment(1,841)(2,115)
Net cash flow used in investing activities(2,775)(2,115)
Financing Activities
Options exercised by directors36 105 
Net shares repurchased for taxes(817)(3,236)
Cash dividends paid to stockholders(710)(19,163)
Stock repurchases
— (3,602)
Net cash flow used in financing activities(1,491)(25,896)
Foreign currency impact15 9 
Increase in cash and cash equivalents3,031 36,057 
Cash and cash equivalents - beginning of the period94,440 87,691 
Cash and cash equivalents - end of period$97,471 $123,748 
Supplemental disclosure of cash flow information:
Income taxes refunded
$(100)$(46)
Dividends included in accounts payable
$697 $18,653 
The accompanying notes are an integral part of these condensed consolidated financial statements.
5
MEDIFAST, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (UNAUDITED)
(U.S. dollars in thousands)
Three months ended March 31, 2024
Number of
Shares Issued		Common StockAdditional Paid-In
Capital		Accumulated Other
Comprehensive Income		Retained
Earnings		Treasury StockTotal
Balance, December 31, 202310,896 $11 $26,573 $248 $174,649 $— $201,481 
Net income— — — — 8,316 — 8,316 
Share-based compensation59 — 2,171 — — — 2,171 
Options exercised by directors1 — 36 — — — 36 
Net shares repurchased for employee taxes(19)— (817)— — — (817)
Other comprehensive income— — — (226)— — (226)
Balance, March 31, 2024
10,937 $11 $27,963 $22 $182,965 $— $210,961 

Three months ended March 31, 2023
Number of
Shares Issued		Common StockAdditional Paid-In
Capital		Accumulated Other
Comprehensive Income		Retained
Earnings		Treasury StockTotal
Balance, December 31, 202210,928 $11 $21,555 $24 $139,852 $(6,398)$155,044 
Net income— — — — 39,968 — 39,968 
Share-based compensation69 — 606 — — — 606 
Options exercised by directors4— 105 — — — 105 
Net shares repurchased for employee taxes(30)— (3,236)— — — (3,236)
Treasury stock from stock repurchases— — — — — (3,602)(3,602)
Treasury stock retired from stock repurchases(84)— — — (10,000)10,000 — 
Other comprehensive income— — — 9 — — 9 
Cash dividends declared to stockholders— — — — (17,994)— (17,994)
Balance, March 31, 2023
10,887 $11 $19,030 $33 $151,826 $— $170,900 
The accompanying notes are an integral part of these condensed consolidated financial statements.
6
MEDIFAST, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation - The accompanying unaudited condensed consolidated financial statements of Medifast, Inc. and its wholly-owned subsidiaries (“Medifast,” the “Company,” “we,” “us,” or “our”) included herein have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim reporting and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Accordingly, certain information and notes that are normally required by GAAP have been condensed or omitted. However, in the opinion of management, all adjustments consisting of normal, recurring adjustments considered necessary for a fair presentation of the financial position and results of operations have been included and management believes the disclosures that are made are adequate to make the information presented not misleading. The condensed consolidated balance sheet at December 31, 2023 has been derived from the 2023 audited consolidated financial statements at that date included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (“2023 Form 10-K”).
The results of operations for the three months ended March 31, 2024 are not necessarily indicative of results that may be expected for the fiscal year ending December 31, 2024. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto, which are included in the 2023 Form 10-K.
Presentation of Financial Statements - The unaudited condensed consolidated financial statements included herein include the accounts of the Company. All significant intercompany accounts and transactions have been eliminated.
Use of Estimates - The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.
Accounting Pronouncements - Adopted in 2024
In June 2022, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update 2022-03—Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (“ASU 2023-03”) to (1) to clarify the guidance in Topic 820, Fair Value Measurement, when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security, (2) to amend a related illustrative example, and (3) to introduce new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value in accordance with Topic 820. For public business entities, the amendments in ASU 2022-03 are effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. Early adoption is permitted for both interim and annual financial statements that have not yet been issued or made available for issuance. The Company adopted the standard during the quarter ended March 31, 2024. The adoption of the standard had no material impact on the Company’s financial statements.
Recently Issued Accounting Pronouncements - Pending Adoption
In December 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update 2023-09—Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”) to enhance the transparency and decision usefulness of income tax disclosures, including jurisdictional information, by requiring consistent categories and greater disaggregation of information in the rate reconciliation and income taxes paid disclosures. ASU 2023-09 is effective for public business entities for annual periods beginning after December 15, 2024. Prospective application is required, though retrospective application is permitted. Entities are permitted to early adopt the standard. The Company did not early adopt for the 2024 reporting period. The Company is currently evaluating the impact of adopting ASU 2023-09 on its consolidated financial statements.
2. INVENTORIES
Inventories consist principally of raw materials, non-food finished goods and packaged meal replacements held in the Company’s warehouses and outsourced distribution centers. Inventories are stated at the lower of cost or net realizable value, utilizing the first-in, first-out method. The cost of finished goods includes the cost of raw materials, packaging supplies, direct
7
and indirect labor, and other indirect manufacturing costs. On a quarterly basis, management reviews inventories for unsalable or obsolete inventories.
Inventories consisted of the following (in thousands):
March 31, 2024December 31, 2023
Raw materials$6,343$7,944
Packaging1,6731,962
Non-food finished goods2,8773,703
Finished goods36,76943,248
Reserve for obsolete inventory(1,389)(2,266)
Total$46,273$54,591
3. EARNINGS PER SHARE
Basic earnings per share (“EPS”) computations are calculated utilizing the weighted average number of shares of the Company’s common stock outstanding during the periods presented. Diluted EPS is calculated utilizing the weighted average number of shares of the Company’s common stock outstanding adjusted for the effect of dilutive common stock equivalents.
The following table sets forth the computation of basic and diluted EPS (in thousands, except per share data):
Three months ended March 31,
20242023
Numerator:
Net income$8,316 $39,968 
Denominator:
Weighted average shares of common stock outstanding10,909 10,864 
Effect of dilutive common stock equivalents49 35 
Weighted average shares of common stock outstanding10,958 10,899 
Earnings per share - basic$0.76 $3.68 
Earnings per share - diluted$0.76 $3.67 
The calculation of diluted EPS excluded 51 thousand and 13 thousand antidilutive restricted stock awards for the three months ended March 31, 2024 and 2023, respectively.
4. SHARE-BASED COMPENSATION
Stock Options
The Company has issued non-qualified and incentive stock options to employees and non-employee directors. The fair value of these options was estimated on the date of grant using the Black-Scholes option pricing model, which required estimates of the expected term of the option, the risk-free interest rate, the expected volatility of the price of the Company’s common stock, and dividend yield. Options outstanding as of March 31, 2024 generally vested over a period of 3 years and expire 10 years from the date of grant. The exercise price of these options is $66.68. Due to the Company’s lack of option exercise history on the date of grant, the expected term was calculated using the simplified method defined as the midpoint between the vesting period and the contractual term of each option. The risk-free interest rate was based on the U.S. Treasury yield curve in effect on the date of grant that most closely corresponds to the expected term of the option. The expected volatility was based on the historical volatility of the Company’s common stock over the period of time equivalent to the expected term for each award. The
8
dividend yield was computed as the annualized dividend rate at the grant date divided by the strike price of the stock option. For the three months ended March 31, 2024 and 2023, the Company did not grant stock options.
The following table is a summary of our stock option activity (in thousands, except per share data):
Three months ended March 31,
20242023
AwardsWeighted-Average Exercise PriceAwardsWeighted-Average Exercise Price
Outstanding at beginning of period25 $62.20 33 $54.98 
Exercised(1)27.68 (4)27.18 
Forfeited(2)26.52 — — 
Outstanding at end of the period22 $66.68 29 $58.65 
Exercisable at end of the period22 $66.68 29 $58.65 
As of March 31, 2024, the weighted-average remaining contractual life for both the outstanding stock options and exercisable stock options was 3.9 years with an aggregate intrinsic value of $0. There was no unrecognized compensation on the awards for the period ended March 31, 2024. For the three months ended March 31, 2024 and 2023, the Company received $36 thousand and $105 thousand in cash proceeds from the exercise of stock options, respectively. The total intrinsic value for stock options exercised during the three months ended March 31, 2024 and 2023 was $15 thousand and $328 thousand, respectively.
Restricted Stock
The Company has issued restricted stock to employees and non-employee directors generally with vesting terms up to 3 years after the date of grant. The fair value of the restricted stock is equal to the market price of the Company’s common stock on the date of grant. Expense for restricted stock is amortized ratably over the vesting period.
The following table summarizes our restricted stock activity (in thousands, except per share data):
Three months ended March 31,
20242023
SharesWeighted-Average Grant Date Fair ValueSharesWeighted-Average Grant Date Fair Value
Outstanding at beginning of period114 $127.87 60 $187.94 
Granted162 35.75 67 102.83 
Vested(34)139.19 (22)163.81 
Forfeited— — — 190.76 
Outstanding at end of the period242 $64.55 105 $138.33 
The Company withheld approximately 11 thousand shares and 9 thousand shares of the Company’s common stock to cover minimum tax liability withholding obligations upon the vesting of shares of restricted stock for the three months ended March 31, 2024 and 2023, respectively. The total fair value of restricted stock awards vested during the three months ended March 31, 2024 and 2023 was $1.3 million and $2.4 million, respectively.
Market and Performance-based Share Awards
The Company has issued market and performance-based share awards in 2022 and 2023 and performance-based share awards in 2020, 2021, and 2024 to certain key executives who were granted deferred shares and may earn between 0% and 250% of the target number depending upon both the Company’s total stockholder return (“TSR”), for those with market conditions, and the Company’s performance against predetermined performance goals over a three-year performance period after the date of grant. Market and performance-based share awards that are tied to the Company’s TSR are valued using the Monte Carlo method and are recognized ratably as expense over the award’s performance period. The fair value of the performance-based share awards
9
is equal to the market price of the Company’s common stock on the date of grant adjusted by expected level of achievement over the performance period. Expense for performance-based share awards is amortized ratably over the performance period. In the event that management determines that the Company will not reach the lower threshold of the predetermined performance goals established in the grant agreement, any previously recognized expense is reversed in the period in which such a determination is made. Management determined that the market and performance-based share awards granted in 2022 would not reach the lower threshold of the predetermined performance goal resulting in a $1.4 million decrease in the Company’s share-based compensation expense for the three months ended March 31, 2023.
The Company withheld approximately 8 thousand shares and 21 thousand shares of the Company’s common stock to cover minimum tax liability withholding obligations upon the vesting of shares of market and performance-based share awards for the years ended March 31, 2024 and 2023, respectively. The total fair value of performance-based share awards issued during the three months ended March 31, 2024 was $1.3 million and the total fair value of market and performance-based share awards issued during the three months ended March 31, 2023 was $5.3 million.
Share-based compensation expense is recorded in selling, general, and administrative expense in the accompanying Condensed Consolidated Statements of Income. The total expense during the three months ended March 31, 2024 and 2023 are as follows (in thousands):
Three months ended March 31,
20242023
SharesShare-Based Compensation ExpenseSharesShare-Based Compensation Expense
Options and restricted stock264 $1,600 134 $1,226 
Performance-based share awards granted in 2024
117 77 — — 
Market and performance-based share awards granted in 202347 482 47 79 
Market and performance-based share awards granted in 202224 — 25 (1,388)
Performance-based share awards granted in 202114 12 15 640 
Performance-based share awards granted in 2020— — 4 49 
Total share-based compensation466 $2,171 225 $606 
10
The total income tax expense recognized in the accompanying Condensed Consolidated Statements of Income for restricted stock awards was $0.4 million for the three months ended March 31, 2024 and a benefit of $0.1 million for the three months ended March 31, 2023.
There was $8.8 million of total unrecognized compensation cost related to restricted stock awards as of March 31, 2024, which is expected to be recognized over a weighted-average period of 2.3 years. There was $7.5 million of unrecognized compensation costs related to the 131 thousand performance-based shares and 71 thousand market and performance-based shares presented in the table above as of March 31, 2024, which is expected to be recognized over a weighted-average period of 2.1 years.
5. LEASES
Operating Leases
The Company has operating leases for office and warehouse space and certain equipment. In certain of the Company’s lease agreements, the rental payments are adjusted periodically based on defined terms within the lease. The Company did not have any finance leases as of March 31, 2024 and 2023, respectively, or for the three-month periods then ended, respectively.
Our leases relating to office and warehouse space have lease terms of 65 months to 102 months. Our leases relating to equipment have lease terms of 36 months, with certain of them having automatic renewal clauses.
The Company’s warehouse agreements also contain non-lease components, in the form of payments towards variable logistics services and labor charges, which the Company is obligated to pay based on the services consumed by it. Such amounts are not included in the measurement of the lease liability but are recognized as expenses when they are incurred.
The operating lease expense was $1.2 million and $1.5 million for the three months ended March 31, 2024 and 2023, respectively.
Supplemental cash flow information related to the Company’s operating leases was as follows (in thousands):
Three months ended March 31,
20242023
Cash paid for amounts included in the measurements of lease liabilities
Operating cash flow used in operating leases$1,563 $1,804 
Right-of-use assets obtained in exchange for lease obligations
Operating leases$— $— 
As of March 31, 2024, the weighted average remaining lease term was 3 years, 7 months and the weighted average discount rate was 2.30%.
The following table presents the maturity of the Company’s operating lease liabilities as of March 31, 2024 (in thousands):
2024 (excluding the three months ended March 31, 2024)
$4,749 
20256,462 
20264,783 
20272,553 
20282,618 
Thereafter240 
Total lease payments$21,405 
Less: imputed interest(836)
Total $20,569 
11
6. ACCUMULATED OTHER COMPREHENSIVE INCOME
The following table sets forth the components of accumulated other comprehensive income, net of tax where applicable (in thousands):
March 31, 2024December 31, 2023
Foreign currency translation$(33)$(48)
Unrealized gains on investments
55296
Accumulated other comprehensive income$22$248
7. INVESTMENTS
Certain financial assets and liabilities are accounted for at fair value, which is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The following fair value hierarchy prioritizes the inputs used to measure fair value:
Level 1 – Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an on-going basis.
Level 2 – Pricing inputs are other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date. Level 2 includes those financial instruments that are valued using models or other valuation methodologies.
Level 3 – Pricing inputs include significant inputs that are generally less observable from objective sources. These inputs may be used with internally developed methodologies that result in management’s best estimate of fair value from the perspective of a market participant.
The following tables present the Company’s cash and financial assets that are measured at fair value on a recurring basis for each of the hierarchy levels (in thousands):
12

March 31, 2024
Cost
Unrealized Gains (Losses)
Accrued Interest
Estimated
Fair Value
Cash & Cash
Equivalents		Investment
Securities
Cash and cash equivalents, excluding money market accounts
$92,291$—$—$92,291$92,291$—
Level 1:
Money market accounts5,180——5,1805,180—
Government & agency securities15,454(14)6415,504—15,504
Equity securities10,0002,587—12,587—12,587
30,6342,5736433,2715,18028,091
Level 2:
Corporate bonds
30,41218227230,866—30,866
Total$153,337$2,755$336$156,428$97,471$58,957
December 31, 2023
CostUnrealized
Gains		Accrued
Interest		Estimated
Fair Value		Cash & Cash
Equivalents		Investment
Securities
Cash and cash equivalents, excluding money market accounts$88,778$—$—$88,778$88,778$—
Level 1:
Money market accounts5,662——5,6625,662—
Government & agency securities15,2821264015,448—15,448
Equity securities10,000150—10,150—10,150
30,9442764031,2605,66225,598
Level 2:
Corporate bonds29,44029327030,003—30,003
Total$149,162$569$310$150,041$94,440$55,601
The Company had $9 thousand of realized gains for the three months ended March 31, 2024 and no realized gains or losses for the three months ended March 31, 2023.
During the fourth quarter of 2023, the Company entered into an agreement to purchase common stock of LifeMD, Inc (Nasdaq: LFMD), a leading provider of virtual primary care, and made a $10 million payment to LifeMD for the purchase of the shares. The securities are subject to a registration rights agreement which stipulates that the registration of the securities is to be made as soon as practicable, but not later than 90 days, following written demand by the Company. Written demand has been made, and the securities registration remained in process as of March 31, 2024. In addition, the shares are subject to a 180-day lock-up period from the closing date of the agreement, December 11, 2023. The fair value of the investment is recorded within the
13
investment securities of the consolidated balance sheet. The gains related to the Company’s LifeMD investment for the three months ended March 31, 2024 and 2023 are summarized in the table below (in thousands):
March 31, 2024March 31, 2023
Net gains recognized during the period on equity securities
$2,437 $— 
Less: Net gains recognized on equity securities sold
— — 
Unrealized gains recognized during the reporting period on equity securities still held at the reporting date
$2,437 $— 
The Company concurrently entered into an agreement in which LifeMD would provide services to stand-up the collaboration between LifeMD and the Company. The agreement stipulated an initial milestone payment of $5 million due upon execution of the agreement for these services. The services under the initial milestone were completed prior to December 31, 2023, and this amount was included in the Company’s selling, general, and administrative expenses on the consolidated statement of income for the quarter ended December 31, 2023. The Company made a second milestone payment under the agreement of $2.5 million on March 18, 2024. Of the total $2.5 million second milestone payment, $1.3 million was recognized within selling, general, and administrative expenses for services performed by LifeMD for the quarter ended March 31, 2024, with the remaining $1.2 million expected to be recognized in the second quarter. The final milestone payment of $2.5 million is expected to be made in the second quarter of 2024, with the expense being recognized in the consolidated statement of income as the services are rendered.
8. DEBT
Credit Agreement
On April 13, 2021, the Company and certain of its subsidiaries (collectively, the “Guarantors”) entered into a credit agreement (the “Credit Agreement”) among the Company, the Guarantors, the lenders party thereto and Citibank, N.A., in its capacity as administrative agent. On May 31, 2022, the Credit Agreement was amended to increase the borrowing capacity and convert the interest rate to be based on Secured Overnight Financing Rate (“SOFR”), from London Inter-Bank Offered Rate (LIBOR) (the “Amended Credit Agreement”). The Amended Credit Agreement provides for a $225.0 million senior secured revolving credit facility with a $20.0 million letter of credit sublimit. The Amended Credit Agreement also provides for an uncommitted incremental facility that permits the Company, subject to certain conditions, to increase the senior secured revolving credit facility by up to $100.0 million. The Amended Credit Agreement matures on April 13, 2026.
The Company’s obligations under the Amended Credit Agreement are guaranteed by the Guarantors. The obligations of the Company and the Guarantors are secured by first-priority liens on substantially all of the assets of the Company and the Guarantors, subject to certain exceptions.
Under the Amended Credit Agreement, the Company will pay to the administrative agent for the account of each revolving lender a commitment fee on a quarterly basis based on amounts committed but unused under the revolving facility from 0.20% to 0.40% per annum depending on the Company’s Total Net Leverage Ratio (as defined in the Amended Credit Agreement). The Company is also obligated to pay the administrative agent customary fees for credit facilities of this size and type.
Revolving borrowings under the Amended Credit Agreement bear interest at a rate per annum equal to (i) the Term SOFR Rate for the interest period plus the Applicable Rate (as defined in the Amended Credit Agreement) based on the Company’s Total Net Leverage Ratio or (ii) the Alternate Base Rate (as defined in the Amended Credit Agreement) as in effect from time to time plus the Applicable Rate based on the Company’s Total Net Leverage Ratio. As of March 31, 2024, the Applicable Rate for Term SOFR Loans is 1.25% per annum and the Applicable Rate for ABR Loans is 0.25% per annum. SOFR based loans also include a Credit Spread Adjustment based on the duration of the borrowing.
The Amended Credit Agreement contains affirmative and negative covenants customarily applicable to senior secured credit facilities, including covenants that, among other things, limit or restrict the ability of the Company and its subsidiaries, subject to negotiated exceptions, to incur additional indebtedness and additional liens on their assets, engage in mergers or acquisitions or dispose of assets, pay dividends or make other distributions, voluntarily prepay other indebtedness, enter into transactions with affiliated persons, make investments and change the nature of their businesses. The Amended Credit Agreement also contains customary events of default, subject to thresholds and grace periods, including, among others, payment default, covenant default, cross default to other material indebtedness and judgment default. In addition, the Amended Credit
14
Agreement requires the Company to maintain a Total Net Leverage Ratio of no more than 2.75 to 1.00 and an Interest Coverage Ratio of at least 3.50 to 1.00.
The Company had no borrowings outstanding under the Amended Credit Agreement, inclusive of the credit facility and letter of credit sublimit, as of March 31, 2024 and was in compliance with all covenants.

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Note Regarding Forward-Looking Statements
Certain information in this report contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Act”). Forward-looking statements generally can be identified by use of phrases or terminology such as “intend,” “anticipate,” “expect” or other similar words or the negative of such terminology. Similarly, descriptions of Medifast's objectives, strategies, plans, goals, or targets contained herein are also considered forward-looking statements. These statements are based on the current expectations of our management and are subject to certain events, risks, uncertainties, and other factors. These risks and uncertainties include, but are not limited to, those described in our 2023 Form 10-K and those described from time to time in our future reports filed with the SEC. Although Medifast believes that the expectations, statements, and assumptions reflected in these forward-looking statements are reasonable, it cautions readers to always consider all of the risk factors and any other cautionary statements carefully in evaluating each forward-looking statement in this report. All of the forward-looking statements contained herein speak only as of the date of this report. We undertake no obligation to update any information contained in this report or to publicly release the results of any revisions to forward-looking statements to reflect events or circumstances of which we may become aware after the date of this report.
The following discussion should be read in conjunction with the unaudited condensed consolidated financial statements and related notes appearing elsewhere herein.
Overview
Medifast is the health and wellness company known for its habit-based and Coach-guided lifestyle solution OPTAVIA®. The Company has initiated its business transformation to build a set of differentiated capabilities, reflecting its commitment to providing comprehensive health and wellness solutions to customers as both their needs and the industry evolve, that are expected to position Medifast to be leader in the dynamic and changing health and wellness space. As part of this transformation the Company is expanding its product offerings to include sports nutrition products and targeting individuals in the medically supported weight loss market.
Medifast has created a well-capitalized business that has a powerful business model, building a network of approximately 37,800 independent active earning Coaches providing consistent and effective support to people on their weight loss journey and impacting more than 3 million lives to date. Medifast was recognized in 2023 by Financial Times as one of The Americas' Fastest Growing Companies and in 2022 as one of America's Best Mid-Sized Companies by Forbes.
As a physician-founded company with more than 40 years of history, Medifast is a leader in the U.S. weight management industry. OPTAVIA's lifestyle plans deliver clinically proven health benefits as well as evidence-based tools, including scientifically developed products and a framework for habit creation reinforced by independent Coaches and community support.
In a rapidly changing health and wellness landscape, Medifast is committed to innovating and building upon its scientific and clinical heritage to deliver on its mission of offering the world Lifelong Transformation, One Healthy Habit at a Time®. With the growing interest in medically supported weight loss and GLP-1 medications powering the emergence of an important new market for products and services to support patients on their health and wellness journey, Medifast is transforming its business to capitalize on this opportunity. Through a collaboration with LifeMD, Inc. (Nasdaq: LFMD) (“LifeMD”), a national virtual primary care provider, our customers now can access all-in-one holistic solutions that help make a healthy lifestyle second nature, whether individuals are currently using medical weight loss options, are looking for further support after they stop taking medication, or as they transition off medications. In addition to lifestyle support and a simple roadmap for habit creation, the integrated offering includes scientifically developed nutritional support solutions such as product kits designed to help mitigate GLP-1 medication side effects, including muscle loss. As the medications for weight loss continue to evolve and grow,
15
Medifast is dedicated to maintaining a relentless focus on the development of additional products and supplements designed to meet customer needs.
OPTAVIA’s holistic lifestyle solution is built around four key components:
•Independent OPTAVIA Coaches: Independent OPTAVIA Coaches provide individualized support and guidance to customers on the path to optimal health and wellbeing.
•OPTAVIA Community: A Community of like-hearted people providing each other with real-time connection and support.
•The Habits of Health® Transformational System: A proprietary system that offers easy steps to a sustainable healthy lifestyle.
•Products & Plans: Clinically proven plans and scientifically developed products, backed by dietitians, scientists, and physicians.
OPTAVIA's collaboration with LifeMD offers access to an additional resource for eligible customers:
•Clinicians as Partners: Through the collaboration with LifeMD, OPTAVIA customers have access to board-certified affiliated clinicians and medication, such as GLP-1 medications, that support treatment plans for obesity and other health conditions.
Across our offerings, we help customers achieve their health goals through a network of OPTAVIA Coaches, about 90% of whom were customers first. OPTAVIA Coaches introduce customers to a set of healthy habits, in most cases starting with the habit of healthy eating, and offer exclusive OPTAVIA-branded products, including Fuelings as well as OPTAVIA ACTIVE®, a new line of essential amino acid supplements and protein powders. Fuelings are nutrient-dense, portion-controlled, nutritionally interchangeable, and simple to use. They are formulated with high-quality ingredients and contain probiotic BC30™ cultures, which help support digestive health, as part of a balanced diet and healthy lifestyle, vitamins and minerals, as well as other nutrients essential for good health. Our products are used as tools and support the process of integrating healthy habits into our customers' daily life.
The OPTAVIA coaching model is customer-centric and boasts an energized health and wellness community. It promotes holistic health and wellness and positions healthy weight as a catalyst to greater lifestyle changes. OPTAVIA Coaches provide personalized support to customers and motivate them by sharing their passion for healthy living and lifestyle transformation.
The entrepreneurial spirit of our OPTAVIA Coaches is another key to our success, as they create a continuous cycle of growth, activating new customers, many of whom go on to become OPTAVIA Coaches. We offer economic incentives designed to support each OPTAVIA Coach’s long-term success, which we believe plays an important role in their financial wellness, providing the opportunity to improve their finances while changing the health trajectory of families, communities, and generations.1
OPTAVIA Coaches are independent contractors, not employees, who support customers and market our products and services primarily through word of mouth, email, and social media channels such as Facebook, Instagram, X, and video conferencing platforms. As entrepreneurs, OPTAVIA Coaches market our products to friends, family, and other acquaintances. OPTAVIA products are shipped directly to customers who are working with an OPTAVIA Coach. OPTAVIA Coaches do not handle inventory or deliver merchandise to customers. This arrangement frees our OPTAVIA Coaches from having to manage inventory and allows them to maintain an arms-length transactional relationship while focusing their attention on support and encouragement.
With the expansion of our business to include GLP-1 support tools, we are leveraging multiple channels to enhance customer acquisition and spur meaningful growth. OPTAVIA Coaches remain a fundamental component of our business, and their outreach around our integrated wellness offering is one channel to drive customer acquisition. Additionally, we are collaborating with LifeMD to activate their patient base as another channel to acquire customers. Further, we are investing in a high-impact national marketing campaign designed to drive customer acquisition, elevate brand awareness, and foster deep
1 OPTAVIA makes no guarantee of financial success. Success with OPTAVIA results from successful sales efforts, which require hard work, diligence, skill, persistence, competence, and leadership. Please see the OPTAVIA Income Disclosure Statement (http://bit.ly/idsOPTAVIA) for statistics on actual earnings of Coaches.
16
engagement. With these efforts, we are actively evolving the Company’s historic single channel Coach-focused business model to pair Company advertising with relationship-based Coaching, exponentially broadening our reach and contributing to our business transformation focused on sustainable growth.
Our operations are conducted through our wholly owned subsidiaries, Jason Pharmaceuticals, Inc., OPTAVIA, LLC, Jason Enterprises, Inc., Jason Properties, LLC, Seven Crondall Associates, LLC, Corporate Events, Inc., OPTAVIA (Hong Kong) Limited, OPTAVIA (Singapore) PTE. LTD, and OPTAVIA Health Consultation (Shanghai) Co., Ltd.
Competition and Macroeconomic Conditions
Certain global economic challenges including the impact of inflation have caused macroeconomic uncertainty and volatility in markets where we, our suppliers and our OPTAVIA Coaches operate.
We are exposed to market risks from changes in commodity or other raw material prices. Rising inflation could impact our cost structure and has put pressure on consumer spending. Increases in commodity prices or food costs, including as a result of inflation, could affect the global and U.S. economies and could also adversely impact our business, financial condition, or results of operations. Our variable cost structure can be utilized to adapt to changing market conditions with potential actions including adjustments to our manufacturing, distribution, and customer support infrastructure. As a response, we may periodically take incremental pricing actions to offset supply chain costs and inflationary pressures.
In response to changing macroeconomic conditions, the Company may take further actions that alter its business operations as may be required by governmental authorities, or that are determined to be in the best interests of its employees, stockholders, OPTAVIA Coaches and customers.
These macroeconomic uncertainties make it challenging for our management to estimate our future business performance. However, we intend to continue to actively monitor the impact of these developments on our business and will update our practices accordingly.
The weight loss industry is very competitive and encompasses a diverse array of weight loss products and programs. These include a wide variety of commercial weight loss programs, pharmaceutical products, surgical interventions, books, self-help diets, dietary meal replacements, and appetite suppressants as well as digital tools, app-based health and wellness monitoring solutions, and wearable trackers. The weight loss market is served by a diverse array of competitors. Potential customers seeking to manage their weight can turn to traditional center-based competitors, online diet-oriented sites, self-directed dieting, and self-administered products such as prescription medications, over-the-counter medications, and supplements as well as medically supervised programs.
Medical weight loss solutions, such as GLP-1 medications, have become an increasingly key component of the overall health and wellness ecosystem, and the recent surging awareness and popularity of these weight loss medications serve as another major competitor, as these products have prompted a huge change in the way that consumers think about weight loss and lifestyle modification solutions in general. We recognize that these weight loss medications have attracted significant attention from the market and pose a threat to our interactions with our customer base. Importantly, the efficacy claims of GLP-1 medications for weight loss are based specifically on their incorporation of lifestyle changes that include a reduced calorie diet and increased physical activity. As a result, under Medifast’s offering, weight loss medications become one important element in an overall tailored lifestyle plan that also includes Coaching, community support, nutritionally balanced meals, and exercise.
We believe our scientific and clinical heritage combined with our commitment to evaluating programs, plans and products through clinical research are primary differentiators that allow us to compete in these markets. Our scientifically designed products were originally developed by a physician, and we have been on the cutting edge in the development of nutrition and weight-management products since our founding.
Medifast has perfected our model over the last 40 plus years, with habits, Coaches, and community at the core, and we will continue to innovate as the industry evolves.
Recent Initiatives
In response to the current competitive landscape, in which acquiring customers has become more difficult due to competitive pressures from GLP-1 medications being sought after by our potential customers, the Company is focusing on a number of initiatives to aid in increasing revenue and profit growth in the years ahead. At the core of the Company’s initiatives is its desire
17
to grow its business by broadening its customer base through increased brand visibility and recognition, and by significantly expanding its total addressable market.
Areas of investment anticipated for the year include instituting a new marketing campaign and upgrading customers’ digital experience to increase brand awareness and drive customer adoption, as well as cultivating new customers through the Company’s collaboration with LifeMD.
In December of 2023, the Company entered into a collaboration agreement with LifeMD, a leading provider of virtual primary care. This collaboration brings together OPTAVIA’s personalized habit-based, coach-guided approach with medical expertise from board-certified affiliated LifeMD clinicians and access to weight loss medications, including GLP-1s. With this collaboration, the Company and LifeMD intent to develop an integrated offering with the goal of creating a comprehensive and seamless solution for customers who desire to use medications and OPTAVIA’s lifestyle enhancement program. In the second quarter of 2024, we expect to take a key interim step, as we begin offering a lifestyle program with a dedicated OPTAVIA coach, balanced nutrition options with our GLP-1 Nutrition Support Kit, and, through LifeMD, access to a medical provider and blood work, as well as prescription and insurance support.
GLP-1 medications that meet the FDA weight loss mandate are prescribed along with the recommendation to make lifestyle modifications, such as through a structured program like OPTAVIA, that encourages a reduced-calorie diet and increased physical activity. Our research shows that most of those who are interested in weight loss medication are also looking for support beyond a prescription, including clarity on how to incorporate healthy eating and exercise into their lifestyles while using these medical solutions. While medically supported weight loss can be effective, long-term success is dependent on the nutrition and lifestyle changes individuals make in combination with taking medication.
We believe by significantly broadening our customer acquisition activities, through launching our new marketing campaign, upgrading customers' digital experience, and leaning into the medically supported weight loss market through our collaboration with LifeMD, we will be positioned for future success.
Critical Accounting Policies and Estimates
The preparation of our financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Management develops, and changes periodically, these estimates and assumptions based on historical experience and on various other factors that are believed to be reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions. There were no significant changes in our critical estimates during the first three months of 2024.
Our unaudited condensed consolidated financial statements are prepared in accordance with GAAP. Our significant accounting policies are described in Note 2 to the audited consolidated financial statements included in the 2023 Form 10-K. We consider all of our significant accounting policies and estimates to be critical.
Overview of Results of Operations
Our product sales accounted for approximately 98% of our revenues for each of the three months ended March 31, 2024 and 2023.
18
The following tables reflect our income statements (in thousands, except percentages):
Three months ended March 31,
20242023$ Change% Change
Revenue$174,739$348,983$(174,244)(49.9)%
Cost of sales47,447102,593(55,146)(53.8)%
Gross profit127,292246,390(119,098)(48.3)%
Selling, general, and administrative119,352192,879(73,527)(38.1)%
Income from operations7,94053,511(45,571)(85.2)%
Other income (expense)
Interest income (expense)1,223(181)1,404 775.7 %
Other income (expense)2,422(1)2,423 (242,300.0)%
3,645(182)3,827 2,108.5 %
Income from operations before income taxes11,58553,329(41,744)(78.3)%
Provision for income taxes3,26913,361(10,092)(75.5)%
Net income$8,316$39,968$(31,652)(79.2)%
% of revenue
Gross profit72.8 %70.6 %
Selling, general, and administrative costs68.3 %55.3 %
Income from operations4.5 %15.3 %

Revenue: Revenue decreased $174.2 million, or 49.9%, to $174.7 million for the three months ended March 31, 2024 from $349.0 million for the three months ended March 31, 2023. The average revenue per active earning OPTAVIA Coach was $4,623 for the three months ended March 31, 2024 compared to $5,945 for the three months ended March 31, 2023. The decline in revenue for the three months ended March 31, 2024 was primarily driven by a decrease in the number of active earning OPTAVIA Coaches to 37,800 as of March 31, 2024 from 58,700 as of March 31, 2023, the decline in the productivity per active earning OPTAVIA Coach, and a $9.1 million impact from a timing difference related to changes in the Company’s sales order terms and conditions with its customers realized in the first quarter of 2023. The decrease in productivity per active earning OPTAVIA Coach for the quarter was driven by continued pressure on customer acquisition.
Cost of sales: Cost of sales decreased $55.1 million, or 53.8%, to $47.4 million from $102.6 million for the three months ended March 31, 2024 from the corresponding period in 2023. The decrease in cost of sales for the three months ended March 31, 2024 was primarily driven by decreased volumes, efficiencies in inventory management, and cost savings from our Fuel for the Future initiatives.
Gross profit: For the three months ended March 31, 2024, gross profit decreased $119.1 million, or 48.3%, to $127.3 million from $246.4 million for the three months ended March 31, 2023. The decrease in gross profit for the three months ended March 31, 2024 was due to lower revenue, partially offset by efficiencies in inventory management and cost savings from our Fuel for the Future initiatives. As a percentage of revenue, gross profit increased 220 basis points to 72.8% for the three months ended March 31, 2024 from 70.6% for the corresponding period in 2023. The increase in gross margin percentage was primarily due to efficiencies in inventory management and cost savings from Fuel for the Future initiatives, partially offset by increased shipping costs.
Selling, general, and administrative: SG&A expenses were $119.4 million for the three months ended March 31, 2024, a decrease of $73.5 million, or 38.1%, as compared to $192.9 million from the corresponding period in 2023. The decrease in
19
SG&A expenses for the three months ended March 31, 2024 was primarily due to decreased Coach compensation due to lower volumes and fewer active earning Coaches, partially offset by market research and investment costs related to medically supported weight loss and costs for our Company-led acquisition initiatives. As a percentage of revenue, SG&A expenses were 68.3% for the three months ended March 31, 2024 as compared to 55.3% for the corresponding period in 2023. SG&A expenses included research and development costs of $1.0 million for both the three months ended March 31, 2024 and 2023, in connection with the development of new products, programs and clinical research activities. The increase in SG&A expenses as a percentage of revenue for the three months ended March 31, 2024 was primarily due to market research and investment costs related to medically supported weight loss activities, the loss of leverage on fixed costs due to lower sales volumes when compared to the first quarter of 2023, and costs for our company led acquisition initiatives.
Non-GAAP adjusted SG&A expenses were $118.0 million for the three months ended March 31, 2024, a decrease of $74.9 million, or 38.8%, as compared to $192.9 million from the corresponding period in 2023. Non-GAAP adjusted SG&A excludes costs for the collaboration with LifeMD of $1.3 million for the three months ended March 31, 2024. Refer to the section titled “Non-GAAP Financial Measures” below for a reconciliation of each of non-GAAP financial measures to its most comparable GAAP financial measure.
Income from operations: For the three months ended March 31, 2024, income from operations decreased $45.6 million to $7.9 million from $53.5 million for the corresponding period in 2023 primarily as a result of decreased gross profit partially offset by decreased SG&A expenses. Income from operations as a percentage of revenue decreased to 4.5% for the three months ended March 31, 2024 from 15.3% for the corresponding period in 2023 due to the factors described above impacting revenue and SG&A expenses.
Non-GAAP adjusted income from operations was $9.3 million for the three months ended March 31, 2024, a decrease of $44.2 million, or 82.7%, as compared to $53.5 million from the corresponding period in 2023. Refer to the section titled “Non-GAAP Financial Measures” below for a reconciliation of each of non-GAAP financial measures to its most comparable GAAP financial measure.

Provision for income taxes: For the three months ended March 31, 2024, the Company recorded $3.3 million in income tax expense, an effective tax rate of 28.2%, as compared to $13.4 million in income tax expense, an effective tax rate of 25.1%, for the three months ended March 31, 2023. The increase in the effective tax rate for the three months ended March 31, 2024 was primarily driven by an increase in the tax shortfall for stock compensation and the rate impact of research and development tax credits, partially offset by the decrease in the limitation for executive compensation and various other miscellaneous items.
Non-GAAP adjusted income tax provision was $2.9 million for the three months ended March 31, 2024, an effective tax rate of 28.7% as compared to 25.1% for the corresponding period in 2023. “Non-GAAP Financial Measures” below for a reconciliation of each of non-GAAP financial measures to its most comparable GAAP financial measure.
Net income: Net income was $8.3 million, or $0.76 per diluted share for the three months ended March 31, 2024 as compared to $40.0 million, or $3.67 per diluted share, for the three months ended March 31, 2023. The period-over-period changes were driven by the factors described above in the section titled “Income from operations.”
Non-GAAP adjusted net income was $7.2 million or $0.66 per diluted share for the three months ended March 31, 2024 as compared to $40.0 million, or $3.67 per diluted share, for the corresponding period in 2023. Refer to the section titled “Non-GAAP Financial Measures” below for a reconciliation of each of non-GAAP financial measures to its most comparable GAAP financial measure.
Non-GAAP Financial Measures
In an effort to provide investors with additional information regarding our results as determined by GAAP, we disclose various non-GAAP financial measures in this quarterly report, our quarterly earnings press release, and other public disclosures. The following GAAP financial measures have been presented on an as-adjusted basis: SG&A expenses, income from operations, other income (expense), provision for income taxes, net income, and diluted earnings per share. Each of these as-adjusted financial measures excludes the impact of certain amounts related to the LifeMD collaboration and unrealized gains on our investment in LifeMD common stock as further identified below and have not been calculated in accordance with GAAP. A reconciliation of each of these non-GAAP financial measures to its most comparable GAAP financial measure is included below. These non-GAAP financial measures are not intended to replace GAAP financial measures.
We use these non-GAAP financial measures internally to evaluate and manage the Company’s operations because we believe they provide useful supplemental information regarding the Company’s on-going economic performance. We have chosen to
20
provide this information to investors to enable them to perform more meaningful comparisons of operating results and as a means to emphasize the results of on-going operations.
The following tables reconcile the non-GAAP financial measures included in this report (in thousands, except per share amounts):
Three Months Ended March 31, 2024
GAAP
Unrealized Gain on Investment in LifeMD Common Stock
LifeMD Prepaid Services AmortizationNon-GAAP
Selling, general, and administrative$119,352 $— $(1,327)$118,025 
Income from operations7,940 — 1,327 9,267 
Other income (expense)3,645 (2,841)— 804 
Provision for income taxes3,269 (710)332 2,891 
Net income8,316 (2,130)995 7,181 
Diluted earnings per share (1)0.76 (0.19)0.09 0.66 

Three Months Ended March 31, 2023
GAAP
Unrealized Gain on Investment in LifeMD Common Stock
LifeMD Prepaid Services AmortizationNon-GAAP
Selling, general, and administrative$192,879 $— $— $192,879 
Income from operations53,511 — — 53,511 
Other income (expense)(182)— — (182)
Provision for income taxes13,361 — — 13,361 
Net income39,968 — — 39,968 
Diluted earnings per share (1)3.67 — — 3.67 
(1) The weighted-average diluted shares outstanding used in the calculation of these non-GAAP financial measures are the same as the weighted-average shares outstanding used in the calculation of the reported per share amounts.
Liquidity and Capital Resources
The Company had stockholders’ equity of $211.0 million and working capital of $142.4 million at March 31, 2024 as compared with $201.5 million and $131.7 million at December 31, 2023, respectively. The $9.5 million net increase in stockholders’ equity was primarily driven by net income for the three months ended March 31, 2024 of $8.3 million. The Company’s cash, cash equivalents, and investments increased from $150.0 million at December 31, 2023 to $156.4 million at March 31, 2024.
Net cash provided by operating activities decreased by $56.8 million to $7.3 million for the three months ended March 31, 2024 from $64.1 million for the three months ended March 31, 2023 primarily driven by a $31.7 million decrease in net income, a $13.6 million decrease related to changes in inventory balances, a $9.3 million decrease in income taxes, a $7.3 million decrease in prepaid expenses and other current assets, partially offset by a $6.0 million increase in accounts payable and accrued expenses We decreased our inventory purchases during the period ended March 31, 2024 to align with sales demand.
Net cash used in investing activities was $2.8 million for the three months ended March 31, 2024 as compared to $2.1 million for the three months ended March 31, 2023.
Net cash used in financing activities decreased by $24.4 million to $1.5 million for the three months ended March 31, 2024 from $25.9 million for the three months ended March 31, 2023. This decrease was primarily due to an $18.5 million decrease in cash dividends paid to stockholders, a $3.6 million decrease in repurchases of the Company's common stock, and a $2.4 million decrease in net shares repurchased for employee taxes.
21
In pursuing its business strategy, the Company may require additional cash for operating and investing activities. The Company expects future cash requirements, if any, to be funded from operating cash flow and financing activities.
From time to time the Company evaluates potential acquisitions that complement our business. If consummated, any such transactions may use a portion of our working capital or require the issuance of equity or debt. We have no present understandings, commitments, or agreements with respect to any material acquisitions.
On April 13, 2021, the Company and certain of its subsidiaries (collectively, the “Guarantors”) entered into a credit agreement among the Company, the Guarantors, the lenders party thereto and Citibank, N.A., in its capacity as administrative agent. On May 31, 2022, the Credit Agreement was amended to increase the borrowing capacity and convert the interest rate to be based on SOFR, from LIBOR (the “Amended Credit Agreement”). The Amended Credit Agreement provides for a $225.0 million senior secured revolving credit facility with a $20.0 million letter of credit sublimit. The Amended Credit Agreement also provides for an uncommitted incremental facility that permits the Company, subject to certain conditions, to increase the senior secured revolving credit facility by up to $100.0 million. The Amended Credit Agreement contains affirmative and negative covenants customarily applicable to credit facilities. As of March 31, 2024, the Company had no borrowings under the credit facility or letter of credit sublimit, and was in compliance with all of its debt covenants.
Item 3. Quantitative and Qualitative Disclosures about Market Risk
Market risk is the potential loss arising from adverse changes in market rates and prices, such as interest rates and a decline in the stock market. The Company does not enter into derivatives, foreign exchange transactions or other financial instruments for trading or speculative purposes other than strategic investments.
The Company is exposed to market risk related to changes in interest rates and market pricing impacting our credit facility and investment in money market securities, government and agency securities, and corporate bonds. Other than for strategic investments, its current investment policy is to maintain an investment portfolio consisting of corporate bonds and U.S. money market securities directly or through managed funds. Its cash is deposited in and invested through highly rated financial institutions in North America. Its marketable securities, purchased during 2023, are subject to interest rate risk and market pricing risk and will fall in value if market interest rates increase or if market pricing decreases. If market interest rates were to increase and market pricing were to decrease immediately and uniformly by 10% from levels at March 31, 2024, the Company estimates that the fair value of its investment portfolio would decline by an immaterial amount and therefore it would not expect its operating results or cash flows to be affected to any significant degree by the effect of a change in market conditions on our investments.
The Company is exposed to market risk related to price fluctuations in equity markets related to its investment in LifeMD common stock, purchased in December of 2023. If equity prices were to decrease immediately and uniformly by 10% from levels at March 31, 2024, the Company estimates that the fair value of the Company investment would decline by an immaterial amount and therefore it would not expect its operating results or cash flows to be affected by any significant degree by the effect of a change in market conditions on our investment.
There have been no material changes to our market risk exposure since December 31, 2023.
Item 4. Controls and Procedures
Management, including our Chief Executive Officer and Chief Financial Officer, conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Act, as of March 31, 2024. Our disclosure controls and procedures are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Act is recorded, processed, summarized, and reported accurately and on a timely basis. Based on this evaluation performed in accordance with the criteria established in the 2013 Internal Control – Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission, our management concluded that the Company’s disclosure controls and procedures are effective at the reasonable assurance level as of the end of the period covered by this report.
Changes in Internal Control over Financial Reporting
There have been no material changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Act) during the fiscal quarter ended March 31, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
22
Part II Other Information
Item 1. Legal Proceedings
The Company is, from time to time, subject to a variety of litigation and similar proceedings that arise out of the ordinary course of its business. Based upon the Company’s experience, current information, and applicable law, it does not believe that these proceedings and claims will have a material adverse effect on its results of operations, financial position, or liquidity. However, the results of legal actions cannot be predicted with certainty. Therefore, it is possible that the Company’s results of operations, financial condition or cash flows could be materially adversely affected in any particular period by the unfavorable resolution of one or more legal actions.
Item 1A. Risk Factors
There have been no material changes to the risk factors set forth in Part I, Item 1A of the 2023 Form 10-K.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Issuer Purchases of Equity Securities
2024
Total Number of Shares Purchased (1)
Average Price Paid per ShareTotal Number of Shares Purchased
as Part of a Publicly Announced
Plan or Program
Maximum Number of Shares that May
Yet Be Purchased Under the Plans or Programs (2)
January 1 - January 31— — — 1,323,568
February 1 - February 29107 48.62 — 1,323,568
March 1 - March 3110,986 36.64 — 1,323,568
(1)Also included are shares of the Company’s common stock surrendered by employees and directors to the Company to cover minimum tax liability withholding obligations upon the exercise of stock options or the vesting of shares of restricted stock and performance-based share awards previously granted to such employees and directors.
(2)At the outset of the quarter ended March 31, 2024, there were 1,323,568 shares of the Company’s common stock eligible for repurchase under the stock repurchase authorization dated September 16, 2014 (the "Stock Repurchase Plan").
As of March 31, 2024, there were 1,323,568 shares of the Company’s common stock eligible for repurchase under the Stock Repurchase Plan. There can be no assurances as to the amount, timing, or prices of repurchases, which may vary based on market conditions and other factors. The Stock Repurchase Plan does not have an expiration date and can be modified or terminated by the Board of Directors at any time.
23
Item 6. Exhibits
Exhibit NumberDescription of Exhibit
3.1
3.2
31.1
31.2
32.1
101
The following financial statements from Medifast, Inc.’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 filed April 29, 2024, formatted in Inline XBRL (eXtensible Business Reporting Language): (i) Condensed Consolidated Statements of Income, (ii) Condensed Consolidated Statements of Comprehensive Income, (iii) Condensed Consolidated Balance Sheets, (iv) Condensed Consolidated Statements of Cash Flows, (v) Condensed Consolidated Statements of Changes in Stockholders’ Equity, and (vi) Notes to the Condensed Consolidated Financial Statements (filed herewith).
104Cover Page Interactive Data File - The cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
In accordance with SEC Release No. 33-8238, Exhibit 32.1 is being furnished and not filed.
24
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.
Medifast, Inc.
By:/s/ DANIEL R. CHARD
 Daniel R. Chard
Chief Executive Officer
(Principal Executive Officer)
Dated:April 29, 2024
/s/ JAMES P. MALONEY
James P. Maloney
Chief Financial Officer
(Principal Financial Officer)
Dated:April 29, 2024
25
 EX-31.1 2 med-20240131xexx311.htm EX-31.1 Document

Exhibit 31.1
RULE 13a-14(a) CERTIFICATION
I, Daniel R. Chard, certify that:
1.I have reviewed this report on Form 10-Q of Medifast, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date:April 29, 2024/s/    Daniel R. Chard
Daniel R. Chard
Chief Executive Officer

 EX-31.2 3 med-20240131xexx312.htm EX-31.2 Document

Exhibit 31.2
RULE 13a-14(a) CERTIFICATION
I, James P. Maloney, certify that:
1.I have reviewed this report on Form 10-Q of Medifast, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date:April 29, 2024/s/    James P. Maloney
James P. Maloney
Chief Financial Officer

 EX-32.1 4 med-20240131xexx321.htm EX-32.1 Document

Exhibit 32.1
MEDIFAST, INC.
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q (the “Report”) for the quarter ended March 31, 2024 of Medifast, Inc. (the “Company”), as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Daniel R. Chard, Chief Executive Officer and I, James P. Maloney, Chief Financial Officer, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that:
(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of the operations of the Company.
By:/s/ DANIEL R. CHARD
Daniel R. Chard
Chief Executive Officer
April 29, 2024
/s/ JAMES P. MALONEY
James P. Maloney
Chief Financial Officer
April 29, 2024

 EX-101.SCH 5 med-20240331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - INVENTORIES link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - EARNINGS PER SHARE link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - SHARE-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - LEASES link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - INVESTMENTS link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - DEBT link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - INVENTORIES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - EARNINGS PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - SHARE-BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - INVESTMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - INVENTORIES (Details) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - EARNINGS PER SHARE - Computation of Basic and Diluted EPS (Details) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - EARNINGS PER SHARE - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - SHARE-BASED COMPENSATION - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - SHARE-BASED COMPENSATION - Stock Options Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - SHARE-BASED COMPENSATION - Restricted Stock Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - SHARE-BASED COMPENSATION - Summary of Performance-based Share Awards (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - LEASES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - LEASES - Supplemental Cash Flow Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - LEASES - Future Minimum Lease Commitments (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - LEASES - Future Minimum Lease Commitments (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - INVESTMENTS - Cash and Financial Assets Measured at Fair Value on a Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - INVESTMENTS - Investment Gains (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - INVESTMENTS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - DEBT (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 med-20240331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 med-20240331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 med-20240331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Credit Agreement Amended Credit Agreement [Member] Credit Agreement [Member] Variable Rate [Domain] Variable Rate [Domain] Accrued Interest, Equity securities Equity Securities, Accrued Interest Equity Securities, Accrued Interest Range [Domain] Statistical Measurement [Domain] Total current assets Assets, Current Reserve for obsolete inventory Inventory Valuation Reserves Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Change in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Maximum total net leverage ratio Maximum Total Net Leverage Ratio Maximum ratio as of any date, of (a) Total Net Funded Indebtedness on such date to (b) Consolidated EBITDA for the Reference Period ended on such date under credit facility. Award expiration period (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Supplemental disclosure of cash flow information: Supplemental Cash Flow Information [Abstract] Equity Award [Domain] Award Type [Domain] Investment, Name [Domain] Investment, Name [Domain] Outstanding at beginning of period (in shares) Outstanding at end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number DEBT Debt Disclosure [Text Block] Amortization of premium on investment securities Investment Income, Net, Amortization of Discount and Premium Other income (expense) Other Nonoperating Income (Expense) Entity Filer Category Entity Filer Category Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Statement [Table] Statement [Table] Current Fiscal Year End Date Current Fiscal Year End Date Revolving Credit Facility Revolving Credit Facility [Member] Schedule of Cash and Financial Assets Measured at Fair Value on a Recurring Basis Schedule of Available-for-Sale Securities Reconciliation [Table Text Block] Foreign currency impact Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Operating Lease Arrangement for Equipment Operating Lease Arrangement For Equipment [Member] Represents the operating lease arrangement for equipment. Performance-Based Shares Performance-based share awards Performance Shares [Member] Weighted-average remaining contractual life of options exercisable (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Investment, Name [Axis] Investment, Name [Axis] Investments made Payments to Acquire Investments Options and restricted stock Options And Restricted Stock [Member] Options And Restricted Stock Schedule of Accumulated Other Comprehensive Income Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Total other expense Nonoperating Income (Expense) Base Rate Base Rate [Member] Cost, Cash and cash equivalents, excluding money market accounts Cash And Cash Equivalents Excluding Money Market Accounts, Amortized Cost Cash And Cash Equivalents Excluding Money Market Accounts, Amortized Cost Lessee, Operating Lease, Liability, Payment, Due [Abstract] Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Granted (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Shares, Exercisable at end of the period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Market and performance-based share awards Market And Performance-based Share [Member] Market And Performance-based Share Net cash flow provided by operating activities Net Cash Provided by (Used in) Operating Activities Aggregate intrinsic value of options exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Debt Securities, Available-for-Sale, Current Debt Securities, Available-for-Sale, Current Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Granted In 2020 Granted In 2020 [Member] Granted In 2020 Depreciation and amortization Depreciation, Depletion and Amortization Accrued Interest Debt Securities, Accrued Interest [Member] Debt Securities, Accrued Interest Realized gain on sale of investment securities Realized gain Debt Securities, Realized Gain (Loss) Accounts payable and accrued expenses Accounts Payable and Accrued Liabilities, Current Current Liabilities Liabilities, Current [Abstract] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Total stockholders' equity Balance Balance Equity, Attributable to Parent Subsequent Event Type [Domain] Subsequent Event Type [Domain] Weighted-Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Dividends included in accounts payable Dividends, Cash Earnings per share - diluted (in usd per share) Earnings Per Share, Diluted Unrealized gain on equity investment securities Unrealized Gain (Loss) on Investments Restricted Stock Restricted Stock [Member] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Investment Securities Securities Investment [Member] Net shares repurchased for taxes Payments for Repurchase of Other Equity Income from operations before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Cash And Cash Equivalents And Marketable securities [Line Items] Cash And Cash Equivalents And Marketable securities [Line Items] N/A Shares, Outstanding at beginning of period (in shares) Shares, Outstanding at end of the period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Options exercised by directors Stock Issued During Period, Value, Stock Options Exercised Trading Symbol Trading Symbol Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Level 2 Fair Value, Inputs, Level 2 [Member] Net income Net income Net income Net Income (Loss) Prepaid income taxes Increase (Decrease) in Income Taxes Receivable Total current liabilities Liabilities, Current Entity Emerging Growth Company Entity Emerging Growth Company LEASES Lessee, Operating Leases [Text Block] Treasury stock retired from stock repurchases (in shares) Treasury Stock, Shares, Retired Milestone payment Collaborative Arrangement, Amount Collaborative Arrangement, Amount Finished goods Inventory, Finished Goods, Gross LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity [Abstract] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Income taxes, prepaid Prepaid Taxes Stockholders' Equity Equity, Attributable to Parent [Abstract] Unrealized Loss Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Options exercised by directors (in shares) Shares, Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Document Fiscal Period Focus Document Fiscal Period Focus 2025 Lessee, Operating Lease, Liability, to be Paid, Year One Schedule of the Computation of Basic and Diluted EPS Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Antidilutive Securities [Axis] Antidilutive Securities [Axis] 2028 Lessee, Operating Lease, Liability, to be Paid, Year Four Award vesting period (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Operating lease expense Operating Lease, Expense Exercise price (in usd per share) Weighted-Average Exercise Price, Outstanding at beginning of period (in usd per share) Weighted-Average Exercise Price, Outstanding at beginning of period (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based compensation Share-Based Payment Arrangement, Noncash Expense Schedule of Share-based Compensation Expense Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block] Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Significant Accounting Policies [Text Block] Common Stock Common Stock [Member] Weighted-Average Exercise Price, Exercised (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Level 1 Fair Value, Inputs, Level 1 [Member] Estimated Fair Value, Investment securities Investment Securities, Fair Value Investment Securities, Fair Value Share-based compensation APIC, Share-Based Payment Arrangement, Recognition and Exercise City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code EARNINGS PER SHARE Earnings Per Share [Text Block] Income Statement Location [Domain] Income Statement Location [Domain] Investments, All Other Investments [Abstract] Investments, All Other Investments [Abstract] Equity Components [Axis] Equity Components [Axis] Financial Instruments [Domain] Financial Instruments [Domain] Uncommitted Incremental Facility Uncommitted Incremental Facility [Member] Uncommitted Incremental Facility Unrealized Gains, Investment securities Investment Securities, Unrealized Gains Investment Securities, Unrealized Gains Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Document Fiscal Year Focus Document Fiscal Year Focus Granted In 2024 Granted In 2024 [Member] Granted In 2024 Awards granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Lease term (in months) Lessee, Operating Lease, Term of Contract Entity Small Business Entity Small Business Debt Securities, Unrealized Gain [Domain] Debt Securities, Unrealized Gain [Domain] Debt Securities, Unrealized Gain [Domain] Minimum Minimum [Member] ACCUMULATED OTHER COMPREHENSIVE INCOME Comprehensive Income (Loss) Note [Text Block] Local Phone Number Local Phone Number Property, plant and equipment - net of accumulated depreciation Property, Plant and Equipment, Net Weighted average shares outstanding Weighted Average Number of Shares Outstanding, Diluted [Abstract] Presentation of Financial Statements Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Letter of Credit Letter of Credit [Member] Forecast Forecast [Member] Numerator: Numerator [Abstract] Numerator [Abstract] Schedule of Stock Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Non-cash lease expense Operating Lease, Expense, Non-Cash Operating Lease, Expense, Non-Cash Selling, General and Administrative Expenses Selling, General and Administrative Expenses [Member] Cash dividends declared per share (in usd per share) Common Stock, Dividends, Per Share, Declared Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Cash dividends declared to stockholders Dividends, Common Stock, Cash ASSETS Assets [Abstract] Lease obligations, net of current lease obligations Operating Lease, Liability, Noncurrent Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Income taxes refunded Income Taxes Paid, Net Net cash flow used in financing activities Net Cash Provided by (Used in) Financing Activities Deferred tax assets Deferred Income Tax Assets, Net Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Income Statement Location [Axis] Income Statement Location [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Retained Earnings Retained Earnings [Member] Operating Lease Arrangement for Real Estate Operating Lease Arrangement For Real Estate [Member] Represents the operating lease arrangement for real estate. Unrealized Gains (Losses) Debt Securities, Gains (Losses) [Member] Debt Securities, Gains (Losses) Government & agency securities US Government Corporations and Agencies Securities [Member] Net shares repurchased for employee taxes Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity Cost, Debt Securities Debt Securities, Available-for-Sale, Amortized Cost Other assets Other Assets, Noncurrent Other income (expense) Nonoperating Income (Expense) [Abstract] Schedule of Maturity of Company's Operating Lease Liabilities Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Effect of dilutive common stock equivalents (in shares) Weighted Average Number of Shares Outstanding, Diluted, Adjustment Right-of-use assets Operating Lease, Right-of-Use Asset Earnings per share - basic (in usd per share) Earnings Per Share, Basic Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Options, unrecognized compensation costs Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Accounting Policies [Abstract] Accounting Policies [Abstract] Unrealized gains on investments AOCI, Debt Securities, Available-for-Sale, Adjustment, after Tax Cost, Investment securities Investment Securities, At Cost Investment Securities, At Cost 2024 (excluding the three months ended March 31, 2024) Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Intrinsic value of options exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Minimum interest coverage ratio Minimum Interest Coverage Ratio Minimum Interest Coverage Ratio Schedule of Supplemental Cash Flow Information Lease, Cost [Table Text Block] Inventories Increase (Decrease) in Inventories Entity Address, City or Town Entity Address, City or Town Investing Activities Net Cash Provided by (Used in) Investing Activities [Abstract] Award Type [Axis] Award Type [Axis] Anti-dilutive awards (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Shares granted in period Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Document Quarterly Report Document Quarterly Report Unrecognized compensation costs Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Fair Value Hierarchy [Domain] Fair Value Hierarchy and NAV [Domain] Document Transition Report Document Transition Report Operating leases Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Weighted-average remaining contractual life of options outstanding (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Less: imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Foreign currency translation Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax Use of Estimates Use of Estimates, Policy [Policy Text Block] Common stock, authorized (in shares) Common Stock, Shares Authorized Performance period (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Award Performance Period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Performance Period Raw materials Inventory, Raw Materials, Gross Entity File Number Entity File Number Current lease obligations Operating Lease, Liability, Current Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Net gains recognized during the period on equity securities Equity Securities, FV-NI, Gain (Loss) Proceeds from sale and maturities of investment securities Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale Entity Shell Company Entity Shell Company 2027 Lessee, Operating Lease, Liability, to be Paid, Year Three Borrowings outstanding Long-Term Debt, Gross Adjustments to reconcile net income to cash provided by operating activities Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Accounting Pronouncements and Recently Issued Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Award Date [Domain] Award Date [Domain] Counterparty Name [Domain] Counterparty Name [Domain] Cash and cash equivalents - beginning of the period Cash and cash equivalents - end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents 2026 Lessee, Operating Lease, Liability, to be Paid, Year Two Share-based compensation arrangement, fair value of awards vested Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Additional paid-in capital Additional Paid in Capital Common stock, issued (in shares) Balance (in shares) Balance (in shares) Common Stock, Shares, Issued Schedule of Restricted Stock Activity Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Gross profit Gross Profit Commitment fee (as a percent) Line of Credit Facility, Commitment Fee Percentage Forfeited (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Security Exchange Name Security Exchange Name Deferred income taxes Deferred Income Tax Expense (Benefit) Subsequent Event Type [Axis] Subsequent Event Type [Axis] Options exercised by directors Proceeds from Stock Options Exercised Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Selling, general, and administrative Selling, General and Administrative Expense Accumulated other comprehensive income Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Stock Options Employee Stock Option [Member] Weighted-Average Exercise Price, Forfeited (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Corporate bonds Municipal Bonds [Member] Compensation cost recognition weighted average period (in years) Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Maximum Maximum [Member] Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Document Type Document Type SOFR Secured Overnight Financing Rate (SOFR) [Member] Secured Overnight Financing Rate (SOFR) Aggregate intrinsic value of options outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Shares Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Entity Address, Address Line One Entity Address, Address Line One Treasury stock from stock repurchases Treasury Stock, Value, Acquired, Cost Method Entity Registrant Name Entity Registrant Name Additional shares earned (as a percent) Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Additional Shares Earned, Percentage Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Additional Shares Earned, Percentage Other assets Increase (Decrease) in Other Operating Assets Granted In 2023 Granted In 2023 [Member] Granted In 2023 Unrealized gains recognized during the reporting period on equity securities still held at the reporting date Equity Securities, FV-NI, Unrealized Gain (Loss) Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] SHARE-BASED COMPENSATION Share-Based Payment Arrangement [Text Block] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract] Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract] Purchase of investment securities Payments to Acquire Debt Securities, Available-for-Sale Document Period End Date Document Period End Date Weighted-Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Weighted-Average Exercise Price, Exercisable at end of the period (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Treasury Stock Treasury Stock, Common [Member] Entity Central Index Key Entity Central Index Key Subsequent Event Subsequent Event [Member] Loss on sale or disposal of property, plant and equipment Gain (Loss) on Disposition of Property Plant Equipment Decrease in share-based payment arrangement, expense Share-Based Compensation Expense Share-Based Payment Arrangement, Expense Variable Rate [Axis] Variable Rate [Axis] Thereafter Lessee Operating Lease Liability Payments Due After Year Four Lessee Operating Lease Liability Payments Due After Year Four Accounts payable and accrued expenses Increase (Decrease) in Accounts Payable and Accrued Liabilities Provision for income taxes Income Tax Expense (Benefit) Income Statement [Abstract] Income Statement [Abstract] Shares, Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Title of 12(b) Security Title of 12(b) Security Non-food finished goods Inventory Non Food Finished Goods Amount before last-in first-out (LIFO) and valuation reserves of (Non-food) merchandise or goods held by the entity that are readily available for sale. Estimated Fair Value, Cash and cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Other comprehensive income, net of tax Other comprehensive income Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Award Date [Axis] Award Date [Axis] Granted In 2022 Granted In 2022 [Member] Granted In 2022 Outstanding at beginning of period (in usd per share) Outstanding at beginning of period (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value INVENTORIES Inventory Disclosure [Text Block] Weighted average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Revenue Revenue from Contract with Customer, Excluding Assessed Tax Amendment Flag Amendment Flag Money market accounts Money Market Funds [Member] INVESTMENTS Financial Instruments Disclosure [Text Block] Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Entity Tax Identification Number Entity Tax Identification Number Inventories Total Inventory, Net Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Net shares repurchased for employee taxes (in shares) Shares withheld for employee taxes Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Weighted average discount rate (as a percent) Operating Lease, Weighted Average Discount Rate, Percent Statistical Measurement [Axis] Statistical Measurement [Axis] Share-based compensation (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period Debt Securities, Unrealized Gain [Axis] Debt Securities, Unrealized Gain [Axis] Debt Securities, Unrealized Gain Credit Facility [Domain] Credit Facility [Domain] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Financial Instrument [Axis] Financial Instrument [Axis] Entity Interactive Data Current Entity Interactive Data Current Accrued Interest, Investment securities Investment Securities, Accrued Interest Investment Securities, Accrued Interest Basis spread on variable rate (as a percent) Debt Instrument, Basis Spread on Variable Rate Denominator: Denominator [Abstract] Denominator [Abstract] Stock repurchases Payments for Repurchase of Common Stock Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Schedule of Investment Gains Gain (Loss) on Securities [Table Text Block] Treasury stock retired from stock repurchases Treasury Stock, Retired, Cost Method, Amount Diluted (in shares) Weighted average shares of common stock outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Granted In 2021 Granted In 2021 [Member] Granted In 2021 Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Retained earnings Retained Earnings (Accumulated Deficit) Interest income (expense) Interest Income (Expense), Nonoperating, Net Cash And Cash Equivalents And Marketable securities [Table] Cash And Cash Equivalents And Marketable securities [Table] N/A Purchase of property and equipment Payments to Acquire Property, Plant, and Equipment Estimated Fair Value Cash, Cash Equivalents, And Short-Term Investments, Fair Value Disclosure Cash, Cash Equivalents, And Short-Term Investments, Fair Value Disclosure Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Additional Paid-In Capital Additional Paid-in Capital [Member] Current Assets Assets, Current [Abstract] Leases [Abstract] Leases [Abstract] Less: Net gains recognized on equity securities sold Equity Securities, FV-NI, Realized Gain (Loss) Estimated Fair Value, Equity securities Equity Securities, FV-NI Balance Sheet Location [Axis] Balance Sheet Location [Axis] TOTAL ASSETS Assets Entity Address, State or Province Entity Address, State or Province Counterparty Name [Axis] Counterparty Name [Axis] Cover [Abstract] Cover [Abstract] Operating Activities Net Cash Provided by (Used in) Operating Activities [Abstract] Operating cash flow used in operating leases Operating Lease, Payments Common stock, outstanding (in shares) Common Stock, Shares, Outstanding Unrealized losses on investment securities OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Cash dividends paid to stockholders Payments of Dividends Vested (in usds per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Total lease payments Lessee, Operating Lease, Liability, to be Paid Investments Short-Term Investments Increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Financing Activities Net Cash Provided by (Used in) Financing Activities [Abstract] Common stock, par value (in usd per share) Common Stock, Par or Stated Value Per Share Foreign currency translation Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Equity Component [Domain] Equity Component [Domain] Cost, Equity securities Equity Securities, FV-NI, Cost Net cash flow used in investing activities Net Cash Provided by (Used in) Investing Activities Schedule of Inventories Schedule of Inventory, Current [Table Text Block] Text Block [Abstract] Awards Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Debt Instrument [Axis] Debt Instrument [Axis] Collaborative Arrangement Collaborative Arrangement [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Scenario [Axis] Scenario [Axis] Basic (in shares) Weighted average shares of common stock outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Entity Current Reporting Status Entity Current Reporting Status Total Operating Lease, Liability Income from operations Operating Income (Loss) Credit Facility [Axis] Credit Facility [Axis] Total liabilities Liabilities Cash & Cash Equivalents Cash and Cash Equivalents [Member] Accumulated Other Comprehensive Income AOCI Attributable to Parent [Member] Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Cost of sales Cost of Revenue Cost Cash, Cash Equivalents, and Short-Term Investments LifeMD LifeMD [Member] LifeMD Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Statement [Line Items] Statement [Line Items] Other comprehensive income, net of tax: Other Comprehensive Income (Loss), Net of Tax [Abstract] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Scenario [Domain] Scenario [Domain] Total income tax benefit recognized related to restricted stock awards Share-Based Payment Arrangement, Expense, Tax Benefit Unrealized Gains, Equity securities Equity Securities, FV-NI, Unrealized Gains Equity Securities, FV-NI, Unrealized Gains Earnings Per Share [Abstract] Earnings Per Share [Abstract] Packaging Retail Related Inventory, Packaging and Other Supplies Common stock, par value $0.001 per share: 20,000 shares authorized; 10,937 and 10,896 issued and outstanding at March 31, 2024 and December 31, 2023, respectively Common Stock, Value, Issued EX-101.PRE 9 med-20240331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Cover - shares
 3 Months Ended
Mar. 31, 2024
Apr. 22, 2024
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2024  
Document Transition Report false  
Entity File Number 001-31573  
Entity Registrant Name Medifast, Inc.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 13-3714405  
Entity Address, Address Line One 100 International Drive  
Entity Address, City or Town Baltimore  
Entity Address, State or Province MD  
Entity Address, Postal Zip Code 21202  
City Area Code 410  
Local Phone Number 581-8042  
Title of 12(b) Security Common Stock, par value $0.001 per share  
Trading Symbol MED  
Security Exchange Name NYSE  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   10,937,245
Entity Central Index Key 0000910329  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2024  
Document Fiscal Period Focus Q1  
Amendment Flag false  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]    
Revenue $ 174,739 $ 348,983
Cost of sales 47,447 102,593
Gross profit 127,292 246,390
Selling, general, and administrative 119,352 192,879
Income from operations 7,940 53,511
Other income (expense)    
Interest income (expense) 1,223 (181)
Other income (expense) 2,422 (1)
Total other expense 3,645 (182)
Income from operations before income taxes 11,585 53,329
Provision for income taxes 3,269 13,361
Net income $ 8,316 $ 39,968
Earnings per share - basic (in usd per share) $ 0.76 $ 3.68
Earnings per share - diluted (in usd per share) $ 0.76 $ 3.67
Weighted average shares outstanding    
Basic (in shares) 10,909 10,864
Diluted (in shares) 10,958 10,899
Cash dividends declared per share (in usd per share) $ 0 $ 1.65
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Statement of Comprehensive Income [Abstract]    
Net income $ 8,316 $ 39,968
Other comprehensive income, net of tax:    
Foreign currency translation 15 9
Unrealized losses on investment securities (241) 0
Other comprehensive income, net of tax (226) 9
Comprehensive income $ 8,090 $ 39,977
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current Assets    
Cash and cash equivalents $ 97,471 $ 94,440
Inventories 46,273 54,591
Investments 58,957 55,601
Income taxes, prepaid 5,471 8,727
Prepaid expenses and other current assets 11,412 10,670
Total current assets 219,584 224,029
Property, plant and equipment - net of accumulated depreciation 50,986 51,467
Right-of-use assets 14,536 15,645
Other assets 13,648 14,650
Deferred tax assets 4,005 4,117
TOTAL ASSETS 302,759 309,908
Current Liabilities    
Accounts payable and accrued expenses 71,229 86,415
Current lease obligations 5,958 5,885
Total current liabilities 77,187 92,300
Lease obligations, net of current lease obligations 14,611 16,127
Total liabilities 91,798 108,427
Stockholders' Equity    
Common stock, par value $0.001 per share: 20,000 shares authorized; 10,937 and 10,896 issued and outstanding at March 31, 2024 and December 31, 2023, respectively 11 11
Additional paid-in capital 27,963 26,573
Accumulated other comprehensive income 22 248
Retained earnings 182,965 174,649
Total stockholders' equity 210,961 201,481
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 302,759 $ 309,908
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) - $ / shares
shares in Thousands
Mar. 31, 2024
Dec. 31, 2023
Statement of Financial Position [Abstract]    
Common stock, par value (in usd per share) $ 0.001 $ 0.001
Common stock, authorized (in shares) 20,000 20,000
Common stock, issued (in shares) 10,937 10,896
Common stock, outstanding (in shares) 10,937 10,896
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Operating Activities    
Net income $ 8,316,000 $ 39,968,000
Adjustments to reconcile net income to cash provided by operating activities    
Depreciation and amortization 3,261,000 2,974,000
Non-cash lease expense 1,108,000 1,369,000
Share-based compensation 2,171,000 606,000
Loss on sale or disposal of property, plant and equipment 13,000 0
Realized gain on sale of investment securities (9,000) 0
Amortization of premium on investment securities (191,000) 0
Deferred income taxes 112,000 800,000
Unrealized gain on equity investment securities (2,437,000) 0
Change in operating assets and liabilities:    
Inventories 8,318,000 21,960,000
Prepaid expenses and other current assets (742,000) 6,563,000
Other assets 24,000 (887,000)
Accounts payable and accrued expenses (15,918,000) (21,897,000)
Prepaid income taxes 3,256,000 12,603,000
Net cash flow provided by operating activities 7,282,000 64,059,000
Investing Activities    
Purchase of investment securities (9,169,000) 0
Proceeds from sale and maturities of investment securities 8,235,000 0
Purchase of property and equipment (1,841,000) (2,115,000)
Net cash flow used in investing activities (2,775,000) (2,115,000)
Financing Activities    
Options exercised by directors 36,000 105,000
Net shares repurchased for taxes (817,000) (3,236,000)
Cash dividends paid to stockholders (710,000) (19,163,000)
Stock repurchases 0 (3,602,000)
Net cash flow used in financing activities (1,491,000) (25,896,000)
Foreign currency impact 15,000 9,000
Increase in cash and cash equivalents 3,031,000 36,057,000
Cash and cash equivalents - beginning of the period 94,440,000 87,691,000
Cash and cash equivalents - end of period 97,471,000 123,748,000
Supplemental disclosure of cash flow information:    
Income taxes refunded (100,000) (46,000)
Dividends included in accounts payable $ 697,000 $ 18,653,000
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (UNAUDITED) - USD ($)
shares in Thousands, $ in Thousands
Total
Common Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Income
Retained Earnings
Treasury Stock
Balance (in shares) at Dec. 31, 2022   10,928        
Balance at Dec. 31, 2022 $ 155,044 $ 11 $ 21,555 $ 24 $ 139,852 $ (6,398)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income 39,968       39,968  
Share-based compensation (in shares)   69        
Share-based compensation $ 606   606      
Options exercised by directors (in shares) 4 4        
Options exercised by directors $ 105   105      
Net shares repurchased for employee taxes (in shares)   (30)        
Net shares repurchased for employee taxes (3,236)   (3,236)      
Treasury stock from stock repurchases (3,602)         (3,602)
Treasury stock retired from stock repurchases (in shares)   (84)        
Treasury stock retired from stock repurchases 0       (10,000) 10,000
Other comprehensive income 9     9    
Cash dividends declared to stockholders (17,994)       (17,994)  
Balance (in shares) at Mar. 31, 2023   10,887        
Balance at Mar. 31, 2023 $ 170,900 $ 11 19,030 33 151,826 0
Balance (in shares) at Dec. 31, 2023 10,896 10,896        
Balance at Dec. 31, 2023 $ 201,481 $ 11 26,573 248 174,649 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income 8,316       8,316  
Share-based compensation (in shares)   59        
Share-based compensation $ 2,171   2,171      
Options exercised by directors (in shares) 1 1        
Options exercised by directors $ 36   36      
Net shares repurchased for employee taxes (in shares)   (19)        
Net shares repurchased for employee taxes (817)   (817)      
Other comprehensive income $ (226)     (226)    
Balance (in shares) at Mar. 31, 2024 10,937 10,937        
Balance at Mar. 31, 2024 $ 210,961 $ 11 $ 27,963 $ 22 $ 182,965 $ 0
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.24.1.u1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 3 Months Ended
Mar. 31, 2024
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation - The accompanying unaudited condensed consolidated financial statements of Medifast, Inc. and its wholly-owned subsidiaries (“Medifast,” the “Company,” “we,” “us,” or “our”) included herein have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim reporting and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Accordingly, certain information and notes that are normally required by GAAP have been condensed or omitted. However, in the opinion of management, all adjustments consisting of normal, recurring adjustments considered necessary for a fair presentation of the financial position and results of operations have been included and management believes the disclosures that are made are adequate to make the information presented not misleading. The condensed consolidated balance sheet at December 31, 2023 has been derived from the 2023 audited consolidated financial statements at that date included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (“2023 Form 10-K”).
The results of operations for the three months ended March 31, 2024 are not necessarily indicative of results that may be expected for the fiscal year ending December 31, 2024. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto, which are included in the 2023 Form 10-K.
Presentation of Financial Statements - The unaudited condensed consolidated financial statements included herein include the accounts of the Company. All significant intercompany accounts and transactions have been eliminated.
Use of Estimates - The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.
Accounting Pronouncements - Adopted in 2024
In June 2022, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update 2022-03—Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (“ASU 2023-03”) to (1) to clarify the guidance in Topic 820, Fair Value Measurement, when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security, (2) to amend a related illustrative example, and (3) to introduce new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value in accordance with Topic 820. For public business entities, the amendments in ASU 2022-03 are effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. Early adoption is permitted for both interim and annual financial statements that have not yet been issued or made available for issuance. The Company adopted the standard during the quarter ended March 31, 2024. The adoption of the standard had no material impact on the Company’s financial statements.
Recently Issued Accounting Pronouncements - Pending Adoption
In December 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update 2023-09—Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”) to enhance the transparency and decision usefulness of income tax disclosures, including jurisdictional information, by requiring consistent categories and greater disaggregation of information in the rate reconciliation and income taxes paid disclosures. ASU 2023-09 is effective for public business entities for annual periods beginning after December 15, 2024. Prospective application is required, though retrospective application is permitted. Entities are permitted to early adopt the standard. The Company did not early adopt for the 2024 reporting period. The Company is currently evaluating the impact of adopting ASU 2023-09 on its consolidated financial statements.
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.24.1.u1
INVENTORIES
 3 Months Ended
Mar. 31, 2024
Inventory Disclosure [Abstract]  
INVENTORIES INVENTORIES
Inventories consist principally of raw materials, non-food finished goods and packaged meal replacements held in the Company’s warehouses and outsourced distribution centers. Inventories are stated at the lower of cost or net realizable value, utilizing the first-in, first-out method. The cost of finished goods includes the cost of raw materials, packaging supplies, direct
and indirect labor, and other indirect manufacturing costs. On a quarterly basis, management reviews inventories for unsalable or obsolete inventories.
Inventories consisted of the following (in thousands):
March 31, 2024December 31, 2023
Raw materials$6,343$7,944
Packaging1,6731,962
Non-food finished goods2,8773,703
Finished goods36,76943,248
Reserve for obsolete inventory(1,389)(2,266)
Total$46,273$54,591
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.24.1.u1
EARNINGS PER SHARE
 3 Months Ended
Mar. 31, 2024
Earnings Per Share [Abstract]  
EARNINGS PER SHARE EARNINGS PER SHARE
Basic earnings per share (“EPS”) computations are calculated utilizing the weighted average number of shares of the Company’s common stock outstanding during the periods presented. Diluted EPS is calculated utilizing the weighted average number of shares of the Company’s common stock outstanding adjusted for the effect of dilutive common stock equivalents.
The following table sets forth the computation of basic and diluted EPS (in thousands, except per share data):
Three months ended March 31,
20242023
Numerator:
Net income$8,316 $39,968 
Denominator:
Weighted average shares of common stock outstanding10,909 10,864 
Effect of dilutive common stock equivalents49 35 
Weighted average shares of common stock outstanding10,958 10,899 
Earnings per share - basic$0.76 $3.68 
Earnings per share - diluted$0.76 $3.67 
The calculation of diluted EPS excluded 51 thousand and 13 thousand antidilutive restricted stock awards for the three months ended March 31, 2024 and 2023, respectively.
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.24.1.u1
SHARE-BASED COMPENSATION
 3 Months Ended
Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]  
SHARE-BASED COMPENSATION SHARE-BASED COMPENSATION
Stock Options
The Company has issued non-qualified and incentive stock options to employees and non-employee directors. The fair value of these options was estimated on the date of grant using the Black-Scholes option pricing model, which required estimates of the expected term of the option, the risk-free interest rate, the expected volatility of the price of the Company’s common stock, and dividend yield. Options outstanding as of March 31, 2024 generally vested over a period of 3 years and expire 10 years from the date of grant. The exercise price of these options is $66.68. Due to the Company’s lack of option exercise history on the date of grant, the expected term was calculated using the simplified method defined as the midpoint between the vesting period and the contractual term of each option. The risk-free interest rate was based on the U.S. Treasury yield curve in effect on the date of grant that most closely corresponds to the expected term of the option. The expected volatility was based on the historical volatility of the Company’s common stock over the period of time equivalent to the expected term for each award. The
dividend yield was computed as the annualized dividend rate at the grant date divided by the strike price of the stock option. For the three months ended March 31, 2024 and 2023, the Company did not grant stock options.
The following table is a summary of our stock option activity (in thousands, except per share data):
Three months ended March 31,
20242023
AwardsWeighted-Average Exercise PriceAwardsWeighted-Average Exercise Price
Outstanding at beginning of period25 $62.20 33 $54.98 
Exercised(1)27.68 (4)27.18 
Forfeited(2)26.52 — — 
Outstanding at end of the period22 $66.68 29 $58.65 
Exercisable at end of the period22 $66.68 29 $58.65 
As of March 31, 2024, the weighted-average remaining contractual life for both the outstanding stock options and exercisable stock options was 3.9 years with an aggregate intrinsic value of $0. There was no unrecognized compensation on the awards for the period ended March 31, 2024. For the three months ended March 31, 2024 and 2023, the Company received $36 thousand and $105 thousand in cash proceeds from the exercise of stock options, respectively. The total intrinsic value for stock options exercised during the three months ended March 31, 2024 and 2023 was $15 thousand and $328 thousand, respectively.
Restricted Stock
The Company has issued restricted stock to employees and non-employee directors generally with vesting terms up to 3 years after the date of grant. The fair value of the restricted stock is equal to the market price of the Company’s common stock on the date of grant. Expense for restricted stock is amortized ratably over the vesting period.
The following table summarizes our restricted stock activity (in thousands, except per share data):
Three months ended March 31,
20242023
SharesWeighted-Average Grant Date Fair ValueSharesWeighted-Average Grant Date Fair Value
Outstanding at beginning of period114 $127.87 60 $187.94 
Granted162 35.75 67 102.83 
Vested(34)139.19 (22)163.81 
Forfeited— — — 190.76 
Outstanding at end of the period242 $64.55 105 $138.33 
The Company withheld approximately 11 thousand shares and 9 thousand shares of the Company’s common stock to cover minimum tax liability withholding obligations upon the vesting of shares of restricted stock for the three months ended March 31, 2024 and 2023, respectively. The total fair value of restricted stock awards vested during the three months ended March 31, 2024 and 2023 was $1.3 million and $2.4 million, respectively.
Market and Performance-based Share Awards
The Company has issued market and performance-based share awards in 2022 and 2023 and performance-based share awards in 2020, 2021, and 2024 to certain key executives who were granted deferred shares and may earn between 0% and 250% of the target number depending upon both the Company’s total stockholder return (“TSR”), for those with market conditions, and the Company’s performance against predetermined performance goals over a three-year performance period after the date of grant. Market and performance-based share awards that are tied to the Company’s TSR are valued using the Monte Carlo method and are recognized ratably as expense over the award’s performance period. The fair value of the performance-based share awards
is equal to the market price of the Company’s common stock on the date of grant adjusted by expected level of achievement over the performance period. Expense for performance-based share awards is amortized ratably over the performance period. In the event that management determines that the Company will not reach the lower threshold of the predetermined performance goals established in the grant agreement, any previously recognized expense is reversed in the period in which such a determination is made. Management determined that the market and performance-based share awards granted in 2022 would not reach the lower threshold of the predetermined performance goal resulting in a $1.4 million decrease in the Company’s share-based compensation expense for the three months ended March 31, 2023.
The Company withheld approximately 8 thousand shares and 21 thousand shares of the Company’s common stock to cover minimum tax liability withholding obligations upon the vesting of shares of market and performance-based share awards for the years ended March 31, 2024 and 2023, respectively. The total fair value of performance-based share awards issued during the three months ended March 31, 2024 was $1.3 million and the total fair value of market and performance-based share awards issued during the three months ended March 31, 2023 was $5.3 million.
Share-based compensation expense is recorded in selling, general, and administrative expense in the accompanying Condensed Consolidated Statements of Income. The total expense during the three months ended March 31, 2024 and 2023 are as follows (in thousands):
Three months ended March 31,
20242023
SharesShare-Based Compensation ExpenseSharesShare-Based Compensation Expense
Options and restricted stock264 $1,600 134 $1,226 
Performance-based share awards granted in 2024
117 77 — — 
Market and performance-based share awards granted in 202347 482 47 79 
Market and performance-based share awards granted in 202224 — 25 (1,388)
Performance-based share awards granted in 202114 12 15 640 
Performance-based share awards granted in 2020— — 4 49 
Total share-based compensation466 $2,171 225 $606 
The total income tax expense recognized in the accompanying Condensed Consolidated Statements of Income for restricted stock awards was $0.4 million for the three months ended March 31, 2024 and a benefit of $0.1 million for the three months ended March 31, 2023.
There was $8.8 million of total unrecognized compensation cost related to restricted stock awards as of March 31, 2024, which is expected to be recognized over a weighted-average period of 2.3 years. There was $7.5 million of unrecognized compensation costs related to the 131 thousand performance-based shares and 71 thousand market and performance-based shares presented in the table above as of March 31, 2024, which is expected to be recognized over a weighted-average period of 2.1 years.
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.24.1.u1
LEASES
 3 Months Ended
Mar. 31, 2024
Leases [Abstract]  
LEASES LEASES
Operating Leases
The Company has operating leases for office and warehouse space and certain equipment. In certain of the Company’s lease agreements, the rental payments are adjusted periodically based on defined terms within the lease. The Company did not have any finance leases as of March 31, 2024 and 2023, respectively, or for the three-month periods then ended, respectively.
Our leases relating to office and warehouse space have lease terms of 65 months to 102 months. Our leases relating to equipment have lease terms of 36 months, with certain of them having automatic renewal clauses.
The Company’s warehouse agreements also contain non-lease components, in the form of payments towards variable logistics services and labor charges, which the Company is obligated to pay based on the services consumed by it. Such amounts are not included in the measurement of the lease liability but are recognized as expenses when they are incurred.
The operating lease expense was $1.2 million and $1.5 million for the three months ended March 31, 2024 and 2023, respectively.
Supplemental cash flow information related to the Company’s operating leases was as follows (in thousands):
Three months ended March 31,
20242023
Cash paid for amounts included in the measurements of lease liabilities
Operating cash flow used in operating leases$1,563 $1,804 
Right-of-use assets obtained in exchange for lease obligations
Operating leases$— $— 
As of March 31, 2024, the weighted average remaining lease term was 3 years, 7 months and the weighted average discount rate was 2.30%.
The following table presents the maturity of the Company’s operating lease liabilities as of March 31, 2024 (in thousands):
2024 (excluding the three months ended March 31, 2024)
$4,749 
20256,462 
20264,783 
20272,553 
20282,618 
Thereafter240 
Total lease payments$21,405 
Less: imputed interest(836)
Total $20,569 
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.24.1.u1
ACCUMULATED OTHER COMPREHENSIVE INCOME
 3 Months Ended
Mar. 31, 2024
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]  
ACCUMULATED OTHER COMPREHENSIVE INCOME ACCUMULATED OTHER COMPREHENSIVE INCOME
The following table sets forth the components of accumulated other comprehensive income, net of tax where applicable (in thousands):
March 31, 2024December 31, 2023
Foreign currency translation$(33)$(48)
Unrealized gains on investments
55296
Accumulated other comprehensive income$22$248
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.24.1.u1
INVESTMENTS
 3 Months Ended
Mar. 31, 2024
Investments, All Other Investments [Abstract]  
INVESTMENTS INVESTMENTS
Certain financial assets and liabilities are accounted for at fair value, which is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The following fair value hierarchy prioritizes the inputs used to measure fair value:
Level 1 – Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an on-going basis.
Level 2 – Pricing inputs are other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date. Level 2 includes those financial instruments that are valued using models or other valuation methodologies.
Level 3 – Pricing inputs include significant inputs that are generally less observable from objective sources. These inputs may be used with internally developed methodologies that result in management’s best estimate of fair value from the perspective of a market participant.
The following tables present the Company’s cash and financial assets that are measured at fair value on a recurring basis for each of the hierarchy levels (in thousands):
March 31, 2024
Cost
Unrealized Gains (Losses)
Accrued Interest
Estimated
Fair Value
Cash & Cash
Equivalents		Investment
Securities
Cash and cash equivalents, excluding money market accounts
$92,291$—$—$92,291$92,291$—
Level 1:
Money market accounts5,180——5,1805,180—
Government & agency securities15,454(14)6415,504—15,504
Equity securities10,0002,587—12,587—12,587
30,6342,5736433,2715,18028,091
Level 2:
Corporate bonds
30,41218227230,866—30,866
Total$153,337$2,755$336$156,428$97,471$58,957
December 31, 2023
CostUnrealized
Gains		Accrued
Interest		Estimated
Fair Value		Cash & Cash
Equivalents		Investment
Securities
Cash and cash equivalents, excluding money market accounts$88,778$—$—$88,778$88,778$—
Level 1:
Money market accounts5,662——5,6625,662—
Government & agency securities15,2821264015,448—15,448
Equity securities10,000150—10,150—10,150
30,9442764031,2605,66225,598
Level 2:
Corporate bonds29,44029327030,003—30,003
Total$149,162$569$310$150,041$94,440$55,601
The Company had $9 thousand of realized gains for the three months ended March 31, 2024 and no realized gains or losses for the three months ended March 31, 2023.
During the fourth quarter of 2023, the Company entered into an agreement to purchase common stock of LifeMD, Inc (Nasdaq: LFMD), a leading provider of virtual primary care, and made a $10 million payment to LifeMD for the purchase of the shares. The securities are subject to a registration rights agreement which stipulates that the registration of the securities is to be made as soon as practicable, but not later than 90 days, following written demand by the Company. Written demand has been made, and the securities registration remained in process as of March 31, 2024. In addition, the shares are subject to a 180-day lock-up period from the closing date of the agreement, December 11, 2023. The fair value of the investment is recorded within the
investment securities of the consolidated balance sheet. The gains related to the Company’s LifeMD investment for the three months ended March 31, 2024 and 2023 are summarized in the table below (in thousands):
March 31, 2024March 31, 2023
Net gains recognized during the period on equity securities
$2,437 $— 
Less: Net gains recognized on equity securities sold
— — 
Unrealized gains recognized during the reporting period on equity securities still held at the reporting date
$2,437 $— 
The Company concurrently entered into an agreement in which LifeMD would provide services to stand-up the collaboration between LifeMD and the Company. The agreement stipulated an initial milestone payment of $5 million due upon execution of the agreement for these services. The services under the initial milestone were completed prior to December 31, 2023, and this amount was included in the Company’s selling, general, and administrative expenses on the consolidated statement of income for the quarter ended December 31, 2023. The Company made a second milestone payment under the agreement of $2.5 million on March 18, 2024. Of the total $2.5 million second milestone payment, $1.3 million was recognized within selling, general, and administrative expenses for services performed by LifeMD for the quarter ended March 31, 2024, with the remaining $1.2 million expected to be recognized in the second quarter. The final milestone payment of $2.5 million is expected to be made in the second quarter of 2024, with the expense being recognized in the consolidated statement of income as the services are rendered.
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.24.1.u1
DEBT
 3 Months Ended
Mar. 31, 2024
Debt Disclosure [Abstract]  
DEBT DEBT
Credit Agreement
On April 13, 2021, the Company and certain of its subsidiaries (collectively, the “Guarantors”) entered into a credit agreement (the “Credit Agreement”) among the Company, the Guarantors, the lenders party thereto and Citibank, N.A., in its capacity as administrative agent. On May 31, 2022, the Credit Agreement was amended to increase the borrowing capacity and convert the interest rate to be based on Secured Overnight Financing Rate (“SOFR”), from London Inter-Bank Offered Rate (LIBOR) (the “Amended Credit Agreement”). The Amended Credit Agreement provides for a $225.0 million senior secured revolving credit facility with a $20.0 million letter of credit sublimit. The Amended Credit Agreement also provides for an uncommitted incremental facility that permits the Company, subject to certain conditions, to increase the senior secured revolving credit facility by up to $100.0 million. The Amended Credit Agreement matures on April 13, 2026.
The Company’s obligations under the Amended Credit Agreement are guaranteed by the Guarantors. The obligations of the Company and the Guarantors are secured by first-priority liens on substantially all of the assets of the Company and the Guarantors, subject to certain exceptions.
Under the Amended Credit Agreement, the Company will pay to the administrative agent for the account of each revolving lender a commitment fee on a quarterly basis based on amounts committed but unused under the revolving facility from 0.20% to 0.40% per annum depending on the Company’s Total Net Leverage Ratio (as defined in the Amended Credit Agreement). The Company is also obligated to pay the administrative agent customary fees for credit facilities of this size and type.
Revolving borrowings under the Amended Credit Agreement bear interest at a rate per annum equal to (i) the Term SOFR Rate for the interest period plus the Applicable Rate (as defined in the Amended Credit Agreement) based on the Company’s Total Net Leverage Ratio or (ii) the Alternate Base Rate (as defined in the Amended Credit Agreement) as in effect from time to time plus the Applicable Rate based on the Company’s Total Net Leverage Ratio. As of March 31, 2024, the Applicable Rate for Term SOFR Loans is 1.25% per annum and the Applicable Rate for ABR Loans is 0.25% per annum. SOFR based loans also include a Credit Spread Adjustment based on the duration of the borrowing.
The Amended Credit Agreement contains affirmative and negative covenants customarily applicable to senior secured credit facilities, including covenants that, among other things, limit or restrict the ability of the Company and its subsidiaries, subject to negotiated exceptions, to incur additional indebtedness and additional liens on their assets, engage in mergers or acquisitions or dispose of assets, pay dividends or make other distributions, voluntarily prepay other indebtedness, enter into transactions with affiliated persons, make investments and change the nature of their businesses. The Amended Credit Agreement also contains customary events of default, subject to thresholds and grace periods, including, among others, payment default, covenant default, cross default to other material indebtedness and judgment default. In addition, the Amended Credit
Agreement requires the Company to maintain a Total Net Leverage Ratio of no more than 2.75 to 1.00 and an Interest Coverage Ratio of at least 3.50 to 1.00.
The Company had no borrowings outstanding under the Amended Credit Agreement, inclusive of the credit facility and letter of credit sublimit, as of March 31, 2024 and was in compliance with all covenants.
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.24.1.u1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
 3 Months Ended
Mar. 31, 2024
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation - The accompanying unaudited condensed consolidated financial statements of Medifast, Inc. and its wholly-owned subsidiaries (“Medifast,” the “Company,” “we,” “us,” or “our”) included herein have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim reporting and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Accordingly, certain information and notes that are normally required by GAAP have been condensed or omitted. However, in the opinion of management, all adjustments consisting of normal, recurring adjustments considered necessary for a fair presentation of the financial position and results of operations have been included and management believes the disclosures that are made are adequate to make the information presented not misleading. The condensed consolidated balance sheet at December 31, 2023 has been derived from the 2023 audited consolidated financial statements at that date included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (“2023 Form 10-K”).
The results of operations for the three months ended March 31, 2024 are not necessarily indicative of results that may be expected for the fiscal year ending December 31, 2024. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto, which are included in the 2023 Form 10-K.
Presentation of Financial Statements
Presentation of Financial Statements - The unaudited condensed consolidated financial statements included herein include the accounts of the Company. All significant intercompany accounts and transactions have been eliminated.
Use of Estimates
Use of Estimates - The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.
Accounting Pronouncements and Recently Issued Accounting Pronouncements
Accounting Pronouncements - Adopted in 2024
In June 2022, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update 2022-03—Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (“ASU 2023-03”) to (1) to clarify the guidance in Topic 820, Fair Value Measurement, when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security, (2) to amend a related illustrative example, and (3) to introduce new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value in accordance with Topic 820. For public business entities, the amendments in ASU 2022-03 are effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. Early adoption is permitted for both interim and annual financial statements that have not yet been issued or made available for issuance. The Company adopted the standard during the quarter ended March 31, 2024. The adoption of the standard had no material impact on the Company’s financial statements.
Recently Issued Accounting Pronouncements - Pending Adoption
In December 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update 2023-09—Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”) to enhance the transparency and decision usefulness of income tax disclosures, including jurisdictional information, by requiring consistent categories and greater disaggregation of information in the rate reconciliation and income taxes paid disclosures. ASU 2023-09 is effective for public business entities for annual periods beginning after December 15, 2024. Prospective application is required, though retrospective application is permitted. Entities are permitted to early adopt the standard. The Company did not early adopt for the 2024 reporting period. The Company is currently evaluating the impact of adopting ASU 2023-09 on its consolidated financial statements.
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.24.1.u1
INVENTORIES (Tables)
 3 Months Ended
Mar. 31, 2024
Inventory Disclosure [Abstract]  
Schedule of Inventories
Inventories consisted of the following (in thousands):
March 31, 2024December 31, 2023
Raw materials$6,343$7,944
Packaging1,6731,962
Non-food finished goods2,8773,703
Finished goods36,76943,248
Reserve for obsolete inventory(1,389)(2,266)
Total$46,273$54,591
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.24.1.u1
EARNINGS PER SHARE (Tables)
 3 Months Ended
Mar. 31, 2024
Earnings Per Share [Abstract]  
Schedule of the Computation of Basic and Diluted EPS
The following table sets forth the computation of basic and diluted EPS (in thousands, except per share data):
Three months ended March 31,
20242023
Numerator:
Net income$8,316 $39,968 
Denominator:
Weighted average shares of common stock outstanding10,909 10,864 
Effect of dilutive common stock equivalents49 35 
Weighted average shares of common stock outstanding10,958 10,899 
Earnings per share - basic$0.76 $3.68 
Earnings per share - diluted$0.76 $3.67 
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.24.1.u1
SHARE-BASED COMPENSATION (Tables)
 3 Months Ended
Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Schedule of Stock Option Activity
The following table is a summary of our stock option activity (in thousands, except per share data):
Three months ended March 31,
20242023
AwardsWeighted-Average Exercise PriceAwardsWeighted-Average Exercise Price
Outstanding at beginning of period25 $62.20 33 $54.98 
Exercised(1)27.68 (4)27.18 
Forfeited(2)26.52 — — 
Outstanding at end of the period22 $66.68 29 $58.65 
Exercisable at end of the period22 $66.68 29 $58.65 
Schedule of Restricted Stock Activity
The following table summarizes our restricted stock activity (in thousands, except per share data):
Three months ended March 31,
20242023
SharesWeighted-Average Grant Date Fair ValueSharesWeighted-Average Grant Date Fair Value
Outstanding at beginning of period114 $127.87 60 $187.94 
Granted162 35.75 67 102.83 
Vested(34)139.19 (22)163.81 
Forfeited— — — 190.76 
Outstanding at end of the period242 $64.55 105 $138.33 
Schedule of Share-based Compensation Expense The total expense during the three months ended March 31, 2024 and 2023 are as follows (in thousands):
Three months ended March 31,
20242023
SharesShare-Based Compensation ExpenseSharesShare-Based Compensation Expense
Options and restricted stock264 $1,600 134 $1,226 
Performance-based share awards granted in 2024
117 77 — — 
Market and performance-based share awards granted in 202347 482 47 79 
Market and performance-based share awards granted in 202224 — 25 (1,388)
Performance-based share awards granted in 202114 12 15 640 
Performance-based share awards granted in 2020— — 4 49 
Total share-based compensation466 $2,171 225 $606 
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.24.1.u1
LEASES (Tables)
 3 Months Ended
Mar. 31, 2024
Leases [Abstract]  
Schedule of Supplemental Cash Flow Information
Supplemental cash flow information related to the Company’s operating leases was as follows (in thousands):
Three months ended March 31,
20242023
Cash paid for amounts included in the measurements of lease liabilities
Operating cash flow used in operating leases$1,563 $1,804 
Right-of-use assets obtained in exchange for lease obligations
Operating leases$— $— 
Schedule of Maturity of Company's Operating Lease Liabilities
The following table presents the maturity of the Company’s operating lease liabilities as of March 31, 2024 (in thousands):
2024 (excluding the three months ended March 31, 2024)
$4,749 
20256,462 
20264,783 
20272,553 
20282,618 
Thereafter240 
Total lease payments$21,405 
Less: imputed interest(836)
Total $20,569 
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.24.1.u1
ACCUMULATED OTHER COMPREHENSIVE INCOME (Tables)
 3 Months Ended
Mar. 31, 2024
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]  
Schedule of Accumulated Other Comprehensive Income
The following table sets forth the components of accumulated other comprehensive income, net of tax where applicable (in thousands):
March 31, 2024December 31, 2023
Foreign currency translation$(33)$(48)
Unrealized gains on investments
55296
Accumulated other comprehensive income$22$248
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.24.1.u1
INVESTMENTS (Tables)
 3 Months Ended
Mar. 31, 2024
Investments, All Other Investments [Abstract]  
Schedule of Cash and Financial Assets Measured at Fair Value on a Recurring Basis
The following tables present the Company’s cash and financial assets that are measured at fair value on a recurring basis for each of the hierarchy levels (in thousands):
March 31, 2024
Cost
Unrealized Gains (Losses)
Accrued Interest
Estimated
Fair Value
Cash & Cash
Equivalents		Investment
Securities
Cash and cash equivalents, excluding money market accounts
$92,291$—$—$92,291$92,291$—
Level 1:
Money market accounts5,180——5,1805,180—
Government & agency securities15,454(14)6415,504—15,504
Equity securities10,0002,587—12,587—12,587
30,6342,5736433,2715,18028,091
Level 2:
Corporate bonds
30,41218227230,866—30,866
Total$153,337$2,755$336$156,428$97,471$58,957
December 31, 2023
CostUnrealized
Gains		Accrued
Interest		Estimated
Fair Value		Cash & Cash
Equivalents		Investment
Securities
Cash and cash equivalents, excluding money market accounts$88,778$—$—$88,778$88,778$—
Level 1:
Money market accounts5,662——5,6625,662—
Government & agency securities15,2821264015,448—15,448
Equity securities10,000150—10,150—10,150
30,9442764031,2605,66225,598
Level 2:
Corporate bonds29,44029327030,003—30,003
Total$149,162$569$310$150,041$94,440$55,601
Schedule of Investment Gains The gains related to the Company’s LifeMD investment for the three months ended March 31, 2024 and 2023 are summarized in the table below (in thousands):
March 31, 2024March 31, 2023
Net gains recognized during the period on equity securities
$2,437 $— 
Less: Net gains recognized on equity securities sold
— — 
Unrealized gains recognized during the reporting period on equity securities still held at the reporting date
$2,437 $— 
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.24.1.u1
INVENTORIES (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Inventory Disclosure [Abstract]    
Raw materials $ 6,343 $ 7,944
Packaging 1,673 1,962
Non-food finished goods 2,877 3,703
Finished goods 36,769 43,248
Reserve for obsolete inventory (1,389) (2,266)
Total $ 46,273 $ 54,591
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.24.1.u1
EARNINGS PER SHARE - Computation of Basic and Diluted EPS (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Numerator:    
Net income $ 8,316 $ 39,968
Denominator:    
Weighted average shares of common stock outstanding (in shares) 10,909 10,864
Effect of dilutive common stock equivalents (in shares) 49 35
Weighted average shares of common stock outstanding (in shares) 10,958 10,899
Earnings per share - basic (in usd per share) $ 0.76 $ 3.68
Earnings per share - diluted (in usd per share) $ 0.76 $ 3.67
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.24.1.u1
EARNINGS PER SHARE - Narrative (Details) - shares
shares in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Restricted Stock    
Anti-dilutive awards (in shares) 51 13
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.24.1.u1
SHARE-BASED COMPENSATION - Narrative (Details) - USD ($)
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Exercise price (in usd per share) $ 66.68 $ 58.65 $ 62.20 $ 54.98
Awards granted (in shares) 0 0    
Weighted-average remaining contractual life of options outstanding (in years) 3 years 10 months 24 days      
Weighted-average remaining contractual life of options exercisable (in years) 3 years 10 months 24 days      
Aggregate intrinsic value of options outstanding $ 0      
Aggregate intrinsic value of options exercisable 0      
Options, unrecognized compensation costs 0      
Options exercised by directors 36,000 $ 105,000    
Intrinsic value of options exercised 15,000 328,000    
Decrease in share-based payment arrangement, expense $ (2,171,000) $ (606,000)    
Stock Options        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Award vesting period (in years) 3 years      
Award expiration period (in years) 10 years      
Restricted Stock        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Award vesting period (in years) 3 years      
Shares withheld for employee taxes 11,000 9,000    
Share-based compensation arrangement, fair value of awards vested $ 1,300,000 $ 2,400,000    
Total income tax benefit recognized related to restricted stock awards $ (400,000) $ 100,000    
Compensation cost recognition weighted average period (in years) 2 years 3 months 18 days      
Shares granted in period 162,000 67,000    
Unrecognized compensation costs $ 8,800,000      
Market and performance-based share awards        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Shares withheld for employee taxes 8,000 21,000    
Share-based compensation arrangement, fair value of awards vested   $ 5,300,000    
Performance period (in years) 3 years      
Compensation cost recognition weighted average period (in years) 2 years 1 month 6 days      
Shares granted in period 71,000      
Unrecognized compensation costs $ 7,500,000      
Market and performance-based share awards | Granted In 2022        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Decrease in share-based payment arrangement, expense $ 0 $ 1,388,000    
Market and performance-based share awards | Minimum        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Additional shares earned (as a percent) 0.00%      
Market and performance-based share awards | Maximum        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Additional shares earned (as a percent) 250.00%      
Performance-Based Shares        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Share-based compensation arrangement, fair value of awards vested $ 1,300,000      
Shares granted in period 131,000      
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.24.1.u1
SHARE-BASED COMPENSATION - Stock Options Activity (Details) - $ / shares
shares in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Awards    
Shares, Outstanding at beginning of period (in shares) 25 33
Shares, Exercised (in shares) (1) (4)
Shares, Forfeited (in shares) (2) 0
Shares, Outstanding at end of the period (in shares) 22 29
Shares, Exercisable at end of the period (in shares) 22 29
Weighted-Average Exercise Price    
Weighted-Average Exercise Price, Outstanding at beginning of period (in usd per share) $ 62.20 $ 54.98
Weighted-Average Exercise Price, Exercised (in usd per share) 27.68 27.18
Weighted-Average Exercise Price, Forfeited (in usd per share) 26.52 0
Weighted-Average Exercise Price, Outstanding at beginning of period (in usd per share) 66.68 58.65
Weighted-Average Exercise Price, Exercisable at end of the period (in usd per share) $ 66.68 $ 58.65
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.24.1.u1
SHARE-BASED COMPENSATION - Restricted Stock Activity (Details) - Restricted Stock - $ / shares
shares in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Shares    
Outstanding at beginning of period (in shares) 114 60
Granted (in shares) 162 67
Vested (in shares) (34) (22)
Forfeited (in shares) 0 0
Outstanding at end of period (in shares) 242 105
Weighted-Average Grant Date Fair Value    
Outstanding at beginning of period (in usd per share) $ 127.87 $ 187.94
Granted (in usd per share) 35.75 102.83
Vested (in usds per share) 139.19 163.81
Forfeited (in usd per share) 0 190.76
Outstanding at beginning of period (in usd per share) $ 64.55 $ 138.33
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.24.1.u1
SHARE-BASED COMPENSATION - Summary of Performance-based Share Awards (Details) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Shares 466 225
Share-Based Compensation Expense $ 2,171 $ 606
Options and restricted stock    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Shares 264 134
Share-Based Compensation Expense $ 1,600 $ 1,226
Performance-based share awards | Granted In 2024    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Shares 117  
Share-Based Compensation Expense $ 77  
Performance-based share awards | Granted In 2021    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Shares 14 15
Share-Based Compensation Expense $ 12 $ 640
Performance-based share awards | Granted In 2020    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Shares 0 4
Share-Based Compensation Expense $ 0 $ 49
Market and performance-based share awards | Granted In 2023    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Shares 47 47
Share-Based Compensation Expense $ 482 $ 79
Market and performance-based share awards | Granted In 2022    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Shares 24 25
Share-Based Compensation Expense $ 0 $ (1,388)
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.24.1.u1
LEASES - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Lessee, Lease, Description [Line Items]    
Operating lease expense $ 1.2 $ 1.5
Weighted average remaining lease term 3 years 7 months  
Weighted average discount rate (as a percent) 2.30%  
Minimum | Operating Lease Arrangement for Real Estate    
Lessee, Lease, Description [Line Items]    
Lease term (in months) 65 months  
Minimum | Operating Lease Arrangement for Equipment    
Lessee, Lease, Description [Line Items]    
Lease term (in months) 36 months  
Maximum | Operating Lease Arrangement for Real Estate    
Lessee, Lease, Description [Line Items]    
Lease term (in months) 102 months  
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.24.1.u1
LEASES - Supplemental Cash Flow Information (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Leases [Abstract]    
Operating cash flow used in operating leases $ 1,563 $ 1,804
Operating leases $ 0 $ 0
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.24.1.u1
LEASES - Future Minimum Lease Commitments (Details)
$ in Thousands
Mar. 31, 2024
USD ($)
Lessee, Operating Lease, Liability, Payment, Due [Abstract]  
2024 (excluding the three months ended March 31, 2024) $ 4,749
2025 6,462
2026 4,783
2027 2,553
2028 2,618
Thereafter 240
Total lease payments 21,405
Less: imputed interest (836)
Total $ 20,569
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.24.1.u1
ACCUMULATED OTHER COMPREHENSIVE INCOME (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]    
Foreign currency translation $ (33) $ (48)
Unrealized gains on investments 55 296
Accumulated other comprehensive income $ 22 $ 248
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.24.1.u1
INVESTMENTS - Cash and Financial Assets Measured at Fair Value on a Recurring Basis (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Cash And Cash Equivalents And Marketable securities [Line Items]    
Cost, Cash and cash equivalents, excluding money market accounts $ 92,291 $ 88,778
Estimated Fair Value, Cash and cash equivalents 92,291 88,778
Unrealized Gains, Investment securities 2,755 569
Accrued Interest, Investment securities 336 310
Cost 153,337 149,162
Estimated Fair Value 156,428 150,041
Cash & Cash Equivalents    
Cash And Cash Equivalents And Marketable securities [Line Items]    
Estimated Fair Value, Cash and cash equivalents 92,291 88,778
Estimated Fair Value 97,471 94,440
Investment Securities    
Cash And Cash Equivalents And Marketable securities [Line Items]    
Estimated Fair Value 58,957 55,601
Level 1    
Cash And Cash Equivalents And Marketable securities [Line Items]    
Cost, Equity securities 10,000 10,000
Unrealized Gains, Equity securities 2,587 150
Accrued Interest, Equity securities 0 0
Estimated Fair Value, Equity securities 12,587 10,150
Cost, Investment securities 30,634 30,944
Unrealized Gains, Investment securities 2,573 276
Accrued Interest, Investment securities 64 40
Estimated Fair Value, Investment securities 33,271 31,260
Level 1 | Cash & Cash Equivalents    
Cash And Cash Equivalents And Marketable securities [Line Items]    
Estimated Fair Value, Equity securities 0 0
Estimated Fair Value, Investment securities 5,180 5,662
Level 1 | Investment Securities    
Cash And Cash Equivalents And Marketable securities [Line Items]    
Estimated Fair Value, Equity securities 12,587 10,150
Estimated Fair Value, Investment securities 28,091 25,598
Level 1 | Money market accounts    
Cash And Cash Equivalents And Marketable securities [Line Items]    
Cost, Debt Securities 5,180 5,662
Debt Securities, Available-for-Sale, Current 5,180 5,662
Level 1 | Money market accounts | Cash & Cash Equivalents    
Cash And Cash Equivalents And Marketable securities [Line Items]    
Debt Securities, Available-for-Sale, Current 5,180 5,662
Level 1 | Money market accounts | Investment Securities    
Cash And Cash Equivalents And Marketable securities [Line Items]    
Debt Securities, Available-for-Sale, Current 0 0
Level 1 | Government & agency securities    
Cash And Cash Equivalents And Marketable securities [Line Items]    
Cost, Debt Securities 15,454 15,282
Debt Securities, Available-for-Sale, Current 15,504 15,448
Level 1 | Government & agency securities | Unrealized Gains (Losses)    
Cash And Cash Equivalents And Marketable securities [Line Items]    
Unrealized Gains   126
Unrealized Loss (14)  
Level 1 | Government & agency securities | Accrued Interest    
Cash And Cash Equivalents And Marketable securities [Line Items]    
Unrealized Gains 64 40
Level 1 | Government & agency securities | Cash & Cash Equivalents    
Cash And Cash Equivalents And Marketable securities [Line Items]    
Debt Securities, Available-for-Sale, Current 0 0
Level 1 | Government & agency securities | Investment Securities    
Cash And Cash Equivalents And Marketable securities [Line Items]    
Debt Securities, Available-for-Sale, Current 15,504 15,448
Level 2 | Corporate bonds    
Cash And Cash Equivalents And Marketable securities [Line Items]    
Cost, Debt Securities 30,412 29,440
Debt Securities, Available-for-Sale, Current 30,866 30,003
Level 2 | Corporate bonds | Unrealized Gains (Losses)    
Cash And Cash Equivalents And Marketable securities [Line Items]    
Unrealized Gains 182 293
Level 2 | Corporate bonds | Accrued Interest    
Cash And Cash Equivalents And Marketable securities [Line Items]    
Unrealized Gains 272 270
Level 2 | Corporate bonds | Cash & Cash Equivalents    
Cash And Cash Equivalents And Marketable securities [Line Items]    
Debt Securities, Available-for-Sale, Current 0 0
Level 2 | Corporate bonds | Investment Securities    
Cash And Cash Equivalents And Marketable securities [Line Items]    
Debt Securities, Available-for-Sale, Current $ 30,866 $ 30,003
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.24.1.u1
INVESTMENTS - Investment Gains (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Text Block [Abstract]    
Net gains recognized during the period on equity securities $ 2,437 $ 0
Less: Net gains recognized on equity securities sold 0 0
Unrealized gains recognized during the reporting period on equity securities still held at the reporting date $ 2,437 $ 0
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.24.1.u1
INVESTMENTS - Narrative (Details) - USD ($)
 3 Months Ended 12 Months Ended
Mar. 18, 2024
Jun. 30, 2024
Mar. 31, 2024
Dec. 31, 2023
Mar. 31, 2023
Dec. 31, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Realized gain     $ 9,000   $ 0  
LifeMD            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Investments made       $ 10,000,000    
Collaborative Arrangement | LifeMD            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Milestone payment $ 2,500,000         $ 5,000,000
Collaborative Arrangement | LifeMD | Selling, General and Administrative Expenses            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Milestone payment     $ 1,300,000      
Collaborative Arrangement | LifeMD | Forecast | Subsequent Event | Selling, General and Administrative Expenses            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Milestone payment   $ 1,200,000        
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.24.1.u1
DEBT (Details) - Credit Agreement
 3 Months Ended
Apr. 13, 2021
USD ($)
Mar. 31, 2024
USD ($)
Debt Instrument [Line Items]    
Maximum total net leverage ratio 2.75  
Minimum interest coverage ratio 3.50  
Borrowings outstanding   $ 0
SOFR    
Debt Instrument [Line Items]    
Basis spread on variable rate (as a percent)   1.25%
Base Rate    
Debt Instrument [Line Items]    
Basis spread on variable rate (as a percent)   0.25%
Minimum    
Debt Instrument [Line Items]    
Commitment fee (as a percent) 0.20%  
Maximum    
Debt Instrument [Line Items]    
Commitment fee (as a percent) 0.40%  
Revolving Credit Facility    
Debt Instrument [Line Items]    
Maximum borrowing capacity $ 225,000,000  
Letter of Credit    
Debt Instrument [Line Items]    
Maximum borrowing capacity 20,000,000  
Uncommitted Incremental Facility    
Debt Instrument [Line Items]    
Maximum borrowing capacity $ 100,000,000  
EXCEL 48 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 49 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 50 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 52 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 115 218 1 false 41 0 false 4 false false R1.htm 0000001 - Document - Cover Sheet http://www.medifast1.com/role/Cover Cover Cover 1 false false R2.htm 0000002 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) Sheet http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) Statements 2 false false R3.htm 0000003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) Sheet http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) Statements 3 false false R4.htm 0000004 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) Sheet http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) Statements 4 false false R5.htm 0000005 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) Sheet http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) Statements 5 false false R6.htm 0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Sheet http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Statements 6 false false R7.htm 0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (UNAUDITED) Sheet http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYUNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (UNAUDITED) Statements 7 false false R8.htm 0000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.medifast1.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 8 false false R9.htm 0000009 - Disclosure - INVENTORIES Sheet http://www.medifast1.com/role/INVENTORIES INVENTORIES Notes 9 false false R10.htm 0000010 - Disclosure - EARNINGS PER SHARE Sheet http://www.medifast1.com/role/EARNINGSPERSHARE EARNINGS PER SHARE Notes 10 false false R11.htm 0000011 - Disclosure - SHARE-BASED COMPENSATION Sheet http://www.medifast1.com/role/SHAREBASEDCOMPENSATION SHARE-BASED COMPENSATION Notes 11 false false R12.htm 0000012 - Disclosure - LEASES Sheet http://www.medifast1.com/role/LEASES LEASES Notes 12 false false R13.htm 0000013 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME Sheet http://www.medifast1.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOME ACCUMULATED OTHER COMPREHENSIVE INCOME Notes 13 false false R14.htm 0000014 - Disclosure - INVESTMENTS Sheet http://www.medifast1.com/role/INVESTMENTS INVESTMENTS Notes 14 false false R15.htm 0000015 - Disclosure - DEBT Sheet http://www.medifast1.com/role/DEBT DEBT Notes 15 false false R16.htm 9954471 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.medifast1.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 16 false false R17.htm 9954472 - Disclosure - INVENTORIES (Tables) Sheet http://www.medifast1.com/role/INVENTORIESTables INVENTORIES (Tables) Tables http://www.medifast1.com/role/INVENTORIES 17 false false R18.htm 9954473 - Disclosure - EARNINGS PER SHARE (Tables) Sheet http://www.medifast1.com/role/EARNINGSPERSHARETables EARNINGS PER SHARE (Tables) Tables http://www.medifast1.com/role/EARNINGSPERSHARE 18 false false R19.htm 9954474 - Disclosure - SHARE-BASED COMPENSATION (Tables) Sheet http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONTables SHARE-BASED COMPENSATION (Tables) Tables http://www.medifast1.com/role/SHAREBASEDCOMPENSATION 19 false false R20.htm 9954475 - Disclosure - LEASES (Tables) Sheet http://www.medifast1.com/role/LEASESTables LEASES (Tables) Tables http://www.medifast1.com/role/LEASES 20 false false R21.htm 9954476 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (Tables) Sheet http://www.medifast1.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMETables ACCUMULATED OTHER COMPREHENSIVE INCOME (Tables) Tables http://www.medifast1.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOME 21 false false R22.htm 9954477 - Disclosure - INVESTMENTS (Tables) Sheet http://www.medifast1.com/role/INVESTMENTSTables INVESTMENTS (Tables) Tables http://www.medifast1.com/role/INVESTMENTS 22 false false R23.htm 9954478 - Disclosure - INVENTORIES (Details) Sheet http://www.medifast1.com/role/INVENTORIESDetails INVENTORIES (Details) Details http://www.medifast1.com/role/INVENTORIESTables 23 false false R24.htm 9954479 - Disclosure - EARNINGS PER SHARE - Computation of Basic and Diluted EPS (Details) Sheet http://www.medifast1.com/role/EARNINGSPERSHAREComputationofBasicandDilutedEPSDetails EARNINGS PER SHARE - Computation of Basic and Diluted EPS (Details) Details 24 false false R25.htm 9954480 - Disclosure - EARNINGS PER SHARE - Narrative (Details) Sheet http://www.medifast1.com/role/EARNINGSPERSHARENarrativeDetails EARNINGS PER SHARE - Narrative (Details) Details 25 false false R26.htm 9954481 - Disclosure - SHARE-BASED COMPENSATION - Narrative (Details) Sheet http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails SHARE-BASED COMPENSATION - Narrative (Details) Details 26 false false R27.htm 9954482 - Disclosure - SHARE-BASED COMPENSATION - Stock Options Activity (Details) Sheet http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONStockOptionsActivityDetails SHARE-BASED COMPENSATION - Stock Options Activity (Details) Details 27 false false R28.htm 9954483 - Disclosure - SHARE-BASED COMPENSATION - Restricted Stock Activity (Details) Sheet http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails SHARE-BASED COMPENSATION - Restricted Stock Activity (Details) Details 28 false false R29.htm 9954484 - Disclosure - SHARE-BASED COMPENSATION - Summary of Performance-based Share Awards (Details) Sheet http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONSummaryofPerformancebasedShareAwardsDetails SHARE-BASED COMPENSATION - Summary of Performance-based Share Awards (Details) Details 29 false false R30.htm 9954485 - Disclosure - LEASES - Narrative (Details) Sheet http://www.medifast1.com/role/LEASESNarrativeDetails LEASES - Narrative (Details) Details 30 false false R31.htm 9954486 - Disclosure - LEASES - Supplemental Cash Flow Information (Details) Sheet http://www.medifast1.com/role/LEASESSupplementalCashFlowInformationDetails LEASES - Supplemental Cash Flow Information (Details) Details 31 false false R32.htm 9954487 - Disclosure - LEASES - Future Minimum Lease Commitments (Details) Sheet http://www.medifast1.com/role/LEASESFutureMinimumLeaseCommitmentsDetails LEASES - Future Minimum Lease Commitments (Details) Details 32 false false R33.htm 9954488 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (Details) Sheet http://www.medifast1.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEDetails ACCUMULATED OTHER COMPREHENSIVE INCOME (Details) Details http://www.medifast1.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMETables 33 false false R34.htm 9954489 - Disclosure - INVESTMENTS - Cash and Financial Assets Measured at Fair Value on a Recurring Basis (Details) Sheet http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails INVESTMENTS - Cash and Financial Assets Measured at Fair Value on a Recurring Basis (Details) Details 34 false false R35.htm 9954490 - Disclosure - INVESTMENTS - Investment Gains (Details) Sheet http://www.medifast1.com/role/INVESTMENTSInvestmentGainsDetails INVESTMENTS - Investment Gains (Details) Details 35 false false R36.htm 9954491 - Disclosure - INVESTMENTS - Narrative (Details) Sheet http://www.medifast1.com/role/INVESTMENTSNarrativeDetails INVESTMENTS - Narrative (Details) Details 36 false false R37.htm 9954492 - Disclosure - DEBT (Details) Sheet http://www.medifast1.com/role/DEBTDetails DEBT (Details) Details http://www.medifast1.com/role/DEBT 37 false false All Reports Book All Reports med-20240331.htm med-20240331.xsd med-20240331_cal.xml med-20240331_def.xml med-20240331_lab.xml med-20240331_pre.xml http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 54 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "med-20240331.htm": { "nsprefix": "med", "nsuri": "http://www.medifast1.com/20240331", "dts": { "inline": { "local": [ "med-20240331.htm" ] }, "schema": { "local": [ "med-20240331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "calculationLink": { "local": [ "med-20240331_cal.xml" ] }, "definitionLink": { "local": [ "med-20240331_def.xml" ] }, "labelLink": { "local": [ "med-20240331_lab.xml" ] }, "presentationLink": { "local": [ "med-20240331_pre.xml" ] } }, "keyStandard": 202, "keyCustom": 16, "axisStandard": 17, "axisCustom": 1, "memberStandard": 24, "memberCustom": 15, "hidden": { "total": 5, "http://xbrl.sec.gov/dei/2023": 5 }, "contextCount": 115, "entityCount": 1, "segmentCount": 41, "elementCount": 342, "unitCount": 4, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 446, "http://xbrl.sec.gov/dei/2023": 29 }, "report": { "R1": { "role": "http://www.medifast1.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED", "longName": "0000002 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED", "longName": "0000003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "unique": true } }, "R4": { "role": "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "longName": "0000004 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical", "longName": "0000005 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED", "longName": "0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "unique": true } }, "R7": { "role": "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYUNAUDITED", "longName": "0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (UNAUDITED)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (UNAUDITED)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-22", "name": "us-gaap:CommonStockSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-22", "name": "us-gaap:CommonStockSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.medifast1.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES", "longName": "0000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.medifast1.com/role/INVENTORIES", "longName": "0000009 - Disclosure - INVENTORIES", "shortName": "INVENTORIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.medifast1.com/role/EARNINGSPERSHARE", "longName": "0000010 - Disclosure - EARNINGS PER SHARE", "shortName": "EARNINGS PER SHARE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.medifast1.com/role/SHAREBASEDCOMPENSATION", "longName": "0000011 - Disclosure - SHARE-BASED COMPENSATION", "shortName": "SHARE-BASED COMPENSATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.medifast1.com/role/LEASES", "longName": "0000012 - Disclosure - LEASES", "shortName": "LEASES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.medifast1.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOME", "longName": "0000013 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME", "shortName": "ACCUMULATED OTHER COMPREHENSIVE INCOME", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.medifast1.com/role/INVESTMENTS", "longName": "0000014 - Disclosure - INVESTMENTS", "shortName": "INVESTMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.medifast1.com/role/DEBT", "longName": "0000015 - Disclosure - DEBT", "shortName": "DEBT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.medifast1.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies", "longName": "9954471 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.medifast1.com/role/INVENTORIESTables", "longName": "9954472 - Disclosure - INVENTORIES (Tables)", "shortName": "INVENTORIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.medifast1.com/role/EARNINGSPERSHARETables", "longName": "9954473 - Disclosure - EARNINGS PER SHARE (Tables)", "shortName": "EARNINGS PER SHARE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONTables", "longName": "9954474 - Disclosure - SHARE-BASED COMPENSATION (Tables)", "shortName": "SHARE-BASED COMPENSATION (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.medifast1.com/role/LEASESTables", "longName": "9954475 - Disclosure - LEASES (Tables)", "shortName": "LEASES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.medifast1.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMETables", "longName": "9954476 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (Tables)", "shortName": "ACCUMULATED OTHER COMPREHENSIVE INCOME (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.medifast1.com/role/INVESTMENTSTables", "longName": "9954477 - Disclosure - INVESTMENTS (Tables)", "shortName": "INVESTMENTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.medifast1.com/role/INVENTORIESDetails", "longName": "9954478 - Disclosure - INVENTORIES (Details)", "shortName": "INVENTORIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "23", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:InventoryRawMaterials", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:InventoryRawMaterials", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.medifast1.com/role/EARNINGSPERSHAREComputationofBasicandDilutedEPSDetails", "longName": "9954479 - Disclosure - EARNINGS PER SHARE - Computation of Basic and Diluted EPS (Details)", "shortName": "EARNINGS PER SHARE - Computation of Basic and Diluted EPS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "unique": true } }, "R25": { "role": "http://www.medifast1.com/role/EARNINGSPERSHARENarrativeDetails", "longName": "9954480 - Disclosure - EARNINGS PER SHARE - Narrative (Details)", "shortName": "EARNINGS PER SHARE - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "25", "firstAnchor": { "contextRef": "c-37", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-37", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails", "longName": "9954481 - Disclosure - SHARE-BASED COMPENSATION - Narrative (Details)", "shortName": "SHARE-BASED COMPENSATION - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "unique": true } }, "R27": { "role": "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONStockOptionsActivityDetails", "longName": "9954482 - Disclosure - SHARE-BASED COMPENSATION - Stock Options Activity (Details)", "shortName": "SHARE-BASED COMPENSATION - Stock Options Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails", "longName": "9954483 - Disclosure - SHARE-BASED COMPENSATION - Restricted Stock Activity (Details)", "shortName": "SHARE-BASED COMPENSATION - Restricted Stock Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "c-41", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-41", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONSummaryofPerformancebasedShareAwardsDetails", "longName": "9954484 - Disclosure - SHARE-BASED COMPENSATION - Summary of Performance-based Share Awards (Details)", "shortName": "SHARE-BASED COMPENSATION - Summary of Performance-based Share Awards (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.medifast1.com/role/LEASESNarrativeDetails", "longName": "9954485 - Disclosure - LEASES - Narrative (Details)", "shortName": "LEASES - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.medifast1.com/role/LEASESSupplementalCashFlowInformationDetails", "longName": "9954486 - Disclosure - LEASES - Supplemental Cash Flow Information (Details)", "shortName": "LEASES - Supplemental Cash Flow Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeasePayments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeasePayments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.medifast1.com/role/LEASESFutureMinimumLeaseCommitmentsDetails", "longName": "9954487 - Disclosure - LEASES - Future Minimum Lease Commitments (Details)", "shortName": "LEASES - Future Minimum Lease Commitments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.medifast1.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEDetails", "longName": "9954488 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (Details)", "shortName": "ACCUMULATED OTHER COMPREHENSIVE INCOME (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails", "longName": "9954489 - Disclosure - INVESTMENTS - Cash and Financial Assets Measured at Fair Value on a Recurring Basis (Details)", "shortName": "INVESTMENTS - Cash and Financial Assets Measured at Fair Value on a Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "c-4", "name": "med:CashAndCashEquivalentsExcludingMoneyMarketAccountsAmortizedCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "med:CashAndCashEquivalentsExcludingMoneyMarketAccountsAmortizedCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.medifast1.com/role/INVESTMENTSInvestmentGainsDetails", "longName": "9954490 - Disclosure - INVESTMENTS - Investment Gains (Details)", "shortName": "INVESTMENTS - Investment Gains (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EquitySecuritiesFvNiGainLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EquitySecuritiesFvNiGainLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.medifast1.com/role/INVESTMENTSNarrativeDetails", "longName": "9954491 - Disclosure - INVESTMENTS - Narrative (Details)", "shortName": "INVESTMENTS - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtSecuritiesRealizedGainLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-102", "name": "us-gaap:PaymentsToAcquireInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "unique": true } }, "R37": { "role": "http://www.medifast1.com/role/DEBTDetails", "longName": "9954492 - Disclosure - DEBT (Details)", "shortName": "DEBT (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-114", "name": "med:MaximumTotalNetLeverageRatio", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-114", "name": "med:MaximumTotalNetLeverageRatio", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "med-20240331.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]", "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and accrued expenses", "label": "Accounts Payable and Accrued Liabilities, Current", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r19" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://www.medifast1.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEDetails": { "parentTag": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.medifast1.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gains on investments", "label": "AOCI, Debt Securities, Available-for-Sale, Adjustment, after Tax", "documentation": "Amount, after tax, of accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r558" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://www.medifast1.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEDetails": { "parentTag": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.medifast1.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation", "label": "Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax", "documentation": "Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses." } } }, "auth_ref": [ "r114", "r117", "r118", "r119", "r353" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 }, "http://www.medifast1.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.medifast1.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMEDetails", "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive income", "totalLabel": "Accumulated other comprehensive income", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r24", "r25", "r62", "r111", "r418", "r437", "r438" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r2", "r11", "r25", "r342", "r345", "r374", "r433", "r434", "r559", "r560", "r561", "r567", "r568", "r569" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r53", "r525", "r630" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-In Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r324", "r325", "r326", "r441", "r567", "r568", "r569", "r612", "r631" ] }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "debit", "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "negatedLabel": "Net shares repurchased for employee taxes", "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation", "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions", "crdr": "credit", "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation", "label": "APIC, Share-Based Payment Arrangement, Recognition and Exercise", "documentation": "Amount of increase (decrease) to additional paid-in capital (APIC) for recognition and exercise of award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net income to cash provided by operating activities", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails", "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONSummaryofPerformancebasedShareAwardsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Decrease in share-based payment arrangement, expense", "terseLabel": "Share-Based Compensation Expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r319", "r327" ] }, "med_AmendedCreditAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.medifast1.com/20240331", "localname": "AmendedCreditAgreementMember", "presentation": [ "http://www.medifast1.com/role/DEBTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Agreement", "label": "Amended Credit Agreement [Member]", "documentation": "Credit Agreement [Member]" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.medifast1.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.medifast1.com/role/EARNINGSPERSHARENarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Anti-dilutive awards (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r163" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.medifast1.com/role/EARNINGSPERSHARENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities [Axis]", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r31" ] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.medifast1.com/role/EARNINGSPERSHARENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name [Domain]", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r31" ] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://www.medifast1.com/role/INVESTMENTSNarrativeDetails", "http://www.medifast1.com/role/LEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r336" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL ASSETS", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r88", "r109", "r137", "r168", "r175", "r179", "r219", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r337", "r339", "r354", "r416", "r464", "r525", "r536", "r581", "r582", "r620" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r105", "r113", "r137", "r219", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r337", "r339", "r354", "r525", "r581", "r582", "r620" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Current Assets", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "calculation": { "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails": { "parentTag": "med_InvestmentSecuritiesUnrealizedGains", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized Gains", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r190" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "calculation": { "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails": { "parentTag": "med_InvestmentSecuritiesUnrealizedGains", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Unrealized Loss", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r191" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "calculation": { "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails": { "parentTag": "med_InvestmentSecuritiesAtCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost, Debt Securities", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r187", "r227", "r415" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "crdr": "debit", "calculation": { "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails": { "parentTag": "med_InvestmentSecuritiesFairValue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-Sale, Current", "label": "Debt Securities, Available-for-Sale, Current", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current." } } }, "auth_ref": [ "r185", "r227" ] }, "us-gaap_AwardDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardDateAxis", "presentation": [ "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails", "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONSummaryofPerformancebasedShareAwardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award Date [Axis]", "label": "Award Date [Axis]", "documentation": "Information by date or year award under share-based payment arrangement is granted." } } }, "auth_ref": [ "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610" ] }, "us-gaap_AwardDateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardDateDomain", "presentation": [ "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails", "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONSummaryofPerformancebasedShareAwardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award Date [Domain]", "label": "Award Date [Domain]", "documentation": "Date or year award under share-based payment arrangement is granted." } } }, "auth_ref": [ "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails", "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails", "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONSummaryofPerformancebasedShareAwardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318" ] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationAxis", "presentation": [ "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Axis]", "label": "Balance Sheet Location [Axis]", "documentation": "Information by location on balance sheet (statement of financial position)." } } }, "auth_ref": [] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationDomain", "presentation": [ "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Domain]", "label": "Balance Sheet Location [Domain]", "documentation": "Location in the balance sheet (statement of financial position)." } } }, "auth_ref": [ "r43", "r44" ] }, "us-gaap_BaseRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BaseRateMember", "presentation": [ "http://www.medifast1.com/role/DEBTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Base Rate", "label": "Base Rate [Member]", "documentation": "Minimum rate investor will accept." } } }, "auth_ref": [] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.medifast1.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "med_CashAndCashEquivalentsAndMarketableSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.medifast1.com/20240331", "localname": "CashAndCashEquivalentsAndMarketableSecuritiesLineItems", "presentation": [ "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash And Cash Equivalents And Marketable securities [Line Items]", "label": "Cash And Cash Equivalents And Marketable securities [Line Items]", "documentation": "N/A" } } }, "auth_ref": [] }, "med_CashAndCashEquivalentsAndMarketableSecuritiesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.medifast1.com/20240331", "localname": "CashAndCashEquivalentsAndMarketableSecuritiesTable", "presentation": [ "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash And Cash Equivalents And Marketable securities [Table]", "label": "Cash And Cash Equivalents And Marketable securities [Table]", "documentation": "N/A" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r29", "r107", "r500" ] }, "med_CashAndCashEquivalentsExcludingMoneyMarketAccountsAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://www.medifast1.com/20240331", "localname": "CashAndCashEquivalentsExcludingMoneyMarketAccountsAmortizedCost", "crdr": "debit", "calculation": { "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails": { "parentTag": "us-gaap_CashCashEquivalentsAndShortTermInvestments", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost, Cash and cash equivalents, excluding money market accounts", "label": "Cash And Cash Equivalents Excluding Money Market Accounts, Amortized Cost", "documentation": "Cash And Cash Equivalents Excluding Money Market Accounts, Amortized Cost" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails": { "parentTag": "med_CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated Fair Value, Cash and cash equivalents", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsMember", "presentation": [ "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash & Cash Equivalents", "label": "Cash and Cash Equivalents [Member]", "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsAndShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsAndShortTermInvestments", "crdr": "debit", "calculation": { "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Cost", "label": "Cash, Cash Equivalents, and Short-Term Investments", "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable." } } }, "auth_ref": [ "r557" ] }, "med_CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://www.medifast1.com/20240331", "localname": "CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Estimated Fair Value", "label": "Cash, Cash Equivalents, And Short-Term Investments, Fair Value Disclosure", "documentation": "Cash, Cash Equivalents, And Short-Term Investments, Fair Value Disclosure" } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents - beginning of the period", "periodEndLabel": "Cash and cash equivalents - end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r29", "r73", "r134" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "totalLabel": "Increase in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1", "r73" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.medifast1.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "med_CollaborativeArrangementAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.medifast1.com/20240331", "localname": "CollaborativeArrangementAmount", "crdr": "debit", "presentation": [ "http://www.medifast1.com/role/INVESTMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Milestone payment", "label": "Collaborative Arrangement, Amount", "documentation": "Collaborative Arrangement, Amount" } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CollaborativeArrangementMember", "presentation": [ "http://www.medifast1.com/role/INVESTMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement", "label": "Collaborative Arrangement [Member]", "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity." } } }, "auth_ref": [ "r336" ] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": [ "http://www.medifast1.com/role/INVESTMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r336" ] }, "us-gaap_CommonStockDividendsPerShareDeclared": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockDividendsPerShareDeclared", "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash dividends declared per share (in usd per share)", "label": "Common Stock, Dividends, Per Share, Declared", "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding." } } }, "auth_ref": [ "r83" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r527", "r528", "r529", "r531", "r532", "r533", "r534", "r567", "r568", "r612", "r629", "r631" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in usd per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r52" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r52", "r452" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical", "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, issued (in shares)", "periodStartLabel": "Balance (in shares)", "periodEndLabel": "Balance (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r52" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, outstanding (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r12", "r52", "r452", "r470", "r631", "r632" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "verboseLabel": "Common stock, par value $0.001 per share: 20,000 shares authorized; 10,937 and 10,896 issued and outstanding at March\u00a031, 2024 and December\u00a031, 2023, respectively", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r52", "r417", "r525" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive income", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r26", "r122", "r124", "r129", "r410", "r426" ] }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNoteTextBlock", "presentation": [ "http://www.medifast1.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "ACCUMULATED OTHER COMPREHENSIVE INCOME", "label": "Comprehensive Income (Loss) Note [Text Block]", "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income." } } }, "auth_ref": [ "r61", "r128", "r409", "r424" ] }, "us-gaap_CostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfRevenue", "crdr": "debit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "verboseLabel": "Cost of sales", "label": "Cost of Revenue", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." } } }, "auth_ref": [ "r66", "r137", "r219", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r354", "r581" ] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.medifast1.com/role/INVESTMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r138", "r139", "r251", "r275", "r375", "r503", "r505" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityAxis", "presentation": [ "http://www.medifast1.com/role/DEBTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityDomain", "presentation": [ "http://www.medifast1.com/role/DEBTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Domain]", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.medifast1.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.medifast1.com/role/DEBT" ], "lang": { "en-us": { "role": { "terseLabel": "DEBT", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r80", "r136", "r247", "r253", "r254", "r255", "r256", "r257", "r258", "r263", "r270", "r271", "r273" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.medifast1.com/role/DEBTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r16", "r49", "r50", "r89", "r90", "r140", "r248", "r249", "r250", "r251", "r252", "r254", "r259", "r260", "r261", "r262", "r264", "r265", "r266", "r267", "r268", "r269", "r363", "r512", "r513", "r514", "r515", "r516", "r564" ] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://www.medifast1.com/role/DEBTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basis spread on variable rate (as a percent)", "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "presentation": [ "http://www.medifast1.com/role/DEBTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings outstanding", "label": "Long-Term Debt, Gross", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r16", "r90", "r274" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.medifast1.com/role/DEBTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r140", "r248", "r249", "r250", "r251", "r252", "r254", "r259", "r260", "r261", "r262", "r264", "r265", "r266", "r267", "r268", "r269", "r272", "r363", "r512", "r513", "r514", "r515", "r516", "r564" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.medifast1.com/role/DEBTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r22", "r140", "r248", "r249", "r250", "r251", "r252", "r254", "r259", "r260", "r261", "r262", "r264", "r265", "r266", "r267", "r268", "r269", "r363", "r512", "r513", "r514", "r515", "r516", "r564" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": [ "http://www.medifast1.com/role/DEBTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r22", "r36", "r37", "r45", "r46", "r47", "r48", "r81", "r82", "r140", "r248", "r249", "r250", "r251", "r252", "r254", "r259", "r260", "r261", "r262", "r264", "r265", "r266", "r267", "r268", "r269", "r272", "r363", "r512", "r513", "r514", "r515", "r516", "r564" ] }, "med_DebtSecuritiesAccruedInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://www.medifast1.com/20240331", "localname": "DebtSecuritiesAccruedInterestMember", "presentation": [ "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued Interest", "label": "Debt Securities, Accrued Interest [Member]", "documentation": "Debt Securities, Accrued Interest" } } }, "auth_ref": [] }, "med_DebtSecuritiesGainsLossesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.medifast1.com/20240331", "localname": "DebtSecuritiesGainsLossesMember", "presentation": [ "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized Gains (Losses)", "label": "Debt Securities, Gains (Losses) [Member]", "documentation": "Debt Securities, Gains (Losses)" } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesRealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesRealizedGainLoss", "crdr": "credit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 14.0 } }, "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED", "http://www.medifast1.com/role/INVESTMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Realized gain on sale of investment securities", "terseLabel": "Realized gain", "label": "Debt Securities, Realized Gain (Loss)", "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading)." } } }, "auth_ref": [ "r428", "r562", "r563" ] }, "med_DebtSecuritiesUnrealizedGainAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.medifast1.com/20240331", "localname": "DebtSecuritiesUnrealizedGainAxis", "presentation": [ "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Unrealized Gain [Axis]", "label": "Debt Securities, Unrealized Gain [Axis]", "documentation": "Debt Securities, Unrealized Gain" } } }, "auth_ref": [] }, "med_DebtSecuritiesUnrealizedGainDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.medifast1.com/20240331", "localname": "DebtSecuritiesUnrealizedGainDomain", "presentation": [ "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Unrealized Gain [Domain]", "label": "Debt Securities, Unrealized Gain [Domain]", "documentation": "Debt Securities, Unrealized Gain [Domain]" } } }, "auth_ref": [] }, "us-gaap_DeferredIncomeTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxAssetsNet", "crdr": "debit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax assets", "label": "Deferred Income Tax Assets, Net", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting." } } }, "auth_ref": [ "r328", "r329" ] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income taxes", "label": "Deferred Income Tax Expense (Benefit)", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r7", "r85", "r101", "r334", "r335", "r566" ] }, "med_DenominatorAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.medifast1.com/20240331", "localname": "DenominatorAbstract", "presentation": [ "http://www.medifast1.com/role/EARNINGSPERSHAREComputationofBasicandDilutedEPSDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Denominator:", "label": "Denominator [Abstract]", "documentation": "Denominator [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r7", "r171" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.medifast1.com/role/SHAREBASEDCOMPENSATION" ], "lang": { "en-us": { "role": { "verboseLabel": "SHARE-BASED COMPENSATION", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r289", "r292", "r320", "r321", "r323", "r522" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "presentation": [ "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Expense", "label": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]", "documentation": "Tabular disclosure of share-based payment arrangement." } } }, "auth_ref": [ "r9", "r40" ] }, "us-gaap_DividendsCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DividendsCash", "crdr": "debit", "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "verboseLabel": "Dividends included in accounts payable", "label": "Dividends, Cash", "documentation": "Amount of paid and unpaid cash dividends declared for classes of stock, for example, but not limited to, common and preferred." } } }, "auth_ref": [ "r4", "r83" ] }, "us-gaap_DividendsCommonStockCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DividendsCommonStockCash", "crdr": "debit", "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "negatedLabel": "Cash dividends declared to stockholders", "label": "Dividends, Common Stock, Cash", "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash." } } }, "auth_ref": [ "r83" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.medifast1.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.medifast1.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.medifast1.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.medifast1.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r540" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.medifast1.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r541" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.medifast1.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share [Abstract]", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED", "http://www.medifast1.com/role/EARNINGSPERSHAREComputationofBasicandDilutedEPSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings per share - basic (in usd per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r130", "r146", "r147", "r148", "r149", "r150", "r156", "r158", "r160", "r161", "r162", "r166", "r349", "r350", "r411", "r427", "r506" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED", "http://www.medifast1.com/role/EARNINGSPERSHAREComputationofBasicandDilutedEPSDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Earnings per share - diluted (in usd per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r130", "r146", "r147", "r148", "r149", "r150", "r158", "r160", "r161", "r162", "r166", "r349", "r350", "r411", "r427", "r506" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.medifast1.com/role/EARNINGSPERSHARE" ], "lang": { "en-us": { "role": { "verboseLabel": "EARNINGS PER SHARE", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r155", "r163", "r164", "r165" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency impact", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r355" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation cost recognition weighted average period (in years)", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r322" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "crdr": "debit", "presentation": [ "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized compensation costs", "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r611" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": [ "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options, unrecognized compensation costs", "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": [ "r611" ] }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "crdr": "credit", "presentation": [ "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total income tax benefit recognized related to restricted stock awards", "label": "Share-Based Payment Arrangement, Expense, Tax Benefit", "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement." } } }, "auth_ref": [ "r319" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Options", "label": "Employee Stock Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.medifast1.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.medifast1.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.medifast1.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.medifast1.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.medifast1.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r538" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.medifast1.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.medifast1.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.medifast1.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r538" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.medifast1.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.medifast1.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r538" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.medifast1.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.medifast1.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r542" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.medifast1.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r538" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.medifast1.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r538" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.medifast1.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r538" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.medifast1.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r538" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r12", "r103", "r125", "r126", "r127", "r141", "r142", "r143", "r145", "r151", "r153", "r167", "r220", "r221", "r277", "r324", "r325", "r326", "r331", "r332", "r341", "r342", "r343", "r344", "r345", "r346", "r348", "r356", "r357", "r358", "r359", "r360", "r361", "r374", "r433", "r434", "r435", "r441", "r490" ] }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "EquityMethodInvesteeNameDomain", "presentation": [ "http://www.medifast1.com/role/INVESTMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Domain]", "label": "Investment, Name [Domain]" } } }, "auth_ref": [ "r216", "r217", "r218" ] }, "med_EquitySecuritiesAccruedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.medifast1.com/20240331", "localname": "EquitySecuritiesAccruedInterest", "crdr": "debit", "calculation": { "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails": { "parentTag": "med_InvestmentSecuritiesAccruedInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued Interest, Equity securities", "label": "Equity Securities, Accrued Interest", "documentation": "Equity Securities, Accrued Interest" } } }, "auth_ref": [] }, "med_EquitySecuritiesFVNIUnrealizedGains": { "xbrltype": "monetaryItemType", "nsuri": "http://www.medifast1.com/20240331", "localname": "EquitySecuritiesFVNIUnrealizedGains", "crdr": "credit", "calculation": { "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails": { "parentTag": "med_InvestmentSecuritiesUnrealizedGains", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized Gains, Equity securities", "label": "Equity Securities, FV-NI, Unrealized Gains", "documentation": "Equity Securities, FV-NI, Unrealized Gains" } } }, "auth_ref": [] }, "us-gaap_EquitySecuritiesFvNiCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesFvNiCost", "crdr": "debit", "calculation": { "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails": { "parentTag": "med_InvestmentSecuritiesAtCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost, Equity securities", "label": "Equity Securities, FV-NI, Cost", "documentation": "Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value." } } }, "auth_ref": [ "r415" ] }, "us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesFvNiCurrentAndNoncurrent", "crdr": "debit", "calculation": { "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails": { "parentTag": "med_InvestmentSecuritiesFairValue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated Fair Value, Equity securities", "label": "Equity Securities, FV-NI", "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r110", "r352", "r414" ] }, "us-gaap_EquitySecuritiesFvNiGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesFvNiGainLoss", "crdr": "credit", "calculation": { "http://www.medifast1.com/role/INVESTMENTSInvestmentGainsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.medifast1.com/role/INVESTMENTSInvestmentGainsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net gains recognized during the period on equity securities", "label": "Equity Securities, FV-NI, Gain (Loss)", "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r430", "r577" ] }, "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesFvNiRealizedGainLoss", "crdr": "credit", "calculation": { "http://www.medifast1.com/role/INVESTMENTSInvestmentGainsDetails": { "parentTag": "us-gaap_EquitySecuritiesFvNiGainLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.medifast1.com/role/INVESTMENTSInvestmentGainsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Less: Net gains recognized on equity securities sold", "label": "Equity Securities, FV-NI, Realized Gain (Loss)", "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r428", "r577" ] }, "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesFvNiUnrealizedGainLoss", "crdr": "credit", "calculation": { "http://www.medifast1.com/role/INVESTMENTSInvestmentGainsDetails": { "parentTag": "us-gaap_EquitySecuritiesFvNiGainLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.medifast1.com/role/INVESTMENTSInvestmentGainsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gains recognized during the reporting period on equity securities still held at the reporting date", "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)", "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r429", "r577" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r261", "r281", "r282", "r283", "r284", "r285", "r286", "r351", "r380", "r381", "r382", "r513", "r514", "r518", "r519", "r520" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 1", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r261", "r281", "r286", "r351", "r380", "r518", "r519", "r520" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r261", "r281", "r286", "r351", "r381", "r513", "r514", "r518", "r519", "r520" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r261", "r281", "r282", "r283", "r284", "r285", "r286", "r380", "r381", "r382", "r513", "r514", "r518", "r519", "r520" ] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentAxis", "presentation": [ "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument [Axis]", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r222", "r223", "r224", "r225", "r226", "r228", "r229", "r230", "r272", "r276", "r347", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r425", "r510", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r573", "r574", "r575", "r576" ] }, "us-gaap_FinancialInstrumentsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentsDisclosureTextBlock", "presentation": [ "http://www.medifast1.com/role/INVESTMENTS" ], "lang": { "en-us": { "role": { "terseLabel": "INVESTMENTS", "label": "Financial Instruments Disclosure [Text Block]", "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures." } } }, "auth_ref": [] }, "us-gaap_GainLossOnInvestmentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnInvestmentsTextBlock", "presentation": [ "http://www.medifast1.com/role/INVESTMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Investment Gains", "label": "Gain (Loss) on Securities [Table Text Block]", "documentation": "Tabular disclosure of realized and unrealized gain (loss) on investment in security." } } }, "auth_ref": [ "r562", "r563" ] }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnSaleOfPropertyPlantEquipment", "crdr": "credit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 12.0 } }, "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedLabel": "Loss on sale or disposal of property, plant and equipment", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property." } } }, "auth_ref": [ "r7" ] }, "med_GrantedIn2020Member": { "xbrltype": "domainItemType", "nsuri": "http://www.medifast1.com/20240331", "localname": "GrantedIn2020Member", "presentation": [ "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONSummaryofPerformancebasedShareAwardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted In 2020", "label": "Granted In 2020 [Member]", "documentation": "Granted In 2020" } } }, "auth_ref": [] }, "med_GrantedIn2021Member": { "xbrltype": "domainItemType", "nsuri": "http://www.medifast1.com/20240331", "localname": "GrantedIn2021Member", "presentation": [ "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONSummaryofPerformancebasedShareAwardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted In 2021", "label": "Granted In 2021 [Member]", "documentation": "Granted In 2021" } } }, "auth_ref": [] }, "med_GrantedIn2022Member": { "xbrltype": "domainItemType", "nsuri": "http://www.medifast1.com/20240331", "localname": "GrantedIn2022Member", "presentation": [ "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails", "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONSummaryofPerformancebasedShareAwardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted In 2022", "label": "Granted In 2022 [Member]", "documentation": "Granted In 2022" } } }, "auth_ref": [] }, "med_GrantedIn2023Member": { "xbrltype": "domainItemType", "nsuri": "http://www.medifast1.com/20240331", "localname": "GrantedIn2023Member", "presentation": [ "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONSummaryofPerformancebasedShareAwardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted In 2023", "label": "Granted In 2023 [Member]", "documentation": "Granted In 2023" } } }, "auth_ref": [] }, "med_GrantedIn2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.medifast1.com/20240331", "localname": "GrantedIn2024Member", "presentation": [ "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONSummaryofPerformancebasedShareAwardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted In 2024", "label": "Granted In 2024 [Member]", "documentation": "Granted In 2024" } } }, "auth_ref": [] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "totalLabel": "Gross profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r65", "r137", "r168", "r174", "r178", "r180", "r219", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r354", "r508", "r581" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "totalLabel": "Income from operations before income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r0", "r63", "r94", "r168", "r174", "r178", "r180", "r412", "r422", "r508" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.medifast1.com/role/INVESTMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r232", "r233", "r475" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.medifast1.com/role/INVESTMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r233", "r475" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Provision for income taxes", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r96", "r102", "r152", "r153", "r172", "r330", "r333", "r431" ] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Income taxes refunded", "label": "Income Taxes Paid, Net", "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes." } } }, "auth_ref": [ "r30" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and accrued expenses", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInIncomeTaxesReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInIncomeTaxesReceivable", "crdr": "credit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Prepaid income taxes", "label": "Increase (Decrease) in Income Taxes Receivable", "documentation": "The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedLabel": "Inventories", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Change in operating assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingAssets", "crdr": "credit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedLabel": "Other assets", "label": "Increase (Decrease) in Other Operating Assets", "documentation": "Amount of increase (decrease) in operating assets classified as other." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other current assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestIncomeExpenseNonoperatingNet", "crdr": "credit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "verboseLabel": "Interest income (expense)", "label": "Interest Income (Expense), Nonoperating, Net", "documentation": "The net amount of nonoperating interest income (expense)." } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Inventory Disclosure [Abstract]", "label": "Inventory Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureTextBlock", "presentation": [ "http://www.medifast1.com/role/INVENTORIES" ], "lang": { "en-us": { "role": { "verboseLabel": "INVENTORIES", "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": [ "r231" ] }, "us-gaap_InventoryFinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryFinishedGoods", "crdr": "debit", "calculation": { "http://www.medifast1.com/role/INVENTORIESDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.medifast1.com/role/INVENTORIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finished goods", "label": "Inventory, Finished Goods, Gross", "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer." } } }, "auth_ref": [ "r552" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 }, "http://www.medifast1.com/role/INVENTORIESDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "http://www.medifast1.com/role/INVENTORIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "totalLabel": "Total", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r112", "r501", "r525" ] }, "med_InventoryNonFoodFinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "http://www.medifast1.com/20240331", "localname": "InventoryNonFoodFinishedGoods", "crdr": "debit", "calculation": { "http://www.medifast1.com/role/INVENTORIESDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.medifast1.com/role/INVENTORIESDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Non-food finished goods", "label": "Inventory Non Food Finished Goods", "documentation": "Amount before last-in first-out (LIFO) and valuation reserves of (Non-food) merchandise or goods held by the entity that are readily available for sale." } } }, "auth_ref": [] }, "us-gaap_InventoryRawMaterials": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryRawMaterials", "crdr": "debit", "calculation": { "http://www.medifast1.com/role/INVENTORIESDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.medifast1.com/role/INVENTORIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Raw materials", "label": "Inventory, Raw Materials, Gross", "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r553" ] }, "us-gaap_InventoryValuationReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryValuationReserves", "crdr": "credit", "calculation": { "http://www.medifast1.com/role/INVENTORIESDetails": { "parentTag": "us-gaap_InventoryNet", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.medifast1.com/role/INVENTORIESDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Reserve for obsolete inventory", "label": "Inventory Valuation Reserves", "documentation": "Amount of valuation reserve for inventory." } } }, "auth_ref": [ "r35", "r555" ] }, "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium", "crdr": "credit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Amortization of premium on investment securities", "label": "Investment Income, Net, Amortization of Discount and Premium", "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities." } } }, "auth_ref": [ "r69" ] }, "med_InvestmentSecuritiesAccruedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.medifast1.com/20240331", "localname": "InvestmentSecuritiesAccruedInterest", "crdr": "debit", "calculation": { "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Accrued Interest, Investment securities", "label": "Investment Securities, Accrued Interest", "documentation": "Investment Securities, Accrued Interest" } } }, "auth_ref": [] }, "med_InvestmentSecuritiesAtCost": { "xbrltype": "monetaryItemType", "nsuri": "http://www.medifast1.com/20240331", "localname": "InvestmentSecuritiesAtCost", "crdr": "debit", "calculation": { "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails": { "parentTag": "us-gaap_CashCashEquivalentsAndShortTermInvestments", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Cost, Investment securities", "label": "Investment Securities, At Cost", "documentation": "Investment Securities, At Cost" } } }, "auth_ref": [] }, "med_InvestmentSecuritiesFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.medifast1.com/20240331", "localname": "InvestmentSecuritiesFairValue", "crdr": "debit", "calculation": { "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails": { "parentTag": "med_CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Estimated Fair Value, Investment securities", "label": "Investment Securities, Fair Value", "documentation": "Investment Securities, Fair Value" } } }, "auth_ref": [] }, "med_InvestmentSecuritiesUnrealizedGains": { "xbrltype": "monetaryItemType", "nsuri": "http://www.medifast1.com/20240331", "localname": "InvestmentSecuritiesUnrealizedGains", "crdr": "credit", "calculation": { "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Unrealized Gains, Investment securities", "label": "Investment Securities, Unrealized Gains", "documentation": "Investment Securities, Unrealized Gains" } } }, "auth_ref": [] }, "us-gaap_InvestmentsAllOtherInvestmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsAllOtherInvestmentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Investments, All Other Investments [Abstract]", "label": "Investments, All Other Investments [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://www.medifast1.com/role/LEASESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Supplemental Cash Flow Information", "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r618" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Leases [Abstract]", "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeaseDescriptionLineItems", "presentation": [ "http://www.medifast1.com/role/LEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Line Items]", "label": "Lessee, Lease, Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r368" ] }, "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeaseDescriptionTable", "presentation": [ "http://www.medifast1.com/role/LEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Table]", "label": "Lessee, Lease, Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": [ "r368" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.medifast1.com/role/LEASESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Maturity of Company's Operating Lease Liabilities", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r619" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.medifast1.com/role/LEASESFutureMinimumLeaseCommitmentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.medifast1.com/role/LEASESFutureMinimumLeaseCommitmentsDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.medifast1.com/role/LEASESFutureMinimumLeaseCommitmentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total lease payments", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r373" ] }, "med_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.medifast1.com/20240331", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour", "crdr": "credit", "calculation": { "http://www.medifast1.com/role/LEASESFutureMinimumLeaseCommitmentsDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.medifast1.com/role/LEASESFutureMinimumLeaseCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Lessee Operating Lease Liability Payments Due After Year Four", "documentation": "Lessee Operating Lease Liability Payments Due After Year Four" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.medifast1.com/role/LEASESFutureMinimumLeaseCommitmentsDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.medifast1.com/role/LEASESFutureMinimumLeaseCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r373" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.medifast1.com/role/LEASESFutureMinimumLeaseCommitmentsDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.medifast1.com/role/LEASESFutureMinimumLeaseCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r373" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.medifast1.com/role/LEASESFutureMinimumLeaseCommitmentsDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.medifast1.com/role/LEASESFutureMinimumLeaseCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r373" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.medifast1.com/role/LEASESFutureMinimumLeaseCommitmentsDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.medifast1.com/role/LEASESFutureMinimumLeaseCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r373" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.medifast1.com/role/LEASESFutureMinimumLeaseCommitmentsDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.medifast1.com/role/LEASESFutureMinimumLeaseCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024 (excluding the three months ended March\u00a031, 2024)", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r619" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.medifast1.com/role/LEASESFutureMinimumLeaseCommitmentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.medifast1.com/role/LEASESFutureMinimumLeaseCommitmentsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: imputed interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r373" ] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": [ "http://www.medifast1.com/role/LEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease term (in months)", "label": "Lessee, Operating Lease, Term of Contract", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r617" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.medifast1.com/role/LEASES" ], "lang": { "en-us": { "role": { "verboseLabel": "LEASES", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r364" ] }, "us-gaap_LetterOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LetterOfCreditMember", "presentation": [ "http://www.medifast1.com/role/DEBTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Letter of Credit", "label": "Letter of Credit [Member]", "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r20", "r137", "r219", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r338", "r339", "r340", "r354", "r451", "r507", "r536", "r581", "r620", "r621" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r57", "r91", "r420", "r525", "r565", "r578", "r613" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r21", "r106", "r137", "r219", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r338", "r339", "r340", "r354", "r525", "r581", "r620", "r621" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Current Liabilities", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "med_LifeMDMember": { "xbrltype": "domainItemType", "nsuri": "http://www.medifast1.com/20240331", "localname": "LifeMDMember", "presentation": [ "http://www.medifast1.com/role/INVESTMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "LifeMD", "label": "LifeMD [Member]", "documentation": "LifeMD" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityCommitmentFeePercentage", "presentation": [ "http://www.medifast1.com/role/DEBTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commitment fee (as a percent)", "label": "Line of Credit Facility, Commitment Fee Percentage", "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.medifast1.com/role/DEBTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum borrowing capacity", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r18" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.medifast1.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "med_MarketAndPerformanceBasedShareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.medifast1.com/20240331", "localname": "MarketAndPerformanceBasedShareMember", "presentation": [ "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails", "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONSummaryofPerformancebasedShareAwardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Market and performance-based share awards", "label": "Market And Performance-based Share [Member]", "documentation": "Market And Performance-based Share" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://www.medifast1.com/role/DEBTDetails", "http://www.medifast1.com/role/LEASESNarrativeDetails", "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r234", "r235", "r236", "r237", "r287", "r407", "r432", "r443", "r444", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r509", "r517", "r521", "r526", "r583", "r622", "r623", "r624", "r625", "r626", "r627" ] }, "med_MaximumTotalNetLeverageRatio": { "xbrltype": "pureItemType", "nsuri": "http://www.medifast1.com/20240331", "localname": "MaximumTotalNetLeverageRatio", "presentation": [ "http://www.medifast1.com/role/DEBTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum total net leverage ratio", "label": "Maximum Total Net Leverage Ratio", "documentation": "Maximum ratio as of any date, of (a) Total Net Funded Indebtedness on such date to (b) Consolidated EBITDA for the Reference Period ended on such date under credit facility." } } }, "auth_ref": [] }, "med_MinimumInterestCoverageRatio": { "xbrltype": "pureItemType", "nsuri": "http://www.medifast1.com/20240331", "localname": "MinimumInterestCoverageRatio", "presentation": [ "http://www.medifast1.com/role/DEBTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum interest coverage ratio", "label": "Minimum Interest Coverage Ratio", "documentation": "Minimum Interest Coverage Ratio" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://www.medifast1.com/role/DEBTDetails", "http://www.medifast1.com/role/LEASESNarrativeDetails", "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [ "r234", "r235", "r236", "r237", "r287", "r407", "r432", "r443", "r444", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r509", "r517", "r521", "r526", "r583", "r622", "r623", "r624", "r625", "r626", "r627" ] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MoneyMarketFundsMember", "presentation": [ "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Money market accounts", "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": [ "r584" ] }, "us-gaap_MunicipalBondsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MunicipalBondsMember", "presentation": [ "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate bonds", "label": "Municipal Bonds [Member]", "documentation": "Long-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments." } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash flow used in financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r133" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "verboseLabel": "Financing Activities", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash flow used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r133" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Investing Activities", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash flow provided by operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r73", "r74", "r75" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Activities", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 }, "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 }, "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED", "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYUNAUDITED", "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED", "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED", "http://www.medifast1.com/role/EARNINGSPERSHAREComputationofBasicandDilutedEPSDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net income", "verboseLabel": "Net income", "terseLabel": "Net income", "label": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r64", "r75", "r95", "r104", "r120", "r123", "r127", "r137", "r144", "r146", "r147", "r148", "r149", "r152", "r153", "r159", "r168", "r174", "r178", "r180", "r219", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r350", "r354", "r423", "r472", "r488", "r489", "r508", "r535", "r581" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.medifast1.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounting Pronouncements and Recently Issued Accounting Pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "totalLabel": "Total other expense", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r68" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Other income (expense)", "label": "Nonoperating Income (Expense) [Abstract]" } } }, "auth_ref": [] }, "med_NumeratorAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.medifast1.com/20240331", "localname": "NumeratorAbstract", "presentation": [ "http://www.medifast1.com/role/EARNINGSPERSHAREComputationofBasicandDilutedEPSDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Numerator:", "label": "Numerator [Abstract]", "documentation": "Numerator [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "totalLabel": "Income from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r168", "r174", "r178", "r180", "r508" ] }, "med_OperatingLeaseArrangementForEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.medifast1.com/20240331", "localname": "OperatingLeaseArrangementForEquipmentMember", "presentation": [ "http://www.medifast1.com/role/LEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease Arrangement for Equipment", "label": "Operating Lease Arrangement For Equipment [Member]", "documentation": "Represents the operating lease arrangement for equipment." } } }, "auth_ref": [] }, "med_OperatingLeaseArrangementForRealEstateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.medifast1.com/20240331", "localname": "OperatingLeaseArrangementForRealEstateMember", "presentation": [ "http://www.medifast1.com/role/LEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Lease Arrangement for Real Estate", "label": "Operating Lease Arrangement For Real Estate [Member]", "documentation": "Represents the operating lease arrangement for real estate." } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseExpense", "crdr": "debit", "presentation": [ "http://www.medifast1.com/role/LEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Operating lease expense", "label": "Operating Lease, Expense", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": [ "r616" ] }, "med_OperatingLeaseExpenseNonCash": { "xbrltype": "monetaryItemType", "nsuri": "http://www.medifast1.com/20240331", "localname": "OperatingLeaseExpenseNonCash", "crdr": "debit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash lease expense", "label": "Operating Lease, Expense, Non-Cash", "documentation": "Operating Lease, Expense, Non-Cash" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "presentation": [ "http://www.medifast1.com/role/LEASESFutureMinimumLeaseCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]", "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.medifast1.com/role/LEASESFutureMinimumLeaseCommitmentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.medifast1.com/role/LEASESFutureMinimumLeaseCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r366" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Current lease obligations", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r366" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Lease obligations, net of current lease obligations", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r366" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://www.medifast1.com/role/LEASESSupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating cash flow used in operating leases", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r367", "r369" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Right-of-use assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r365" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.medifast1.com/role/LEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average discount rate (as a percent)", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r372", "r524" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.medifast1.com/role/LEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining lease term", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r371", "r524" ] }, "med_OptionsAndRestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.medifast1.com/20240331", "localname": "OptionsAndRestrictedStockMember", "presentation": [ "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONSummaryofPerformancebasedShareAwardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options and restricted stock", "label": "Options And Restricted Stock [Member]", "documentation": "Options And Restricted Stock" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "presentation": [ "http://www.medifast1.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Presentation of Financial Statements", "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]", "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles." } } }, "auth_ref": [ "r76", "r77", "r78", "r86" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r108" ] }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity." } } }, "auth_ref": [ "r5", "r10", "r87" ] }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized losses on investment securities", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax", "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": [ "r115", "r116", "r117" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "verboseLabel": "Other comprehensive income, net of tax:", "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYUNAUDITED", "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "totalLabel": "Other comprehensive income, net of tax", "terseLabel": "Other comprehensive income", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": [ "r5", "r10", "r87", "r121", "r124" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "verboseLabel": "Other income (expense)", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r70" ] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedLabel": "Stock repurchases", "label": "Payments for Repurchase of Common Stock", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": [ "r28" ] }, "us-gaap_PaymentsForRepurchaseOfOtherEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRepurchaseOfOtherEquity", "crdr": "credit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedLabel": "Net shares repurchased for taxes", "label": "Payments for Repurchase of Other Equity", "documentation": "Amount of cash outflow to reacquire equity classified as other." } } }, "auth_ref": [ "r28" ] }, "us-gaap_PaymentsOfDividends": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfDividends", "crdr": "credit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedLabel": "Cash dividends paid to stockholders", "label": "Payments of Dividends", "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests." } } }, "auth_ref": [ "r28" ] }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "crdr": "credit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchase of investment securities", "label": "Payments to Acquire Debt Securities, Available-for-Sale", "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r27", "r131", "r184" ] }, "us-gaap_PaymentsToAcquireInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireInvestments", "crdr": "credit", "presentation": [ "http://www.medifast1.com/role/INVESTMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investments made", "label": "Payments to Acquire Investments", "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period." } } }, "auth_ref": [ "r71" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r72" ] }, "us-gaap_PerformanceSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PerformanceSharesMember", "presentation": [ "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails", "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONSummaryofPerformancebasedShareAwardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Performance-Based Shares", "verboseLabel": "Performance-based share awards", "label": "Performance Shares [Member]", "documentation": "Share-based payment arrangement awarded for meeting performance target." } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r557" ] }, "us-gaap_PrepaidTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidTaxes", "crdr": "debit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Income taxes, prepaid", "label": "Prepaid Taxes", "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r502", "r511", "r579" ] }, "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities", "crdr": "debit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale and maturities of investment securities", "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale", "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r131", "r132", "r572" ] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED", "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options exercised by directors", "label": "Proceeds from Stock Options Exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r3", "r15" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment - net of accumulated depreciation", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r8", "r413", "r421", "r525" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://www.medifast1.com/role/DEBTDetails", "http://www.medifast1.com/role/LEASESNarrativeDetails", "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r234", "r235", "r236", "r237", "r280", "r287", "r315", "r316", "r317", "r383", "r407", "r432", "r443", "r444", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r509", "r517", "r521", "r526", "r529", "r580", "r583", "r623", "r624", "r625", "r626", "r627" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://www.medifast1.com/role/DEBTDetails", "http://www.medifast1.com/role/LEASESNarrativeDetails", "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Range [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r234", "r235", "r236", "r237", "r280", "r287", "r315", "r316", "r317", "r383", "r407", "r432", "r443", "r444", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r509", "r517", "r521", "r526", "r529", "r580", "r583", "r623", "r624", "r625", "r626", "r627" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.medifast1.com/role/INVESTMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Domain]", "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r138", "r139", "r251", "r275", "r375", "r504", "r505" ] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockMember", "presentation": [ "http://www.medifast1.com/role/EARNINGSPERSHARENarrativeDetails", "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails", "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock", "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": [ "r31" ] }, "us-gaap_RetailRelatedInventoryPackagingAndOtherSupplies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetailRelatedInventoryPackagingAndOtherSupplies", "crdr": "debit", "calculation": { "http://www.medifast1.com/role/INVENTORIESDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.medifast1.com/role/INVENTORIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Packaging", "label": "Retail Related Inventory, Packaging and Other Supplies", "documentation": "Carrying amount as of the balance sheet date of items used in storage, presentation or transportation of physical goods that are targeted for sale to end users." } } }, "auth_ref": [ "r554" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Retained earnings", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r54", "r83", "r419", "r436", "r438", "r440", "r453", "r525" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Retained Earnings", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r103", "r141", "r142", "r143", "r145", "r151", "r153", "r220", "r221", "r324", "r325", "r326", "r331", "r332", "r341", "r343", "r344", "r346", "r348", "r433", "r435", "r441", "r631" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r169", "r170", "r173", "r176", "r177", "r181", "r182", "r183", "r278", "r279", "r408" ] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevolvingCreditFacilityMember", "presentation": [ "http://www.medifast1.com/role/DEBTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revolving Credit Facility", "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://www.medifast1.com/role/LEASESSupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Operating leases", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r370", "r524" ] }, "srt_ScenarioForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioForecastMember", "presentation": [ "http://www.medifast1.com/role/INVESTMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forecast", "label": "Forecast [Member]" } } }, "auth_ref": [ "r288", "r570" ] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://www.medifast1.com/role/INVESTMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Scenario [Domain]", "label": "Scenario [Domain]" } } }, "auth_ref": [ "r154", "r288", "r543", "r570" ] }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": [ "http://www.medifast1.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMETables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accumulated Other Comprehensive Income", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r25", "r614", "r615" ] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "presentation": [ "http://www.medifast1.com/role/INVESTMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Cash and Financial Assets Measured at Fair Value on a Recurring Basis", "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": [ "http://www.medifast1.com/role/INVESTMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r336" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://www.medifast1.com/role/EARNINGSPERSHARETables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of the Computation of Basic and Diluted EPS", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r571" ] }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": [ "http://www.medifast1.com/role/INVESTMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Axis]", "label": "Investment, Name [Axis]" } } }, "auth_ref": [ "r216", "r217", "r218" ] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://www.medifast1.com/role/INVENTORIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Inventories", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r17", "r58", "r59", "r60" ] }, "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "presentation": [ "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restricted Stock Activity", "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]", "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units." } } }, "auth_ref": [ "r42" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails", "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails", "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONSummaryofPerformancebasedShareAwardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r290", "r291", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock Option Activity", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r13", "r14", "r41" ] }, "med_SecuredOvernightFinancingRateSOFRMember": { "xbrltype": "domainItemType", "nsuri": "http://www.medifast1.com/20240331", "localname": "SecuredOvernightFinancingRateSOFRMember", "presentation": [ "http://www.medifast1.com/role/DEBTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SOFR", "label": "Secured Overnight Financing Rate (SOFR) [Member]", "documentation": "Secured Overnight Financing Rate (SOFR)" } } }, "auth_ref": [] }, "us-gaap_SecuritiesInvestmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecuritiesInvestmentMember", "presentation": [ "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment Securities", "label": "Securities Investment [Member]", "documentation": "This member categorizes all investments in securities to segregate them from other than security investments." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.medifast1.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r537" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.medifast1.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r539" ] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "verboseLabel": "Selling, general, and administrative", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r67" ] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": [ "http://www.medifast1.com/role/INVESTMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, General and Administrative Expenses", "label": "Selling, General and Administrative Expenses [Member]", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r6" ] }, "med_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.medifast1.com/20240331", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardPerformancePeriod", "presentation": [ "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Performance period (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Performance Period", "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Performance Period" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Award vesting period (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r522" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r309" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [ "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forfeited (in usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r309" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails", "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Shares granted in period", "terseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r307" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r307" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding at beginning of period (in shares)", "periodEndLabel": "Outstanding at end of period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r304", "r305" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": [ "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding at beginning of period (in usd per share)", "periodEndLabel": "Outstanding at beginning of period (in usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r304", "r305" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": [ "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Grant Date Fair Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Vested (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r308" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "crdr": "debit", "presentation": [ "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation arrangement, fair value of awards vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash." } } }, "auth_ref": [ "r311" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested (in usds per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r308" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails", "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails", "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONSummaryofPerformancebasedShareAwardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r290", "r291", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318" ] }, "med_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesEarnedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.medifast1.com/20240331", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesEarnedPercentage", "presentation": [ "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional shares earned (as a percent)", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Additional Shares Earned, Percentage", "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Additional Shares Earned, Percentage" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Shares, Exercisable at end of the period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r298" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted-Average Exercise Price, Exercisable at end of the period (in usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r298" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intrinsic value of options exercised", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares." } } }, "auth_ref": [ "r311" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Shares, Forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r302" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Awards granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r300" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate intrinsic value of options outstanding", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r40" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Shares, Outstanding at beginning of period (in shares)", "periodEndLabel": "Shares, Outstanding at end of the period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r296", "r297" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [ "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Awards", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails", "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise price (in usd per share)", "periodStartLabel": "Weighted-Average Exercise Price, Outstanding at beginning of period (in usd per share)", "periodEndLabel": "Weighted-Average Exercise Price, Outstanding at beginning of period (in usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r296", "r297" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": [ "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Exercise Price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "verboseLabel": "Share-based compensation (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period", "documentation": "Number of shares issued under share-based payment arrangement." } } }, "auth_ref": [ "r40" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails", "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONRestrictedStockActivityDetails", "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONSummaryofPerformancebasedShareAwardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Award [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted-Average Exercise Price, Exercised (in usd per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r301" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Exercise Price, Forfeited (in usd per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r302" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": [ "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award expiration period (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r523" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": [ "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate intrinsic value of options exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": [ "r40" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average remaining contractual life of options exercisable (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r40" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average remaining contractual life of options outstanding (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r84" ] }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYUNAUDITED", "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Net shares repurchased for employee taxes (in shares)", "terseLabel": "Shares withheld for employee taxes", "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_ShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermInvestments", "crdr": "debit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Investments", "label": "Short-Term Investments", "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current." } } }, "auth_ref": [ "r92", "r93", "r556" ] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.medifast1.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" ], "lang": { "en-us": { "role": { "verboseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r76", "r135" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r12", "r23", "r103", "r125", "r126", "r127", "r141", "r142", "r143", "r145", "r151", "r153", "r167", "r220", "r221", "r277", "r324", "r325", "r326", "r331", "r332", "r341", "r342", "r343", "r344", "r345", "r346", "r348", "r356", "r357", "r358", "r359", "r360", "r361", "r374", "r433", "r434", "r435", "r441", "r490" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYUNAUDITED", "http://www.medifast1.com/role/EARNINGSPERSHARENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r141", "r142", "r143", "r167", "r408", "r439", "r442", "r445", "r446", "r447", "r448", "r449", "r450", "r452", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r465", "r466", "r467", "r468", "r469", "r471", "r473", "r474", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r490", "r530" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Comprehensive Income [Abstract]", "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementScenarioAxis", "presentation": [ "http://www.medifast1.com/role/INVESTMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Scenario [Axis]", "label": "Scenario [Axis]" } } }, "auth_ref": [ "r154", "r288", "r543", "r544", "r570" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYUNAUDITED", "http://www.medifast1.com/role/EARNINGSPERSHARENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r141", "r142", "r143", "r167", "r408", "r439", "r442", "r445", "r446", "r447", "r448", "r449", "r450", "r452", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r465", "r466", "r467", "r468", "r469", "r471", "r473", "r474", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r490", "r530" ] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": [ "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONSummaryofPerformancebasedShareAwardsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r12", "r51", "r52", "r83" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYUNAUDITED", "http://www.medifast1.com/role/SHAREBASEDCOMPENSATIONStockOptionsActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options exercised by directors (in shares)", "negatedLabel": "Shares, Exercised (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r12", "r51", "r52", "r83", "r301" ] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Options exercised by directors", "label": "Stock Issued During Period, Value, Stock Options Exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r12", "r23", "r83" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED", "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders' equity", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r52", "r55", "r56", "r79", "r454", "r470", "r491", "r492", "r525", "r536", "r565", "r578", "r613", "r631" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' Equity", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://www.medifast1.com/role/INVESTMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r362", "r376" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.medifast1.com/role/INVESTMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Axis]", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r362", "r376" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.medifast1.com/role/INVESTMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Domain]", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r362", "r376" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental disclosure of cash flow information:", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "us-gaap_TextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TextBlockAbstract", "lang": { "en-us": { "role": { "label": "Text Block [Abstract]" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.medifast1.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments [Domain]", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r272", "r276", "r347", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r425", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r573", "r574", "r575", "r576" ] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonMember", "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury Stock", "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r39" ] }, "us-gaap_TreasuryStockRetiredCostMethodAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockRetiredCostMethodAmount", "crdr": "debit", "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Treasury stock retired from stock repurchases", "label": "Treasury Stock, Retired, Cost Method, Amount", "documentation": "Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method." } } }, "auth_ref": [ "r12", "r38", "r52" ] }, "us-gaap_TreasuryStockSharesRetired": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockSharesRetired", "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Treasury stock retired from stock repurchases (in shares)", "label": "Treasury Stock, Shares, Retired", "documentation": "Number of shares of common and preferred stock retired from treasury during the period." } } }, "auth_ref": [ "r12", "r52", "r83" ] }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockValueAcquiredCostMethod", "crdr": "debit", "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYUNAUDITED" ], "lang": { "en-us": { "role": { "negatedLabel": "Treasury stock from stock repurchases", "label": "Treasury Stock, Value, Acquired, Cost Method", "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method." } } }, "auth_ref": [ "r12", "r39", "r83" ] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfArrangementAxis", "presentation": [ "http://www.medifast1.com/role/INVESTMENTSNarrativeDetails", "http://www.medifast1.com/role/LEASESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r336" ] }, "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember", "presentation": [ "http://www.medifast1.com/role/INVESTMENTSCashandFinancialAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Government & agency securities", "label": "US Government Corporations and Agencies Securities [Member]", "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac)." } } }, "auth_ref": [ "r628" ] }, "med_UncommittedIncrementalFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.medifast1.com/20240331", "localname": "UncommittedIncrementalFacilityMember", "presentation": [ "http://www.medifast1.com/role/DEBTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Uncommitted Incremental Facility", "label": "Uncommitted Incremental Facility [Member]", "documentation": "Uncommitted Incremental Facility" } } }, "auth_ref": [] }, "us-gaap_UnrealizedGainLossOnInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrealizedGainLossOnInvestments", "crdr": "credit", "calculation": { "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 13.0 } }, "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Unrealized gain on equity investment securities", "label": "Unrealized Gain (Loss) on Investments", "documentation": "Amount of unrealized gain (loss) on investment." } } }, "auth_ref": [ "r7" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://www.medifast1.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r32", "r33", "r34", "r97", "r98", "r99", "r100" ] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateAxis", "presentation": [ "http://www.medifast1.com/role/DEBTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Axis]", "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateDomain", "presentation": [ "http://www.medifast1.com/role/DEBTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Domain]", "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "calculation": { "http://www.medifast1.com/role/EARNINGSPERSHAREComputationofBasicandDilutedEPSDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.medifast1.com/role/EARNINGSPERSHAREComputationofBasicandDilutedEPSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of dilutive common stock equivalents (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment", "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation." } } }, "auth_ref": [ "r571" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://www.medifast1.com/role/EARNINGSPERSHAREComputationofBasicandDilutedEPSDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED", "http://www.medifast1.com/role/EARNINGSPERSHAREComputationofBasicandDilutedEPSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in shares)", "totalLabel": "Weighted average shares of common stock outstanding (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r157", "r162" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted average shares outstanding", "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://www.medifast1.com/role/EARNINGSPERSHAREComputationofBasicandDilutedEPSDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.medifast1.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED", "http://www.medifast1.com/role/EARNINGSPERSHAREComputationofBasicandDilutedEPSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (in shares)", "verboseLabel": "Weighted average shares of common stock outstanding (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r156", "r162" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481071/942-405-45-2" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19,20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "330", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB TOPIC 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//220/tableOfContent" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.1,2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "250", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//250/tableOfContent" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-11" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-2" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//330/tableOfContent" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-1A" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-5A" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//842-20/tableOfContent" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(d)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(d)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16" }, "r504": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21" }, "r505": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r506": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r507": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r508": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r509": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r510": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8" }, "r511": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5" }, "r512": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r513": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r514": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r515": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r516": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r517": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r518": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r521": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r522": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r523": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r524": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r525": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r526": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r527": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r529": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r533": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r534": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r535": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r536": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r537": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r538": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r539": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r541": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r543": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10" }, "r544": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3" }, "r545": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r546": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r547": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(2)", "Publisher": "SEC" }, "r548": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(3)", "Publisher": "SEC" }, "r549": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r550": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r551": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r552": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r553": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r554": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r555": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r556": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r557": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r558": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r559": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r560": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r561": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r562": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r563": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r564": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r565": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r566": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r567": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r568": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r569": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r570": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r571": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r572": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11" }, "r573": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r574": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r575": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r576": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r577": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-4" }, "r578": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r579": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1" }, "r580": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r581": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r582": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r583": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r584": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r585": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r586": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r587": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r588": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r589": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r590": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r591": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r592": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r593": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r594": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r595": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r596": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r597": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r598": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r599": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r600": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r601": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r602": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r603": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r604": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r605": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r606": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r607": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r608": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r609": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r610": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r611": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r612": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r613": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r614": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r615": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r616": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4" }, "r617": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r618": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r619": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r620": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r621": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r622": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r623": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r624": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r625": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r626": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r627": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r628": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2" }, "r629": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r630": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r631": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r632": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" } } } ZIP 55 0001628280-24-019046-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-24-019046-xbrl.zip M4$L#!!0 ( &^&G5@9I01_8 < .HE 7 ;65D+3(P,C0P,3,Q>&5X M>#,Q,2YH=&WM6FUOVS@2_GZ_@I?BNBE@.[+CM(V3!LBE62# W2XVZ&(_'BAQ M9!&A1"TIV?']^GN&E&,[3K8NNB]N< 6J6.)P.)QY^,R0TGG1E.;BO""I+OYV M_O=^7WRT65M2U8C,D6Q(B=;K:BI^4>3O1+_?25W9>N'TM&C$*!F-Q2_6W>F9 MC.V-;@Q=+/6<'\7[\Z,PR'EJU>+B7.F9T.K#@5:GZ3A127YZ*M58IDJF&24C M-4JR/%?)\;[V^N+C_=_/C#KI/YPTT?/VGZ34]\E)4F(VX'XJJ03O5$1J[1 M^4(TA4143MZ?[1R06BJ%%=0WE&. ]\L0Z4HA/),^/_F+YCD<+"?QYX_^R"W) MX(3=<",*.2/A:*9I#NYI"NUQ5UO7"%N)[ZTKQ3#I_R1L+OY-2N?2-SUQ4V4# MQ.3T)<1DM'ANA418F5!8Y R-(70E9+41;-:XE MS !9)"04Q$R*$G=.2R-RF>&1$[;4C6ALE-L2J"@C[Z5;L$@I[PCCKNGT>*9@ M#(8T(1MA#!;(M$/V@5B%[K!$D1/S0F>%\"U?5OWGY*A3PA,HM3=(4YSQYKHI M,$%?4Q8,9+TU3+,*TYRAFQ+I8MT-+P6"Q]\.!$GDND*0&2^KH/: /XBCV:VU MZRH'?L[*V!S2^-V;+VI>!M MO'=X^[01G->OWH^&[\Y\AZBN$F"*L'FN<1O"=B.DHP 0!%RGACB0@H#*U&A? ML#B+E:!'IDB^5]IGQOH6_9@XG341*;6S&2D\]N(0P% $I,7H7]]GA:RF)"[! M2;>M@40HL4X.Z4WH.CQ1\2[>:BX JXA0UB^8N-: &X'$MNP\4+XQ4(Z!>)Z/ MX0P)SN1?42D=O]TCB**"W1>,OAV<#MD/'\FCQD>T0D;[/)1ZG&PSV?K=NW#6 M2PFPZ$:*>=2V#@I 3C/M ^5!BJJ@AXOC%5FN$ZXC(P/.ND2ZPDJO(V-NU"!. MV.*MT2KL/7V;>JVT=)HGH&.Z#RF@8DVMYQ0 MG>IV1C56PDPK!JOTMI+,Z=(#Z%Q5,H*Q,5RB"?C6,M5&-PO.[D\-RVLK "]@ M*BZ+#=&UJC2DCOMN0G7K:F#:AVHDRZQ3P8!0GTZI0I%A &VT4,UKAD50>T?X M8FWI&NS]8@"<[1& (Q%?SZ1I UMQ="G/42#J&>+BGRCT'FJ)'=@WWCY=^P6\ MHB.8T\<*,[5M\[P%N^0'^2!-7#[GG]_QB'19F(P2Y MCC-C-+=1P?ONKG ++4]"[PN8DO.YS;+6<>S7DN<36DOK&SSG,T?H\AD4_=HB M]T+UX3-=R&,OB/3G1\\DN]]M8N^$NA[M0\[>2'[L'"$J)9+I+<>6.]%G)OJ#3#6>?R1.B+ -=M4.+QPA.T)A4Z>GI@M6?!V=6GZ *$67ZK M$=*_1^[W;0E\P$EA,ETV>?+L[$6E]OW;#ETB@^<.M-%#V"D0'8 3CJ8[A/5B M M35S)H9<1:LY+0[87<=-U)9&[L@M,X+&PE1;N 7>/M=2H3!%[S*:\(.JFM. M@3]R?;C:R-K39/GC#,1=&[F8Z"HX+'0ZZY2EMFEL.>$WOC-F?Y0-W:O.@*C8 MO'H9/$CB"^'&X;]:CMPU#T+34:.VV\:#=^-WS[8F@^&S;;^I]7B0G(Q^?[7O M!Z?)\UW7U1X%1T1GP-^^EM6'@^.#98<.CY-1?2^&FV^2&:);+K?UG[]L0T _ M8B5LYKINYM_RI"ZQ63=B=-H+7U2\I)F]?C4&IX1K_)YA^_KH=?O&['=$;2)" MHM[%8SN(=O04V*N&Q_A$4K"KSKX9M^^=3[\9SUT5FG)Q?4]9R^XO=CV MX%'(3D\DO_5ODVKKP[O!23P#G]'6UTHKT(7TEJRZR!3(:YOM+I_YP*F[QF^M MCL(W7O\#4$L#!!0 ( &^&G5@"%*185P< (TE 7 ;65D+3(P,C0P M,3,Q>&5X>#,Q,BYH=&WM6FUOVS@2_GZ_@I=BNRE@.[9CMXF3!LBV*9##[5O1 MPWX\T.+(YH82M21EQ_?K[QE2CIW8:5UT7]Q@%U@W$LGA<.;1\PPIG4]#82[. MIR35Q3_._]ENB[3(/H=_L# M\8MU-WHF4WO0P=#%TL[Y4;H^/XJ3G(^M6ER<*ST36KT^T"?=D[$Z/CTYZ:G! M(,\'I]UN;YB?*GHY5-U!IO[;.\!0=$]C?%@8>GU0Z+(])9Y_-!A6X6RN59B. M>MWN-P>QW\5Y;LN R1P&IS^3C4U+TDU@+-AJU.O#4J#;T)9&3\I17-]!,K7L MGEECW>A9-_YWQBWM7!;:+$;??M %>?$#S<5[6\CRVY:7I6][Z_#\6>]E]^RXU^G?7\9N"\@0?G)_T0K> M_^??5Z)W+-N]P:%\(=Y[ZS>6'ZQ]_V'4Q?[CK@ZVN7[?$OR3;^ZDC MOI?&EK1HB8QAUVS\+FXOO M2>E<^M 2UV7604Y.GT).^GN7D^^D1R80_6(A;DH[-Z0FU+J7&F7A0FDA&IA! MZE+(&6$[;0002;^FUT*"DC[Z5;<)=" MWA#F7;/I<4_!&4QIHAQA#NZ0:0?Y0;<2P^&)(B?F4YU-A:_Y9S5^3HX:([R M0GL#G6+)F^LPQ0)]15ETD.U6<,TJ+'.&84J,%^MA>"H0//YZ($@BUR62S'A9 M);4%_*$[FMU:NRYST(<,&G9TF9E:P2: LY;!%D"GG5F("GEGR#*4C5EALH&# M?S U8*\T&VYQC]J@ X!H@98XG8_^9-)/16[LW"]1ZFBB?7 2$TF^F?R&EZTU ML/FE,QO>/A6\#?8.;]="%C'7R)T>&^*<" + QD;[*9,#)ZH TS';\;72/C/6 MUR 3YD!G34IZY6Q&"K>].$2.%0$T*9%7M]E4EA,2EZ"7][5!CU@N#0_I11S: M&ZITE2XU%W-E AO;%\Q!:QA,F&!?=IXHOS=1CHEXG0^1B1XLRE]0]!R_W".T MH1K=%[B][)SV. YOR:->1[:B.'T:2BW6S4S6?O^O*RV= MY@7HI-R1S4NV5'M6T\C9/DIOY#KK"0YA!QD'51( SVHCF:*QK.C$2I4Q(FG\ M>FF"O\;$'<&B&$_J"UASOW \WB,<'P\V<;PS86W >7>JVQG5>!)F6C%8I;>E M9$Z7'D#G I$1+)U:H@GXUG*LC0X+%NIMT_*S%8$7,94>BWM=UPK,*!VWS8*J MVE7 M(^%1999IZ(#L=2<4(EZP0#::*&*GQGN@C(ZP1?/EJ[ WD\&P-D> 3@1 M\=5,FCJR%6>7\ARUGIXA+WY+S?;\V4F_]^K,[\*^Z7)[&1?QBH%@3I^*Q;&M MP^,>[*(/\JXW<260:S@S97,3%;R% M;@JWV+(5>I_!E*SG-LMJQ[E?$\\M5@OK ^[S^2%L^0R&?JNAO3!]^,B0'" & MASWHW3B.G0_%W3\?#)3UG5\ODE=3Z>\J#6:_"'I2419B/!K*7F"/?T.F.0IX MT+_UQ2'Z0J#OU99JN(=;JGBRIY9P;ZT(!YOZ=<2MJ(H@,FBT"$0?83)?JLUW(\/ M3EUFKO.W-- $:C>C>[6#F)&]815/M%74T M5HWQ"')Y4/-9@&LV&]A3;*OZW-)=0X=Z"-%M).\601P(DGQ@W"6DG,=#FS9D:L:*6< M- ??KCF,I*(R=D%HG4]M(D1Y#[_ V^\B]YW/>,46XFZH:1X#?^3:"+61E:?1 M\H\S$'=EY&*DRQBP..BL,3:V(=ABQ&]B9_R:#"5 \PHR(BHUKU[2=KKI16UP M^%\M9VZ:.['I**C-MD'GU>#5HZW=3N_1MH]:/>YTA_W?W^Q)Y[3[^-!ULTO9/GZX/A@.:#!XZA?W8K>_3>\O]:>7TIN1-U6?_Z3&W/Z%@_#?;EK M%O^5K^L2VV\C^J>M^+W#$UO<\V<#D$O\31\<;/X^?!]^+P([XK&5X>#,R,2YH=&WM6?]OVC@4__W^BG=4M[4229, A0*KE '5F%;8@&FWGTXF M<1IKCITYIBW[Z^_9(;1=U[MNMUO;:5452-X7^WW>5Y-^JC-^U$\IB8]^Z__N M.#"4T2JC0D.D*-$TAE7!Q"F\BVGQ 1QGPS60^5JQTU1#X 5->"?5!W9&2KIF MFM.C2D]_O[SO[]M%^DL9KX_Z,3L#%C^KL<-&AS3\QD$CCI9-2@/2:GD1#5IQ M3-H=+UK^Y==0%-E+F4*O.7U6RYAP4FK6[S9;N>Z=LUBG7=_S_JA9OJ-^(H7& MQ10*EU]+'3#-Q'M_W! M:+88'X\'X6(\G<#KM[/YVW"R@,7T5DL>RL[]#KQUY^[ A?EH8'?O-UI>_<'O M.YQ#.)R^7HR&CPKN"N1#[P"FQ[!X,8)Y.'L>3D9S9_KGJ]%[" <+0PD\+[AK M&OSOMC2_:,M80"2%H)%F4L YTRGHE,*;%5$(,%_#C.92:4#BL509^)[S!G8- MRY.=3A!XO9)N;_S>'B12604?2P5 18P-Y82H*(6&7R][ATS@A,8L(87&6B$B M]YK&@W,:K133#'$@(H;11902<4JQ1V49*PIC"OX; MSA@;&J1445SS]FWC+NHP)()1#C,7!BE1<1T_&$U0.2ZFV1F%:9*P"&TR2R+_ M2V+\\-I%Z[@4=%T)'#-!1,0(KP3J@!?-$N3(5ZI8$72SEG E:S?PVZPUYI)8 MYJ817V6OF$S4H3$6!J*61-#"F5YPNH8PTH9BHJYN) S+DA;V8;:&#T*>(XJG M%(DI0=M;G=Z=BW1.XAB' H?3!$.G4Y5MANX5NNN8)_<4P;O^7F7%CU_^.BX' M;J-I<%@@\)N\258>=I"SVIR9+3BKR4*J;*04@YR0O:K;[T8E;DG*R[3%A@K%!O MHVPIM999UXSA9Z:R181O^K*-G))\.:&[7CFE:QS-=5RMO"&[EK2OXYNTP.TT MV[=2/=>_E?9/6IM-UVNWOK_:0[?=[MQ)[;X%H@0#\2[0@<]JC5HEL(F[;I!? M@']]/C:A> -RF?_X]+0.?;Z^WD,V=C]FDY[L--N]PEYA&$[&HU=V'G@1SH9? M8:9GC/Q*;U^3^3+K)E=M*N<(C>0L!H-)[S-\P7QVW. A(_W9M'7_Z#Y"#&\9 M4']A^0U8AKEB'(+#\HCR'R&L>+;C1-EXOQ>LW\KZ*';W_UQ,GPUG8S>WW\6_U3]YO/3^OW#^PA!O.4'CE]8WF_#V;>GLR\<_JZ^,,EE M8<^5744Y,>/"C5I0A98O*O]$V1?WGKLKF6+X#V[8NGOP%02P,$ M% @ ;X:=6(07_M/_KU_^G5/J_7Y^_27>V-IM0RY-N'4H\JDMOAC>6 MO#&5_FX[/XU7(CV9Q!O9SJ14\F^[M:=SQW@9>Y)24:KA9>&OSLV0:)6Z5M-+ MU9JJEJHMO5J";YHEK:E5U:I:UYMZM?AR4U-K#5UI::5Z9M MN3<3JO]6&'O>].;SY[>WMS+\;8R(Z\EES9Y\QA%75%4N!%>;AO5SY?+WH6.6 M;><%KJRHG_'G(7%I>/G[QO5O*KM:;K5:G]FOX:7&NU=RJ;9R,?Q=?K%?/QL6 M7$F1_)\]AU@N4I=XL%[P5KE6 EHM1SAS2R^$3!?/@;D,V2N#'W!*:GBQ3HW% MA6PFX1OAAY4+\4=CQ\0-R_6(I2TF;KAV59$;N^[PKXB^0%\;3'!M_;/_8X12 M\<_=12:E4JHH)5E9/F3;V&0U\J#P93N$WS__JMX-%W[S,;P.?V?_W7?_WJ&9Y)VX#R4HCM7S_[W_WZV7_R MT-;G[5]UXU5RO;E)?ROHACLUR?S&LBT*[S?>;_!"ZO@?#5VG%OL(OS^ ;' , MS7_]N_=,1[\5M!* TR(3?!(U;KH6O&Y^"X-SB-FS=/K^OW1>D Q@PU%)J17: M%?A?2ZZH2NO7SRM/3?&2VYGCP!ON#5&; MT@2>,B[I9#F&>J$M*R4DS*&O#X7D\OWW\(V[>$.CT$;J9_6")[C^ GA$Q4=;_WNQ@L_KT+$H2,*"Z-1 M-P;8* YO7,8 ,"2)B<<;#^#\6\$U)E,3N8%]-W9PQ%$,E]]='0#.7K=\1_!* MUYXY["\FQ6Z"6;.AXZS#[RD#9OB7H>/?(X,Z$AL2C97,M[W_707L^LWM\*O5 MIT_9BH5_ :\['L*3H:)4D>'_PON6ORV&J4G5Q[58T )4#\PA M>BD3)\2SG0.IOW$_?GE'+7MB6'&/38J0E4=\7AW]WL6OS!E\S4[-#8_/4,PND!7U!>\G_4X>7O4]-0S.\ M[W0RA%?H!OS*?.Q"X(G=]#T0F'A/%RQX,(GMR10L;,MS.^\&:*WP,O@>;-2^ M9VL__6?]^CGV%0MJ+$9R-C9IY9SD'5TWT'$$TYH8>L^Z)5/#(V9>R"]7\DY_ M#=R;F8GQI4=O3!V\SJ%C?-HK[5F:/:&Y68N3.Q@G7HMGZA'#HGJ7.)9AO;BY M(?S)79H3$W[@,(MSSB2_KP1R0_N3.S:Y!ST'/K]\<@\DSY81#PMT?P$+.D?^X]]#-[B!FNA9)W;_U# M/<0L"9]WU_RC/<0L:9]W[_RCE&Z&(7XE[U[Y.91NEO3/N[]];J6;Y5KDW;7^ M4*6;)>'S[B9_M-+-DO9Y]W0_."S[4=DP:ZN4=]_XX\*R9UJ@W#O/9PG+GF>Q MU+Q[UQ^B;WA8J+Q[X^>/GY]IX80K_^$Y;:IPY<]+?^'*\[,6PI4_$^&%*W\^ MVG/KRG?@";IASCP0)'VJS1R0\]3MOFOF3*?ZO6-/<#EF'CN9^3@*01^> ODZ MCW_ .LNXGF-H(+TN-_M'Y38.<(%+?";3F=M(0N>-.#H>)5Y=E.YD:MIS2MF2 M/$YQ?2^2]ZK<1@VV+,PU",0JMQ&"4NX!"WG.0]P7*>#:%YP=':RO,;AQ#K@^N3ER#"Z27\RHN1H,L7_^Z M!J5ZST(;_B(MUUI>8A9GY],SK4_>PA>1I6&K8G><&-SJI>) Q%=X@P'9U('W$6' M>,?!J7W0,\D#OF-%VY=#%F9!%LO/=RCJ>I;_/%J@GI<(U*'+DA7<*A?)_?5+ M#W#E9?G/Q/UY"J1]=/SY-$D4=>X"9 ?OL2=>3%S'QU''"\C-XG(78CO]COOU+"YW 31N.1?/\$SQ&!3 PL/V:ZSFS)2N&%WRW M+3KW3:3[F:7G9_VY#3]QM?XG$@,"?W5NXU]GNR. M!K?AMWRA[T?_=_N5.A;^]X-@[*G2- M[NC06S[QA^6 KVO\A^J_$\-:.E"K5^%O[C?;=7.$3VZCAUS@\U D=#3-F6'8 MV:,.J+-*R01,K?V#.V]*2S! M_"Q02%'].D,HT#X6@\:A M;S,43-.P7GZG%AB1)F[@Z1/#,L"F95/OOD_AL1?:I$6NE!42,7JX'EI 'NS GSK5 M_9=V7AR:A.^/<^UDA(6L9N/:<1O4WK76WZ@'$O%QY%\CEGCW$G,;,HY;8B3X M#]1$$\-C78DTAY&;F(*C$RVWS%V(]O3].\Z]E"M:>VTQ=VGMM4N/TMHR=]'1 MTS?E$>L.Z\Y=<#9!5HX(?F#]DL_&^XU# M77OF:-3U_QQ3HK/QZ,9K^U?XAZV#41G5:LUAK='0ZI6JUJ@.%5TG>FM8EX=U M55>&_T2;:7F/Z\U-6(^)897&%'733;4V];Z\&;HWOI$KE3\75J\CS@M_.Q.B17^KMFF[=S\"9=Q-/HR@N&71F1BF/.;OPQ@75SI@;Y)S_:$ M6'\INL1R2RY,.+C0-?Y#X97P=O;G6S"<2N6+:5@T'![ [,]?D"@EG6K!H8^; M&2RC@U?!< @W8Y'&#AW]5OC3_C5I%-H#U R2/9)N<Q2[Z4LPNZ'M>?;D!E$)]I-G:,0,9L@FZ_^\!&RYXH/6 ];P M]/#-P<]E^.GSYO>M9KE5B?^I4I;9]Y_9\YSPQY!7& / /3 3G.]O!;6P-ME@ M^.K4DW1[AL1 ZG^9$ET' _"F(LGPC/ %G]G,=Z^T^B'+7%];YD;L,O]XZ VZ M=U)_T!ET^ZM@C0R>E]'VN[<_GGN#7K-#4;HKWY8EI5*KMOB91;)UN7]\_B[] M"BK-LJT'4-&.H4F!YGM& 0JV14&R"-H-.C5N[FR-Z7'<&2DPI3>""]IRI?0W MIAB73VDGI43 C263CKR;5N0+APVS%4W M$*Z5B&[I2?:W&=C>H)WFSW1J.UY!8MVV/3 ;WKV;D?%.]1(820NJ@IO]OHVD M"6?: 9?'/&J6DI3RESE?_O1>1YTG[_]0WKN/CT^#Z2G'\_]'YV'@31X ME$">#$!H2+(J/3Y+"\-_MJ5(J)F(68ZMP/\66ZI55YQ>1CIXDV M>]N1O#&5_AUB3O*-6XG9W ?P^Q.[O>O[A*O0U>&;T@0>,<;;2CJ9E^:4."5J MA5!6"^WOF* JJ7)10CL\+Z(BRR5Y?.9UEN<2B ,'WF:@W;Y=(HZ(Z2Y$8K70 MMJ];) Z>.P_]'A-\0B8>*!.]!>Q"H3AR[,D_@_])GBV%G\O<&'/)9GB+NY@N MAE^D>P.<'>"1(75N4HC[+@NDX,W^O2'GU3 Z))=4N=90#Q7>O%B\::GQ3%]8 MOI'E83942)$ZZ#2J&R/B>D6I9VEE;LF23+)\ZKX3S6.3QT"(LYBT1%S)G5(- MPX"Z9%B2X;F2-F9VQ2\))UG(22RBVBS7*XV=L8CDWZO-:JH[=@ZJE21 LBT: M$L8[E.D[1CQB1/0Z0>WIAZ-0KA[ FYA#N"@_PQ+I6/:B,[^U]54S%0:DX?:' M1Z>._8K/6=JGC4+[CIKDC3AT*Q=[^C[J+J))U[8( _+>"S8*_!3.5=W1++1E MM:0VY&JU4MM)WSTP#J0&RI1*N0%R0')MT]"ED" \4+B1B,*?&%0E,$ALL$@< MZ5\SQW!U0V-&"4A?(PIK=IGS0BSC/^SO7[+#Y 51M%=^+O?+4GTYD'05 MD=*#7?YE$VM)0KXBTC-G1=8>Z;O"?;_ \.63*%L;L*A([CFXQ$A%3NG., MU^T2\,,CRRL;$WM0#Q=1&=/ >QNF/SA,H'>#J MY#H)TZN^$V=N$DM?'\RA8WFRX67F_V=,?>T8O$@IM!4@I9*WA1]0DT['MK7T MA9(42:J%=E2OK=/@E!;GQ$(/YA(-:U8&8#U%KRJ5FI9J@.M-9>5(>.ZA452\^/%0.B^9VL_ MB]*4.-(KEHJ1_AMU@(S1<W+T3E#X% M]KN!5/'C]^L.&,J<-=^K 6()QOH/V_GIY,U *[MC&[8=P_\X;$V]]\&]D=9@X1O_F8!*_%)EC\DGQ M)SF$]8??A_^"*>#U[%*X"4<1/ ?WK%TV"#9(XGI2JR+I9.Z6)6ZX MUWEJ">6/=R%XJ/O+Q8N5R#KB,@929B%66D*L"+&2E5@!3B:2"<.F$M$T$"L. M0=F G.:@*1#[K02X*\7\X$Y &L$[G% A M8G0(%Y$0T?>!@8"TB@%^G%L=^\ M(T6;#QA/V?/[4: MU?J7,\\C*ZA@ *>SN6AGG5O:K.SX6;%UJGY)$SO-PX(A!!_B5/.%<%;UDCBK MO\T8N0@.2ZMB^SEQXD.ON/?*@R!%$')XZEP>H(/B[\:9H_KDZ+4I"0OS. MZ'#KDV$_6I1D:,ED=S']Z>GS>8JC'3Y9$3R<6$?2&,6%IEA "M2-9;-XTLSU M_3E83?]L7U%Q3="^UY8)03*R*U!WGU_GF3>0CBV4I(E>Q# A7LF<> M$\8HE<-LE8#G#->=40?#97+CB^NG,U$6U=/\! O73[ @;GB'":]Q/9#I&/O6 M6$P,3U&G"*2=@3Z#6+*LZ\@E&2)S7Z$>\:3.U#%,W&VI?%$4_T@XVPX)$'G/ MZ (WSRS#QZ/_ML(:1I4""$/- (/:_:W0>[B/V;=D@V!;^'WVB,?E0%8A##,K MZ38K)H0/!&L';$5X5F4!Z"JFS!=;:J.H5!?G6,*AMA.MW;;R,;D(B_)?J"=: M1&MJ^T;8C4--5BI^:UFMX-V5Y2UDZ-KFS-M^"P>5GIA7L:;?URM5):M)UEC4 M)!L[2QO_A9:&#B4_2V0$\[LAYAN9N[@$HG#9Y10NDY6SE"V+/UBP>IR:;5!A MMP5#-XAC4#>)?.5J/F!/T/>DH\Z-$E#+E9J2S;GF" M04Z!VK7[_0I&NXL1G+EFL0+0&3;6@GQ(L3+ M+NQ@IL06\?*5F&"F4ZD_IA1$3%24^#LX,5+CCFI^ XS@6R%"\B%"$ 95(4*$ M"#E$A-226BC$'4OWIOWF"KOD*H0* *,FA(H0*H<(E692H<+2O%S, F/I#6/; MA+>Y0?J%U/WWS/#F0MYQ9?B<6>6$LOTCLO#-<;>9WF4!#H6,1 M<^X:S"A92@H4)?XA"+SFF;HST[=;'J?4'^%A6Y]";'RTV$!0R!?KS@BYD44B M8CV0&^I";OP-CR@9'LN\92( OC##OU&"F+8[PP1R,K1G'CH@/ZDG/1ON3R$6 MDXXO2DX M77#Z3HBTY(WH] \KTHFI3TR_($&P]QTI.(_>Y@^7^BVKF!$@Y$(^Y (NNI + M0B[L@D@UD OUA5SHOH^-H7'@Z3K!Y!_.Y+""RLXT7%'R(RSY(6=1\@./;XN: M'U=0\R-KC!Y2E28%+-5"?L=>+\2(I]U-Y=03U/)*6FRE>]>[[_0'1:GW<%N6 M.@]W4O_'UW[OKM=Y[G7[Y^O]FW#\MX\/=]V'?O=.@D_]QV^]N\X _N@/X#_? MNP^#OO1XCU-[_-Z5/OUXZ/RXZ\'OVQO,\C*O3S^PB[F.U5XT9/%!W MB]@VNM)/0*XEU=EJ\=0O=VWW: M;YG*DM>#CDMT-7G]D(+8R;LFRBLM$]/W2SP3U9AAAEG]"0I [Y_MU9!+C0/3 MFM,A[RIL>"S%4E#])*_:UV"7:#]?'% _>BE8%$VC%*SG0[WHDRYS?.7^9_I* MK1E=9XPT,ZQ(?,^3P?F_CYKAE_6@!D]3VUHP=N;JZ]5BY6BUV)(:%HN=N:47 M0J8W 1KN'7O"LI3@B7\WO/'MS(794:?[KIDSI$H'B_NZ5!^0]V059-6P@JP* M7K?8A4*>3K5@VP7%OM=%!8W@ELOD%O7LW"(7VFJU66PU M54ZX);5*'+'_Q;Y7KI9KW/(!TXZWMLN:,[NXK;;5>%3233]6 N2:3_9H%:3B MXRC@EK0<@,4I&L5JM7$L ^P XBG4Q=KK8NW2JP?.'@%[%'!4+%6O%&NMHT5G M1LBY*&\B/C+QNV.[K$W/R/ .$I?!E!.Y:3RR1+POG:$L911^8@1.RQ#8NT%I M%)66LL$0Y^F0Q&ASF!F3&"!G\@@$V+.0_T> '9-FJ_6BVJH(L"?12FG">H<9 M.WF\/R.5G1-OIT]-^/*E*+U0BSK$++*<0:)/#(LU-L)TDF.T.L^R[.1.4$#< MWWW2=BR]LT+7[OL4JXZD%7-UT.ERJZC6-G5Z;J-I E()U>-I(-4 2+648K/! M2X"6)PV5Q585)X.[ G?+I^L]=[=^\7 M+LU"NU%L52_ *!>*DB/@[E&4&0"W56C7U&)-E@5R>=+'W-U_45HUWDWT"Q88 M09,)ZEN9OR1)K3I(N)WC_NO:Y>QA[AGV8DZ\IE>_<;7'4@HIZNN;P!%[L"T[ M5$0/-&U$LXJ),T5%X64W2^R#[H'3IZ,,&!>&#Y\. ]8&=F3 3G/3=-E@\)QL M@>9$KJ94E#FWXD\N5!DYHUA?88*TXE0IM)5B51%QTYP Z23B=!^D-E"CLL.G M!XM13I+P#E7"N=VI/KELRDPL50MMM5BOUC*R\KC(DQ#H^S"!ED:684WKYJ;^ M2VT4\I^>D%&8X#2;/V<97$8!#CZL[S2;/]*0@D"FH57ND??+3>P^^8;0,IP> MGH$PK!E08]G?X"NCMG_= &G=??<< E U+.+,L6*-"R(+7^K8;#,[='#3ZDV6 M"%&L-3<59W[B\R(RPQ\'[-E9XH@#&FR'2E4VTS:NC@-X,AJXN_^Z]C:>'/O5 M8'UZL/7?-6C]#]C<"&19X%I\I19-GZ%=;:*GJ]2/SC(36I,_!"72FDODY>/2#U]#F1D"?WK %*!^>J MU2J%=K.HRO7\.P*\AZ\%7PN^3F7Y',776 RD56S5FX*QX95 M)3G<-$@RNHNRX>+C!5WB6#!4-U)AM"0-B6MHQW@3G(GW8XL^QWG=] MHDX?UWFGA::L"_(0)^'=7Q$B"YE=6S43V*M@ MJI1C#!41F!$&P048!+J!?3)T81)=ZQ,)I''0B-LGVLCC7 M?!)+[VM&E*I$XL)4MMO9LG)P46PV&K6:]R@FV+DI_Q@O;NW@/.DT*U86= M!_H061R0?8-MTG),TY?&M:PB?+QO] M.A+D4V@GC6[W'NXWNW%,)K;5 M]VSMYUT(O$7(+\#?JKP>&>]4+_V'.O9F++!>P=RAIB(K7[*5U#" M:^="-1,NW. VK !5KF=<5N)TK,8T^&?63?G ]LV9+O?^WO:L%X)_VKUP#F(WU9P_>N=]_I#XI2[^&V+'4> M[J3^CZ_]WEVO\]SK]K>R.2_COWU\N.L^]+MW$GSJ/W[KW74&\$=_ /_YWGT8 M]*7'>_CI^]-S]Z]P7>^/+D[T\7M7^O3CH?/CK@=7_\+]+#_]*/?+H-E,4*HN MB&\0V/8,'JB[V\>>1#4QM;:4P4R5:OB6J4MOP@]?=,.=FF1^8UAL9.RF+\'C M \&-@F=-A;+W^3\',JFEE-56 \52X!$'+PXD5AEF^GGS^UJKK%;5V)\J93GV M^VV/DIMEM:ZD>M3V[ZMJNB?M'-3N^>V)(NR,:;0V+HLQU?EK^CX 4PEL"^] ML2N!90EVR'?B:&-)E8MQS> /HDW$=4H17>.;<$I%J2;9[\^B@M0E$4V-0U6: M@&B61-OSC).\Z@KR*@XX%BWZINU9EBI%=@5W@E\?':*E#Q]1RC=>P+&=1LJ@?(27O-Z*Q3&Z+ MK]W;#OQI2=K,<:BES27/@8>9+.PGRJ\=TP;A-LHUOAH)B'T;T'J I/;?UK'T MP9+P'?U?,]?#_0300(^C 7E_LAWV@^2&"Y#)Z'S2@P3N018K@_O:PFS1F9Y71]SFD*D>Y]7JAUF#31!F"F;04"^FI>( M@P'8\&*VI<:57RDL$L#@L(MCN7N9,AVP4UAQM9U>P1)P?$R8'SGAQ0LS@Y MH"CBY( X.2!.#F1U/3]'Q9,ZKDN][=D*5UR?TP\2J;PLXX[:-V!@21I^H/^>&6!<^7:\ M.%]R#9GUU3WA+X!%Q]+Q/]TE.#K>+7$<#*[\@:9XVD 8./RM1K':.+K9*#]9 M-((]+I,]:F=@#Q78HUJL5H_>G^&KA&HN]&'/>H45M)U#,S"O(KMYC\X(:3A_ MH&G[4#>JA7:U7E0:*B?IR2(K_N.$Z3&XJ17:M6JQUN*L?_F'^>^1\&?PB!)> M'P9 SR1)_<17=VT_X"HRVC.4I_VQ[7@#ZDPB)$W+'W7@CV:Q53MZ[YD?DUO@ M)Z%("7ND5IZM I,8ZJ]G_9W+!'FC[Y]!L@ M-=-R01.X((NXA3!.^8/-'B%Z#&Q:F&_94#CKU785\>U@V23Z/L7T+I?%NFV_ M6D*P@T%V[V!9-3*I-RXRGMKB1?[&;Q,/;(^868C:O)_+BR_;F*$ 13'4#\*[GOTQ%%P5_'$<[5843;/G0JX\WKDE;O[+S+; M:YL;94]A-/.B-#4)*G+PHC!9:,JJUI3"&G-$TV:3FY MY]@1704FR*HCNK!4.0+0/FF:!8!:3!W7:UE5N!$F:F(I>D='U,'NV1YY%R;J M<<(TI*6? #0@[P%?I#8K6I5"NUJL5'BQ*H1Y^G$"-3L0R0@B6>8EA72/4 VK M.9O)Q^):D*\K&5\\,_7+!U-@_EXKC0EU:.29H)7.$$V]Y7?'ALCP ^ MWFYJ@G/1*,K-S-SJX MN_]*HJ$1;'Y;=YN*X6E)+5/'ZBIRW0YSK Y.)(8!^IG$,B]U[T3FY-F]JR/0 MA)5HZD7Y^$I@(MJ6CP%>8"V?8YW3?6F?EV^I)W=.4PL8[*PA%QNM/.<;I05( M#H*45PSVY&YI:K"K6->M6:S&J%.!=E'%1Z1:K2OPOF=K/\>V"4AS_R)A#1!O M+G*M+JKKPJT]F=CX4ECIXK)9KO3?NV3V$W7Z8^+0G89*[^%^H_L1>QE#U1-Q M'IT^]DC76<^CY2,#N5U9RNWJ;@VR;32UTXRF5FA7RI68PO8;7TC@#THN/N=& MVCH!]KN;MHW4-M2J<;W$;EB[7.\Q&J>2V*=&*P]UYT= -3FR0?V./-5*:AJG'=@1-);]JM'-UF9)ITT:&XP ?FWY MY2N/$%?"P.)57!%/8CW;?3=/E8L2-FUG2Q^V,%_Y22U* ,0I!:2\4G.^!Q-7 M'Y)/+D6#UIJ;C*M@]P!. NQBN^8#>[$FP(;*$3:N*9.X T-&4A-3PNX.)<.2 M-#(U/&**).)#3\XL2/H$%.U9MSX]4]LYX(TKC6*K+CJN7B"&]ATLR0A#-1P/R'L<==>PVP8G1(0S2#SVV=RQT,%YZ?!E48;"FEJK/U"/P MI2Y1XE@P>%<2ANJ!$C0D93>@9(0M[NC(T(S4>70R%@AN*F"T\G)621BM'R=6 M3X GC*A: 1]CP.8P[S'WA_/0)NCMY0AQ5.D)A1--4_"25M RM M5+"?80441-RV?EY2P\3YO$L"_1ZME@'H94RND(O5I@!]?D[H)9HH!Y4($PSN M"@H1^E69#RE'F!#P_N1VU7WDL+931H5ETY'@8A1#\N,@'4O/0$U<4D'H5)#A MM&B;X/QKY?SD9V.RX?Q+*D=]E:D6RT"7%>#,NWC)15;M0H MK+&3-?KDRCYB*DC,P9ABJ55[ N^>P_0ER_8PB=K!*JR2 2-[<5@2AL-*$'AC MZE)$I8Y%65'66UBW?)J EN$(L$PJC48Y]1VV;[R MC4--@HEO7]X,W1N'+!*Y*UB_RO(6,H01S+SMMW! :KD&8ZJNY?)%_L71(M,9 ME5&MUAS6&@VM7JEJC>I0T76BMX9U>5A7=67X3Z56"&\:+QR2*7FAI:%#R<\2 M&<$$;XCY1N8NHC(*0CD]'+YQ 03K;#BES< $M3 M!Z^"X1!NQB*-'93-?]J_<@U@-E;=&-CH%L6ZA9W.2#L.%6=%[X:>8H+B>_>N M=]_I#XI2[^&V[+LQ/[[V>W>]SC/X-5O9G)?QWSX^W'4?^MT["3[U'[_U[CJ# M+KIB\)_OW8=!7WJ\EVX[_;]*]]\>_]Z7/OUXZ/RXZ\$UOW _MT\_ROTRZ#/3 M) [(;)#2]@R>I[O;A[ZFCS".P<"Y$+-,6VKXR*E+;\(/7\*XOF&Q8;";O@0/ M"V0SRI8U+U#+OR *'-_:^4:WZOY0+TM^:I' M9\1P--64,;*X&7(2 CL^UT?>'0(#0"P3)5/'NZJ%=K.HRILG.'.;)";8X#+9 M0#TE&]0*;;55;-5YZ1"09>X8]RJMH_]KYGHL=BIYMN106'C- ,_<6N@Z_%XC M[EB:.O:K@>[0<"[9"\.&",-F;S9Y@W<8W-$I++W!PHU^/[2)#8/[C_^%R"T_ MT#Z(DA4^FQ0_8'^D"'53R\LZR,NB$I,ZF%NS0> IH:(]"9[P$$^QU:AR@J=, M4[>Y%[P/ME5BRM6OLAZTG\Q"DUX::VP1M1.JKU7"[OHT!,K> F%3LP,>WBG* M.W(0,C=OKOZ@XA:IE_G2XCF:HEKGI>/F=9F8K.15:4C\/(X)+B335UE4^+PT MAMAC5C)2?D5*WD8(F98=5#R%4I0;V]/Q,Z\))NR[PQ9V<^WD0KM>X25RR$W9 MM3H*P?.(-PQ]25C:EF#.C2-AYH(-?V#^S=3!<(DW+TI3DU@><[#QA-X4XRZB MY%I*6>C"Z.'3.N_\3@P+%^'1ZL,2/(Z> J(_( DKLAU=&D84P. / M.GND;5+$1-7JR'BG>ND_U+'CD*1BNG!3D94OG,")F_J]9Y3,SQ0&^1^P.E]@ MO9B09UBOU8]^22[69LQK$3B^.^T/U O2OS'T9WA:D UKV/I3_XJQ/%+'4S=UJ;#GUS:"C,W=]+V(.@D M%\&-"[5YAE?&UI@J1.#ZVR7:IJ3"\A8;3R!J,,A6LJ%.TT4*NR,%#/*7AOQ\1ZP3KO MT9QAUZ6>R_;!(OVZ;T2SSRVKK*B\KS+RIN79SM6ISE-L98)%Z6"ZTQWU_]NS M(N1-K4 5_Y@1+V7:A18]I1;]$$2I6+ZVV*H?[UZ ED:DO[)ISR>;/7I'JDUG-KZP W:6K$5$P 11FZN<7:X ME7L2G+585*39.D9@\V7A'IWVK2CG2_L.HQ"Q>3'BK$WF >H@"0+S>35JO")? MI66A6H65MJ@=?:Y-F,G\8>N84'46V)+!#%"*]0HO)[T^^FC.2>$1WXX(ZR6R MXA8CTWX[O'Q4 DOGBANW[2]1B+42G@+B?YW_<#%E;>E]+NB?FJ.40KM15)J; MP>/\=.M("Y\<&/U7S K[RQ2>BA740KM>+59RW;/J(W@AD]:&&97\.TUKP[,, M[J)LB>T)1FX6E;2O(5^,^[*C3S-'&V/!L[W'L(^M@%96&V&J)#>:+IXF6>8' M/)$YRY,=V!WMWS/#H9U78ICH-]W;#E8[6!Z_Q<.XJ?4=GMDNRC&5M#9"7<*! M_J",Z:.6?&<&=2V[4]8Y]9VWQ3>KYPQOVD!+W95&CCWQ2UK@/A6L:+#(HL+% M:1SJD/#W0'=DJXZE?_>)/G\<;>>YU"*VCFF[BEKC)&E&;%U]H"C/ F*[17IV MI[;YVK+*G_D;%H?;4A7N*O:H3FKZKI3U E;:4MDK@4AFI8&;55$_X\(0E=:R MS@Y1+5:"5=Y4\GG-\>)#ZB;9CIJYK&A&8".+K:@M\?>39'YMB<0O8GR'1^+K M[+AXHW$,1XE-H8L"9=+$@Q."4CY>S(O=&;$[PX-JC7=H[@V+6-KU[L[D\(AI MGOWGQRE*3U>B[]31#-?/*=+!,M<\VQ&GG#();7JV]C.@E:UMB1B1@-G-=#1_D0 MIQ@I (L3(P66CD=%P0'T;!@$*,*Q;8)W>&5FZ"DD*I:F#B@4L4$0;K^0W6K5A*('Q;:+#6*QR4'+N6F"X?=G2:/?G18COAR#WY M-/LU/'+X^??D%SL[AV]_-BJ8-U7-HN\0%WOR&=GQUPS*(_?DLP E[LG7BLW6 M,9&3CT!E)IOR&6V+GF93_BR#NRC=NF53WG;@3RLHNJO-)6,R!8A?5UPJ0\>J M.QI1S7L<==\UUM/@F7CTT4+YA/^/\=M7$#)@+3]3UW,,S:,Z_M"Q]-4O(E?& M"29L1\W+%ID(;7WJZ$Y>,^@HF?,$H[?US2I>FCE#BD:EFR_Q4EON58P@5=1-=S(_M5:$>N:/ M*?:H9\Z9 O, ZL5*;3.EY.JXX@KRK6^WZ3RI) WIBV%9&#RU1Y(WIM*4@>^Z M$KS2,'[MA(R?FH_K8)Y7B]4J+UUBQ79;ADBK\X0T["[0*-9CPO*YK@"05[%- ML4G6:(NP/NU> D=D8BSUWZ>;_L6(DBI/HJ0)2JM1K#:.%B4YV>83["C8<94= M&SRQ8PM+G:O%1C6KGJ_7N,&IPE1T>X8-@#@, R<9W1485/W9=&I23%$CIJ0; MKF;:[LQA=966646&Y?,/X/^P%N,9G1K/_'Z1/-SN1;J[2 X=P62I'I] ?+3K MR1'X4^KEN!ERK7I/U6\L["/R1 S]@7HQRK.)R6J58TZ5\!-X$8B_4,0G39]+ MAGBYT*Y>SOG!/&NSQ9$F[%IFSG0_&YJL-:1,J=Y6;7A_^G'V8S+K\@)EQ0D( MQ+6HR3!38 %8=%GC9(M2:-=C.B(>Y89FL4)\!XX$DPHFS2YS88U)TP63FEBR MI5FLU[+JFW=F)L['H:_/'BKZ4,5'+)4)<5X,RX_$*:N\K5' A),U6N7*/K@J M"-?!F#([90+OGF/N@65[\'3B8%L",&(\^N(0$RP8QPO2$ER**-:QFS;2Q6)! M1>)A31K_= =<[GKP!3N 6%XU>B(4"891Q8(14]LU6)C'H2;QC%?ZY0(8Q@YFV_A0-2RS484VW-_HO\BZ-%OC4JHUJM.:PU&EJ]4M4: MU:&BZT1O#>ORL*[JRO"?2K,0WC1VEF;P"RT-'4I^EL@()GA#S#CE\\A(-]LQX\ 8H3(P:M@.(2;L4AC!V7YG_:O M7 .8C;6E!S:Z137 ,EU).PX59T7O1D8>$Q3?NW>]^TY_4)1Z#[=EJ?-P)_5_ M?.WW[GJ=YUZWOY7->1G_[>/#7?>AW[V3X%/_\5OOKC. /_H#^,_W[L.@+SW> M2[=_[3S\WNW#%.&'Q]O__>OCM[ON?-[I56N MUFJQ/U7*%M3,VR4JMS-B89=);KE5B_\E?-(>/V#W7EUKX[H87]N7UQ_C4S83G9H9@)%!I0E< M-W8QWPQL[>_$T<:2*A=T>WIU>E)<4T4]2O)2*R4C"#A023LP%C1FP!_&3=Y2CU+ M8O"\)5/#(Z:@ZF%4U;399&:R@ 2KSQD0U9Y,'3JFEFN\4LG?7Q,4/HC"S]0C M\*7N$[9+'#RSDJAK@"#FIFK' V4S9RXDZ3%$M-?EY9;<1&5';F+&A-OSF/1O M6TW@%.\1[XE_3ZZS1]?Y/3[=XBLQB:71HG1'-.NS>:_0; M!JQO-S;WY+HOBT/Z'I+O(*7>>*QB(EYL@:[<'K8_&CH<<=!A^_<\;, ?R10Q M&_![.*(?J0J_M2-$LP9XS^H E<"ZP/J)L-Y*C_64@K]>:"OU8JV15<:)8 ;! M#"=B!KF2A>1O . S.ZLGT"[0?BJT[\D&SD#V-\$(:E2+]2HO-0H%.PAVV,8. MRG'LL+/Q1K.56>,-P0F"$T[+"7LJ:!VO%UH5,)$JS- M8>S>XJPGGK 0P\]*SCMP%A\N"$; M++W[3AW-P.;%+!KY.,7OTZO0:J&M%.7,"AT+_ GI(%9'K(Y8';$ZY_,J>5"L M-;X4ZQ5L[P4K)=%@ 75I.)=TPZ&:9SN'-4^\O!#-@1XJ434+FB75#ZX4V+[UY1(Q/1&!SO#I9>J%;>/L/8LYH8M9N8+=&P=OY0(_@ M;;$Z8G7$ZES>ZF3H0V:B%IL%+M*'.B';EO(2.N.G/['@$.<=4!X+B(K )6*UE;*9,L#A&+P+=8 M';$Z8G4N8772>0CUA*VJF=Y8J:Z_/.CV0+W'$3@.3[;#D@X]SS&&,]87:F _ M@?M@Q?2U5BI*H:TH'#2V%H@2_"Y61ZP.!]+X?,)8Y408"_]<7+7//P]_3M+N MX[#0L;A?W"_N3W?_1P?/6#O;,T30%EU)6&]&W^S::-#H-WD^()(6=( )^NBJ MH$%U>X9=>5D7F/W]8?)C&:7-XFI\1%L3I>*W-6FIFQM9AUG862SHF2SSLV&5 MHZ!YRC*R65(FG]P;Y];L8=TD5?B52B;]5P13"J843,F8\H"F2"E5*3:*:11; M]:,;Q0BN%5PKN)9Q[0'MG389$QO:*((I!5,*ILR"*94#NDRE5*78=Z>I@"ZM M";85;"O8-A.V/;)=UJ[^0$HEN_Y @F,%QPJ.18Y-4M;I*#TK8Q\C#/_6\QYI M$OOHXBIQ"$)<)< AKA+@$%<)<(BK!#C$57Q>)< AKA+@$%<)<(BK!#C$50(< MXBH!#G$5GU<)<(BK!#C$50(X2H!#7,7G50(#X MS$I'A24MX)_PZ@EQ7@S+SUU55M.N-6IYU GRB=N_#AU\F/]YWV.PD ^^,/PY MR)"%T9IDZM*;\,.7<+"&Q7**V4U?@H<%V;:UZ4:"+!ND__.7-T/WQIB%7*[X MF<@!'P1O#GXNPT^?-[]76N5JK1;[4Z4LQWZ_[5'-;U4S&U"C7 M%-[&U"PKM3IG8Y+E2/ON:P14O=RJQ?\2/FF/>MQ=0ZFU<5W, M"15?5)[G0$8CMK[18.Q0*DW@NK$K44NGNE_I2 J*'*DK1R".HM#BLL@YB$JY M45LY"A%S&H)O C[,)D/J2/9(8IK/KT8D^>6(MA993T^+:R*I7]Q)8@=\! D/ M(F$'QHKGF(@I8:O#4L_RX7E+IH9'3$'5PZBJ:;/)C/7.D5A55I^F*^T5>KO; M*P@"[R+P,_4(?*G[8.T2QX*A;V]X*HBY4[4[E+@S9RX$Z3%$M-?%Y0%E:=,3 M;LOYT#T/$.\1[SG->ZZ@__:BTNL=U2BSZ0,72+FNAMLI*[4JRH=4:I5EOU*K MTCSVJ#X_O2N/Q@Y'+)2RX$7<#//)%7&E9O:P1**R;;*21054 78!]A.#73UY MF1;L5B(7:[6CJZ$);A#<<&)N.*!HT2;@JP#XJ@"[ #OG8*^=7/1C&7BU56S6 MCBY@*]A!L,.)&[HI2=MK9L 8]4*[7E1;F]YP\AYN@B,$1YQ606SP0^9LT #] M4*L5*U5>S*4K:"K_0#W11%ZT7A6K(U9'K(Y8';$Z'%E@]. $=P=AB==(P]IY=EN/XNL497U]!M@G+A2@-B4MQBI,IM5R" M%!>Y)KMR3?9U,<2[OB)-;R,D[3@.L5[HA%K>U_GRDBL) MYF+K,8RB5 KM>HN32$,&<;?+!M=ARD^L#G_*3]G3![&C_VOF>LC-[L!>'GW MDP\]*SCRP%A\N"$;++W[3AW-<.GCB,4C'Z?XO1O'_3)P?Z4NV#\? !/L+U9' MK(Y8GQ+J1::&_N56>Q(M<3-Q-134Y79S?7 M'>#8;6&Y/X@YHXDYKHHGA[+JI"W@(YA;K(Y8';$Z8G7.Y[9EHA=K/.G%*]CR MP[Q)W_.0'#J=.=J8[?Z-;$>BDZEISRF5//).M_MG%QG-V)YB?\0FH(L1C'O; M&9#WOQO>&).,@2KP1?P681Q[U MMM7(1Z?67C1\1J^1Y==(=H$F^S_=,61FN M@9V8P]/EQ"@-8/^BHFX&+84$X UC0@*(U1&K(U;G\E8GE?9,OM5WOS1R[$GP<>EF'N93YC;4(@)A8G7$ZHC5$:LC5D>LCEB=0ZSI MRFYS.K2ZV'8+VWCI:/^>&0Y:SJ[WG7IC.W614P4/8A7KEIEZ8M=8 SCL/V]%6;Q-_N>?7+'<8%<:#*=ZZ3_4L>.P5%TH.4[ = 7;BJS! M(:M-LVQN*,I^BC"<6!VQ.F)U+F%U4BE\>;?&9]IBI1/NLA[= _4>1P/R_F0[ MK'* YSG&<.:1H4D']A-Q*!H#FTJ_5F@?76M+0$DPNE@=L3H\KTZ&?M<)I'"= M'RE\!?N(M\0=2[KQ:NC4TEU<:Y/@1J)G^]N(0;>,Z]I!%/%ML3IB=<3JB-41 MJY/;G;N[4*E'&J*CMD^]KX(MKQK%5DMDM?"/(,'?/*].EBF^BZBY:/.4U.JNQ;*$FLU&1HD=62SHF8RMLV&5HR#H8=V3,Z%,/KDW MSE+=P[IQ;950O]*H,'-LJ5F**%@JN%5PK MN/80KJUFH4J50EM5!5,*IA1,F0E3UDZN2O'L2DTN-I6L>A8)MA5L>^UL6S^. M;7>>$*IF?D)(<*S@V"OGV#T9#1GH66Q!T:@46YD=$CT7U^[9C=$-=VJ2.4Z0 M;F=R<=5E7B7 (:X2X!!7"7"(JP0XQ%4"'.(J 0YQ%9]7"7"(JP0XQ%4"'.(J M 0YQE0"'N$J 0US%YU4"'.(J 0YQE0"'N$J 0UPEP"&N$N 05_%YE0"'N&HW M.#ZS@JQA20OX)[QZ0IP7P_)S5Y75M&N-6AYULLXGEBO[$HH53"@>C*E$-&P3 M0:RY8;U(ENW!TXD#7UN2 2-[<8@I38GC2?9(\L;4I4 -2Z>62Y$N%DO#)1ZV M2S0L8FD&7.YZ\,4$YN665XM\1"@2#*-:@W%.;=? M.$;AYK$,U[IES=#]\9A MTG/DKB UN+*\A0QA!#-O^RT>YU^UO9G)?Q/SP.NGUI\"C=/C[<=1_ZW3O\U'_\UKOK M#."/^]Y#Y^&VU_DF]0?PQ??NPZ O??KQT/EQUX/??]F<8$*&K1;2J8-_S5S/ M&,W/1":Y+ 5G3!YF$WB$)JT>*I$WCI' F(V1H1'+ZX >F5D>:)$GT F:0=T! MW/C5M+6?RS,C=?^8BF'-J-[Q@N_PL=35R!0!X\R Q?L_OG_O//]#>KR7^KW? M'WKWO=O.PT#JW-X^_G@8]!Y^EYY@Z6X9\E;&N\9/\%OP.L:YRV&4Y,5IFH0S M_4ILOSR58*J7H.&T7:,%)F%IGI MAN<;($E-$9S4=ZH;(^)Z(,4LK0PFCBX9\,O;V#;->=S9T#=T@#@!8 M^H3'$I7*E\6-[&_Y"UI"4O#;K3^PQ4_!UV]T_9N9N_C&=L(O[9D3?/D+-N@R M9SJ,84P=:EC2F+Q2:4BI)4T=.F6EY.%;)(6C8UDUZ8= =]C>7M\KC/#E^ O#GV9F0PY;F U2GVJS1RPV((KNN_: MF%@O5,)*9(;K(L@^16C:[]Z&(P!EPR8,KS7G14FCCD<,M$W]TVIX)S[1-UR] M,?&8]6KACT@3A_J]V*7A7,*)18BZ! _,T9X8'I"E+/W5?J.OU"F&Y+*GAH4O M@8D E,'40C05)7BX1'1D5A]=B#_#9<2!*_W7%^'M,&V'46S]6C AX,T6U:CK M$F?."$VD$3$<7.TE[P4$7$(Z-'T#4KLSTP>W/:5.0/3E'!>0PHN7XX-1;X!]&"6NA@QA"_P\?&[Z!+=J$S $%$GV?4HVM!F&F1HF$M+#%L'4T;SVT-4)]IS'] N[& MB#H2DL0QF"$;V#VV&R%6EJP#.(E(<,>VX*/F3W:WIUNKI&"N,W'2$J:U%0JO]Q( M6ZY!8<9JC43]P?YL^"_&W#8+C&()$>2'/C$I&."N!]CU)4%H2'?Z/Y@A% R) MN:EP\R>9_0=[KL%:,#J\S S?48:U70RON&5T:'>!8IJP;T)V9?[8*[L4Y0SH M+7_\KC_^.88+PM%KD=$[T8$S$39U[+$Q-'SQXA)SRP.+TB>%S0.8$R6AQ/9$ M$)ZF"2AS?/N8OI,)^/1%)F8^J>P&4,&.K<]@MA;@*B+W KGKXQTMY]57XAIL MF04;YN94F'OH$TY'@1DA4DQ\8D'X,EJNTG0V!#DB#0,;$LQVCXW!1RZ;]4*- M!"N-X&,OI4P-( %P&A'C'WU$8$Z+>=JX![)P R2YYOMA/JW"4(8O?%TV0F9; MHUR-/K L=8F#,164#BQTZ.)-?I2 O7YHP^3"YS&MY3N-L>J"T8U9/^CUS*D7 MN.<^\]E.X&Z_$L-DNP0L[.)B?$6CON]R&QI7@;AB, HX-:I@P%=WD !Q;E?@ M!853"O3;XBEC@J[(0NE(!KQ18^YOG(^<;K^/#SWP3'$7 I:UMR'U-O3"4^!0 M=@)RY5(Q+-C 9X'3* >0Q*U .?@=2Z4!>X(^7A8T<#94%;KR#A',H/$T#NW,9Q%R.%)XZ)4;4? 6)%*$)BJ-5:;A- MKOJ!15\TA5)OG[ $00'LX$Z#QY/IU&21&5\,AB%5A),]>QG#%][VJQ="$R1J M."24Y4MABLNZE+4K(FE5].F&'V*,7AU&@EA4:=.XCMX.@\%HK"\ *.HKXH52 M,Q1UHT Z(M]'J(U3"0*W:?(=-O:FUO:C4NTD-A+L))Y)K"IIMPU[%GA)GNW, MEZP?XUC(FYN%-7ESL[#W\$?W8?#X?.ANH/_,F#M\!D A%K&O]A]A&S-HL2/!.^61CKAN-Z)0.$MO\)Q@"3 "&EAUL1 MKA=$+:*3#@)>_EY(>,T:P7RBX(O<&]"3R MES@8RVGRE[;+V;Q(5-\8"Q@V8C])4#X] %"T!Z!%LN M],) ^ YQ_Z08C7DZ]-6@;RAWEA(0S9B9!?ZV3V,0?^L;0VQ98[2OPE-8+['B0V\Z"-O:)F@17)A/OH<_@U?I[B\W M*7Q4EL^[E,.L "U,SB13E]Z$'[Z$N<"&Q8;(;OH2/"P0WBBQUNK/,K#[/R^% M6;GB"[0@S3QX<_!S&7[ZO/E]K5FN55NQ/U7*2962N1';62RU?"1$6CNM&4TFDPY86 MN+4=+7"3=OK<6XLZ(96S>\]'MQ0]Z6K'=Q-]CMKDQ_13/G/]^V2SW:A_OUC5 ME/V\Y;+:2%L5_2PS3E/>?D]OIX61 YCY'D(F;87[FEIHUXMJ=;/]4P)QFVG3 M!P'>BP+OGAY(V8"W"NYWL57=;$4?IR.3HWBMI74.L/@4QFX.XMJX^2XQ>;[& MT1\N4I^I1PSSV=^.7D!T0=R.I3^B=]P/XF.I\8KM1(KU1D;"-N/.[1>\['N$ MT:F7O8[+WJHK&8NI_%FW#_$Q^2Q,C0M&[Q:A-:'Z4HT"9>^!E/KC :[VMP41;\<$Y(]4[=5@:#4HNYX!"EH2BOUS?;< M'XZ@C*PY]MY:N<:W;!W8'C$34SB8ZK)6\=!P^9= Z6T)=9+P[J7)ZH%YJ M8:*"[50O*A\0-Q2L(EB%&X?C$%:I%MJU:K'6DA.X&:NE#+-,9*]6^$UD5],F MLG>)@^>X>E,SN M/SKFA7E)O<1Z$QH>\6!TQ8,"L.+ S NJC^!%@'EMYA^8 M7,T-]]^)">8@&,@+E8!?AGZ*.7O\>HF#15X[O&)B(Q5@45E6.QY-P:=&SMR% MYVH6E7#*TIV!"=JZ!*-E!T\^;EQ^I:%(D13_G! ^1\=!X1F=E9OQ.,\KR(K- M\RL'9IBN,P5;THZE!S39DG!:KW->I&%[-9QEJFF0,$K]D[9!,9@(2G$5A@SA M?G&")4A6DE2+$GW'6EX1^.O$(\ES5V,KS'YL-FNK56Y4&FF36>N5ICH@]"C;@9VIIV$ ])1M@1E.KV*IOIA67!'+9M5"SW4KLLXX2FS^R_='/_[>G1S&=/<%K^\FAR? MW;K")U1*JRDD=\>G]@,+)3^.6!#6?5S2F 5D4ZN35J$M5XJMRF;F3TIU(M)_ MN 37'EODI.!J5!BXFO7-XVKG =>'9P:=349WDV\/';/I?_'L#R$4@.2M+ MR5DKM"OEQM';B?S$O03N+QOW:C:XKV-&_/';A]F&Y(1)($R";$R"(/WZ0+MW M^_&ERY>>Z4AP<>(UG5D1.'!Q K:1J6&1:E4XM3P$!0N. T5/0-%WX-6Q&D#:XW=D;4.C"?< MW%QVGNP&;[MW[,GM\HC6YOFU#FOOFCK>UBJT:YM';1>'O-@)L+03;7(XT2;N MW6\>OX].=#FJ13M)J@=['N2-M9-+T3L>'NFWLX-G!5W'S'EYDSNDS=-R"8\H MJ_P>4:ZF/:*\;+'U.,+5IY8;E&]AYU%OL6M)Z 92_8G,6:^GS?.9S9ASQ&@X\S-V-Y_P0!'!M7#/H787O"5AMN68:]N6Z*3J6G/:= %#&\- MOPGZ9=G8_&NPT5H76!^[G0H.WAUVN]; !:=B3^\7!CO/8Y] _0OW5!)U= MZFMCV\0M5;^WZ10@AA=,;)V:V-K7T,:+SH61=N/!Z6ILU=2?BE_RB_ M:Z9CN#]+(Q1-K.4K/(!U<2RNWOUJHV(SL;MN\ PL#8D$Y]/QKIVB0VUMG.E> MR(6HY.@XL )^,Z.O\PW1T4%YSO[Y \ELO3RQM\LK:@4@JMWH,P=[[2XE#*8D MK(N)H+]OT$\=5N^@.0SWSV&X/H. M9KBK<(GP@^%*_WV(+5W=:4L?O+H!*B.;D6M[E]U@/D\XG1C;O%DMM.OUN-!B M6;H#@0"")(Y?D-&1. &/+Z@V-ERLB1(K*(HQ_(WB)5J182%*7 .$E2_G_,:! M0+X1R$D=F0XOF!CZU 8)( VI]X8=G/'+5Q_G(9LA5/UC_\M.VJ%8H03$D#]\ M?^6WR!4V1(;(<%(_RGVXPV%MM^>^>,!VIJ^LYW98XB%.4++6TQ-L:XAF %A* M,# '+2?;TMV0TCOD7XC031&W,49_'="[B9&$NPM8H*!:EM)@]X!JBR0?QH^4 MM3-'FC(KTA^J:,@8'P?%AHQ-T9!1-&2,&-=*K'&MYJ3VRJJUY(MUYM\N!;;? M^1J>&;&MF( -&LWZ,I))3/]W'3M^^SVH'>/GF@$7-7?+TOT!+FM$$K)^UL?D MMO4>[K-6Z;\C.=Q>8/'\[FP<.QP9[U0O_8-UY;17:=:6L5"Z'E82HCN"N?GY1W:H4VNIF/F!N\25$ M]66+ZCJGHKHE8[^>GKC)YUF-BP9(L>:Y/B;KWX%B^C&Y8+<<5I$*;0WL^>3=X@4]:WXE;B[S\_ME;CN'I$;PFJQ M[9]6\*K@:S8R./@L,,BG_-I3B"<;^54MM#>+60KYQ1MVLC^B>'[Y56/R2^9% M?EU!@/G>=D;4B"DF<-G!B:P-QR-]K6 59LZ2=>(D%AIN4I)-R>=.:(Y&L6VNS\C?)%P"_G\#N?>9I: M""9.MV^U>,/G%<0\UW(C\(!,>';Y\,R(RW,'X\5]]>S;;6JE A;%T>8$/^&& MHS'%$8-=161-MZNL:A;>188+ MS6D2X,DPS)$@.$$YVZ24R2=7G\T+BG!V6M5:R\@+RC_+"Q7&O]>52(75L_"Z M\H]GH<*$"LN/=WB$"FMDY!V>F>43%(3/0Y&VSK9RM7XQM+?PI'G8&M6A$V*P MP[G1 IJF,:*LVB/09^Q7IXSL6ZV6(?9KQ2[]U=5?L4IWQFFW34!),HX5=&EJ;Q<%C:^B^&;#X &'R M\N+0%RS:9\ +#^LE+O;Q:Z=<.E[X4C_P('*"\%57]!"KNP6Q(>, M/9OXW.K8XX8N%]J;1TICJOL.QM2A41Y,/].8*H'=H,9XGSJOH!3B9_Y@6WY9 M;+\FR,#VB!G]'2OA/]C>/RB\5;-?+"P:&#0K51F^ M.ZR@N]8,(:B&&RE/M2I"CZ]!">.AQBM-J%AW'TQO3HVNNLD;,D1 M:1W!;*RPI#T667>EV12?L]/:K%;.VCM"E1L[>D=@$?-MK1]2U%AUNP* :'U]TN%)NU');7)'E4IRO]'#^:9>^ /'. M.5\9Z4Y+\$T\@[V.1 M]R%5BX]9(/&V]&^[@D1<4&=Z\9[F>,V.G:!^],74&8V(% M8=E%?&5KHI+<*K1AD3DY^BHJ9XK*F?N26(\LMW$\+ZTE(C"UCUH?E?[J7O5R MH75$?D2H&W2Y97SB3+5\%WD$"O M%MIJK=S@Y<2WP&?&@O%4.7$9"$8\$7FTJRAPQ[%?S&;K^ZNR2YY@I>DQE?GZ"+Y>-N5R9N*NP.TB4 M-T&4JZVRG-51=0%0WH3BV8S<_4*Q%5OF1PA%WC"7*_OV>*&HXEY=72TW-UN! MB4#NB>S;XWJ97)[GR)N%NUB?]!T 5%7.K,*ZB&AP+/'/909'>@,D$/>)S].K MBH#MI<"6-]OX*'&J"EQ>"BYY-*#3B=--L8E%)UJ5\ND6'G*I><@9Y?RKVY*Q^2"'E5$#@-&WPQ$CG2&BX'7 M(S94W"=BZ/>V,R#O?\>WVB8N!GP1#]ZT90Y5=@)W1ZU'?^BLD-XI IPGGAZ0 MN+V97;(QNR0E[3P;_L9R=!/#,B:SB>21=\DTR- PL3C:VW+TDCT$O!*_X.AL M&M3""RO88373Q5LWBJV-#JANNZT:ZFJAO\VZ;G[E75].?50YU#7,9U?".>76 M/*L0NF5C9ANLEL6?JS)P37E3/ ,V3!-)D+I"ZAJSY)4NV.ZQO)EJ&-+EP)JI MYU "\654O_N%,'%Y@5Z,.)9&2ZP8NL060/)K;?,\M53U52?+&4\W9NS7?0P$ MB6&A3%"6PB'Q/14F5D"X!+=6F; %>X+ [S_I'*LV:S,$C2N]C6WI#2NJO_BG M[X!K1M1QZ(JFFA"XASB6-*3>&Z76=M5E!5[:&C?6MY1?GU#]<%;T/<+'40?L M*;R%F+X*[,)(*=JP6&8(C,0%8Y64)6>I<>7F_[Q;+V^97(.[R6'+O5K<] +% M[ '3 C]^<#@86!,T3+ENNB/L:Z^?2W(E!UJ9HJU3;T9H.(37J)4O@SZS^R3 M_.678J!Y;9?Z]8 #W /I_/FX/CKCWA/!N$1> +,NELJE.L5:PL!G*UP@O=A M=[^P+=E38;B9R'HM(+" M_5LK#W]/+$>\,8'KX&_/@)^""L3K-(>E8]AD4_?5/TACVV$PN 'GG3IX%0R'<#,6"60 B*0_&951K=8&=7E85W5E^,\&&!*LJC,P!?;&08OSU\^D';? :RP0"!VE M*:.O&/Q"]8X7?EO-29'MDU1/EXB.LP*I,IPSF<4\.9."(8W7$&ULP&<4^DM) M%B>[HC78]QEG.RNRQSV\YP\^>I(6^C 0\=Y*0,4T)$M OQ?08S@05.1S?,ZK8<]< MFNMM;=51?X#CZM^ZT=T[0U@I7U8\V7 M (VI_4P\!!KC9_KAT= )A_N!1KB:5BS/,3H'-%]I340C/)(D(*)R[EN6(47H*/6*'!!ZKEU$Z!EFT:[M6)$12F*GU4@Q;./F1&:*C$(,U8%[R\MZ@S:"F^8(0 0:.B8X_ZOB) M;782OS$6_(Y$8-*,2A%%1V!1$>@CZ2=Z @D.@*)OBP<$Z_$##HI:O6%<5?1"TA@[JR8 M^Z #B4#9\Z0)!RXW\V364]ZNIH(=@T7: .>^'@)(P1X+U-PQE]*/9OB;Y*S"/T9 M[/+-=/D=:2[5M72Q2R_'=Y JV5?[(QM5@IDVLF@&D'<,Q0G?/0!**GPW,=,H MM!L",CF!3%#-3:R.6)TS%2\[6ZPP^9F45?-$%8'$78;)OMHKV1@FS4*[*OK9 MYAU"<7;)'OP<;I>T #+-K"K2"_!S2)Q_9YGZNBA3 M?S%XVG+:L/4A(HE5)A$0R@>$MK>GVW^$6?V0(\P19+%-2+6Y>5HU>0LZ$>;+ M?NM1%K&]78;@OC/>V4A=W'2\H/25*X50G"&X!S^'.]E85%N$]O(.F2U2YV-L M/2R[G%59=@$AGJ3.'OP<+G5:V,*"EV3=2X_MI;+C*B*@MT.BUO=5LSE$HB:. MSC0J(CIS*?B*$;?[P)5YM*\A>OQ>#)ZVR"OY(RS AE)HB_V'O",H3B+M@<_! M!F!#!<0]'R-YJ\!']:P.Y&2TG)P> M=CLE6'-_3BXKXN23@V-47T::+]WF5@-[_Q;EQK9:I=?%T$(39:.)/N3L=*,. MT#U^R_\B@"LTD=!$V6FBC,YZ;W)LH]"N5R[ =MS2*'.U38QH'!-M'"-7UDZ* MB\XQU]TY)@<]8F3ES]$ZS0:K,\TJ[XH@_(^U=JT9'AW3OV)(.N((UFH5W9T7TR97-5(@W]X2$Y M,VWF>2;RM) \,;U^TY(GI^U.''H XJL9K.2B&;C?&I2%,:._W]JN]V![_Z#P MUI#QET_R;UIO*9!V\9N50KM9CFF-$BX^M@MA\FAF1<3/2CE^#<8I,6O"[\NW M3:X0)H!B&GD4@]9)AKOL8 7/&:Y(O/^_O2]_;ANY$OY74,Y,UJZ":((W[<15 M&MF>>.-K+4^R^]-7(- 4$8, @T.R\M=_[^C&08(D0/$ )6QMQK8$-+K?_5Z_ M0TY&O).#TR],GIRNYB_!RIN')K:/AB/V+]_[@?P1/F<4SE7$ 2"\S\ZF.4 ([L2 ZF0)I^^R:$.>KA4*E M'/&86K1?S0F(L!,+P5'MA2!&B%-C9$D(EIF5B@MM]RIP4EPMS93B^>+]JO-F M/HHP%.(+T(6)D[@^XKR[<'5\S&BP.CYF-%@='_/QW>7UN^N=QKO0)X4118P+P"Y9C08+?R9VJ:N@"YND"! M2L,ZU4_7S(JCY=/!F:%.3P4XR-O5%BRM0QX5I(:3LH#"\)9[K[&TI$F,4YY_ M*8)Y2&/EI,2D+_ @-W5"V^'QEC,3I2C\ %ZEH97RL&L%ZYHQ<;H&T,FY-A?D MVLBMXC!2X;&;LS1?[OPHY4L<*#!QU \'/_F;:(.@S'AFY&Q3+8,5'5\D@K[# M6E^F&,9!U5JH#@@)J8#"(&Y_11U()Q3.L'E3O<-L"BL"VITUNVII:\"=\-@. MT%VQV_=S$'#]NX,UY]!YX'U>%LQQ[W@>,XZ +B/8*?"]N /&MUP3Z&=929\# M>WPOD'$I0Z1R3@-KUB?,($ 8A>,0W0R?(\EH11@"'H:.:FD8>2S$WQK!@Z9 M@ZY_X\"AK5 +V?9B0]L%,S'0++##;D2H;,+L2&2P#^7,3380X0NI0,4'D^5@ MHR&@E"9#.R#8KVDR\=R/E71&<>IXEAO;J:TZAQ/%@1P8/4V%<6;\YR2.Z/6, M76J&*D@)D$.Y">_=TT.P?AP$PCY3LEC2J4DHMK(?OF7L9YZ1=XSDC=LXE7-= MM5MV-&>EK6^)6NYGZP9N?9MW7RU06S :=L5BK6)1P^G0TZ';B%53>MQ9-II/ M:?.NF:@9+Q8N\3;*:S.<:5/7OP,>960AB)>B(\MB<<7&1$;8-!"R'-.?RXC' M0:_5'0_W,R-PT.J/BW]UPL&%_9;1V3Q-<3^#]\YJD-)1AA(6#J':G$E06Z@1 M8U4?1[CFM$\&7(4C")=R.(P>2\N#$%@%J!_D4T>J5)@[MNV*TV1&7:'679@ M!31FE#6^P0HGYS!O@COE1N+ME(MZBO?W5*!,B57]5K_>!)#&'5,#+ X9]J>/4E"KWSV9-$)ZYH"R7;E_I+Q\QZ6O XK>8&:WFV-:898?]"M25G: M'BH9&WYXG/RP)25X3_R T]#T4;LNE;T[V'L'4]$9LZT@U?G4!D3%W1VI_\DI MC8IO^/<+?WI! >LP%&@V3C!,S8:%^&G-,+6"C$XV)F40&7,F=C(FRQ28G^+] M/?D0YV9,5C08RU8U/&(-NA,('HV*W6)RDD#Y,OTC%)R+*0?<:3>VB5HW9*/DZ>W%4O+Z M+@/>'Z6M]SA-N2U#E#>*>1719-T+TN7+]+V#"NC_J%2B4I@33O+L34\?/KP; MW7EU(SYE5 ;8O?]DV@R?A#/>QN(SK/C]3KBWXA-)WLI\83Q[,]![@PA'T:-?C@"0[SWX^I^!(X\U ?&:J^01D$1W\"MW3FJJTHI=[Q]VIR"_GC#:^6/ M_]AE0E5-65E#8HM@0P=YL=][T^VH:_1GH?1 1+_2G/DBYF8\(.9%&#TM75IM M]O$#&.O:3BEB)&&3Y[,^JN=N8]UPG'YZ1+C]?W^$FIUWW MI]9R9(]BI%2*4@EUB_D7;;T_V-?-UOY0>: SE,8_#:=9\;5&WHASE/@9@)+P1VYB;>G_UH-0FLUQZOM/2#GZVV M]+N\NOKCTQ\?+[^_>ZM]^?ZW=]^TJR^?OGY[][=WGZ\__..=]N$S_/O=UI9_ MY4]P;; T=5 M/* 3(VX E7:90HHW4QAJ/@*1?I] 4;:/US5/VN5TNO4L']+K],Y6/^6U=:]%@6PF%LX=?7! M@;4:!0J*YW[M&D8T6MUA57?Q)"=^6"1QS428DJ:@)+4K26G?4T*[I [#&++_ M+*(OT^_FSX)0@0%F8'&2C'-Y M:SHN^HS 0=? %=?"PLHP1X3E&*?[[$U_]7:V#LW4'C'J5X3G25"/Z6OCU3O' M*OT['U,5R]T_OP^1_OKK]_>O?Y^TZSNN2:!5_JG,DUVI4< M5C-5 %;-\&BT2K8M1,##DRE=C5LQ1]K4= +MUG1CD1G&IV94F=R+8A'@R*1H M!H_?^;%KRP%] IB)AB:$PH6/>OQ='#%%O9YQF@(Z^5,:WY>.4G%P'(=&LLN5 M\5/)\1,1W0GAJ8&#"Q-ED[,P:79+M#*J!4<]\[RL]!8Q/8XV;_"#Z/XRUB6)(Z$,,NY9J9=\M?"TI)>X&:YY4QJA-=?!2WPM4,C5J&&*^U M_XE]FDH6\-P=) ;E7A!.:%Z(A#W/47-L #-JAZ2]8E#09X3GH"W\@+J1,%(N M\XOAQZ*9']*'Y'B?%.]A,N,D(:"46GP0Y0&^%L8XN^8HN](XK>^ M&^/06D^H%E#GZ8V-(&EL6%YKXM7*)&/AG^DK$\%[":[>.#/X=__XEE!8$'& 9 % MR=0P$9-S'+8E6%K2=#1**O=H01MWYR_@-SG(\[<#$<8N;@>6\$R><9OT+YJ( M, )-'H$-%U$Z4T9RT[9(\8A #3*B_(\"S?"0OE.9[)RU@18,"BR(T:JM;4_!.D!=81T U MFZJPJ4%[\Z8>E-9YIBF-&_(ZFTE\&3CAU-+:3N+;>$]Q3".Q'"PSN2"_4R[( MBW!->\_:@+E^5'EI60'&,3YLJ\L^->C.C$+?R4""K:V-^=1DI^_1U_T' M^KH-\U05Z1A5^+,Y7[S6\*_DC;S[=^SN%?!<'FENR8EMPI\ M2N?4 ,+.*:%F<]KI]JR8DQUW3TWAD*8N/1O_R.C+=XJS/NZ)VQ9UVH_,:6MXO+0\&IR)FHR'FAIAW4]9[F>A>USG;S?O-^S68 MTUY;^2@.Y?WG89]CQ_I#HDT-V!JPU4?&I/(E M+VVXW5+E*YQ.MQ$Q)T#ZZ+1([S5(/P'2QP=$^M3Y*>R+_XC +\)W/R/*]]HB MZ,S6<7F;>4'5Q6)P7=;QN5V=!P,/VBJ3_DT'@0WM,6+;\'?ABF.>:86_Z; !H0Q:U9.D/ ]RJN=VML^H2170G7 MGT^>]/1^Z-A@^?ZXEF6SJK* MV2H61F_/%D:#X(.*:C8H+CW[L^]9.UH7?>QLU+#T"3"^)6EU-XQOYN]!P]^G MPO:6:\J#\?>P''\_].;B<$/3'C-1;-#J:>5Y1K-'.UGGHV=ONFU]T*U7H*C! M? 7,/]1N'Y/=/ER=& MAZ]":I#_0.M^_\C?;XYK@_O#V?K[QSV&XT9Z>UOYX9I2L_XI2LT.,+^YV5FS ML\>YL\>>3RA'7#1E<,W[C^?]8U_$GZ !&]W&7_G! KOP"VWB>_9#!AT_D03V M8<6JA7WG__9Z% CL&8>?;=F@/8/VBG4+^TH)[>'5WJC!]3%Q/7I8BO_NN,8I MG,,&UW46YWO."^P-29J/!EO&EC=8WR^'5RSFV%_^;V_TZ&[OSP/C%4LZ]LWG MXW)\OI=^4D<+_Y[*6VMVUNRL9CO;4[R A&Z_U:]QN.^['YGNLJHJ&2Z5L^>Z M<%#;CW&2G=KN3IT/3WF7M%OSPUW 4:D[XKE"";9S,[AQ/ Z^ M=?*$^Z\XC)SI/8;$\>6$-I@$ #6NN0C%*_67U[83+ESS_I7C$83II==R?4DP M&'%;CK#A!_G7K]60]G:K36DS*M0GO[QYMGMGT&J/._6;7=_O%G^DZJ;&K?ZP MVO$.OZ=: JK95(5-#=J#C4MMB;AOCOVO/G<6DXS?"DO,)R+0NH:N==J=;I7R MW[*W(8]CZ#,FV#4SLDN#*PTETHQLBBP?VW!PS MY@B :()J9(,V("PO[W" -O=SQK\2(#/6?@/)TI!,G2$"XG5QH[H=,G7V!L9' M._:^^<8YGQM: M-Q0/DWVG"(F&A'TB,KJ45)2KW*D<$1L\>S,:Z'C^EIFO/97[-^\W[ MM7C_:31',IKF2,W[C^?](S5'.AG3?BH31M[YX(^QNGZ+DWGHIDC],?9/'0R: MWBG-L/L&;.<#MD/*F#UW\!BT&Q%S J1OF:]S:*0;#=)/@/0M8W8.UYUIT"G9 MG>FQNZV_^[ 3#W.@9$Z9>2,\Z\%3.Y_(L-G1B7N$#JB64^_LJV]D,V.X'-I/ MU"-TT,/Q8'NJ;6]P70K7XQ/U"!WTG[WIU6M,R&-'=55IOF\;=$#"O-<[_-5C M@_4,@Y^L1>A@N.<6H0W&RV'\M"U"!Z-R?'[LR03'Q1I55_,C+-[ MY3C[H?<0S6C8/2OSPNZDT2[V]K!/(R/&O68:^-EBOH0Q3C.?ZA6[;U"\U];# MPV'M0O8-AH\QV7LX @ENZ)U!@_SZ(+]B9_'=D;_?E-0&]X.^U$;E'I? M[X_+A?)K41GV*$:M-SMK=G:,G3WV]#^N6NLT56O-^X_G_2=P<7[E!PL_,".A M37S/;J[--QF#%2L+]IVC.\+A6V.]MZ_(0!/0+X?VBK4%^\K;''40W=T&U\?$ M]D/I9TWIV]/E1F/,FCI\]*RA](;2]SE.YFCCE<=W>\T0\H9):L8DZSKT M'Y]+C&=OQKVCW*\V3-(P2<4@]IKF(L?GD@ZX%7U]T-ZB2B@J]C+"N#K\:3NW M;^AY/);CQ2:_ #]60)^;P8WC<<"MDZ?E?\5AY$SO]XTEH[T-31W,D/D^$]J5 M/XQRL%S%1,?/K]_R,D+ MKM7:Z:%[S]YX_NJIETX*!P5Z#T7Y,R>3TDL2W67@F.XZ4NN4(K56PD'$+^? M'6\!@]X- 73JQT$TT_X=FP&X:DAM"$6=?J<8B$;W J0=+_*!IC3S!I! 32/A MWXL8P&^& DAI#GB!H_C6#USGHS,5G][JV@?/TIY_-D/;_//[3V]?Z)JI MN<)$X:\M O_6L?G+MTX0Q:8+/P,2#.XURPR$3D0\-VT!+U7CXG:^T<]@F9J_ MFOZB!\5PVIE]*T"4@U[6WPA+S"<##D *)D3C%6>>WJ,35 M.TY"; CN0%AH+MG:G1/-X##X1%ZN;-3#DKM[> ^U@/WA Z\" 9AQ;L7K.\>. M9C)U-/N6-,W:Z2OF)/3=.%K_RLI$[^-+,*,/>S*Z2]#)_'>67,XG 5MT"&#V+!YC2;9"148'<@*S-RG%*DAJ]#I=T\_80@Y?O%)Z5P)GB736$ V=.1_BFEU[+Q:2,1;FRG!" ),F_3D5.J\UB1V8F MR"_+7[?@5R]7?SYHMWJ]<>&OVBVC\.?KEC*&K6&_VE+K?][O%G]DETT-.MN6 M*HCN*+P 98@2.1\ELT\VU(FP2CQ-N&)8&*[(LUB)B-BC!T*W!!#6$,YREE]_ M0Y9?V52F=1E+V0!925P&:J,-# M$&)4C<7O)]>SX8K'R15K.O%4YXJ-M1KCT?I:C3JQQ(.5Z&X%RR=7HA]%&+[2 M"E5ID>)$"\4NUIY5KB&WRHRSYJP=]$WE:YL,AXWWQF$;TND/H73*E%T]>6+: M04SO3DS]=OL\B*D&/L^2IW>!S[_:&( ^)$FE6.\';* M=;69<&TMN9M2[V$<=#?W:6/N29S^'=PW/IM8[^. MVSY06E.'K^'CAH\/9+ELX^/-MLN& ;*/@8D+;9['EA=H)6W[W4TY3HXG$VGD MW>:='X.Q(O.6P)0);AU+4,),&)F UW@A[W)=UYS(BW%M(J([3&N1:ZB\EB0- MYGLVBR1-V;%Q*PX0OF.Z&H!#A!%@)$DD\J=54Z*ZQ2E1E)":;OA67 :!Z=W0 M;B[G0*XE&R@,4@[I/GO3WY(/9<="BQ=H%OX$ULSF(J6@D-?'80IIE14EX4XI M!S*C9AE.=X!2S$M;N )AN0 S-$!$)4DZZDY(91HYH6;2<;4[,X0%+3>VTQOH MY"$R75S'M.>R$4Y1N!9QM(3Q,8?2]U3M^H)A(*%3"Y_RY M2"[,54H>WY6O;)G!H&A9)LB!8>UCNMP*I:102D%;G7KR2?_] U)/#TRDUC;Z M@?_GJSUCI-*\OC#]1%CS7M_3]!PT*L-!(,V7 $)BLA 4,O,Y M2Q22VN ])(Q56&Z5Y&8H/R0)%?.: J1$,#1:9;([\;3;$^CZ8(QN33X_N+VU MDGI!]M:H:N(:EABD=2XK&6O]]G@E8PU^MIJQ]O;=;]]W20N3BQ5\HO/ #,.U M8=8):SA*R!$)](NE4FPMI*A-O;[%T^[!#/.948WNB3)C7RY M BH."_P=D.C$C%&(&=ZA8SMF@"''YVB:@U0 0>3>\ZMHTG7:KW\'66"" Q"$ M] /C]8LEOT"S&&*I$?4\\_HR.)-%P*:405&Y1_YJ^CG^MTNR 10:2"1*DP\$ M.2.V=@66[<3T?NC:Y]9E2T<)A,<"@C^A82NN;2_TUZDO,XG8" M[U/-Q#=&KO0>EX%J[X#9]_+D%X_>7]-P4VG9/N/X*4AB6HE<#% M;P $,/*FA!-^\^.'W[Y\>Y%#Q*4\QCJ$L-Y;]Y3R[=C,,+6BDJ)C,/-&1JBH MF8=;*KL^P@>^3!D2[P'!+J#XD_G3FP4DJ&?/(7.22300M[Y[2Z3.=#&5X&##X'&0P^B4Y(#A[W9=J<$5D;0& M)?I!=;C.W(FVR R I+\D.! )6!2'!4XVRU-\%&SMA*2H( O\ESE*\YQ^R-0D M*5V&YBJ5Z:"Z6!+0I8D87"0,4/F/@HS'IR1C&LI;5SK>0JUPSCC@F-2J.34X MPXK6[P7A.1\8]X9L^VR4<#T'@W=VPQ:9$$FA8FJC,4BSB\I@9=;NS+_"E2R2 M)V'!J1.$T06%(9$774=XA ,T3R-XQ3%=%]9QW20.&H8B*O&A0GDA?EIB03L] M0X3^L15A>:/_#M,(%N:]*DPJ,H>3J)!I613D!;@*TYIEQ"6;X&CHD^#F$+00 MB"13A0H 11,JL2K9?27%4W:UQX-WV<+<% M_5]^1K\XED]=4BDY$8?%K"<3Z7O0'-L1>3U=U(K"&LC-[$HN%^(,^3P M;PDW)-YE*3D]$6:0>IM@/YGL+A>.W.ZE"_OR\,._H7U7?0MT=Z4) M<)-!(W#E.F".1"/^N?:<.VV]I5VF%?>Y2$-/+_P*@C_%R$=Z 2:S_<7[AQDXN"'%BM+#10>\_.TA M1RO3B&7GHPU(NF\\6HMQP_3@TC%(E,D;46 Y273\5>W21EG"[)FE(3O.]YA( M./T,Y=5&@QH12+F0YA2,O+D4ZD ?GKCA?UC^K?!,LA*DE'?0UDM)!Q,(\E[< MBNS7)0+(L4O60R=2ES%&'Z.&J!] F.H:.:XH6E#*!8[%D3ISPK9'@56Y'"O- MV95P%!],5%1DJ6FI7-$X2/IK@)1P $H3>-"CAAQTD9?\+K%ZX>-.($U<71/> M#8H4D%MS$=Q@&!1]:&S,PKTIZ-^8E^)SFQ3U'BI4(!]PNSV;GIF;/X2$@XT* MUIG$@;\!,8\ #W>*;_%QVNSJ'?#G@"^K9"YD]0AG_ ?RZ# 3@EI#6I2^F M)>]\8FN&5UP$88^\+0EO./(D#AW\E,IEV!Q42$@KM0Y _GKL%H!*,&,WRN$) M*^W#F>_:O)$;X&]5H9BEH!S),"#IH\F2BL(R/\$!2>J?^"D&WQP;P#A%:/]7 M;-]D%RWHP[)T^*;IR8:F)[VFZ4G3]"1S4?G0*\ECJ:IY\*0?"&XV5=FJZJVQJC _088%Z>/P;?5I^O)J [N^@<6WK>&J M$86',5KM-FL]>6V%/L:5OWP8<%U<8<*O]GL0<"OA(.J[ZK-K#S)Z]J;;ZA=$ M,>5!SM12RS9_K!14-OJ5;.\K,PCN09L6Y;%L:H'8-\;%+1 SSK ?1Y12BN;> M=L=8JO80C4W53V@I^(\TN?:"0\]V3LO[??XN7>AK[>V'ZZL_ MKJ\_?/FL77Y^"_^[_/A_UQ^NM2_OM?-JM]3(EQD,4WE\5QX_22]3F2G91H%S85+N MHN3ZKX%SBV&(M-Y!^PA_\*T%@!@WH5U:%/XVQN.^CD_2[SK#2[5(YN7DT6Z7 M9(1,$N$,S>15XUW!J^]^2CKP6 RA!UL4$H9M9KZ/L! M>AV^9(G9/US, I/2KD%JX@6K!\B^N0=I9\UP _*;& +T;%T!5?X4KV(L9P%? M7/X-YQ.J'\+:[ &%($!=,]#N_("=4'+[E.L/NZ'/9O;1TJ[Y%NB9[GC0]:2J;>(S<8[8N_RW!>_LG5X*E\=QJ33\_L M&VI3QY6YS,P"[ZY:&,:=^?'-+,$G-J]SX.R91JQ9&.H9J,OTYS",YY(NP+-P M.965N3X4&] H4TW-T/>X5ROH>$=@* =*85>$2 MN1)&(C*?Q&Z]TQC9DC!LNJCS85=TP[9VJTN"$*&6;&'#^5;(/%R PPL4ZMY+ M,X;"CTF/ULP'_BG8F(HP:N/YF1M=A$B\H)?H_B8CKM/O+0EN+BA9H UEP;<# MX28Y&6!^QRZ':7"Y0-PZ(2$ 7MAP-/BMQ'42YP&0.X$5S]$:M/@*B$N2[C"E M^1[HBO.-[XC9IY&T%(N.?U;:,['FTW;"MA-:<1A2@<2,*K$HS]VTV3;U_@6B M@3"6\&+LF;%-H@ 3:#"CV\ZG;D\Y%1&7;2ZQ+$"69O+X#$J+I=N*&X M0[J3Q%< U'+VV,"HKSV&J9JW#JQU?A23R%N'XPPS8;KHJ: 3(UR7HI.6] ]_ M>/Z=1SF1,GNF!M1WFW/@BOBYO805O%=::"3J)1O!")[,O7[Y?_^' ) MWM*P]SI_^SLC=\F1 7-<7(5].:JS [3/O. $8 M,4+&D?G&U(;G* +MN[="9T6&4B=;:*$BJZGBXW1@EQ2/NKZT[\&O=JPT6(Z[ M+MSGPK0$W3)B8G0BT):AF+]YA_U(SQF!!&"Q8S)! :[D6T?I95;(*MR+HX"W M+9^6QR;#BA;RZ)XA!FM*2RQO&ZMJ7;0K%[@,&@%$BC2X (1S\$.EL$PX>\RSYY)F9K^>VK! M3N9M^2:X"+_A:Y\<^^*:OIV^B%_W@XDXQ_2O2R*DV7T(?ICI74PQ)Y7TMLKV M B&1(JC7UNZ!/,@P M$ )BMX55DM8"[)GC]:URU% AF718FW5F%V[-$T+RB5 M4^:.@D(#LDJU'?F:X!,A\8,E"B](F8<<*#PELR?@ED]1V *1HIS /P7=RUI" MJM3(]]W<)79H.>RZ\X(V&+RNOZ!2[8P(-L$-,^>"! 9J:M+2+)5X" 19ZA:[ M_UG)H40%UZK,YQCX343U&7(%7IYJ 8A?&X,?FW2FBXW1L1XNSP=I@B+I/\^_ M91^-)G,HZ4PE^90)D&"'(2@QCU:O@]EX) @E6Z>.?\/:>[=>T+"+6_T3'NM;\1=BFO"X&G;*M_*GO^1DK()'N+4@8VZV'< M_N\?OUX8\DDV>TA1J1T*2CO L#;Y:Z@(8!V\_O8 >:S(B?IRI)EK_R"US0*6 M9[]-*9LB#$FED\=/8M,HPR75K[Z6ZEU>&9[WZ8M$UFA]!A1N,)=Z3Y"PS$SC M:2V-XTF*K_B9M/S*Q,P%3MHH&LV3S.[1*2*26I!@4E-HSK1X( O8#,!.J+AF MX'0! UE9VY,,!^$N.(W"E,"ZSYK;7*G+:10ZN+Y"96TD]AAN)VWF$=.$%DD4 M.4+P5=8*OJ"<;\3J%,<@821/(C'QHC'&X2_ #/R1KLE$B_DI(3]">'-DIM,T M2V2YC ?$8N98ZE,DXD('VU1H@6_:,8LO=T*>7!M)OTD">8!K(.1@H65UF,Z>S!%'Y M'>S]8904!#4JAZD/>B-)%V6!I=HH9)(&\TH7))@KXW19,347(DK4$$*6F5M80RW4WY1+BPM500X5S/*/ 9#?DZ^:,ZUHEX] MY85^(W8>+G9J0%TG%C4RL'1*(+PZ*0A.>?++% %H,[K.#WS #+A"@X+^Z4T! MY2)P$@-%1; %[ 6E=8#OZ!?(X''F2/ _Q> MB4VN1!,0W1?=5L$T1PQPLR/* 52^3#1>"( MB!*':$<<_:- 5@C,&6*P32PX-0EX,$27D?SCE:!@JWQ>0L.:#V?-K\K__K,Y M7[S6ON*5T&F-ZZN5>RB^IR+IO>U:2=>PU0U?&-E D9BF00EX_&*H$O"2&\@S M"R10VO$)#3/Z/M\CKKV+4&PO;PEDV^TTY!.(T(\#B\NI0;;>."@($H>@B2T< MD_^9VQQBL%#["N:5E\7!212*NN^*5KJMYVZ\GKKGG;K0,_-69-AMXF,&*B92 M<^Y\IK39RJ ;>U!G;KW49='*=:I,!DMR;O#:BMLIDEQ&+O8G(E1U2&R%2_<] M;6U6:SF[Q@/ALF@,?R;Y93JFYM*U62:QSIIA]G?^3I@R^+%D6U[=9A*CGCKA MRI 1:.*)'T?:N/TK)S[[<]G8/X$L]=5Z\DD[28S-\2*R<[(@8HN:TTN5,4WW MRW1CJ\W]$"L$0IK(9?+XK22#FN^A,R\*RAJ1E1I(\M@00I8>/G$D7$S ][)S MIF9Z(?X^1A_Q)I??_PCW>-FU\=>I2@ TOA;ZB571A2RCB0%9:9 M@;YQ\G>EY-$$?H3U,@O_#HN 6AF:Q,(IS!.!9R^H3D+7:!*?[UU@9D: 7;-M M/9M+0K4^D0BXR(\KC@R9P MJ>6G+BN'R#91MIKMW(@P2NL$J$13)=N;X"N[>!]CDZM,N%D)Q^C:K1,AV4F# MT:$2S5#/2CJV^!2)A1EZ1=OPQO?5NBWM2YS-LP/*H4Z*F&V%&:39""U?"@4^ M&;4T>H'SH]+$2*7GN*-/+E/MOS3;Q&9 >(P* :7:6)X8,'WJ^L-"HX?S]6WA M4I*K1.\%9FD%,GD5G)V0!(N&U<,W=.FXIBYH+O,I/U G^#D5?R6)$$7OD%SU M59LJ174RLXU*(L!%,MU[+H2YH6J*()-2P>(S; S8Y4MB[K"U=$6<+U9"80/* M@0K>013,,:(7SDR5U@N.UL+DE&3*J$SDUJU*>T[1D"\H.E=Y@#0O%@%0>4P] MN<*%$[#UCJ*OH3#I(B'IL$+"E"6I&,*8@B-ZDM?+E4^444VIJ7X,$N+>XH0] MS$LE76D1_2%!H3F6$"$ ME@'66F7S^Y0$H%O M^O>"O9E4+BR9!5RRX\?K2G:XE@7M?Q5^Q?8M2)AS/T;!CD,!Y2#"T">^P'"W M293M"3V1'*J<3<8& ME04HD@7R9W@Y^\_,-%>LT92UR7&0*ZU5K4#X4CN--%"Y.IC05"W*+6&YL-&- MG(6T<%'DST.8L=H_]FQ3 MCDI+BHF6T:9&MB/U@KD6D%,H2Y'PN4RA;!*H2RMFN8^&1!_5L0?4I+\ =V"D M)4E):'!(:YX!?KI/'RA-N5I'7:;#7QH$[X%?!?SH->?TJP=H' :0A(0'(&>XFE M<)[Z(<8L;2$6Z^-B U;!!>RM-984(VQ8VL3U[1^O)8B0OX6_:>LT&BGQ:?] M-F5?):CL^]'6%,/^(<7' M\N>+CX[2 [L&8,N!='8;A1;2GFX<#VEIU_P79M6G#3/5F9 ,#@D@U$BAZ<)W MQ'2*#;%4!$FV; ?#!)QC]!!T\"* [+%7AJZ%/QP7?&2,U%,+)OP9RFPA_\XM MIZGA)!@?+>TK]T<,!?=(?-IX^,!SXM-YYVF;8^WY+(H6KUZ^G#A1R[U_Z=CA MDX;5"[J_P0:-= ]']8"@^; GB6P,%G(1/0>5FVX12;>(0=,MHND644O?C$<^ MD6.9M'<*14;_L-W+_?]2%TSV<*3W-ULOT+.%J"! MC&"@)S.P;++LPL2DSWK.LHG9E4PXT-&E)->$Q[9.L'6/X$;L,8[<(H=$)C+Q M%"KVZ_/.9[Z+I=HG>>%I^9-T%<_/_<9$'G^AKG*DX^1A7!(=$AEV1X#_XW M[%[W=_C/"_#VJ<%\ Y3GUR#83* 7\4+[^OU=2_OX_2T;_D\=,ES"C+H:_2V6 M\,^O\5Y\9CHOX.? 4A\C>_?^X;WZ]@^_(B*E2E\K3)*K,UL@T+!&YDZ*@=S@5%+;3#46)K O$N'%,F<8VGG!R^!U1(VLP([1:J>&T. D"5@JN:R"0!I:H)+ M8X:S37ZSGE(H)[NH^"OU*KC!:8Z>1(L91S,_D$ES-'-*SF*P!4^:8EJML#(=RK9#C MH\2 44V1ER9ZX25W&-&DANP,K(1\@7HIDN'AN(Z_^7=X84XBAJ>L$0?Y:8O? M)*XS]STGDD/34E.)@T&9EJ 4\\T%3Z@*PP$'5DYMXF0Q7!?5C6E9/@T3=._/ M$VNYYLC)Z!4GU "N]_*6Q4DFS6.FQAR+'?#H.!(=U1]EW' .>F:M7#XD_ ,3 M%I,I:RH7P@30PA^H]03WUD*%+@*9()Q;C1;0M44N1I,I@07Y?T,_(NESRZDF MV(7%]W$ '*CIZ055I&&%6:C3'Z@[YH*R5Q8N+)J=B[:@DW,+;50OII>?.V [ M-]@J765PP/,R>%=4OB/)C^81J)[8NGS$#$CC8_KI#YG&E$>+U.N %,PK92E= M 'V%+)IF]S51^FD*7BC$CWS>3VY."=H8P&Q4/P";29JD\-6"/%SF(SJ.0L.Z M4(3DA4\5=QA84<].O3!NT!U[G!=E1#&F;\'1>8;X!!&JG M"]CWA87#<"D=+//;Y=:]&7SE^O=C?FXHLH1Y?MS[J:#W?(:X-C31(+]0#73S MV XS*:9]G^^NJX;*#2+;U3]F[)2 M[M!J0E-&^1>XB./]D&T@ELI(AC!O. MR!U3(LH^)_:!-_$3.&DHR9CC&9'8VYYE@2P'1 D:S;" 2%GO)/R4#4CF?[8: ME;*#P(52Q1F8:T2):U/\H@68=TUG3F;;ZBB+Y5;ZZ=!.<,ZLI!-6,I$"R$J& M>&5&W$HU(H,G508@"F*+AI&Y*$[26F!)H4)URY*^S"W54%ZFGITN9UBK'N') MS8W*RM+7HD&R Z9LI;4KPDT&2 *?*"X FP;VEYO6AOUGE,D=)KE^8>8B9V4V MS'*5>U(!C0I)BC+Q$W5A>*:1!5441,&C;7-> #X3^TF >A<'Y).@A5QL3835]I M_B;3WY)=4/,8H&' S5)[.-+=2<\W90,HD2R\= )NQ*--[51L+?6N3Z?)\2(( M_8N,+9UJ58=FSJ YC;F+E=H7UX:@&XGUC^='"DLAD^S Z*S'DAE0!0S$F6:< TO)JYF>98GXIWEO*!P<;&:A MV8SS[*))J(EU\JJ:I/;@8!O$J&9XQ _P/+F-JS9Y/ICCA&G./'(U)3+64D=0$! MYDQ]G"H^X>M!'EI-_DUZ)8 -,5*_!=.H#:.!UN..#G+S,SZR]50(!SCQ0T&7K+:2BL1[<4/,*1(GA-HK9.',-^])+Y@0K$K@E M/;B9C37PYV0%=68&FMPMDX6>!A12/U&.IDQ];#9?/R[D4R??H$HE#$020"7(A#:Q-B!O5ZQPHRS;50$^Z/"N.0F8BO6F'W^0R/HEP MT]"2IW[=*MM')_7&81ISO*@6<_Q"V=RT4VCWB#GZ:%M@Y%E[@H/;P79K*]V$N)9CJH7BXR Y<-; MJ\'C[&Q>OEWV9!0Q8Y:LS-0]0RF3":6N&-I+%0'%A>%,MI3#H62$:\8>]S3$ MUXI-4KW('OVO DLT*<'SY-!L/S.'=SUAR+N,;(K^AA[[*A@'I*0"!=+>ECD" M217FSJFNPQJGNB(K(/M=6G3QB8#^ZKM@J8',TY I,<.LQJB-1] MGTG>KN085 I)]21=M!/\R?4K?$E%DCEAA,-K1:?)WIBN;B@;T4->\S#KPHZ3 M:?+\#KD=E%K7TCZE,)&&M(IQ2Y&9S<'352G46JCQY1YJ%%GWE'<_*0O8H^0- M[%G(%[13[J&5)HI)R:72Q%"E^EQPQ%=U%(9T BN>A[*K$I X.4XJ31)SU/B^ M)KD&S6V;UTEN=')'H,OB9.X#9E900C.VH?9S5ZV9)%>20XK=TL]D($^S .CB M%6TQ+YJ%RL@_0^V"IDSLF6!&T%0.WZ.^W/0W:JW 88TB7I16+/ M&S:<#$4F M/4GNWR\OO\K[LNRE=BK %HD HXQ"90[#4I]]X)R."NYG-K=E2S+B8JN@-SKX MVGL?+ VC??%WNIS'1=A9<5TE:K;N#UDPH02F9$4B.U=6#-OU53=?;C%#!M8" M 'U+TY6_),FCYTGG\D94-B&0F)96!,5/?A**P6(9CWY5Q"'E,"= \'1'%NDY M 2!H(L,G<@BZAD[2@.@&2;"I%4^O3$;-E4ES95)+"8%VZ-3')!!2]'@T-#BG MKI"E'0[WTLCHF^>D9\#\,:EAI/AIB46$9A;R&$887I2>(0>'ID\N=3HBCV@1 MBE?J+Z_!&,4VNZ\Z[2&_7'AK]HMH_#GZY8R.JW>>%!IJ?4_[XYZS::.O:E^>_/'7Q)E,74! M 2,G_/59]UDJYFD.X*NV9@ #O,P_-EYYK+/XB0^^7M%E*\VRB,[W+4;&VTRG M-DN1]59!(@LB>R>0'.VQA^!M];&ZX\T ?GB#!MO^\7,N1^\^T:/_HEV1Y_]$ MC_]KT?$E\R^Y*$:/;92'P$;:-&3R)*T;\9"O]RO/GO!WMDANG$E]0QU,+R2) M6980X&EL(%N<[C,&?Q.7]9 M*Y0Z%?'9Z@Z!;.C@V0,'^+$ZG=@8]O1A=UQ"&&\]=Y:C&LHX>\KH]D;Z>%3& M2CD]99Q(-I+WL4(9E4ZXE01.>;3G*!TZO=Z+AQS1*$WM\JCK=7(5.MN5/PMI MKD[,R9CIC5OC(Z'EE.?\MT.]UQONX^#;;/U'!CBCW='[X]TT=QG(;9*H!9 K+U%/JNOZ M?=WH#=8CD_JIFC7(+0W:G7WA\U:J^!B"!2JX"J7,@?W1)KW:_+^ MGNRS,PE%7 O7I9Y*LN>6;-@G&\H%E#JY#]5:6Z-BC:,-&K#;/ZFA=JZ0&W?T MT7#OUTZ//.@[[.K]SO"X8=\F&E\",=U1RWBJT?A:V$B%'2E(QGK]:$?08+:YB0 SU<>]P09S'"[<^6 Z&<7[FUDD#7+V^WA\> M2Z\WR0_E$3/JMSJ/RMQJPE'-^W4(1]7#!BH.&7RA;@>R(/"Y;,^P(@5.80LT M[^_I_:>5W_5!]JC:#TV?>N7A]MP8K1JH>X/;HTST,O1>N_?G M/QF#]NLFUZL^Y$RX&0[[K>$Q<5.[:.H3N5 \G#%W9@*\H_SBJ4-$EJWHFAM EI'NC_L]#IZ%YO#/*JHUC%*>@YWOW1F K&K#WK]4WI0 MCPZBX%NM1IF/:;\?(&'XE(S?U4>='8W[ Z0,5T]O.316SQ"E'=UHCUK]/2/U ML2BUAUW5'*V2XU3AWS/<6:TW=[!X>CT""54R8[2)F/HT!H)^&YD_'WD%]9I" M,D/OCTYJ%)XIX/I=O=O9+3OY"<35UZ7+&/JP2J^0)JA^),0,*]5UG4$\_6CI M,G6]*&_>KT6B03T,H^+HQ5><$!>J$7Q/QA!:%QSK# ZGSA\OW RP@P:[I0T_ M 3MH7=.TMMX>5\A/;>R@(R%FV&_U'Y4==&ZQJ.;]FKW_J.R@8E?^LU )EH>) M3]>L>^V:GNL[=:_=]6*O+N*Q&!8CO6L,]FW2-+3T)&FI.];'@U%MB&EG>CIE MW+!\_^3*QZ^)G[ F+-W(BSO,N?%V8=5RE*K&:0*R[-*RY MXY&!X)>CN;YEW^FAEP78=(:/-^4_I;-@S]>YE. MP8\R,WS8:8V.F;1?G[AE4S2PC33:K4%#&N<8=6VBMELE?IF&HW#V,%I_F_TH M[[ &HU;5(JY'_WY#&>5KPC0>P51]4;(#X* V^7N5"F\;>>QJN M@%%=]#>D40M3_L"N@.V$"]>\?^7YWH;KG:?X% 'N961.7 %_VL[MF[_ ?]33 M#8L\\D,K)G6-72MT^[TV$CXI0LKM2N_W6UIW^$Q M$P2>>2-4O%P#BT,S+7(ZA1EXP(+:<4!9C,XO7[]?GA*5__APJ5WY)H#MS@RU M7WKZH-.M@" PY19F #]'+/?U<:]?%3] 0K@KS?$2%)7_/.YY$3C XP 9S0X MJYXVN=?,A#)Q75S+B^<3P+P_;9!?@'Q8$A#8'>JC=EL#F *8"-)LB>39L3_2 MAQN>ZNH$[PQ:\9^+P+=C!+P3W3].[__*=1QQB^#GGXL$:7K%HD@GE( MG[-\SW:XTO;.B6::$X6:!1H.?+0@A-5!Y_T'EI=K3IT@C+1_QV80,3?E&#GA MN ;=922NDG,*G"C-4AD&B(D<$(LW+;?KC.3 ]^Z[LQ %C7P$]Q+ ?$ MC,-2Q?'@V<@/[C6 .AA5<_B7+J4(;"8T;V'CH0SMQ('V/A9NLK/W<113'3_0 M+ 7]PW.DV^S]]6G)]GU9C.O:36;3.9O=&"]1.,Z-5#9[9]CJ+I%XIS?(DGUE M2R\AWMR.JM&N#18B[,_U[T *2I-1U\ *!;)R@:+]Z304$5)T&?)]"/5>@@9% M-K5@'70QTJR<)9 [G@)YI]/6)F;HP*]\QXO([,+$@%^KR@N\,DY?VBXYU!92 MX#.+9?>_)!D8S@\ XA8 %B,MA54X+U MI2;[MH(1"'8E2X;JC ZB)N-Y 3O\,NRV^CD!@^/50, I>5<1V/<:8WSPJ:Z M1EQ+(/+,/>RDN_#9:'I%AC,@X/6=8TS$!\/VX,*>PV5>F>V?>AQA3RW(7L%86 M@.O.GN'"CM$:4&[PFK-/IP<[^Z:\R;^8M=F+!IPT_>NS/SGM:;\_FO2'0VO0 M[EG#WJ1CVZ8]G@R,R:!K=R;_;_CLS7<,;2([7<$'@:S"O[PTWQ0AN%XRL5CD MK$J%01X)V MA:N@,@PC4H&DI++>^%S8>,\":X3Q8N$'^&.&#&PG#!.=R0! @T,Z[!#\%(I0<]S$?J?BJ;N9 M\')4LS9:I!=0OL64KVVB_#J;?\6B[K/O7?Q^>?D5+#[<")QMO;DU:K4YC+H' MFZO7&N?64H;7:)WAM?3E,%YK$Y - M=_19$Q@(Y(?EN [O$_8F4*^@T% +39.%YG(AW &&3N?H!3&$26L7/UYK8B[V M98K3=LXF!.(4-Y?,!$-Z_4ST#EECN.R1_-+/>#.E%&)&A)-6@ =CE_1/^N%< MI*#(\$@?71$?+6U-T\P-.BA=#@[9:_4KAQZ,TO: 4ABD"T#9^ %"/+0"9X*" M?N*#[<7W&_BNVB"JA]63UIECRHK_-41(-Z]CE??S< 70Z[4ZJPI@U&D-"Q0 MTO1.\O^1"-[SR?[H;&P%=[*$D$Y%29RYFB2,!_C0+]V,]JLT]QJHHA[JQC@*\5K+V'Y 9OY3NX>C@# M W\*NH,^$4:^]2/O"Z->@)_YD1B?F8BG_A@K@.$8 M7$C255DOY$FG4G*CS>EM,%J*+>J6)/LZ4V%9F>0MT<-PR5R4-#$X-4T\"?M3 M<^R_/MM^#=#I=Y[5D^J*PP4;0']^+/3!DQH7+"S$-VER6\C8*TH8"F9A1C]2 M#IS5\>#9.=-1(&[,@$@80YT< B /W1:8A@=?LU%@(;1TD&+ #:'E^F!2*0MI M$_61*'-"%61UT:;&2*].'TM_*J\X0DXFPR Q6FT1. M?1=8!+>_;@\S$V3J1 B/%L=[3ULC(P\.>9%('4I[>+7JV:^+S>AR7\N31?6, M(;7L!.D9V<9G4Z(E/3^&KE'.M+1WDKOA,P#M[%X+#IG$-%'!KIK:7!,(E%K!C*.(JU-WH;*V^BTF[R-)F^CEM)) MR0:R-K+" .5_8@>A//+HV" 9YF0K,>^#?@ A#B(,M3 *%U853HCR"$ DI1-= M T@#"5/E\!H#7^*5YXN9B7OF,)9\#E]6$B?CKYV?_,\;6U3/&"::F<^\62M( MM:I,0C8$M>?T;[ C :"8T_W3$HLH-8.4Y?+BU<,@1OM-13"U\B.S9Q&*5^HO MKU7MIN/1^>FEUW)]*;=15BT5*=,'^=>I&&NU693)DEGY9?GK%OSJY>K/NQUP M.8W"7[5;Q3]?MY31:PU&XTI+K?_YJ--M-G7T38TW+[6E('MS;P)CY;F"[@-L M:]2DZ21QTW<*ZWSBL,Z[@K!.E8G?94ODR_;-K3?H4"Z7:6CPX%&INX!K8Q.8 M8QK"Y6#Y1^H=_X[>-9@9'XHAW,=-N13%[+QN*+>AW#.CW.>& MWNT,RT\M:6BV5NA[DC1K&".]W=FQ%^;A*/=Q=^5NKR_G.'X'[E/"8*B/>^UC M]ED^LPF_YV>'-=@YDMQ&4Z/!32UQ,]8[@Q/AY@E$N[X4YJ0=OWOY*6'0U0>] MH_8OWZM/\;AQ\[RCCWI&92^PP4LM[9D&.\?!SJC=.PUFGH"GN;YD]6EYFUVP MR\:-S5Q+W#P?&NW*\YX;K!R:8[I5;Q ;S!P',V!DCHW&QSP0=--ZW:?E5X[T MKG'4.:B-A5S%KS2Z%71D@Y[X: M_GK([FY;'1+*\&F MF/*<2@2;397=5%-,6;F8LML44S;%E$TQY:,@V*:8LBFF;(HI#PV>IUDD,>[H MHV%5?[4I[ZD5$I\DY3;%E WE-I3;4&Y#N4_>6G@"5Y)-2>6S-_VNWC=.E!G6 M7*TT-94-=AKL/#K!]@3B7DU9)39P&76:!,NZ8:4IW&NPTV#GC"3:$_ TFY)* M&>OHZMU!XVW6$SF-/]-@I\'.^0FV)^!M/M4"R^Y8'P]&C;%<2^0TKDR#G08[ MYR?8GH"_V11;9DBM=:KNBHW5W/@T#78:[#PRL;:GLLN]P6O[M,X.Q[9?T'AT M?DC8%R:<$&!E0FIU_! ZP?)RJ'ET>D6V8XT^F_M)%;T\7QT%SLXR2U>6%R"INS"G\Q^NT55*V# M%4Y,AA<&Y1#66C^%O;9TCF$\@J&<36TCYM)!TB:2B1,Y\$%;*#C"$[\ 3$9Y MF""HADN8JX!X1LZ@US)V6Z%;2(.F]LLJ:ZB3(%VG1 J4HR$GM09KG@X$2'WX M+!S4FIG># MZNU3LH\5!P$6H)IA*)#V059$H/!<%$I3^)$$P6"9X+.<;5H6J2IX^9Y:)E"U MG&4%L=0A]&?5,4F0]6(+%@$!DK"H-%FE-OTOHBHL6:<59:DL4E>O<#LH+J5]G"YJ M$T#$?.'Z]T**M0+#5]*-1&X/VZHL_-!!0_H5R580VFDWE5_S?0!D+Y9V^HHY M"7WT$M:^,U@ <\+5GGTX/=G86(D _/A=RO +/5P3X%&S'K,U> M-&#CZ5^?_:F$5P:. >E(X*(K^" :F']Y:;XI0O YR-8/'BKO,$9AZH ),(E# M>"8,-:J3%S?W>E98:'/S'M@>C&UT<&V;^!"\&I)1* (R=F-BA.?E=,Z4)^O" M@L].XPC<1*VM.I$D0ELOG/T.$?_&T2S -7-;B1I<,""//?TC?E@@BZD S)8X- MXTGHV X8%+"5Y[!95WGV_"JZRYWVZ]]C$U +UCHY[QWC]0N-5")95 A)#70\ M,'0*;8Q@25->?IX73%?B?[N"\$>NQSW^)!"$&5N[ EQ,3 ^,BL^MRY9.1G&$ M?OO"M"A2%"XUY8"/PX=;&H#BDWF?"SB5^##T_\ M(/#O)*'*3R( ?0_CJ$RJ!(,PTE#:22$S80_'TZZ_O/^FL[#Y^.&W+]^TYQF M7LJ/+N](@9<%W;JGE+<=DMA$>POLRR4?#9C#@5^& IP\6"(0M[Y[2Z?AQ:9P M))?B+\@5N,9*7,,5$9P/246^ ]3B.L!=6W9GNJ&_M$4/^)0Y,R*:L5A$ ]\E M^R"9 U)YCEC.T0U\]E^2917Y A98?X3Z"N)*GQQ,_7C!IGU[^?!;C@C?QWT M]4RG3C"7] ?DX8D;_H?E@W]KHMBQ0##XTF8W%PO7L<@&P-/D-D3Z[9),[ *' M-\_*&%,$(9C0:,ARD"/,2\<$6*S%)%OLR 8$5!#X#LE>)@K757("Q6]ZI-W# MTH,28>D3Q: _1&*N@3_ J_GF MA#_.2FO0F>7F ]@\Z%T.O"06 9P3KSQ *0+OD!PS;1!]P&69^-5\O"*!]>)PKR/7&O%B&A3:)0UVY W 0>:Q2D&M#NUGWN"=;'@"C2OQ/0 M"2!!OZ0(0_P6(DUG4T*&/S/[6?@@G@DJ! V'I#RJK]PS032%YWRR@AWV45"T MYG="N_NC==U:=T+-!I/7BER2T-$L\..;&3SEP4%M\E70U([XID*C,! %+SB* ME<(1421?G@&28;F \)8G>2>*F27@W<]P@!GJ-L"8R=_@S7'+VPR TQ"-#,WR M#1#>4&:4@88$@7-R8AIZ(0#]-/KU$7XEBQR*;Z?*2*K3$ M/DGQ"GMK]&3GM!\R<_!74],)Y/&EDBVDL3L_=NU$8&) WL/M)6X+7133)LEX1GD( MB\G72'*2ETP?2)U> %#L1B0@$_\WE!8LF#3P G,^N78@L9PID I\QQ9H N$V M\ B"GL3MFU)&9%1":J*A-:Q"_DIJGE3>Q2:H00!M;46PFW"=]6GXGS#Z_ M1 -I6]!\C#5E2GA"73PB$CAD_"%QFUD5[XFZM1T)._MPYG G)&OZV$'(^KQL M 96H$,B@RD0(#YV*! E*[0/\\)Q9*B?BQZ ;&(= X\77W[N[">.SREXASZ'7 MHI!NX+NL^;\&OB5L=!3.CR@^D1&"%(UA%\N-;67.7_00;@&/WGX@4];?1M^:_4=;ZT(GJU MV 4'V[+4U\D^X@.P8!<>/4X2TO%0UO)Y9-C3EA)*KLPB*@Z5=\3I85+ WH%\ M=5RRA\ " P\^OWM43 %>4M@8F*4MA2'^E:*U 7:@9K,YR3DS+3#W4EV V2D4 M,$9M8()UV])^4Q&M""\C,_@#O.!9I$%JX5?3X %'(AP2):@EP+9TPEF:!]=I M&UWM ]IJ> <@68?"8X;QFGYQPW;L^\"<"XP94V28@2.5"H632,M<+T @^V2B M?@EN3$^V>T[(Z3MH/OO.O.>W0BS8=!I33RXJ)0UBXI#\,5W$MN89EK;ZAD]JK0<*6E7552TM+_Y=["90)>6 M:+**2]2EKDHLT^.M8V:%[9"[1H:\O'*-.->?0S%T7 ?31\"4ILO,=1;SUETG M\92EH(U%D9Y)W@QAP&0,$@Z%WW/F,E[>!,IVEEY"[$W-6Q QN$G8"VI_Y4EZ MY$7-,;*4 \7.88O1Z RES&6+[BZU]W!Z/SA/"5,F@D7$CP>=\D$US&^?TDT( MT!!K'%V3,%&2A H#W@/C:T;[XN\[$\;8J/FU=Z>EX8BJ&R?DI)YK2J<'(+SC M2/)U>FE%MUHL5*5B*DTSISHAA@T"[6LVAWGE7!7.JN0$Q=(#T)@5CCX C7WP M=J=78EYOU3!#@LMW'_/V/L?JVO&:"SJ^)M>2"FA[W5N_->J7 M<2M7PT,HNB^Z+:- W&*R)KN2;71.0Z;-D&U'NBS^BEF5%K@GE^!+Q> _\C-?79.\&["7;@)S MWLB459GRR?SIS./Y*K3)L?QDWJ^USVIR@/\#;^(WD1&"?R2A>$1_F,%_>)X" MLE,D('?M5+EVRE%[==!1:;(^0<^6_S:]&"--AG:AJ;]WC1(K]P>AA@\!W M:[EYRH._%Y,@4>[)/SKCG;3[2;O:G91\VD=M:K>-WTLBX/S@W!NU!IV-D&X MNG=-=@*0EO+^:P?,/2F1W>8'G.Z@->@UN*DE;DXP+>%DOM8CT82E.S#+\UZ@LGMEC JSE MLVS9/"U,8LMZQ7PW>RO&<4J,N57VR!DNSJ8SK M6BPBKE0V!K@UH\<-D9Y=T]O?TK?QONS9BUI7.15G(F[NW7-@)!2"4:;L8G(O MIM)Z?EI^%E(#>Q937&VM8SXVD!WE#\O:<9(B2?=/7;N;.=:,6KO=FM2S6)8& MKA9'IUV&9<(E-W8IW&::.$$*?EPRC0?8N[;SM3!S\+!L5V49T9I M5>!O/H@QW/;;1!9CBCC*8$!U4V&49C=U]U%A-.X=O,((#FA= - "(*-77,9Z MOUK54N.RH]P!Q,^9,W&BUR??X,%KD;;A[=0YSX.6]HZ1$99N1G+T[-_QJ-4> MCZLF_XY:O>[>TFS'@[TDCXY&K>%@\U*[)X\>+^I7HK8-<\70%<2 M"F]%: 7.0E7<2* 4A8"7U+#18UXK#@.D-ZOMUK"_]G*U)"BW!1VJ?NT 06WE M&RV+"W]Q N.A1Z.J#A?&WG_\G^%4;(-M]1@:\V&3^3"+HL6KER_O[NY:L,W6 MC7_[\A(,>^S-^%+8-V;P$LQW\^78:'<[XY>P6Z"?7J?=,_IMHS/L#%_>]MJ= M\:#S_\3/[H71FD4@JKYAMQ#N%F.G'5@1I=BM*2([Y(.GNNU)V?))@%=@AN#$ MP*]:VG,G>8!] ]@M.$+8=@-\'B6=@8S7>5]7LNZ3VU&@BT-E8*.+OVO/WV,# MEL]^2X/C7'2-_K#[@IJRV)DL@2'YN'UT8U?8[Z(*%D,W84@'ZF(V&/1."X$8&/5@0:C1G8R$"4@7-A7V"@NVUTC9_B MY\^N(858:K9).VU= T&:(X.M.$$\70MJQ*!UVQUEGEV;P<3T1'CQY:>L^3!.#?>HS7BYA&+F\;D:L1-H;CI;!0W*SU)&W'3B)NMXJ;36#>- MN"D4-YVJULV&]LB%H@A:)=VWZ.PDAR&A)T9\U&E)#CT/YQFYMXOAX.,]L7_ M)/.,MS<79MLI,ZBP,U894MQ>4;;T^T#7YMK__O;MH_9<_&\D/&XS^)L:,)IT MB=8^FMY-;-Z(%Z^TY\X+3%"P<>2XC7^CFSK./DO/*6\/L//D0EDI*1>2-G#\PGPK9E\]9DC52)B"%S3]3UQW^C;RC;+2EY# \/=;)850#8V2ZU0U=@L:W"[]O;H MZ;76Z*^_''DY\>U[^&,6S=TW_Q]02P,$% @ ;X:=6)?V6HA-"P %&X M ! !M960M,C R-# S,S$N>'-D[5U;<^(X%G[O7Z'E97NKQN'>G:0ZF7+ M)-1RR0+IF7[J$K8 51N;D>1<]M>O)-M@L+%L0KK9D54H .:9K86=^57J8=+3STN_7'SY\^8>F_7DSZH&V:WI+ MY##0(@@R9($GS!: +1#XPR4_\",$]S9D,YU:DK7J'^RSJW&;_/+9KWYV:I=F-JG M\ZFI-:QF18,75:3-/EFS^FS6;-9F/M-G>DG-!5I"P$USZ.4SO2HM&%M=ELM/ M3T]G3_4SE\S+M4JE6OZSWQO+H:5@K(V='UNCGZ?$#L?7R^+Q%%(4#E\B:VLT MO\8S2%GUS'2796%NI5ZOAJ,%+YS"'3N40<=<<[<8T=C+"M%J,A%_7A;/A:"* M5JEJM6J,5$U9TRIU;5M)BZW)HAHVR_[#$H",$3SU&.IPG-MH!CV;DWC.7QZT M\0PCBP>1C428; V(/&:0S!$;P"6B*VBB+%Z\_@" ! '0L\U(9/Q+4;2T*S8^#*R&157FK@Z>Z96J9Q=JD>U.82K7)*C-+[T MX$X>#2)17;VXN"@_BS!-UB Q[N1X37S4JC4>"CG$[@O@[++YE1;2'4.'S13- MIT-(]TH=$N?DOEA04,C%B$! *$9AZ!%)EG<_>Q M;"&<9?[M#A47<%2(,(QK-0I+!@J#958FOFEJX5GY?$73&%0E'Q/AO3P#Q MF M E"_8TMS>QIZ0A8B!JQ+E,-C(]] )FV^A65[S.0EV\-_!>!M.\QK/29#] M_VZW">V\=G,2T[,/"7E!/N'/ >858,OE!70)B'L/HVY*+2.%^J-#=B'#3?Q= M5^2_*M VQ;8&)-67\N[8'2X>1=;0N9:?=R=T0!P,22'<\4IFNNTIE$@6W R] ME^;3X:!M#,9&FW\8#WO=MCXQVN,)_]DW!I/QL-,=M(9]XV&@/[2[_%%V]^=E MK$2JQN$9K\69( MITI1PEX_!/8MD>]!$(/G1N_I@Y8QOC.,R?A(D._AJ02XD0W@@#WP^;^#J7+\ M/23QYK*"MQ+L3P9_<>*.[TP:TQ[@[&DV'KWW?#7ML8C8W_/'0GW]X"^"S2E*'P^:!0 M\$7SS VBPO\)?/$%C8_Q0[^OC[X-.^/N[:#;Z;;TP41OM88/@TEW<'O/?=GJ M&N/, 9"1G1+A<[&%PM2T7>H1).#V&0L@(ZS!AC<(F1<(O.[@*X_NX2@/0E$: M)0P7NS!$J OD9T,?#7B(C>_Y>G&GCXS,SHX1JCQ>K>QZ/&0!. \@F13(\=+> M&UTFE/X]7^+U27%60%M;&)$3UR MW;]FFP+3Q46ST?@CO#EB G%-DY*G'Z=-A6HX@X1G8 !R3X;4HE+I]3]A]%=7Y0W[01 M@]@^J+P*297NCW6_M^JK@$V1_+];(;70Y9QGQNC M ]DK<8RUSQ,*-/%^V%H:<&= R@-<( @D B[R'77NJP$DA*OTB%Z+;XR1"LGS M#&UY?G/-MY!P)9?,!X.6D9T2NLS-_'< $ST^9J[Y8[@2,JAN,5[[:(0H(]CDR4:ZZK@P*Y@KD8ZU.5*0WL@*0'\' M.S[MO.42DA=W=H^(^&U/\?M;XOUY:[R !.E/D%CT2!,\AR1E&&3OJ?!'OF!1 M3D5$:U(VD,*!+[V08>$W0PY.S'O(E0#N:\H4/>WZ;AA[JY7_B[?0;D&ZZ-CN M4]>1H2OD' 921J9*Z&)]FC5T40E B !"!H@(*3"F'8]Q=_4YVZ6W["&^^O"] MWA(SX:[<2VP.EDH\8_V=-9X^?Q ( %("B(AX1S/5]=^K;X#G]^H[HC^_*YYW M?N9@J40SU@#,VAQF,M Q(]=YY'O'<6*> NQ\YJ V,-)A?)%K,>XC?*&+9!\BP[8 MP?N7-!Y*D&+=Q&V0BKV3$>_2Y44C2J/T?JSI)ZC_[J[^4MX^O,2_WCK@1!QO M$AS;)('@?OY^2Z##D-5UQ.DH?;2D1J4 /4X7\P\<75+7&]U5?*'8X:6)> ?Q[ Y M%.O2ORAX+3YMB671O:R'&7/*DQE^B!YOML2!QZ=!O\.Z+'Z,S5ZH>] M;DTIV!5&TW96!1&6)Q=HILF MUX3/"X;X8J$P+A/IV]F8V<3H9&]D7Q<:)V1"'Y(?B/'Y$6GNWJS[RNDV9:,] MA5B4"DG5Q!L"R*%2GLX+#&\R]D"JHU';Y)_VQ\-$4VF+F< /0%+-(R]J4\7&EL]4\9_QEXW/0 M7G,$+0- M*@Y74!6I>7B<0CYMN4('U]^?1Q3F<]MS4A8+!5D>TW[B[(C6;M7L95[UI!!+ M7*?Y'7]Q%NIM5BV^J4:")=UGYJ' 0/KE$)A)-P+9T9+8=23+E M"10T/40I0MOK20_#*;9Y5@K64]KVD#[C^>@;@J3C>F3O=#V0V^$ISI2[V3>: MQ;R@%H:HVQ\) W]QW(J*T^$*O0Q^SIM')* M-B2%VG962)^72MH3742W\Z#4M>?R+$'S-/02R$X@=^YNW3I?!]VLD&:B/5%( M$U=-EKKI3R,YS?5UNX@QGL7>$_&\*"K8O6:F$YWH9B57:2Y__? H17[ Z0CS MV&*7BQ?1=_2F-.ZVWP;FMKM>@77TYP;P>ML M88DDSUB'&ULY5U9__QOZY&;U[W^YPRN7EQR[_VOP%-9HN7OSQ[W[;G/S]__O'CQY\^A6;\T[1Y]YQ3*IY??OK9Q<<_ MW?K\1['X-'/./5_\]SCP936:MG\3R@-GHY]GB MS5?3Z-N%U!_$M7/O)\HK^09I%'VLY;]%*=GS\LGGN\=';X<')X,7N(O)T>O#E[NG@Y>GISBS]># MP].3H_V#P[VCUX.WA[MO7Q[@GW!8B\>TG\_AEV>ST=GY&"[?>]] _N49/H04 M]5.QQ/;?CW[$\Z^CB7X3=#@P^M3!)L!3L)9CQ-%[[T+BH M==I<_LNQ#S!>O#NQ-,\VC=B@E=]EQ3J34^(/12'S(0*SP MS#@=8S&&_F9[M32=MXV/[)YJ#O?FLG9Y!,_@4Q_-B279G,\#_IU/_:>AUC#Y: M( ZX)V7\)!B'C MS3F\J?:J35@X$2FFVIG.-0!]]FO1 M(':/L4#(!I,=#HDX[V*9_,H J&QE[8FV-;_VM-9_?0[>G%Q]T7_E0 V!7AB) M%QA-EG3#L9RL$ID8'C%J# EQ9!LP:DPQ&A8QX?"=D/$6E%[%\+69M)G@M^#] M&>-!<>$(@"BK8S823$DH8=X$R9UT-M5.[E?T_NMP?3G3KGWIU:>A=H>!:XX9 M-B?1*(/RY[PL%&4"R03G H_ :^>RJ^#JE3FMPI;;$Z*R=NHMX[7OH;E_T$)$ M2P5::Z 8JLNH+?$0(_%).*=!<@75LZUO(NI3E-P-5RIJY 9+_O[\KOVW[K89 M]XY>OSD>_(Z?.?ACL(4]QV\^;SL;D*L/N=)NY-[T[+R!]TB-T8>+R QMR5$N MNS^1\QRXY<09B2P,2,60R@Y!B)8;QD0TM>.<;\"IFVP)*@6'P(FP.>,,0SOI MC+.$^^AYHDQ"K.Z[[T^VGM9GU>+ K6Q[;8G7=4]WC*\@NASCFVFS$'S;-J,P M;WT8P^GTC6]@T@X]%59$RM'R*E= %T.L**%),&.\#&A=NO!?ZT/NDX/KBEC; MU&IOJ,BMBHH:6K8I(O[ 211T9L0Z91+F/B%1V6$F=5(""TMYB@<,]JUZ?5PMXG/]A'NG?*A2=('%_LOMH]W!N< M_#X8G)Y43Q/O^?;NDL)5AE,I!7PU\F$T7JA]:?S:H5;,&0_V(B3C9?TA&4N8 MB]EQ:V3FM&)-1&-=U:*>,8308O.=& I M15M[">H:@,TWN3_@MTR;SV6[-'J,(JC41 N&T03WI51!:<*$\I"MM(G7WIJ\ M^OP^&:[UM7Q[HWI-"5=C[)L&SOTH76QW8CRY2("OCU#Q()3EF7 5<68"%\1[ M:O$W[;Q6VJA<.VA; 5:?[%@]1M361[UC9G[V'N&4_PS^;S[ZX,<(9;;;[OFF M^8S.]P\_GL/0N\!T%I1DE &1$N-)*R0ER1OG!%CG;.WSBBL!6X4LXKLC2WV= MU#ON\W[:M*?0G!43MUP:FPW1Y7I'J2>.V4"D48!CI90PRO!/TD26:^^0WX5C M%3+([XX,&TN\MD]9E*P.:9;92&9(X$X2Z14E ="UJ6@]39%[H+6WA*\^?Q5= MJ^].UVM+N(OL!BW023N-?[V?CE&XS$77*4& ,J MX/]4MK67"!_"5'/Q@N$,DHRY,ITPO7 T$Q^!$Z/1.V?#K FUD_M[%R]ZD\9O MSH1O)':/$GD]/W9[/#YIKW/P)&N'-E6P1'"ZXGS#*6P%!O%:5O=B#W"Y-UE\ M?09LJ( NB9"-MXX;11BSI1('(:!!#VC03=:0N:*J=GY?WZCMIC0J.O;C-^A1 M#B9[_GS4^O&0.J; 2$XPG\#99B(E%C3JC()B)?WPU0=W#Y0^&;L-67!K.Z>" M\*LQ_!A:/YI &OAF@LG#;#?&^5D1-:27D$=QU ZUY38QGXD-NK0/L)I8'"&) M A-/SW7TO'8P]S"J/IG"RORHK)**/6?.SJ:3Q6"7.2:FD"RH& B5!84R&-8R M&H@*M"R]>BU=[6JPFQCZE.)7IL%&XJZWN/V5?*M4Z Q3L"P9CB #"&0F1.(L M)C@L9JELC(G3VFM!CX38IX6 VIZE0V55WBX9Y'+=GW%AGA)?=#*.'92]K:/86 M@]<6;L6%K'(JK/W\9NPG+:8V95Z>7U3Y#9G.UG(I2#(!8S1E0RDPC"1%AWF- MH$E24WUAZWX\?8J"*FB_FN@[JFPZ+F(\RF]GL!CL,%$I@A&:\,20G\ISXK0, M1".4H!6#X&L[NV\"ZE,T5($.]81?MVI\.;2KI2:.,F!.$ 49RND<08(QD5 M ML]4>%+>=G."]":1/H4T-_6\L[&IZQ\0+\/'I2]>%"UC(0ZO1,D&R),E<=EL< M)4YH("(D)3!BM\+5/B5Y/YK^[7QLQ(!*8G_J,]J[)[_OOSKZLW[)_0-/V=)Y M[ >&5ZD$'Y5>]KPQ1O@PPF][\1D] 1)C?S3QDUAZ\L9V]&&Y:>!#\,S11$QB MR W,CXGWF$UISS* S89![2AM=70;QZ?^\V*;=W_:',/YO(GOT3D>Y86QO,@A M==1E=<@09T+&*5>Z$1M%<:I0GTIS.&YJQR4/HWIDIM)Y'YXNR'0KH*VKJWHY MSMVXKBPY#14UKIP7("YF3V2Y;B!X!40)Y05#DZY3[:V AU'UK9?3$W)H75U5 MY]!1?CDJ IBDV9!A-)8B6(S-=#F)ISWQ#"+1,:047!EM];J/VS >F0;]4"Q9 M5QLUET\B0%KTMUNP\^A\T==N\ F:.,*Q#UU,+$F;B3?2$LG+3J[%*#Z"]UKE M9,!5]TX/@>I3YK0MQE155-62TQNUC<?^/*)]] ,YJ6;*$I M*P8O8?E??+V\MF'P"8WGY!T<^Q8&.4-LAQZ' J7J&BVG(I)Q0:R/D03*F!64 MX4!K6ZSMCK!"2Z"[V+BL-[S.1JV"B,Y%PIU,1(+TQ+G@".4ZB.PMI4QM)^R^ M UV?%LI[S/$[^A-UH?Z:[8'OPO=EZ? */HZ!MF0>[9K,M50 MNY_ NHL63[NS\/W3JPCR8;"7B(PL(95BX@] [= $^6N R> M6,HSMTH(16L727&KQM7/%X.MXFS6+S\^J3E)H_Q7FHG*>$FH0RX$01)Q(A7AD>6>;:R M]FKA:LB^AU7G34EU1VOXVCJK>5_ #6P7QYHNM_KN/ 0[M)S9;!&<<*(T M@RZED1DG1[E+V7/OI'-.Z]K'WU>$]CVL;G?/L,VUUB&E5FG8-:0LR<@B)SXZ MCO0'A_(HC2"X-DIZD"'7WJ1>#VF?0N$GXUMUE797FG3S0IB4C=1"DZ@0F0SE MIF+K+2F-*C%V%C2+VJ'9 Y#Z5*2T)4+55%*GOG#9FJ8,-P8N%66&")T,#E=9 M$DQ*A$LTLMFAYZ[> .:;@%9AC?X/\'OK::BC^_@B-2;*;F M*>L V5D=JU<:/?J*"/-CF9+U%5#1Y9PW$$<+H>#O8[CH +Y[5AHT_WOQ_I![ MEJC/@61.$Y'4*0SO@1,H-U!*Q;Q1M?O>K8)K%<;8'XLQU=55L6&0;^ %&K94 MCJJA0UQB$1J<5EH29SAZPV0#P7_+D=0@E=40E*_=1N1N)*N0Q?U89*F@DHWI M<0;IQN&/K]>Y%1D,8W*>@[N:M2[?JJ1]ZQDH+ MA_3'T'U5>5<,3R];6GVY%N>JQ2J5;K-%4H:F[$T#9Z/YV9 )20.EFH 3IE@Q M2D*4@2@=N=;E.7*F;BH(DHXE+2I)(A?,\&*Y3KIYD?0O12LR1 M/QAS*BJIZP*&NPHW@Z0Y"R2V2:'4>8,II4= N D6W\G.Q]I!T[IUN^L?4SF= M[D9T PWT>M",_!A-6Q)>66$(9R9@ON,Y9CY)$QJRHUYY863]4I4[@/3I#-?: M6K_W.IBU15ZW&>SX&!8=!+_@>N/C7_Y=L787]7LG\_/S\<+F::T]LY8HFE7I M9L]($)$39:7&X0M;O_G=(R'V*7ZIQI@NU51E[^;K2*>3_>DT[8\FH]E[S(CQ M]]DP*ZT9H'^D*>MR:!D#I<0DH3**+)0%P<,#'N/!A_3IO-+&>J\KTJK[,PM( MU[%83+N+C9NL@Z+Q343-X/CD]]WC0:DIF+>+[YWF%WXVBGZ27H[&<_1D@S<;Y!!K M/JA*GE%CD)5RD3\7'(:T^P$:_PX.YVX-VM$MR>-N@'W*@+KDVDUCUYT6JWG#.R'>)XS=]*_Y55W.VZ@ZGD8E_!; 9PS_WCERNY M+^B.5_.T7-1;OK-5&=CG$RUMQ-7Q5:W+?J7)PQ]LLPD[@EU M#@TOHYIX'QB)$N>8SUQE5[MP]QXH?7*4G3#FV\W2UU-)O8LBOS7BMV@GEY5^ MY61PQ(_NGI570VN >P@:WPJWN MU=D7]S=DG3I _/HMN\"; ]JV$PQ"<25,(F!!ELO* W&FK$)':@4S- "K7>JP M+2>XTG..X0X8(BAKA5)N0GL0 ?H78IQW$7A%N'14^#<^0.##T5HH EA&YN"?& M4B"!.B (4!F06DA=_<[VQX+LTTYE_[CV:#4^"=OVI_-F&*0/JIPL"DY@DJ43 MP^2'1F)01H)Z$6/UM=S'8NQ3\Y7><>W12JQ2+K,JPMW<0O,%IC>&)\852::T MVP[,$JM+ 3P3(47.A&4/):YK/_R1O5B^7Q)M1SW=KG[L[NV]??WV5;FVZ^CT M]\'QWM'K-\>#WP>')P=_# X.\>5@_<7_1WQYE96/=0=3:=WCL35"#IXA+RH[A(VNP^Y,(OO3!HW!9'FS;_Q\VOC)[,)D?-DP M^R(UEI6TT4M"K2K7FCA/;&G[ZUVVFIL8,JU](*V#8?1IW:1+WJYY"WEGC*AW M4_EJ [G_L,8= Q&>"L^3)@YC"2(SVE-OHR-)"F$ 7%*Q=F%O*3='%1@1\O6_:^QM!GWD#R[;X?-:7N$*83?UQ&UUP4 MWVQ01U#U\=4.$'4CD W#D!,P=XGAOJ?T#C]K8UMZ8,M>/U%^9=[\U.,&NMVIX 1E]29E+ MSC,O4@@89<>(XY64.&DH,4QPI14+FM8^D%(%>"\.=W=!JEL&=.MJKI*A+^]J MO5\DAD(RB6-X4DJXI1.86E*TX>$P?O&Z7)*DMZ6IGF6X. M]HNQ'P;KC:*EM%2:Q4J")M:I4EW#F-3.F'1SP6]E _OE(1M?\G-#I/L?#D?+ MJ+NT4#B<3N+RQ= E@]$/SB.,CLH)=I\Q)I&9",$]CTRR!+6W U?%UH=V&YK>PMAG M([L&+QX9>VZFLGI7\MWE!\K0><:01R#+([",TQ.%X"E8$H2DS'.*\4_MZMC[ ML/39=E8@2A45=&8AKR=%LR%D&3.S@<10[KP)&!%;*2C1UGE%N=71KYOCWWA4 M/W)\CC2Q+CGB4T3-VFB)S8X1[Y)BRAOG1>V*TJ?(\;WQX.;?8CJR+^:N;ZX0/J&+.X:M#34FFPSX0X66[^(+'*5]F=>658;*&.V=8<3(4EIKE2'644M0 M("FX1(VP:47OLP&,/ECPCEEUU61O4VG=KPLG, DR8:$<.F'4$1>#(91[E5B0 MD2FVIH._:UWX:2N;ML"-2J+>6EW25[R+^+]*L=$]WUF[@F@5Z)6JE.]:P/QR M&X6G0>5D@7#),&6B$F.TI#/RQ3AN.9,VU+ZWZ%MXNE@OOWV3RU )Y:V%13 $33=E26I)S MDO[U \J2KY(M6=R2;"#O_W"_\Q^ M>8:#-,S]P>>__?+[IU?@?OGWO__I3W_]7P#_^>O'-\]>#M/I"0XFSUZ,,$PP M/_NC/_GR;/(%G_W'S'\^F/4__QE\DPPH>9O MF_]V])<8$C-)9U!:2E ^*Z!7'"27E%329)?5__[\%RVUS<(G,"XF4%DS")XC M%).++$5K4WY6\?]16^DC^7/__/MFZ/T M!4\"] ?C21BDBP?0X_/D_ \OH]'/SWY);QWW_S*>_OV;80J3J8+N',*SI>^H M/\'\;5!? BY \C]_'^=?_OZG9\_.)!=&:30\QH]8GLV^_?WCZYM(^X/)\]P_ M>3Y[S_-P?$R(IY\P^?$5__;+N'_R]1CGKWT985F*?C[D"DI7./]6/^WYQIB^ M$)!1.HT(]"H.*L4;8ESTZ9MC/O\LR%C"Z?&D(>*;G]T4[_ D]%L*^,9'-T [ M_2 XP9.(HY90KWSN)9QSD-<1UH\\P=PO83SA?T[#D^=3?"_>OWMY^.[H\"5] M<_3^S>N7!Y\.7QY]HJ]O#]]].GK_ZL4_#M[]=GCT^MW1I_?CQ MZ/#__O[ZTW_]_N[@]Y>OZ?UWCXN>#'4Q9O)L^O];F^=>&C<1K#_HUS7K#?TX M>W@=X@XD@-\G.,AXMLC- 1X/TY4W'=,0\7CZ:N]T#)]#^-H[FM!^ M5[<^&A&^IF_'/95Y85EQB-I84,@0G D1(F.N:"%MB>DFH\9SAM+0XY13LT<0 MMX1\CL>3\?R5JB4YU=!R%&=B;S"N3R$>8T\XAMPE2R-1OF['NHY)@V6!FT![ MM&*JJS%-$5P=SP61#D;SD/'B<# A5A\>3Q]('POT_[DQ\OAB=? MAP/Z<7SPO3_NI1R$CC8"1[#?,RKFNB+$(4$.>W&(HW,*; M>RAZ&6* \95P%!T#%X_7"IZ3'[#UP-RX' & M5!L618X)M/#5(A)D0'N49!;YR'CTFIO67M'*X!X%33K1Q$W*B$TI\Q$G-%;, MAV$TZ \^CV>HK!/%,>,@Y51 E5(@TL(&R1HD\UER%V)C?BQ&\AC(T$#&-S4O M-]7\IQ&&\>GHQW0[.]O99L!"CE%[8F/QG(&RBBPB[VE[,X6@2J9TRHV5OQ3, M8]!_&TG?I(#:E *T$%5H^!+/_G]]9MM\&1[3YX_/!/%Q>'S\:CCZ(XQRSP7I MK=7D1RM!('7A$+F/8&UF7M(>EW5K@V)-B-NG2^,059A7&G&NAA2Y/>%,T*,P^#S=+7_]F@BN#R*O9Z\ %'_6'N!2=) M6UJ1,RT$#<9*"!8C2,.*]LHR@ZV]D:8#>-S$VYVN.S")#_+_.QU/*L3QI^&2 M8,\4=[PQX$$^_(ZCU!_C^S*5]ONO]?5Q+WG+,DU&H 67%N%L'2W')0)Y><9P M%:WCK=>]#H;QN$F\:[W?I+)N8H2=S:Z7IZ/^X//9##N;=9>!SN'G'MF))6D" M:S#4K8.3N2!2!!:B%\&AB[;U,='Z*!\W$3O6VDV>F8YX]L]P?(J+ 2NMC0[) MT4P0GAQDI\ ;]" \V:I9<,E5ZP#3VB"?),L:Z>PFR6P3@W)IFFMF00!VX\#\%9!G2_!'G%20O1!0BI R 3*TMH9$T$KPD((P M(? DDFZ]*RY'\X2HW R/!U,>E;8'(T/P'.L1I^0 M$#)78$-"0^M@3K)UT'X57$^(-"TTLX ^&T?VEV6UU.#S.YR\+[3-?AB.IEJ9 M3$;]>#JIJ=B?AA]H$A#^D#'(&!)P\E=!1>?!E:+!Q125,5'JTCH!:4/(CYMT MV]3G CYN?.#PLO^MGW&0QY=.1%^$\9<>TTGHH!PD(2PH&6BB2)^F&1?%6K1> MM\Y]78;E<3.HB0864&/CD/ZR,W)MC%59*G(O,PW6TCA=P0*T=CK/O#"9MS:> M5\I1:'+ M^_KEX<''=Z_?_7;TX?#CT3\./AZ^"Z,1.6S?B..3T#\>7V722CW(=<1Y]WW(=<1XS[G-'U>D02K44/&2E7'^S)/P?V L[#/C\4?,+T9Q'PLL:;,^%+7 M4'2T<85B(%O+.$,C>6Q]3-'ASML397=Q=6,ALG?A!&<)R*O@ MZ^A2YUW8=G._2F]R"D(6V3I. MN!NFW7%]],$2;1T%=D"PCSB>C/II@OGRC4E1O)7D7]4%GT8L9(10,V.XY-[R MR$KPK0,_"X%LWQEOJZ\;=XPV%787UU,WFSGS4*<,)D=> 69#E6EC MU!M'+=(7S*?'-4WT+BSC96#.G"@FDPD^"T!N,RA6]BL$JHXD1N7N>G M%?BMQ4JVR](;L96=*'MOPC)3^/3FJ94;T;"HRPOB8AB#_.$X#"X;SBN,J:/82!?CV5$\ MY?XT6?="T+9T_%#XJW/,2I%UG'%:14B3FT;^'LUSQ2RSCGN_]?MM>\/;NZ(S M^TW;=53;134XNZ^N5Y)HHJH,8SN+ 4L[,!FX+J)P-J*)IGA7%P/L@BV2\Q.P?9Q1O M[YBSN8(:KCLGF'MOP^A?.*F#Q%%M,E"+ZD^%,17+#)\O.7)F))@@D4:<-'@6 M)5B'9,H6GJ*\=DOB1K!EU6<]88YTHHX.ZD1<@G:6%S6OCQ1T9"YP$(712'U@ M$'.T8+C*/F'VV+R>\1(H3YA$+974L-3$>#3I?:RRF!I^%I/TTM2GUK(!B3OP MBA8]@Y(QX11SJ^6[T:=>8@G]=,&0*P]\FB&%^\N\X:)Q#F)>1V\%&.MX_ZM0 MH/VB<+>COH'PKZMO \DU-!:NPY'12*UKM31A%"TDD_VM([#&>GM+DCHY/9D!24B /7DF3,1Z5Y(G<-K2WF*]<1IC46*E M??H.S5UYZ/9VY(W$/FPALX9^W11(^'X)".=.> (-GB/Y"X))"%P:X*'(3-9! M-G:E"\MW*>_R0Q^@\NXMLRYRM^HV_C),SI8268PJ*ED(+M9B?Z+6F5$"BK+( M@]&QZ.;UA2X#>)JVT.:ZZ*#NVCF8F;V_"IRNLD:O0MGAH<;]E+-,S1M(MLN5 M8 ;+9LVB\9Z,"4G\34I!*%X#%G+[4M)9NN:%W;>AZ%5. 3K1\SH";1Q(^XV6 MKTDMC4L[06QLT6?/0.$B(W M$?6PG9PZB)K?._ED^N6?.)ZGTYJ6^A:*NH_L';( MQGSP#4?A,\Y+XWT8]1/V; PF>>XA*FU!Y9IGC3D"NL)C-%%EO3<)K>L-[6ER M?\\HT\&9VZ;#G%I=XWG=YM]&M>IXT-%KY(8F^[0!?#$0$SG3]?@PL.QB]LT+ M>[8?QD_&;YD*716@O\\&=N;V= OJ:1]0?C M?IK6&>V9$&R.*H) 4U/[3 "/-$ZKF0@630ZRDSG2Q6">YDS8.2VZ: #0;HI? M'1CO.2=RJ5G\VG/RD6S4X')PX)C0R()1(?+]W12NC>9I,G[WQ.B@'<%YNCZ. MOO5G^9 WY/QN./B&X[IAU3&-/PTGX?CR[VM1UW?#R7_AY".FX>=!_W]F.=SS M!C*UGSBWBH1M7#IHF?!@-$V(> MU\(02WJ(<')2XV%9-'70^V-1. MF@_D/" UG4G73"8GA8Y&2(C6DH-M!C7@_%D=#I-Q)P6FO_T)0QF$_"?4Y/GRNQ[%?JCLXF7I5"%RTS#KG=? M7Y#0@SLD+3O5$61H&P8L(5K+ C/09];7PX,+DP,Z!/AFV M[Y_:6_;>V&ATTR^7KI3.TH6<"#%G3P:6KI=)5O\6>9"GZ6C6&)UU[GU@-,;E4&Z @9S:Q MD%J'FE=#]F3(UZ'"%O!JXV.^E8)Z9.#_B@/2V61>+_7Z,)(+)A9?VX)+!HHQ M,NU%,:"3-SX*EK1KS;LVR)\<+W>@\ 6\W?BXKK-@]-EZ3T[L[*7Z/M[C.B6& MQ0))MEHGA23. @9,]AE*7 M[ J45%NC9)7 2;)NF4J,6;+R@[0/)MIQ=6Q/;H[L)6D6S(Z-3_VZ.]H\_Z2S M/[HNAYZ-"5U)!5R>K@M8R/3C$83DCED?=0JMCW!V-M@G-W\>!JT63"B_O88% MURK_':1)_QNM':W;%]SQF.Z:&:PSOOUI;2!9X8ZG"$%K96FID2B(I?'') M\_:U^3=&O3^M#8+ABC-N@0N4Y-6C@ZBU@5PXRS8JS9KWZWV*K0W686EWK0W6 M4?9^MC9PP@N, :'8I$ 9J6L[0P&6AN6"C5B:%\)]9*T-UN+ K:T-UM'%0RD- MO\J8?K8V6*NUP5HTV4:-^/OH^*'PU])4%D$S*,894)&S.KL3I,R-UIG9XK>> M9[T78=U6ZMO61.#+T3!0RY<03*&/"YIK**D+TL$C.V/DUYS(7I MU]+Q:H7IUU#0/A5FNC,N=QZ,^#@\/GXU'-4_ZBD>>4DE A86:W1.0HV) .?9 MUA*?SN:]*=UTKQ'N(<\[=G[VET /<[J!JO>_DM4W6 MH!!AZWWY&HWMYT3:R43:@&!=%#^GTTZFTV8TZZIPUE:,61\\9\@R>$;;KZ)Q031%@[$! M/7*3G7LX1MZM_M)>:N%:+:JI@51+F9]?-;L\>3(I*A19'0^K:G>]6I^'=&6# M<4G$(@M[@+[M.B)X0.OC@PD3=4;!!^7[KBZ.G@Y<>Y,TI%CUJ7B&P&DW2^3+ M%!6!_SN/]G,=='XY9O.;@?T[F_9S,77+X(4;P3D?O-BYK'9V>G(31CV&Y5" EUI%-QWAV%ZWUS:UUGMG=-:Y[CWQ_ M[G1YVN6=YZQ61"6378L$7M;,$<:\(Y]<>K\WD:,W^W>G"[D7TEL&DM6<3QX] M1.$9Z" PYY0=O?3S3M=66=K=G:YUE+V?=[I$(;'5LS2.3I,]$*?-W1&$89P[ M1 R^==7)1W:G:RT.W'JG:QU=/)0[,:N,Z>>=KK7N=*U%DVUJ_3O>'M6G>Z]HZVZZBV<;?[F>]&F!9? M'#*\:*68 I&LJTV]-#A54U^4D^B-846O4AGTCL?L84"GAZ"F.&3(3 ?50)F>22CE7RH$%,AU1?N4C&>L*^PP*SRK"?,DD[4 MT<$QZ738-58XW:BM5M[KFONER;]6A1-W4U+@O4UU28?D]KN(Z<.9YN8P6&!*29<@*!5 66MA1B"!DXC M%5I8QFU<4VWB,:GM/G)J:/5 *:6B.NWIUC',C2^*TEJ^I-O:8 MU'8?.761$E1#;J_'XU/,+T]'_<'GLW3$LW#*8D^LQPN6Y*0 4VI],)]J:S.T MP(UGPB1C??O4^/5A[F'DH^.#]8Y5V4&4=<7^.T;&(D2,P**N!>EJFV D(S"A MM$D$C1W$1!YOPZ1-.-:!PI9:?FUSY=X<'AP='KT+)*E)_QO>/P%NR0>UR&I; M!6.C5+4W.!XCOD'2X$LS/Y++JTSBJ_!:\ 8YUP^BI*;>_!W!T^ MWT#XU]6W@>0Z5*2-7BKA$B CTU599R%FK4%H(WBRR(U9::_:M0*7A,7;ZV\= M@376VUN2U,GIR0R(R$:3TK'%$H)\+Y>\Q>F20DY:_>? :$U+"LL&@O$*, 1,QBH>4^MCQH5 M'HNUTT[:72057,JC.!CD=\-!N'CE$WTW#FF:F3<_#5@!;E=)!^M!W4U20@,E M7X^Q;$%#720OK F;K!7EG+#5L32@L@T019)@LR^%,>0.6Q>LWPM"W9'\L'L^ MK:.8YIG96$-?@\_3Q?@2\&FGWG!\.)Z$R7Q'1J<4D[EV=>!D"+D:9.2%02HB M:]2R*'OM\M22-.W5G[F#HZUOY:OY\;6Y@R)K*S$LL> ME*+I$X5&B#(X7N7#TJ8$N?;(I\F/3>3>P49T9LY=!?P)1R?ORXOA8#(B>?2\ M"<)D'D&&4JTZP\%Q:8"@>2W1JZ1:UR"X&]7VR=-] +B9%CHX?+R*;7YTE4V0 M/"H+7OM,[C5]"3)ZX,5@]JB%XZT//A8">5QLV%S6'2P45T%=J^#Q$:O0+C.7 M][1*V:!4Y*YG#DI*DH 1$D**/I+W[F7JEAMW8WS,M&FLH0Z0F&.M]\WH5ZV)\0HS:5$-+ MT^K:IC*\?O?/PZ-/;P_??3IZ$<9?PB"_Z@_"(/7#\0%);D*V7AB?CC"'R7GY M(;(+/V(Z'=6\H%_#N+]!!:"FCV^1-M&=/#9,MJB&*C].7'&_R&Q].P67):,YXUE%Q?#V=C*<2F%\$4MGSK!0#3)G<(\831*R!V,BTTS&S$%J7D+P%SO;= MQPX5N8PR&VJA@^#F(FCS"WY"!>XS>ZCA2Y6D+F+?%'=^.RD.7&T6@LP5I+)QY(CWG(R^9A'SS17[6L.+('R M%&SD!DKH((PY/35643P7#IPVB<5LU11F2?'U+L, M]'TGZCI*[8"@;X<#_'&VB;PZ'>1Y.D8Q1BJ!G(02R6$1S$) 4T!H&:RT2=K2 M.@EN,9+M6V&[T^ZPN6HZ,.!_/_IM^ U'@SK*%\/1U^$HS MF'GQ&$@..+RR1 M>0D(S$D;],!B;?+-:=J%FNM3;*;IIM"ZV-JPOP?,)TRUKI7:Q<)U.B!Q?0W' MOPXOYH8O'LNT"%=2-#=0&(@Z!G R9BUU+BJV3H18A.,),VECM73@-OP:CL]* ML2).WM1W5U54(R &@<8F0PNHP-KRQX#S*4!A.A)]2V&AM4^Y#,L3<"J;J*%A MA:#;<,UFPBK(.O(1EZ/:CPS=R"T"C/0K(2?,ZBUJ@AA"DH MH!>CC%8)6D8?."GN<*ZVS8EU)-X!%Q:OE_/;3CJAMMZ"8[0>*LD\^'H;UI)- MS@F@%M?KBFW,AMOP;-\$::6W84="[\ 7NM@=7T_;[5VZ:Q!0%2-E!&M,)"\M MJGKBYT&$E),K)3#9>G%8CN;1D*&1P!O?#GN)<7*![/?!",-Q_W\P_T;#/6MR MPGB423$HVOAZ-9X61I4E,.=+CNAT]G+>X#LQ0NIB#,JR&G3FYUHY+B%;C])J;RBI9PU9) M*=V5\I?8@[O6_3I2[53G%=/XS7 \/H^2">5]"):VI6PU+79.@X\^@-+<>&,) MZO5.82LH_,9CMK?!=Z&1I3)R-;_A>A7:0TNBTELR=X(@,D1D\XK U7G&H MK^&C'JG&-Q=KX_F]V+XY_)Z.3W-_\/G2&0U! MKW=TQ@P:Z]$#T'0=T:R: ,7 M%E/K!,J5P3U:AG6KIB[JW7P+_>,J@5?#T1&AO+; 7J;^]()9+R=5DO$::ATQ M4,J0/V8]\5_$)#!+KE3K0[-U,3YZ=G6JM"ZJ==V.-Z73D]/C6H_[MQ&9;U<- MAE^Q#$?X*7SO!8.&)X7@19$D,4TKKQF6F$4$K MR"%VAD?CLXBKM"F_]2%/3OWW$^\"Q6\<=JU2N"F)HR_#T:360KT /^X%S#'[ MFB00:G]H'3F$(HFRP=OLG?(QM$Z271W=HZ50QXI:P*F-4BM7V?=,\L6R>M\@ M.'*?@N,U+8@L7J8L\]QYHVT7)D;['5*I6K_%DB.H2JKQ:$>2-AFL$Y$[9K,2 MHHL=TZO#LP?=[+R1EOSZ/NC7CKLFQ4D?'=92T!XWW5H'[LZ/C M1DK>L /??32T!\1*(90HBB:#-CM0J5;*5!DA18Q1\)BC_-G1<1=\6DV(]K^+WUH*O1Z.:J>- MAK(9[54;L*<7Y/>060ZU@Y M=_!G96#;M6G:Z'"X+04TW'S6!!M$K<!R]:]]*#*2H<$^Z7V M6W;V;6E]'<%VI.U7PQ&F<%[.(F7),=0*WL61E^R=!%=8@*QKCAZWL?"53MA6 M5/75IV]W^V^DE@6*WD"F750"/(UC_.]38O/AM[J!T9^=6:K)^$#;%6AODM$^*.\XOM\F$= M<7?/@WEA_<"5Y\)!4=.[Q;4PEE&,]E3N?(S6QMRZC_!"(-L_F6BDJ-O5?P\I M=V!;O*:M\03/S>4WEPMM%[12R* 448REU4&YW* ))-DSJ,-J34!;H'ST\9H MJK .J@$L@3:;.JN Z\C6N!78;NR-9FI9VD JUI^VTT#I8[P,0 M+'#*UFZA-IC@A4,,#Y\@=]@?N^''.J+OP@[!8_K5Y]]P@*-P7/M#Y1,2]GAR MMJ8>?O]*TKOH$95MLZ,V M?E>::7U00++>=[NPA5];11)=)'3&7 MXI%+L-[0WHO20*QM7(L-/DAMK&&K5(G?75)'2SDOR^181T@=!%VNUO+[>.D* M<*T?V0N!(>,8(4[-I^(Y.&\D!.^Y\B$4KEUCP_9V1-NW9/?FHE9#575 I _A MQU0JGX8'B:;-""_?JV<,LTJ:@;"U2$,:D. *:9(@RV>%K>3VISQ!6C06 M_=)L\[:WY%\>_OKI_K?B+_]UBUOP2]$TNO5>U_V+YM47^F92168R ](LULP2 M4DPQ'"+SM2-DR 9;+ZI+H+0P0BX^=M8]S]%^1EXY*)4LV44%(=0^>M);VLR" M\N27=SJZK=X&;Z'C1?;")E+=EYO9+T8TYR:O0NH?DS4^=9Q""2(@+4+D+15R MG(0'EW7]T0:7(MG?MGF'F!LH=A7_VEBOUR^D;2;?+BXL7D$T\[96P=31H=TB M/+LYJ]M45[>J?@-!;XL$4B?/=8J09-3$U*9,V[3V]-^7>< MPVU#]^O(MP.=?\1OP^-O_<'GJ^#FK8^YXCP$#ZC)IE,T/"#?MD"T*A4?/..J M]6GLK8!VX"]LK+-A5P+O(*3P!B<3'+TO9]CF!WI>"962@*(<[71!3#MC&L 4 M7 Q>W2S2OC$)%N%X!+K?6+R-0P"_UR/CDSZ!RJ\':30U(L/Q-4I&H45VT@!# M:>OE"0[!"@<\2<,=4XCBVO61A8& 59[U@%7LPK194A. M$R+./ 3%R)SU.6#13$;71<3Y*HK'8MIO*-_.-7[I,&457!V9]\LP[<;$WU1G MMU)@0X%W8/(MQ:>8UTI%0]8&,E"&OG,A*>"!$>U=28&WKB:X72+<8>YOBP?K MR+GQCG]P,HV/GFU[Y_?F9UL3<\+%C+4%>B'C4WA5P]FT QH: MR/D#'_K>?7_I-;["/P4Q=PM6@-&RFL_%H[>?_G5/X5]7WP:2:UV&YQ(AW M-D0(.1(CO8W@/+KD]&0>C!%. M)E8T.)X"+2B:_$"!"*P6SR^*^^!;E$BZ\M MU]"YK]B'+636> -\&[Y? A*E M3RP*!3ZH:>^J EYR!"%R\MEC/*@0.!=K" O^D/ M<'Z,>7Z^=69*_CHRD^O9Z6?L(5H4 M$1D@8[7N>V3@.N1;0&O,?+G1;ZZ/SLBA;%_OCHZPA#?C^X MO.#R'B,CR7 FP#,N0059((2Z"696O/,E*-GM6=9R;(^#-)UHHN'Q=S669@O@ MI^$D'+_#R1LDJXE(_+$61N@)I(6.%P^%U8H(Q1F(QA!"&9UD6: 4<@6C\[9G M/&Q--Y5@PY.2*:ZSH..\X^B+X65<7K(0-0:06 ]M$TJH!V]0 Y AVZ(X7Z5G MZVW/> 2:;27!#H)#5\?Z(HQ&/\A\F=^.RAJY8X&6DDA<*ZFN)[D>WD8A78Z. MY=:^Q&UX'C83FDM\:66Q)??19B_7+Y%4NV4JK15);=U/OT" M)*N*]6(!+)!2SYV(<=L2B_?L?OMZ^!_0/_^,__N5?_NW_ >!_O?G\(7DWDT\/>KI,WLXU7VJ5 M_#9>WB?+>YW\;3;_Q_@;3SY-^-+,Y@\ _$?YVMO9X_-\?'>_3/(T1ZO'5K^= M_UEPF1*)%4 80H"80L#^A )))8(($D45NKC[,X:X4#F3@% A 5(X!9QE&ABB M##0&X]Q4@T[&TW_\V?TA^$(G5KSIHOSGO__A?KE\_/-//_WVVV]_^B[FDS_- MYG<_Y6D*?UH]_8?Z\>][S_\&RZ13Z0@LQG]>E#_\,)-\6:)^DJ_DZ!/N7V#U&' _ ED.8/:G[POUA__X MER2IX)C/)OJS-HG[[]?/UT=)LI_<$S]-]9V;VT]Z/IZI+TL^7W[@0D\L]^5H MR^='_>]_6(P?'B=Z];/[N3:'AYW,YUNC.BZ9XS(CCLM_/4;LIS/8C\3O&3L;JW_]@_S9Z MT&IT^5 ^95<]-5Y>WLVU=JO@+_I!Z/E(*\TP5 4H=($ XDP 1D0.\IQ+SGFJ M,V9&R_6W/=)3\/7+BHV2EA^A/P1(NCRBL7.]F#W-9;766>)NG:_X^8^*9K(F M^F\_;1@\ YW)8#)/@L2MJ2:[8B>_5I3_OTCRJ]IE*E?[07#8HMAY^D_C,)-; M8T^<1S.;[PHWD]["59;BH30$.4IAY,D>K9 *X*) MHYC\6M'TU,,67-HM4!QIPVQ/H*#>BG9:ELUBO+#"E((8OA"E-/7;5JH<_J0G MR\7J)TX=8:F*+00&4<+3 J[4S^/),,5S^GSU?Y[&R^ (\4! MAP5,B<9"4>QCMG;&[=E$E90"O81=R=LMSQGRA%F9+T[[%LNQY)/D%\T73_/: M!8_F&1P1I]$'^(SG/VV,/ZC=R M/+&>Z2_\^_CAZ>'-;#Z?_3:>WKWEC_8WR^>1R+G$5-KXEZ8:(*8E8(4@(,V$ MUKDI,@K3D+VH$.(]^YTUV42LZ":R)ARFYD%X^BE^7RB%F0+'13(SJYWU%2,7 MR0JY-2_)VU/(!5N(+A!$LAE!I >U(EU V;4KG<;HZC3(N8V"]#M=_?=Z>O.H MY]:6E13&UI^]%(OEG,OE*$4<8L4@D*F2 -$B SQ-!9#"Y-9E9SC%18B=\2?= M]VGCJ?);,5 [;PG?*J2R9@+-P5CO?ASJ'?A#:ZOM]$'9*'>1T4[^6'% MQ8\.NC4C2$ 1'-2O D/[+2$ K+OQ 2/$+Z;7UNO,D!VN3+Z MFR5QYTX*QK,11D+!+$6@T,9&)SPE@!.D09[3G) LI4IX&993A 9R5LJ-@V2J ME\FDIIXX.&?^F]>M:)W>P8^%09A=6(E?;8)8NLF*Q8.BV:[^" MHYQZNYPX+XU/GQ-E ]X+]X\?^(\-K-X_E1D2U_9/82/BJ5[8-Z;)XDG>EZ_8 MKRKY0?R8O)U-;<0[5F5&Z-6;Z]MWEV4@[/)"/VNCY]J:C:1*DTJJK(NM81R9 M>2(K=]'4OL6?XIP?^ #>[^:;?;GG<^W23=7;V<.C MGB[*+_!R/G?NBOLBWSQO'OG$G]V/+G_C$TT>*\7XP3HLSYK/%S^&.73Q M9L3/WWL1G //4QQ]\,8QD#293!I<)N(Y:3Y7'<=4;C$^AH>I\>'RSWZZG[K)%Q= J;$.%5HR( M%.!<<( ,5(!#+0 42$%"\SPC/,BP^M'MV6PVN4C4>"$G,W=.ZKP6:9E*C.7* MQGQKM@+#8E]P/6UD?,@"+6 3+<=!XEA(&CST$@H'RAW+<'E2'=8LA4&Q9W0" M7S_#FWO38MH6M6U[LVO;RC]N+=7+J?ID/[V/_&&5;ZD4U= 0#HR&UOX(J0 U M&08FQP0Q1%-"1;!C%YG)GHU5G1Y5N7K=$EE[F9H #^\% 0\S=17(CF@/F;1] M0A'3;8O-XO >7$\@'W3F^J(5GH97&8I?]/)^IMS)[6*I=4-?8:IIIM(,$&+# M8R1@!@3B+J&8LA0;G2GCYT0][>":C:35M< $(/)T)E M#TKK\Q/KC$R_$P0&2_[S$[29#^CY1D^^TS%#4G%U/;4>7+F'N[A9WNOY[3V? MWCRZ(18?9Q6OZN-3F:6:(:KSS# [+2Y32E -6$YR "F4>2H4Y!".'G=N4)^_ MRL?B/T2S=J7P5K*;IZ6[9*_*<])E(O3=>#IU_[#Q86.#;>$DZK3#-LA,(V@] M97=^C2E! "G% ),T!2FD3'&8"69#]\>M^\:_YWD^?#W;?Y;U5/V^YC>2__T2 M,S;\#FP50S6D24IQDJ65)ZD%LBOJ2B3[UU*H 9W_V/,P5$00C>_7%2;$GH[@ MV"$Z ]T\DW=:+-^M=TAO]??E&XOC/T8IUZE(*;8QA,X 8E CK$&4A&*22J) MQD%)F4?H]!Q*O+MZ-(T@99CL=P61#,?G5T4Q*HA%W-DZ(%JNFI]ZO/M-B"H*O)[*V8/^J)>7#[/Y'D>3(Z()"4!38AO^&"\ P*8"A.82YSJA$Z6BO>([7_8! 5KR^=K^B M0:TU.39(4CE(/![W9TA.C0I8^N0W4S9Z4'8]V6=79R1?CJN_.+] @Q M(5'&!%!"6E=#% 6@6!D@C,B-P4BELAA]TW,Q\S5:[01#U*E)UC_R+$./<4DS M^4%75 /CS!.8^=F:>#B$F94*@";AVKPD/UR=0B/8>O@)&CJ^G2!B[OQQ,]?VO7]+O9_'E$ )AH(PD M1&=YP8G7\>Z1\?L^F2TI)B7)9$733XV/ =*NMQ'$#%/4, F]5?.$' =TT?II M?[J;??O)OEFIH?W+1ON.C3>(NIT09J5?IQ[K>'"PM..XM?K&?%G:P.)^-K$O M+ZI-@LW-)NGN4"JK8651#L(5X)3E@ NF4I(IF,J@8-V+:M\Y7"L>G/_9Y.*/ MJ]T^CZ2D,S#UW'Z-C53@UFD,D,+W.D.$CK5/Z45SV#W&$!CV]@>#7C[3>-RZ MJF8CQC'+4FL6:%'6'D40"&(((*Z2=I'I7 7F>FX-/Y@Y^+4DUU7G*R@"E3M8 MP*Y:?$JV[JJZ)4)LG:P&?QGEVQ+LJ)9M/Q7NW-853M[;T)A/_J[Y_&JJWMFQ M1SEC(J50@P*: B#[)Q!26@\W,QFQ.L9$#GT]W&-$>E:MFFQ2T4T1@]S?4S)U\H&/#CJ8(WQ*K*8W?/+9;JO:9_UM-OGF M;O=NUQ>HJK1E&8>YX@84+#, "44!TZBPBUQ!&2X$RWC0(M=*K6?%7-/>+8\1 MMO:U ^:W%$:#(4Q/CR(0L>)TD(B15LYV6H,NI%YB[ZZK?B]U]%KEO59/$WUC M+K_Q\<0MW.]G\R]\HC>U+3]K)YVE66Y9EXO[YJB6I!(J13#0PMUITD4!1)%B M8$B.TT))13*ORKJQ&.K;,Z[9*\OHN-L[[HSF_7C*+3]V;:LJM*U*12J7"O6> MC^=EZ2WM3LMX\MF),7=:]H8OQH$G96=/EZ"*U:D<"X[P\86D<#;BT9BC=O-L%X9H^7RQEQ]EV7!(%?F M_&;J3(;[O]MY^&99F2XM#XOE?"R76KE?7$[5]@\:3XZLJ96YS!G0U 8]2/,< M4((SD'%20 &U,B2HIE(///9L?NT,ZO'=M*Z:*I^3\<,CEYZ5OON<&C^[^L* M!QY7E,PZ0[MBM^J*8(VIX^&B6O\:K%PD&R[K1]SJN//#[3?>SJ;+\?3)+8=U M(:'9-&)9RAX!CV2L^^!P4/O=(\2[)KU/4N%5JM:%KSZX0EB-9%-KI!R%QTU+ MF1%5L,B$3@'$T@;*N9% Y)@!*HPL4LZ-UM[])P+H]FR--U7<2E:V4LA=F:$U M-_[5G$) ;;>Y/4(59D?;4'K?1*E#@ZL0N/QK8?4$6[?26)_UH_UM>G5_Q%*E/5 8N6JE4AHPU6Q*J#B,V:5EU>[^93?]+SLLZ"E:A, MYU_47W;J\FV18<#DQ%K7C*2 :PN_H2BG2M+"3D*(7WR$3L_6M$&UOG=3$0]S M;H]AA J62@)ML)#E B!*.!!93D$NL2*4"X1R');W%P&E3@E_39S*RC[5W;*$ MNPL=D=#R<^HS*H[WI"U%W_\]3C Q?NJZ\H M77W7N,V+OVG7T%NKR[JLH':WJ=W&L8VR7(K#$Y_D2)]XK MJ%UX_M2\=)7#,R3X?=1#/'^*HE5.C,!*>"V>S5;^?MT0Q]FQ:B*7W\>+DUZO]6C:.:$ 5G[- ;E\^AH0N M; T(12VH_D\,D<^H#G06^<%J!\4 J5E9*,IX';+&B\#92PX;B'D+OQ>,^[W0YV"E]G*UCH_+:P&HC M76)=* P!3S,%$,]2P&EJ_R:AQJZS42:8_V%.*ZW>#W"JJ-4=T\XWQ[0+QT#( M(40[7C[G--%0"#V;J0"XW#ZG+FEW.HXY\>4$',%$0Z3;L4L;,K%.5KQ$;#U- M:1]AP!,4+U&V3TW\7CD[K5/:V7^:N+H?Y65D%^_-];T-^<;?='4;^<-LL=A) M$Y2(N7L6"!3,=6]S-0V9LW.%U@@QE6(MPEJ G,?/@$F=#?[JJF9;'-97ZSMG M;7::#<_-N>$P#MQH"X8W^<'Q]^-029OGP!4_9[,3-R^5LGD.="T9FV<-V\UD M'B__41"!:*8S0#FRQA!#XEI96O=/: 0S74BN<4B3^2@U0CHWG)^56E?720FS M8^=62'F!XB@#E449JB+**RF&$EP')78)E-6X[E3&90'6_C41/.4<"0"1+@"" MV$9FD",@.4O3#!&2(Z^]WL/#]^R%.&)EAFV84NY X*>)W04+4[^U3#WD*1R6 M(9*B[0P^J'8=%FQ7I8X\%;[=4:?([B3&7GV7DR=7SOF7V50__\+G_]!+NRR[ M4F6+NH*9.SQ:+$=&9(JD10I41G-W RP'5.0YR!G2J5*R@)#Z;H>'*?)0\EJPFM>_3<2SIV3TULN R(=9C)*>-VNP^YE M@63-7%)REU3L)2O^UH44R_/\14#2\;EH^V_K#(AZMVV?_M$/VB.*A%?+'M*Y M% ;;8XH$17,/*M:0'0M5;N4-?QASX:XUC_5BM:W_[DEOBFYE'!70CQGE>5#WJQT/HBV;DG<)&LN'J^6.4=7226K]#NY%&5OW0%7%S]@+)\P,AHDU.)#) DM8XV M3@40*'?EQR64V-V!4#)J^\:A).O9P)8$==6&YFFA7%>:ZLK J^E&$_HE>!X( MO!9^7W4.KVM-Q.E]]4YQ0N?Y)FN9T MG,[AFNIT97#@!7P_U[EN%F:$-H7@$A1%;A?BW!7_+3(*-,,9U@7#K*!A=^FB M\QAB>MYV8PQ%X,O?X>OL+R:AFVG,'WI M->@H?[^/M>04O-'6A).$PL\MZIVIJ6IM/5G3X\1K@&[0WCZ?.$V."$&<+59K1KF+2' M2\E!AVQ.+V3\]_YC(]1M@_\T4G%V[D.D;=F>]QIFL#WX$*&:&^U![W5,7])+ MMX__:3[[-E9:O7G^:H>_GJXWRB[E MO&;%]70Y'T\78UG&^MD(DHQ;WE.04BB!70VL= M?;W+N[MYV;#3ZF)--_E6U1$^6&_BQ8I,[,Y@0)C]XO/R2N+MM02];!KWBO+K MJ_ZPR^COM)XW677R'GSK[IUQ8AR!CEA!2A2G0-$,@(H MUBF0.:>84"H5]>I?V)%^S^:\;!Z^(7IQH'SY15*S$F;*0W'VL\\]HA=F=*, M%VPX.XH?R1J&4A_4Q'6$9M=N=1VFFS&ZM:_=F(95+.N6<,J8E)@!J7(-D',[ M&809R D47,),P["TLH-4>L]*GE@69L[#_[9=7=9M$S;_W3C7WGXII%9,.Z!^ MMN5LF,(L2/\(!9N75@0B&9'#- 8U%:UB[AJ$]H?##PCJO)_KJ44FK;=K)=/, M:(6!D@0!9(--P S5 "M=<)P1"!GR/0\X,/Y F4S7T\31]-_*/@3%Z3W],P4, M4](=V3KLUQ\2TG][_DQAN^W&^TYHT-9[BR0M.^V'WAIL8[V%Y>8^>MMCW=R" M=ZZZN*SZO]B_3W09.TU5G>A>?3:PT!3F6 -><&8#$TP!M3\ " FLC,RIT%Y& M(X1H[]'(AH5R%>0-VF&.@!>$?GY!;&!" XT-]8MD3;]R$GS@"?8"0N2-Y!1X MD1S41P@!8==E"'HWW(/8#D0NI9P_.>MC]4TO5FT52$YD6MC @1(, <*( <$P M EBZ!DT2*^67E>U)K^]-YXIFLB+JO_KZ8'7:Y8B,P+D[#3MH='!*?&#Q=U(B MP]/-:3D)4QPW)D#6%K?&9Y3!W)P D9IN3\AK7=V@)H7/FD_<);^?^7CJZJR, M"D126*0,2(PY0(4U;T)AET65\U2BE"">CZ;E897R=8':"'I]PZSZAIMDO3_A M%<'DSE)T'&!')JKT)_XL]N\=LYF99 ;MQ!7)RW:",TR28 F) 6("0T8(1G( M&,&NZ9N!.BB7(8!V_WYBR4GR6+%2Q9"U'U 7EPJTFR' ^EF'GN *,Q5KI#XU MD%IY3 U&^CC#"I<_UOE5 .5ASZ["(=D[M^HP1#=3LS_@^GI^3F@N#$T!SB4# M2!)L+4MA_UE 99#(N! JQ+(<)]7WZ55%K:D)86:C!20_*Q%']#"C<$CO>ZE M<%JX2!K?0FA0!3\M\*X^>[S1,4G2QM7E.=:->3^>\JD<\\FGV6)<[E&MOM&" M,)H3HT F7#(VAPA0237(BIRAE*$\3X.27GR(]JS2:Q9<0+5F(EEQT;E^B1>> M?CH?&Z4P[8\ 4'@B8(#$L5+Z?$@.FYP7 ,)>FEW(NUT-QDS^XWXVL6\LJDO4 M(U7 3*1I88,'EQ.7&PTHRB3@K( LS22&FH;@4#RE.4)8YF14W4*VDS=?#H'0+CEOG-[P MB;L5=#8HG* \)1:*E"#7"Q1Y_L M:*J?Q,*:,3M?5]_L'RYUZ=W,=;X;&6N?B]1U=K(6"*!"6?ND.$G=/V^3R;3-[/YF[4D2:*:J@8(!Q"Z\QD%%"1 M<2 ,U5F62XKS,+/QNN3KV5BMNS5WJ\7UN_A"/$WEZ^*Z1P,]6.FWM>"^-=_Z M">!?Y\2^= &>GJ3[?93OZ7=JARL(=QZ;'5->QNZ._%0MW(WYD6$2(2TXH"IC MKB8& TS) AB*35[DAF1:A)5TVQH_Q QV*L>VII:,IZY\=UG!8=UX8'5*&YBA ML860W_+36>HPX[\F4[5CB)AI<8C_6(D56V,/FT=Q2*R]M(F##W73KBL^=TW@ M%Y_TO+0)[\:3)ZO7HYQJG(I4 85T9O5,(2 RP@$W1*0<(\(@"=.S(Y1ZU[@5 MW4TYX00DJB)^=JGA8_#Y*6$$2 )WM%986(J5PW61U$3CJ>8)J2(IZ3$J@ZKK M"5%W%??4X]U4^.MTOI,Y=3-M]NH62*=99N-4J IJ(U:H 7F+MZV6^C M[Y/1^>)8>%ZVT1T9823F10Z,A@0@0BD0A1(@A0SE7/!*7F)O [=V]:6G?ZEVT[O6>G)8S MVH='@C!Z(_%S^7JAEN*1X#S>7#P6@8X&>QTT;%RRU3507&#K+AD F)QF#Q-7!3A VW6FF8C%.K!N3HM M6RQC;+D MWT/5VP-%/S6/A$PG=5_1+D'84'<>2W6,?-6>YQJL]_["1M)_#X*#V@%_ ';M M0<";W>S"]53.'K3;;'EOV7X[FR['TZ?Q]*ZNO3V;+MYH^YWHZKE;IS)7WY=S M;FF,IWS^?+W4#^XK&_XC1#+%I3$@E\8Z!I Q( PV-DA3O) Y M3"'$(4G@/?(:Y%F$9Y-7'"7NRUC5]'=5L$7)KCOZ=+_M8(_ZG#T_0_9*YB3, M M;34>\ E[.RX3RYV9N@^OF2^S*OIL%MQ.HA V(:R=#VR>F@%GH R'=-^Q D MPTM''>ZM;G]2]8)QD>3&1_TPGNJ2#>L[,I@6I@ JS]V]7I0"CB$!N<@8SX7 M1F>^U:2ZL=!S;%BV&W'=A\J_-/@J?[CAK'&ZEOSJF$M*[@(J+W6<@79S/0RN M85;XU4/J7]^J?VB[E;SZ^--EG*)6YPG84N>JX\"#E;XZ3_!F-:PS1WJ9)K(W M3\O%DD_MBG-7-R.5&1:IJPU#96Y=>55HP"&G .D\2S&C!5>RP^W%V'R&Z%;G MRX^K9K(-ZJZ9K-!WXZG+;'$A]4NWD]V?0:J5D'D. 7$5Y)'(.1#(QF88$X$T M88+J//BJY_/G><\361 VV7U\KX*.8OO1- MA*/\_3[N$IR"-W8KX..$SBB><+U8/&GUSB[^T[NJNWQY:Z#\W7:[(^M(($ED M1E($B$GMNIL6*1!9CJTEEX8JR*@*J\X6S$'/H=;-=H^XJKNC&L^UM!H:>AX7 MC*ZGA>T3LT +6J9"5;PD%3-)Q I:D$[OIO M 2DCG'K=\]T;N6=C4M-**F)^QF-?^G:C<)9,8HKH/+SI#@=NT_4_.&5F,L?&+GLX8C<$7RFN,#?#Q!,?HE+H9^/6=[>OIHXWU M/NAO>I*OFJ9PD:NBH$ H5P2?93G@6:9!P062+-,T-S3$4K?0ZMGDEJ22/,Q> MMD'C9_@B"1QFP385+ES':D?W(JGE[R'+T4/$2$:FC=*@UL)#Y%VU]WFEF_Y^ MU,O-T?HH,\JD&DO "XE=FR,,.%094(K PGI:J2E42 [2UN@]9PVYW,4J-RA, M37<0L#)GNAT83T."CFB!$HH0YPDRR$VDK"RN>_3TH022+ MNSWVH#;VH%B[5O7P0YTS0^>:+_0[7?WW>MK(1/JLI1Y_*R.>+)4RQ\A5 DK7Q*F"<&Y"E$.=<$8Z9Z7"?WI.\UR=Z]KWZ3W/]R,?JO$Q-+S3]M#0F.%TS M*$O"R0\K%GYTA7N:B9+)AH^HJ9$A@L=+<_2B.G3*8@@4!](/@UZ/U0IDI(5D M1+B"&P73UE[8:(KFB !(>9YJ6%"1H1"/[,P>0EU+@\NZ^\4D7@.0SHT_^M/S M?AO]]-[/YZ7;]OAWYXG6A,?M=U]-E^/E\]6#GM^-IW<_SV>_+>_=:3>?/H\D M*K(TS94K\6S# 0@-8*[LL\XPU1ET-9^-[T%."YV>7>**?[3^\^ MN&5X<:N_+]]85O\Q*E*=BAQ!(+$+62&VFLJ0!MK^#VFN6($" _=V@KU'\A^N M+K]6D(IW\ZH@G)?683;.\Q(RUM+83&W:9 M]1)\;\GU>ZN;;M\ZI_II_EQF9529II_U46_:IJ3S"O:U>VZU8]6-U@7W7-J6X#U,P9GXM0Q M;:/&IB1ZD:Q2CVO"\4S :>$BJ7\+H4%5_[3 NVKO\4:':W-'#BY]/:Z55,]^]R_CB;;*/-6N-/-#6S 8 M"E&[\L85/$QYCR9 7"05Z6@8!%PXBX9%MXMEW3$)NW;F)6;;];+V 8:[1N8E MR-9U,;\WNN[MNZ8TL_GS^_%TO+C7ZN?93"U&1BJB<^N/:&9R@)0-.QA.$8"% MC3BR+.46VI!#LL-D>C91*UK)G2,6NDM_$!??3?ESI0W=@Z_I721KF4N2%VY/ M8!&QEFV[9-$VV0\2&7A/O4W0_2WTUJ?/WC&_G*K]!G#KCK&,0YFS+ 4TE0(@ M)%/ 39$"S0DND$JYA+!C*^U6PCVK[X?KRS?7'ZYOKZ^^))_L^_ MW'QX=_7YRQ^3J__\>GW[]\X;[>V(!F^_1\.I\Z9\F8-9]P/JN0^WE[#Q]^W; MR;[4;KX7&"U[_'[OQSJXWR?UN=&@BZL<:4$04 QF '&I :.B #F&VO",(:19 MV*H?1+]G>W+DI+K)TA_7&N382FJ^ G/)0U'W]2EZPS+4V8@.8X3#?R\P>DL" M:*?^PLD 7M"<3@KP&Z9C3$/,!\K.*/ MS:&'+?-X0*B]@HZ'GCGCYOAA3U9 Y8I[%(#D6 (DL+*Q0<8 Q%AE4N:IH5Z' M_*=)]:Q:A]:7*.YG8H*7223%H>G0:U?5!AW#67< MP:/6U:D.? ^7?M'63!H;;( 49FXC1*2 %Z( 6B,L4$8TA$$;(>$L].Q-M5?6 M.:/.63C61293AG((-#0N"88S()0N0 91;G0N)6(JK-E 3VB?TWQ@E>:QIC@H MQ 'N;6\?:=BZ$[,8W(I=UUFZKH?4>[TC#]#Z+7C4QL!KJ'CD 9!GR2.?D<(3 MY]_5R1#OQPO))Q6E]_9GBU%!J,**,6 83:V](@8P"35@149):C*[0'#?M/FC M5'HV_RNZ246XUHJD).V?,G\J4*G]\U,$2Y4\* MUDR3/_UPO"3YU4':\ZH]RKLG_5%_7][^IB??]"^SZ?)^,>+691/"9%9%L=58 M:#T,EAMAO3FIK6O'J-=VZAN-T^ M]]9Q'3ZW;3)Z55U>!HK> '6'L^/,#E]_%BQ Q4)A,*&'=/&>D, T$R 5)E2*XS M0X0,*MW3(Z\]&\TFX<;^?/*KHQV8K]3GC'D>@KR.>0@SLQVG(/R8HW]P8AU^ M],CIL$ MB&YVJKA1TDR^542;[:R>[5P-ULWJT,1X1MDO!/;@QY;51-4,QS^N[ '&EVY; M=8BUWT?'JA90HS6K:J/1S2QOV_^K[XX;/3)4"X:LPR=-9NVK4 PP:2"0F91( MBT)F1(79UX-T>C>4&Q]F4MYRT17=, -Y&"(_2W>VV&$F:\]GNSHA<+#-:14H MDO$X3&-0*] JYJXZMS_\XAU>_Z;'=_=+K2ZM"O$[O4JH^#0?2SU2D-*L8!SP M%&* M(WT*"T@X#ACR"!1\)0$'4L,PW?/8>&*5O+HB)6NU=-".4^K2O-ZN8:A MK9.IL9(8:0X(E1E 1%! 7(;:TH[M_9=,0!J#M;Y9$G) M@W?/W]_#UR"1X!@)NWZG=NE&BDO BB('!!%>I*) J40OV! X[K<0W";X_T]? M0L]167]S.WC =KCI\$J+6C6K6FDHM+7B!MX Z'U6!M\'J$N>-41JML%>[Q*L MY;)_?7)-3M=+T:*WO[]^>_GQ-KE\^_;FZ\?;ZX\_)Y]N/ER_O0YM MK^.)J^>R$!VK0'.^H9]L&$A6'/34=2=,ZECFT8_HL&8M"(@]G=* M>2RNIU7R6NNA)=5,IH0;(*2Q*BQLN"F4T0 KE1L"BQ3RV#F^407HW7DX>8*] M79^HUX/JN%,?*5Q]L>F,'ZZV;UVVUT=Z3>?7O4S)4+%I7.9?5VS:R\0$QZ;] M<-%MN7O/Q_._\LF3OIX^/BT7'_0W/QHEJ22+&PY:(/&SW9'$CC,T#JB24GU(JGH7B2U_#VXH1XB M1C)<;90&M3(>(N^:!)]7POLV7I<[599FN4*$C9:S)9^T:^])2D&ZNZ;GGZ6\6(X?RD*]VU_VBJ-DL6;)OY=A M.W3MVAT5D##=;DC=K'"\ 286 O[-'*,AT:V78W=$@GHY>DG9TLJQ_?W!.CEZ MB=%LY.CW0L>R*^I_/U5C+VYGETJ-W<3SB;MO?3U]RQ_'UE24?I+8\Z6F:N4# MW9AF&4T;3E.1&:1<>VKFY55>B057E?XK>L5,M?\[4SI$<58%)H2P(1F;K^2 Z8X!)1R@RA5!F'E6TJX M.7#?)PTNS\'12APQ_WK!6[*W&[!S) H\6? 3)J@.\"'..Y7^W1IHL&J_A]AO M%O@]^/MP5;B:+MU 2MG967R:+:P>_K_CQ_+CP$P7&C,,,D,40$SG@.>:@X)A ME"&%%4;(5S&.D^E932K"24WY(JEH)Y9XH-ZT '5:B^*('Z93724/4K+3@G52 MN99A!U/ TZ(UU='CZ6XQQ6Z1L4T6B*%Y+BA!@*64 Y3F%%!"*)!$4(BDYE ' M%GLX2JOW,[&KR\\?KS_^_"7Y=/4Y^?*7R\]78=[]<93\?/0HD@?JYUY5V)XR M8D[*%LD?/DYG4*_VI+B[ONGI%SHW?IX]Z"]+OBR#I@]NHJSC^F[VP,?3D302 M2ZHQ2&F6VKB>9X"F&@*(""KR7"%:!*5FMU+K>9&M.ZZNB2SQ4E=%7VTI+BXGDS+] MMOFC57]3:DQF=,'L>IU9?]K5E.>%PL"ZV"H56:X(#FSL[D.V=]5?4[Q(+!MU MNGWCQS[M4<^!U=<S%5Y$!S8:(4#L6X^@M[NV2*R- M4Y71[S;!9M-R?%?$6ZA"YZS( ,ZI 0@6UMOG3(-"%85BFB.B [LAME#K.RBO M;NEL:'8JF=Z.EY]9B(9"H.\?"D"'EG@>@D7K?M=&:^!&=QYB[_>T\WFIFU+? MSOET8:R*7$[5%SW_-I8VU+@Q[\=3/I5C/FGE+,9GKV62L"6_=[>L67D2=$S\[\U)(AYFECB ' M&Z<^T(ADRZ*R-JCIZP/474O9"XWP-+&O+IA[&"^76MFX;E[:;CYYSV59 [U. M:(1:"9I9ATEH4@ D* 4UTE\B78LP%LL) T>$A63/CG27FA MUV[6^L DS%2=@N-T8F@W7/S3R&+CTRV;K/-G$Y1,%B)K2TZ9US"#I9:%"-7, M, MZ+TZ.[-?I7//)^+^T^ME:UL6H@$(SA#A(*;.V+U:$2*@_5U^ M3J;L#KT@TQ>>+[NAEI3D>LF5W87PM &,#$S7_:2M+-%=J.)BNK[E7R:3$R M4++<%8(H"B$ (@4'@A829$6!C+:^#2J\RE2VT.A9D5=4DXKLJO.:)>R??G8, MG7;%C21SF,)V$#U:YFJ(-%!)'T]\-/@3% MZ5#@3 '#]&M'M@X['8>$]/?MSQ2VFR_O.Z%!/GN+)"T^^J&W!O/)6UAN^N!M MC[U,8Z.2H_7]_Y_GL\5BA%%!-!$9@)Q*@(RU-E1B"A21N& %0@4MAFQB=(#' MGNU427V1W-5?MZOW4M9Y&:P99,OL^,4$+XQYF.F,V6FD8KQ9KJ5D_A44##V- M[$M7!6WA\'655^D.<>S&(&VDXO44O]7SAQOS=C:M TR=[W5"S%Q+[X4-K:!TOU/M36>N 6LIT2"XUNNRI[ MG2<= ZX:\HJ%?KN#'Q:WQW[@.P1?O /X80!\>GX?>;/K%< O#WPR>?.T&$\M MK9' *LY17%I"29K&B&7O7; M!N3T/LN98H:I;YB$':[T'93CC+M\V^,-?(GOH##[M_<./Q:^G?).BZ-''W76 M6"HI@1!:A3+*5<:VJRMG60$PLJHE[/^YW\+J1Z[O_4W+0-L)6V":GB>$IW=E MX@(3N GZ(ICX;^+$Q:;;GL[Y& 7M]OB+W++YXS'(8'M!_@(UMX8"W@HS?8OY M#I^>'JH]Q2YDHP*G0.L"P7HNXL?9LG%-'7-&"#0(D-QE;)5%22E1@!MLM.8YYC"HG_LI M@GWO:[Y]^_67KQ\N;Z_>)3>W?[GZG+R]^>73YZN_7'W\R\\WG9WCR>?[F=37?6>&F4I*416&)"E*@>(0PRXU!*8C".4$L%42GV#[=W! M^]Y/<^22DE[=2Q1SY?/GR:N)\VT['OUZ(*.CWHY0BS/"@N-N^(A <*%!$PI!51J MBAQ"BA'S4B$?8CVKU(KT1?+HB)?E%?6*? *2J5ZZ_5DN;G?1]'JG MF_;O- RH+$K=T75Q\[1<+.T7,)[>K]\\& M.Q?)N_'DR3W=1V6.KJ!$,C3!Y 2&=!$I@ ):0 KH )9 MH3G+M,ESRL,L6J_\]F[^FMPY#=[<7E\7= CL[MSO_/D9RUV5&T"10.'VJ>;Y\85JWHA/Y?+-=C#,..H\,/-B)9[M@S://$T^&IT39R,OE M+L[FZZT#[/H9H12"C#O%2B4%',,<<*,-U=QDT!"_:.;@^+U''VN*?_;/X-E' MH5VISI8L3)_6I()+MAX6SC\;Z2PANR4?!0D;E&=T5)B6M*+]=P;+(CK*;C-I MZ/A#'6^3R7NMGB:ZWHO9NQ?1;/1S*9?C;^/E2<;G55\7:PQKFM.)+WL1L1#*M8%K_,9&O8^5S0 ]ZYOQ1LYW'O:OOAQ]=U1 MU1]GT[=\<3^R2XG)A=$ UJ<(]6S=+!5@7T=(5;7_WHQ6CTVY6+,D#=TUW;U_5A"\2!X>C'0D ?U&]U4XHQ'*Q@F@/ZTUU@67/<>HT2.N=EA/['S4RA/-""@$*F$'7[U4 :@H,#"G25*M":*3#CM%] MR/:^'^6,>*)6Y!-5TTVLS:_R@LH+[T^+QD\"[[U[H>MG=F(C%F9M*NI5#.V2 M?&H&+C:=^%R9P8J+J&GXWC+'2\4_37+H='QO$ ZDY/N_>V8+GAOC].G]9/;; MIM&4SAG,4TI 05PQC+S( 8/.<*204:Q2B4U0,8PV8GT[*>OV=.[(TEF.DGKG M5EVMN'EZ(I'0"'0\N@/1O25/BX2Q._(<(O4R#7E:A#[:CZ?MG6X*OC8<#6-2 M!LBR8 64.0$(DA2@3!? N@D(<&ACD2S+92:ST53?N7Q[/_4^1LKK8V;5Q]PD M>+8GL)PE"\?$_6QB 0L,/HX"YZ?=9X'1[0+^9EG?7N_C;"+X"A9)H8^2&529 M3PF[J\@GG^^FQ)>+A6XT@&3&I 4DA77H"0>("@H8)M!I,I)(*H1U4)K4]O ] MK\277[YEE 3TL0B0-VQE\4+TZ+-BN-AUYJF.J M^M9>X(*K/WBQW=9"V6FX9M'_F#K@L,,64RE.(<2,XR M@)A* <>I D4!M1"(0J6#8N!CA'JV!67EH0U=^W%;RAV[21[%RM,SCH! H&?< M3?APU_B$9+%KZ;XE:5*F[Y=[WXQ,?*W>*F&DN,,@I4 MREQ60*H!ES(%5"MA):6BD$'N\3Z)GI6U+I2R=!03^\T\357+OJPO+'[:>9ZP M87I9RUD22QRUR-?8C\L2K>_['H&!>[P?$W"_G_O1)[OIG1W!!;:?YC,7\:HW MSU\7KOI^?25Q>E>G!(WU8I1GJ=!$YL#^QP"491BP#')0,$Z9A%A@ 7UZ\X63 M#M+3\#9]EI&DS. QD]EOR9-+J1M/$[/B(^%K1L*4-P!;/Z7N![$P97=@E1MU M*RY4DN3Z,6; G" 8AD(0((#VHYP@'9M2@=1NCJFAMM77RU M-F'5MD!9!*?(L2&: &Z47>FU]\(NS6_(27 M1$-]\J,@^7KE,40/].0%*1C>P(G!8NFFM^E-# SODI@??=\Y-OQ&Q= M^6$\U==+_; 8I4+FF L#.-,*("7MWS"10 K*TKU_1ZWW,[WKO1 M\9"43$3I8[F!T$_#(P(3IN;G8A*IJ>6>I+TVMMQ0>P7-+?=$]VMPN?_:.3'Z M^I#;E3#<7_[*QW/ MI#>7QA:74_5Q-N6;G]S:ORU<^#N;KM*SC4B)040!(]TZG[DL5)9*8')3&)PR M9C0+.K0.H]^S\K^=32QSLSISN]EZ;<:'3H.? M[>@1W#![,@2NXK#W>/O<&<,,>O)_-/VL^N5HX MGZ;^'(G2#$F1 PJI 4AK5Q0!*Z"(C2"T*;007GL(H81[UMV=Y)2MY<[,YHEC M)ZGXZ7IK]@2P[7K>)UQAFM^&U/MMI#IT#P^"K.O%XWC0=;N(_-F55'?E !?6 MB=+);(UHE23&=[X]UT0IT26'?^KCAK(?'-XWED\,]T(WF/V$/'ZCV?/]U97W7EF><"5,04&C" $HY ]R8W'E*RK!,:XJ\7",/6CW;V)T.;(NJ M/8UW.W(?L$X;T8@0A)[ [#2DV\:@@ZT\!4;7AGUG@1*I6Y_G!W)&C[ZC4GHW MZ-L?X86Z\QT5Y7AKON.O=(OKOG[Y>?9-SZ=NZM_.YH_ECH K5S-5EW=ZZLK9 M;HBOOD^(C4@S!834UK(1G0*!E $%E7G!M40P#ZK4T(&'GBW>AI_DO_&'Q_^> M<,?'<[)8LQ$6(G9!V2]^[!F[,%/Y]4O20*[)3K4553/4,!@]1)]G(!(I-.W" MP:!QZQD0[0:UYPS5<5-=_>^GQ;+<]OJLRU9'M[-;_OUOX^6]N\1H_3[KYQVN MQS7B6F>&I0S0C&36KN+W/] M:!^Z+TO:N=!$/SQ.9L^Z3J -W$X_8P(\M]9[!K6?JH#OM)R7<: #V.7I-/A- M;M87B"+NL9\/4ZS]]C,X&7;O_7S(]O;A(PS9,6VHON)C+:LUMU\:U[A=CZWE M\XCCC&B<7'=\F7VYNW__,O-Q_>77W^\L?DZC^_7M_^/3!WZ!2.?E8K M)CIAIJE!>=WSKJ7R:WBRD*=DL;*%3I$;-EW(4_B]?"'?]SJZ0=_X>.)JB3KK MPB=Z.TR\?)C-EV['YNULL2Q;F8PX-47** .F(+DU!N[*CV+6 4)I*I04JN!! M45LH [UG%RS*-7AK/R+0L0F%U-.;Z1&H,[>RUJP!Z[, QYS]V8JAQ'$4T5OI M"$,L%R64_+!^24=P]IR1KN-T+!C@$DKJ+.C-C79$F=2IIJ! G !D6 Z88 Q( MQ&E.#"J8"$H*.$BE[W/%,E6FRS6#PYCXF8JS)0T\$BR%7%\GZ.,N?YM L>[O M'Z0Q[)W]-C'W[NFW/MSQJN%LNCZ-K/(9ZQJ:ZX(PNK]XSB6B(T5 ?N%+YP/LMTM14*8\ X7@ M!4 (N]IV2H!,Y9!R7F"!@VX6=."A9S/1[(^R8J LZSA[>.33YS\NDMV\F$;< MUN4*4M@$>.XL] MKX&9#?56IK2S09Y.4,Q"*>L4IC(,7N/;4 M":+#5Z&Z#=7-N!WLV5UW8M]OW+W>D1W!U&"(* 3&I +8<"0#U$@%4D8U4I33 M3 75*^O(1\]&[LH8+LJSMF>C_\S3^9J-!E[CF"GY7AT*! MSE+7*? S<0, &V;F5@PE-4=)Q5+99ZLZ4VLPY J&EZQ>)!O>XEFW,\&)9.&Z MHP?G8LW)BOUE-T0>,(<9UE:=4!&@,$F4LL)!H0E&K& M&%&H]6RY2FI@9L"3RY_MLMO2"I7GKDLL )W7W8=J#487UUZMB/> M5U'%(S+V4E!QE]8+%E,\(G9[(<5C+W53[=7ECU6/ K<+*T<<$YJZTBP0I0@@ MS#6@.:- $X191HH\RX+*-LU%0"(RIQ6%%ZQXNB5B>['3[4<[KJUU4N,7/?\VEOIPSM7' MV?2;7CB7_C<^5XM;EX;4_+T[&OTX6_Y=+S]K.;N;NN/29A_7$<\-RH1*09X7 M%"#$"!!$:N#V2E,$Q!K!NT_%J&^_3#S MZ>E&O+99"C1YIY)7UZPG)>^;'M>.9_O;9?*LE\F&[3)/Y"GF)L>@",=RDP;A M>5BW:\AIV'/C!B7>,?%.2O?A6V_STVPR=A<<-DUG4)XC8Y<&J0P&2$,&:(H+ M@#*<$H@5,SRHUN9Q4CW;\PWA9$6YCWIY8V[Y]Y'*I&*09("GR@#K&S+ B>0@P\I G3'K.P;MS?; 8\^FHW%9 M_*Z\"VQ]OW%IL,NH*MAV1)\B;Z/SDL '6JN;M]=[N<]'LGO7;%TDW-CY=3>5 MHMJSOF"+9PBCT+X@.FMS=2X04WKM=6I$%@Z;R]49YIFFN:@D(4"B"9 M&2!2K:WM94I1:(2DQ.>B4SN9(,L9?KVINL&P(1]\V_P$2.V&+Y[H8;:K(>^6 M[5JV7S\($=R_GD8< +J5TN@(1% EC=/RM131:'EYL/H9IP5HEL[P>+J'7,MZ M?V7Q6;N:FG;0&_-^O)!\\G?-YR-8F#0KC (<<>LA&IH!!J$&FN!4%YIH ^.E M7+:RTK,CZ+X?EY@M)T_E#6A7,6MI/R^=/,RFR_M%HEW+IN07"_[]?_O7C*3_ M'687B7LK\'3PC,GP\P6'@3C,;(9F8:[9%8.)XW"@%$POE(;(Q&QGY/4D M9'H!%I27Z3=B-WMX>*.NL<'\YGGS2,U(N7M7;\E=?==S.5[HQ?7TDYZ/9ZK< MU+N>+N(1\2]T@F?Q"6!UTTW:ZGM%.Y$U\:2LK^4?%K>"=7I'(!8$8;9S)?V*;+*BFWR.*+W_MD L%+IM M#'1%(VAGP$?$EKV!UM<'VQWP$:*Y/^#U?-<= FL_:AZVJU_C#BO"/+K[R@:)+)[;3(L;KQ=9":^AN M;*?%/M"/S>.E,*U6>CRZFB['R^=+I>PWL7AK_WHSOYW]-AU)4A"=80T8S&W( M0!0#C+O[='G*)")%SOS*6;?0Z'DYKJ@F-5F[&)5%#N:)(^VGSFWXM"MQ)*G# M5+>3P-Y*ZR'2 55=:/FGN]FWG^S;E9;:OVR4LVW,05320ZB5(OH\VK%,T>&& MZ-4YW59#]'6.8&9XC@S) ,F4 @C"PN562:"RPDBJ84$*%52W*)B%WO=P:\K) MAG1@&:-P5/T6YGZQ"E-Y5\RZC"Y6W+C-TQ\<0W;1_C$YA&(_Y8\Z8Q*K'E(X M \,62.H,T%[%I.XC=C4M)*'+%.G96W@? S%IW%"[,#_I*%)R\>DB!6VN'6V,,F#!X2 M:R_5[^!#'=7(^@ZK0C2;Q)NK,A-$J_>607>N\%1M@]Z8W;N[U<6BD1:I0B2' M@/(, J1,"H1D%'"5XS0K.$L+,OJFYV+FK8 Q^ KYLIO<^7_@EDNPKN/#RSLN MW:OVQ)D+3PLP-+Z!EJ/!7K,%S8K!Q*E.TF#1[6X>NL\?^^9;5-QBV:LH/ UK MYV+"N&]S.:^O>?3^L3V9SO$O#&B@!R^QT(B8EE(:F*D6#Y$SU.(]=^KO5T]=Y61UL OU6WM59'HI15GDTQ52;3)I'H%B5,=9^&EDZ="V?Y])%!UG(QH251= MZ8#2:(!XD0/!\Q2DDK&\**#6 MN=?&1PN-GNW[BFJR)IM4=/U/0XZ!<_HT)(+(8;8S7-J@HY 3\G0Z"CDVYF!' M(2>$:AZ%G'KTM14K6H]4O;1K/D:Y804R@H(\RW* *')Y]%D!#-2,I@2;+ VJ M4O%BDO1L1+[^/FH9G9IN/P_R=S&)W5U*OYI'5^O+:O]$U8\\\7_U%9%.R?%/ M4B7)<[J&JYSDRU"W9? ]'\_+"P&_:+YXFI>:N5C_\"]C/7?W0Y_?S=REM1'' M!5:Y=45UCBE T&2 8L1!2C6F+">&(QZR= 51[WFY<62KJSS)FG#R:T4Z\/@N M#%2_!:(WJ,*,^D&47,_3CY=_/8U6L%GN)'4D4QI&>U#SUPF679/5;9#N8>ZM M7?H78V>TZE NI3"G7""0JE0"I%P2KRO"C:@L\EPK6F0Z-,[=)3)4H+NAVSG2 MW+A[3*Q#\>[19[NM]#MU]&_$TJJU MR^>Q7O>]<\K?S^9'KJZ/D"9YH90!A+KZ/B;#0'"M .=&*,:RC"H5=B!U!C>] MGS%M:CI,'.' 2/,G_C$ M%;#/1UF18II:LXBI2@'*. &,"6LEE5+61G+.4%!S@A>0H6=W:<4&X*O;U"M& M$KGA))F,S58MC=E&D/+(^%GS>:<3XX$_B(##X]<[S8.?(Z]/BK<:O.WU@UL+ MES2D2YQXD4^47V9J8AXN#RS!\.?,+S-%!X^<7XB5'NKH?;6<+,K:SUK9]=H^ M6F>C%C+E7&4"2)IE-EK'&1#,A@0I,R3'F2 BN)U^0JJ=B*?I1S%BQ#U, [RL/K*7]W"J:@ MRGOA.I;B;]ZT+?F*O%Z'N$M.*8)@!W4'#S_9UES#,;.V*=E$UZGE.?JW_VTL5IL/2 M1;(=.X,/JO:'!=O5V"-/=5,VJ^X/LVG9F:NZ57/YM+R?S5W2R4AADQ=2Y 7 M.0&(IPA0JEVM7XASDQE4\*!$CQ9:/?LS%>5DX4A?)'Q-MOO=DS;<_'0T$AIA M"EL#\:4"HKY'M2$<3T<]I(NDL&V4!M5>#Y%W5=GGE?#:K)UO/91_?-+SLFB@ ME;F^_B2E,3B7 A!()4"YHJZG"P3$8,PH)++07C6_>^"M9[O1H%=?,0P^>NAC M0MH-S O#//A1056,HCE5)^Z4]3X__D5M7W">NM7!?8GY"JJAVQ.B+65W8U,< MK%)O3U UB_OV1:)K.=&JA.'S9_[;+]9YGH_Y9#'B!!+KVU+72]PN;RFVRQME M'##&,J'<'F"8FWN02L\+E265/*QHA18//02*GP][MJAAB\6:W$7B!%Y3=/>) M9XNHE4);Y(I6(?00C8$K@[:(N5\1M.WAKI5 WX\G^N/3@]#SD=0X5:Y7@$I- M 1!E&:#<.IR"I[E.18&*U/O&Z^[@/:M?12YQ])**8&C%SP8.[:IWKG1A&A<@ M6(?*GOL2G%'2LS'8P+4\]\78+^)YX)EN:]B1X[5J8W8Y0H(A;>P25A3$*A%3 M!'"984"XHAA#;:CV:KWA1Z[O;9N*2I6!F\S$9'Q7^@^!*]P)R/R6NGA A&E@ MVT%Z33S>NN>L7=(HF*$L'W77WWK[>C9-=%6B*[2QN1>@ M?F8O%DR!L4PE=].>O?\K^'A]45JI.KJ)OB\ MTTWY/\UG4FNU<*5!G0&ZG*I?^-+1>;XQN]9IP\%($I-2&T>!M. *(,RL2< < M U6D"'/%A4IQB-?4D8^^3[=JKJJ:NPM+NKS$_U!QYJKRSDPR7K=O[VPQNLZ" MGS$9 -LP.[,-ZY<5K"NF'*@>CE4\0W0F0)%L5%STI:\KPZ?/(4*(H5,Z"N0@0*P,XAQKH# E-%#&/JM^;TB$Z;"/A>>EK-$Z.03'ZN+Q+&4E#P-=-FI#8XA+CH=I/]Z+CFU MP1-TP:EUH&XFR+F)FQK$;_E\_NPZ+E77 Y$0>0IQ"F218[NN%QC0G*4@U3A% M#$,D5%"A@39B/1N6-[/Y?/9;V>&C<S0UW6 MUJ;F0/= )(T1A1(@Y48 5.0<<%ID0$*!4L0A(3D).MGI@[4:#9;?&SE=, M)U.]3,;5E3G[<^DZ%CXV.A;.UFLU[]CML9<9]3PS>N%Y"K-N.U.TYK>\F;AU MJ]']NJ6WY,:_ZKFW9)_XQCIGZH/%88^=>@1Y[Q2J3UI=6_#^=BG+R_!V=$MV M:O\JJ]J;U<6YZD]W>ZZ\/&>=/0,A+#@@2KA+D-;L0X5L-Y0ID,.C#;&;]O/[*\D>+(=:SUO0N'IR?77_>EB-FRMS'Z\$U[]T4[V+;WP&-AJK68+T>?]:.=PGN^T)=WU9#9M$$T0L7H:M'1(#MKWJ(E$&'2![XK?92&2%2G.[.#%=$("4Y(!J*('& MJL&6:,49I2GD@%MF #($&(M M&": 4(4)1BIC+.A^W1N#R\V/S$;/@POQ/ ]'UYLH@ZV?7@Y;KKF):FRM1R?."_K>OJ6/X[M\".< MPPQSF@%#J5O4,@I8ZCJ48Y<"7$"8&A&66G203N_902NJR:,E"ZSAD!7AT%R? MPRAY'O*<+WO@8<]&;$?1V<97@$:\R M;XT59#JEN/S!0\],]RO\7Q1 MYTWU6.!Y6ZR^BCO75%ZVL/.VJ">+.N\\WG%_0]YK]331-^;C;%I%Q9N]VY+8 MU^EXN:A3%9]OW+T#CS*+E:)0][7B*- [[GQL!0D ;&]PTTUXSMXUKRMD8W^;5DKY]\ MPBA Q0JTS^)EV'@Y!FQ[86^405_WCN_(($0RC#G(,\T!XI@ "@L--%%,,T13 M@WE8J\.A6/O:G/UGW([]_6W!_DXW7?\YMUE?>F/U MS,6HO+7[:3XSX^5(9,AP:H-FH9 "2+E"UI3D0$IJ,D9842@=4E6N,7:0ZQQ> M1*ZJW_A8D@HSY$WY_6QM1ZG"S&$ET*=V@8(-U '6(]F0YLB#JOD!D78U\= C M'9.#QE/K,;Z=:S5>ON>R*IIKH^9Q>4OOO7;='MQU+WZG1QS+3$-E72XJ-4": M0>M\200X$;E(A5 \#2IH'4![@&W/BFIBM$Y^X(N$NP1(1SW0C0H!U$\[>X(I M3'L=$R[NK-A(5GQ<) WH+"O)AI>(^4'A ,3*#0J@/&Q>4#@D>SE!'89X;='A M^]GQ5B]6P9:U;JP/)IH9Q9K +,5Q-?!GT%+QU]]C6WKS4V M;J[O'<\NPMS(YE1I 5&(,6JW-SR[U??G970_[>]=^V1&T?6A+_OKQ"PBT4/4-P5*5(DSP$6J/9E MUGB[789=TXM%?TA0O-BY4\[TR:E,24E2E*IZL1B,N^Q*,2[* M" 89$4_\JE?:W=)P2I'FM 1&(>/02CD0"E<@+ZS]5:I4!0FJ';I";V+#VU,_ MP'Z)'Z&87M<4YA?$)51#F%4>--"B:EG264L[^Z6EGG"\@:>[G;]R%!C70^=J??5 ]6L)ILYNMF?CG(@5$N?GCR/:..E#]QK8P0//[(, MBY7J#-%#9=Z@?EC4BRC[RL<3S"5Q51)MY/WFA][(I8W7%YI+*+DJ &?"[LXY M$H 34@#%-*L(@P7A+'H"21?%B0VX)9?I/3UWT%?+C9;VFSEFGDBG]OR,.:E. MPLSZ;$9(74*U5]&!_$0C0(8DG6+81R>]YQOK,23^X "/P0FT%Q@DI%!<>- 0)WZJ8"*0^KQ! M1IQJ+H*/R&4BG9%^L+_]_'=['-F(!TOJ5GU=KI9N[9VEU9Y6%E6!2\Y+#'0N MB0.4LC&*L8X(JI^6@ULY3'O;W#0E]3)#0J5R+']%Y/4J0(BX<2=C3D=W$QWFN M=4:APU,YK.WWVKHS-R*95H6&E%1 2*.L(]'V)XHIR 7+L9(45WZ#R2+I3QS, MG(Y%7M+'B2]"PG^N>4&]A/OQ494W>O#-:; 8RW-0S&FQ$F79N=YPN4K64!U*? MM]4\3C47+>B1RT3.U_[Z[6']4^N3X_'O^FNE-XNR,LC&B :4!&+@QM4 D3M< M-R.9U*K4N0JJW.RE-/FQ].1V)G!6=J]R_!Q'$I'#7,2>Y)-+J>S/AFS"T^-5 MT5+-QNZE,^]@[&OB7DS%OOK 1'61V[ZZD=_%7Z5S-YEDPR!XO?'U5(NOXF' M7]0F!Y@(8?_($>"(4R 1$40AA*@.:C_M(C)Q]/IJO?FVWKAF MO5KN=QP$IK?83VQK1^_3WK];;W?OU[G_KG1M6_7FU_ _K66H/85U&^T_N MK-Z\W(1/HGX=_%C M^?7Q:QLQL5)*HG((2JTJ@!'&@%%8@A*6W""B50F]4OD7*T^\![2T_,<'/Q5[ MV,N.$B8P.FS()(P*>YD?,>#WZ7JS#?'M%.-T4&_W!Z(G,9P7TQR*P31#!#,H M05$P>]ABA3UL<5&"2B@KDS36A&!(N=T K8E+ZYY6A<44T@WIR2]X221]F*%Y MEL/=9+>[W699/>YJF.O=VH8E:5,$'M*G@]COI30WS/XUD3N@]J\^$@Y,\GHM MZRL;U^RY,+0P5%?V>"44<4T.+C%H#UH&4H2*7"%:4%] DM.%)][Y]J3J?F%_ M_)$GH@_;Z1B!PHS23Y8@F)$NQJ/@19XL-!NL2!?[IW BG;\/,X2O6C6H)%K= MV2/RRAV7WRY78B67J\\?Q4Y_NGO[<5_I21A&K,@!5)5+F2,%N!8%X%10KJ"& MNO0*#P-H3EWS:0GY64V(GH8-:B+I X_:#0/9@8/LP$+F>,A^<5S\[7HD&JTD MU7YWZZ/.W,IZ0CRUTL:[K@BI&Z]F'W1^"^=% 6O?%;+2+&XM0K2]QXMY=.;" M@#;G<_>XV^[$2EF^WJUL &GC%MD@1$I$9.E:H#2L),!YQ8! K *\L#\JP6B! M\2PXH=P3Q,'4G7 MI$/A.L(UZ>F I]5/A&O=MI,9CY,:KV:[A+'OX:0_("6D1[1ZDL%ZA',P,[1' MM(HNX3WBEPJ_U7JSVBUW/V^5LHMOV__\MEQIN" %KW(7;**2"("UTH!5" )J M*"X@1+DFQ/>*JY?*Q&ZFH9NU%&_V/V2.=G:W"K@"Z]?3]?NP)-*'.9%HP8/N MRZX*%G5YUK_J;#=I5P4[O5:[_N&XR.%^H\7V-_F:?^6)=8&#XX*5.OW@AF8JB;/N@FW:6<\V -?&6A;;,I>$B71 0 M(G.B7=^+Y*S;?(@2SO?UH&=C-_*/^G.-W[/:U1CQA4&,.@SOHA*E*_05@%<% M!U14DFJ*E($\; ]_2F">[?M(,Q WOU,GOOMUO*116[6OD!$;=+/_H;I?OC T*ZM(K\=!$\6_$9E479^VGKREF2DBT M 9QH G#."B (8T!IGE>*,)@77J!7LW []5WO@7S;SY7IFH&H47CSO#Z/#-Y+ M>BD37/7^.GC5VPB1W9GLY.6V]QR-(#<^T_J>PS#]TXXOZ0U')BQ?S)L.2WW. MI?FAI.GD/,R7;IU+G4\2M;,1C3N+OUM)%[[KU[KY[[M5W;AW9WG;D^BLY^\P19R?P .?#C\H MU(/P7.NN4V9;N(1Y(153E0WH<>'P#DL@=(6 E@2*"A=,4Z]<7L_Z$P?C+<7L MW2IS-/U#LRY57 ^31PH89LQGLD44KW4)Z1\QCA0V+L;S?:%!$=B ) ,Q4]=3 MLT4Y RR?QB5#'XML!JX1 -K)?DN]??O]_?(?*^N/'ES#UM_%968?L MKOC7FWHC;=MO[1%$-U@@VX, V7:W?'C(ON@'E8G=V7/*1CB!G;I^K\4O3$FO M[, KQ4991P9NLK=_@/?O;K*3-^#8:)M8$C:Z!DF>JD'5C^B\C:5!BKAH" U[ M.A*9?[5;JN7#H\/Z/Y)R=Z6OUU\MB846.>=2ET"7TLT"K1C@!3; J$H@G@O. M<1!,R#6"4U\LGI!_8AN.@^S/AH? $4)7=>CG,%)J)LQ5C%1*.-"[IZ2ID-VO MD9L7RMU3^ OL=M_G(F<"+[?R8;U]W.@[+D"N1$H*HL2$DK$S;[9R1'(>82-Q3H?]Y^? -^ MO?WTYG7VZN[W#V_>?[J]?W?W/G"T\$B]^_F6&749GUCHJ&C,_G0\9#43"1U0 M(G6DFF \DIMY)QRG4=W%!.1$R\8Y/[OH'#^F$I?S9_'FU- M: XK6;FYZ 0"S$P.F($::%E@5*B?GJM(K)R/=X$IW5Q80IXMR3!#X]RT"S MP_10ZS M)[/IM1QX8)M2P5//[9IHZFLL%R]YCM>U*;!CEXLKM=[%\<' W M;]>;3^+AY'CZ6E>[A6&*2NYFU7.J 3:%!E5N/1\O(:T((X52- +'/)"-B/1X M!!;YA[8NW=G;LL9JJX\QQROKP$$*@:KV\V=3:"YNP$++B(-):EG)',4GEU ' MYH!9;X!C+^&XA3A-I!J]$$A]WC$,<:JY&,D0N4P\-E/3*O=FI5Y;&UY0S"JA M90DJ91# &'%0N1ECBE"!"R8+AKRJ:GLI3!Q+'1".6GA22S5[[9W9ZM?+L*=( M(FV8+P@6- K5J5.84?!.3U><'>>I4Z NP*?N#SX[V,G02*>/ZX<'Z_/=@XM< ME4P9:8 HD;)VG"-@#5O:DQ-E2D)-)0VZ>YE?A(D=Q95I@<^&AN+[@OU"EY?] MVN+OOI/BIUP9!#C)(?#Y7LS+PUSQ%>"O"L82^((F1&D)Y>1YMKN6+1?T#@Y% M%4RA2N3*;FJ\LGM\*HJP33;HRA MJ0O"3J8W3#HA-]%W8)YM<(+W^GQ[WXDP+VD(;MI7\$)V.5^N_U);6^"K2+V? MA9)/@"1B&?VZGQJ_$$+FG!L.9&ZDW6P( 8Q5$@A>\))():E=)N!HU4MIXA/0 M4TR,$< @3[3CYY"3R!SF0L\A0!JJ$XP'NRK;%% ?3^@\'[Y'E[B#H!Z=#\0B M>;RRGF(C'MZME/[Q_^F?"PZI*$IL@,*< PRMS585%YWJY?IDY6MHPVPP6- +1HT>8$9 >YRO.C.G1(] E MJ$??!R-/=X_55O_;HUWSS7?[Q[YE3XM*FKP$%%)7]XXJP' I 9><,Y%CJ&50 MI48GE8G-[4@SJXD&GG@Z]>)Y/ADK;>!IXDS0"3;!08E2!>>=-.8-I8?$O A\ M!S\<9XW[OI:[E4L.WID/F[4]LN]^?K O?.=:8KZY\-D-5!*FJG)79%[:F%44 M0 @N0,$J5O)24ZQ-6).]'^&(*H(PFW4LN%ZWK67"*BY3R^VWM?V+N\[XUK)T MDWUS3&5BI>J>N)JS,./V5+.?M2=475P3[[&+S:GN=:VR9IAG7=?:<)/5[&1O MKBHLV#>$R9_(67@2G=5[A"GBW)T$/AU9N?E0OT^MND_M;WZX'_6"E0XTCV@ M*7/HVS0'UJ]@@)R#P455:1[H7_P(3^Y?]K@'#K*BO@<%57VY]JV]7!.G<-*Z M82JP%M-/PP*2O)0Y!L(("3"BEA,$[5G&* %9CG6I55 I;#K]CH0T[[K6?#.A M)OV<='K]Q-_X=F*77U-1>%UJD,2IRE#]B,Y;=1JDB(LBT["GX]SR'V*S=!>@ M;B;/[8_E=B$TY$6)"U!HHVR 5Q+ &=(@IU(K46IA'42(>S@G,+$CV)-KACS] MZ2@&EK1?:,3/S,?(&6;002(&&V^?'(G,]&+Y60VR3[AST^O]7#@LT6]ZN]7Z M '/TFXL!?K.++Q^6-L)JBS1?/^I;-T'B?VNQ>6O?^T*A"AE9NH1 GKN,= $J MI3G W/!28<,5]K+": ZF3AE\T38:<@3] 7_B-#ELO;/H)\R\&W9. ,UJAK(# M1]FA>-ORE-5,98ZKS+$UM3;] 98FUVH!7>4;>J 5BH3#1?[D^QHW$HO=?M%:M,K,1,8-6BW9HZZ_Z7OQH MCY&_ZI4VR]T"0U[E56ZW%R:%JTG)70,/!D(14R*E-0H[_O70F=@E?=BLOR^W M[O['K#?6F.JNW)WX$>&'.K7D[6C&RA[L29R@KM^X)9G]TA)-"#-W1:QT?J"3 MRMR&/B1JAR4/?GR,J7ZR@6Y]87?HH:\85P)6!D""#<"LI* 2(K='1HBIRHO< ML*#.G!XZ$YMJ^YT]D(V&(NA34XBMCA(^RE:#Y(XTU5ZIDIKJ)95G,-5>4;M- MM?_CS].P@ZW7YN9OGTOZS]PR<,.X..0WK+ZH&TTI6H((#4M4:7Q !. M%0>JPCFN"@X1]@K NA:?^O[=T7!%.A#]4OUM#_L14 ]\H8QAOS=6Q#"'%2I= M4!%PGQA1];\7B\U6^MLGQFG5;^]GPM-@[U:N4G&]^?E^O7J[7JNWR]5R^T6K MO]N?MPO$-37.= IE#S 8*5?O:W]2D!/(18'+O/1KP+Q**^1;%]4R:8D"8REE MIB6;?79T_3,SPZJZGL]*)G[H@:8EFUFZF2.<[2EG?T^I ?\<5#)-Q.6:;K^Z M6[RLTF:]T=F#V.Z #7G,_?V[F_UO>YW\?#8Q%0.#'3S7==( MF+_LOTM_R[YJAV^U4JZA+EV6]UT/NR^"%=+YN8Q"+5\^)F) M/>Q/?17FJEO_6YHTEI=R!])5P\_/EI;R$N,T_>3W0-SY\978?KE=*?<]?O7ZGN$F4%N9U#YJI?SCAXN9$ M@=F1DW1'K6#A$QV@_.G.>BP*5L?Y82=\@3@?XP-8^<&-\K$GK=UNLZP>=V[[ MN%]_L-O*:K>0I3%%R260&"& C29 4(J!808KBI"0A5GLUCOQX.=Y1O(3Y(\. M7'G;5X/R*I^@O#;YI)MLU<"[[L2/,#"4$D!72 M4--"L5*&^/XYWT#XCM#_!N;5NM^6,*,NPS:*(+AB![R^::[X3IAT:*$-F^EV MD43Z2K2WC.5FUATGD>K.]Z%4RT:V";GKN]?[TFO,A<$5YT##T@U^X I4,H= M(PXI@Y"S*@RV_73UJ]Y&D"ZQ+OH].C\T;A NV@]&U9A F)= (7L6QPBZ0;@& :VX*5F!W*DQ9A N M>H9!N"AN1BR*&H0;(6"8,9W)-G(0+AHU"#="V!2#WQ[\$T4(LZ%Q _XC^ M",?IH!OP167W253CNZ^D30=LK1SHIZK.$Y M2-N!^EE+W)P-CO?/+Z"^9X)7^-P%02E%^FM4$$WP$I.5'$W!6VR]>)N@/*8, MCK,@&//^_N[C MNS>?0JO%!Y3DMYVD$CS,S1_++(YD)YK6ZR-@LA+R 5(SUY%?%_JRF-SCF3[7][KS5>XR M9*E6Y2@!FHV5:5* RA0&*::QX+O.[]5>]>?-#/CRZ8^?M=NO:]=6]^+$0HN#8%"4HN6;6-4$".,X+ '.* M28E827(>XIHB>)C8.[4(8=% MUK*4[7ERZ>ATKFB$1A)YHQ@.9G5((U1T[I/&+!7>GW%KCUW*';W>/HC/"UGP MLB(YLX$/*0#6N0:L8AK(DG--*$0ZI[[-&4]6GCIMO*>5.6+^#1E/I1_V#Z-D M"LP5^XD3U('1R7I4^\73E6;KO>@4X+3QHOL#<3OU[^N5_OF[V/Q3[]X^KM2V MS1!:(R@DI@C(BAN %7/S67D!$*QH29 F#.F0S;B;S,3&4A/-OM94'>1,C9H1 MMOOVJ,=O@QTO=)@U-?(V!+.:X@2(Z\-")=H&>XC,NM,-"WJ^F5WY=)QQOEVN MQ$HNW4R%P\5AUXV4D)KFLM"@<)W@&)D<"*8)4!7+65Y)DN.@0BA/NA.;K[N] M^W3_^YOW]X&W=[YJ\[/B"9019M8'!IZD7B:_WPN4.Y'E^U*=U14$JN+<-X0^ M'NF=/LQ$?]X#IF7JVWNVV=G*A.DA/; Q *%SE!!2D!Q8*X8DH.&#(, M2$*@1F6EL0G:\<>Q,[%K^70"L=Z!>AV-,C/R'?@YI/DT&Y]BCE1JL)-*HXM$ MOFLD,[.ZM#2*._=TB5:-'5E T]'3QJ8\K+:DAT%4/!>@"PT)(4")2 5QH"KAAR+JJ7.("6MT4 M**1_,EH!X"4Y(#G3"!NE#*E)VA, M$-W):YHF!3LX5Z*?22973)BM#H )G,F*ESKJ6[@<;,-OK;H\,0UEU^N12S&POV0=MO[VJW$)7U7IA20!'2 &.H;11:*F W M$ZH4I(9@DJS>MH.!B;W81;VM:EG(-J['YQ>QS83K'7.L!&XLM^M MKAXW^[21/SS*4RT,>X1HV0+CE3BQO(VY4XPA"[4/G%BG_=O1,I^N-8NY=;*_ MMZ'N7\Z,:="$&>^VVT>'L=#B^ LH!*+V2&*PM@96B0*(O&0 YL1N]#JO"B3# M;I>2\C?Y+=1I EV>MA///VVA\_T$G&R>0^?Q1Y[(WNWV4-1P_*)&*PRI\KE[ MJ#MY^VLT0P^I-5E7\R"1<&BJU[K:M:#R2[W]QVJCQ%C7M),&(,M7S@&TK*M+S :=Y2O,*8Z6]S.1:: E*C! U1#%&@D8 =Q&9V),U M)+,]S>S/AFI@Y62G=CS3CR-E#LPVAHH;GEDYA+RG$#*38A) M]I.:V#!;PEE-.=N3CK3/ 87Y66D:-839:JP&@DWVNG")#'> T*SF>UW@")9DU0=X16H(%!H#"1E"%@SS@$WHK)_*,,EQ(J%09WTT)G8B+N:?Z(0H_O4 MY&>]"80/,]T8N5.T.$V +-U'Y;E;F(;0IJ]]/+9"_]W*VH"0N^5W_5KLQ*O' M33T]P2C,1>7ZBR5U -1: &E!I06C!=,$E)ZM^,/$9K86-OR]!/:#NM09"WU MT/+\'F4-6VQ*%829;*ST$;7YPZ*-*,WO67CFROQA\2X+\Z]\/FX>XW;GK/YX M(+Z5?OKFQF7>K M/\1FZ8;:N*H-N*A8D3-=,I"CTIXS)"Q!Q>Q?2Z(0*ADQ!HF@QFE/PI/?'EC" MV;:FG-E#\_>6]OC*+F_-^AU-IM!71/;BR,)-UNCNTT%W>S[J0JZ$S<^!DJ=J M<_8E.V]#EI\F#OL_%A=\[)$1WJXW'P^-.36DPM?UZM/. M@1<9PDI$C0&Z,-*-QRD P]P F9N*C-+Z9(I(HHM[.G73>N'*F[H2P-_:QF(%T8X2]LH@#"@^"LH8._ LZ#AH G M8V],3]9JRJU.IO8LC-8YQ%H"5LH*8$X1$%QCH$I.I3U^,$Z]X!+\R,US>WKZ M)3\4+IYP$7J+.JA W[O45&J)NE&-UDC$S:J/H"/N5P>7G_F6U4?4R[M6KZ?B M=GU7:.3FZ-ZMCM<;VR-<82$5YXP50&)HC3VGRAH[K0#BC!M>0459$$#Z,+F) MC?V3_*+5XT.]K9W C?]*UKSV_#3Z2+,PNOBQF;"MKLH.%YF97_>US<& MDT [^DF;:+>_0FS6G=Y/\/-=WO.I.*._W]1-03]KC_)1[Y:;!B?M=[W[LE:W M7UU[V$(I7N:N$JFT&SO 3#%0N5H&)F!.44XP5&8?[-_[>P ?VA$Q_WVX.]AS MDFW;$T#-2S,-8#ON4."E8#\OD4Q?4;[BH*,V$&@9N,D<"UG#PTW6<)'.5X3( MG,AC>)&P0]&^=#SKI*&UBV._-Z^?!H__4RZD7:$%WARA4V%C:2 M*.T!0EO'4JA[:&1]"<.+5JR\:UHH>HLH<0",6*5B## I!) E)" M2AMN<@&I4BH$LVU*=89GQB]Z_%O$&!NXR>9@TCCH]W)U1HF N_ M:/%O6'&ZO#S6W60M@^F<>:0B$OGU4.JSNOA(U9Q[^]AED@WS/*0:D T32\)M MI&A/AP#+D@&.- 9%21G4IBQS'@3H/4!K8H?>/=0R$J)[2&5^WB21(L(\1ZP. M4HSUG @N>XC2"9P?:-;+C^]L_XHK> M_93I9_?I513F L9H)[PT/DC85)7R?D3G+9P/4L1%'7W8T^$U)?5\<%?T9I4) MV^E4"FM[D&,*<'<*P0)+P*G"0"+#>*$U+Z174VG/^A,[@99B]FZ5.9K^]19= MJABV[ 0"!E[W/I7M^G@NO_?M750R4MBXHA+?%QI433(@R4 U2==3LU63#+!\ M6DTR]+&9H8]^6Z[TNYW^:L,-#@W'N08$YC;<$"('%6$%H$H7N2)$,YP'([*. M8FGJ_-0)P-%US)WJ$G,G^].QFM6\!D8M"=Z77T0S[UL(@#T3V;+F(OM%-WP$9H&\5.A[69M6+:&WMJT^WK7Z:!GX MVTUVRD/R(4/^,B>[R_4@.?.EKK\2+F]W YX-O[/I&7NR4LW\:%?W=2P$J\O M%A@10IC2H( < 5SJPGJ. @)NL(3:.I.",=\KG7#R$X<0]=R>VXX!/O4_'KDZ MZ<-NR^,"+DXBE'[]\FA:58;YFI>J1?_;J6FU&7=Y]?Z_WZ:YL(H7;N ^*V+1 MV:Z[X@4^O0T;L6BSK;I/>C5+[)+K*MQO5J[==9RD>W9N,EJ1FYJI;VYJK3HMBU_^1.W;WD0?I8V+G^% M]+5S!:P0%_U=NK-/7]:;W;W>?#TI,3]D#(]%!@L-"T%(60%.G,\Q)0<5MEL# MA+D6#&FD(/1%W1G%R<15AV^VN^77^O;DF/8."U/B=>P7]\VBN? 0\*9C#*8+ M &OF@./NI-_&_NZDJN#(XER:#HL-9]%X7)@XO>:#@\W1VKH2=\:O/VL(.EH- MY]'H^ 7CP1/E>O-MO:F_FFZND'[EF@,PU48?_ &A-048P M*C'.E48"&:\K D]Z$]\)O-F#"9ZP<)/53%BM92TCF>,D'%9Q2(W#SG\"Y82Y M^!1ZB0)<])!V%.[BT/JSPR]Z"-N%PNCS6-RI]%:II5M6/+AYE^]6K\2WI8VI MV@(@^XBFVBC ,7>=P4@";AR:*M&F(HK24@1!'0]2F]CPC[0S1QR\6V4M^;#S MYK#&_(Z8R?009N/G*E@>5'"]8"SX&.DE8Z*3XS"M60^+7F*?GP_]'HJT\.U6 M[[8M=.NA(X&10M,2:E!P!XQ,N &<<@@D89)47&C&@\H%.JE,?;W?4,L:VH%6 MW*D53^L=*VN@U=;D;O9PQY,T9PR*E,I(.VG,:YQ#8EX8Y>"'XXRQGM6Z/7S? MH((E-Y *',$,*4$"%%0N\DB9*0RL#!!_;)/EY_8_!IBT?U29ZKP,[UX <-L MSE^V8%/K%B&1C9TM/JMQ=0MV;E4]GXHS)W=?G^__'@R7:@PH4!E!&!5(Y+05&(D?D0G=STMMM_<;4=V6>':Y-MM%Q_ M7M5SV]:K.I%BCW(GZ=CM^J&_V3=>LWXVFUI?@>?:1AFG&-IO_P#OWSF8B]-! M@ U63CHS#Y$ZD?%[D9S5)80HX=Q1!#V;SGWL]_N5>F]E;"=CV'!8,8D=+@ZV M+B17#(A2(T!D87+K14HNR5@7TD5XZKNPCES(3?;FW'V,]QR=2HWW'F-5E<:# M3.LKAF2R[V=9II+O-A\WZ M^](RMX"X(CS/;4B+.0,8%06H6%4 8>7 3$M15E[#::\1FB>[V](^R5_NZ8?F M='O4-6Q)*940&*M&RQ^1NQT6;D32MF?AF;.UP^)=IFFO?#[,8+>;W:+.\NK- M-['9_7POONHZ9BI+:Z#,82H63 $L*P0$*G)@<$$QSY$H_?!Y^@A,G;,Y(9DY MFD$19:]6ANTQA:QA=A@LIK?Y79-E:/^SSY[L??9O1^/K7786H[LFU-[8KGXN M?%=\M?ZNCV-T!+7;'2ES( JD KC3;SM0IP.E6U/V!N+/2>[US-8GU3J:T M^O7G/[8./N9NWZQXZP;#-A,2#V4%2C/"( -6+@HP500(;DI0%I B(:6AW&O> MN4\K[%9L$A$9CDN4.F)0!#40)6 MH *4W!C(14FI"0*P["8SFYN1SHK,P_K?L\?&>K)#LWCVH,.G%O1HS<_%C-=% MF!LYJJ$F>+,'8DIX>S0L4B(OT$-D5DL?%O3N6N/VNU@^N$[Z MM^O-)W':7W^K_L]CT]]DHX@[G>3 MU0/63PL[#KP!L]X Q]W-:7G832:,?:G9D=&Z"=\RFC @2:RZ5"%,*K;F#7H2 M*_,B3$J]_CAL$37/9-+)7#Q*A#JR_K!ZNBR%'.IZKR\VFQXH\# %F;[$ N M/<9'ARR)P3Q.*3P+:D>'B'WP'%T?G1D9NZE>>[?:[C:/#4_.P]Q_$:N[;VZ) M[1\V$G#W*A_T9KE69U.!:HCOU];*#EWB"UYJS2%1P+!2 DQ@ 5A5&4"*@AK" MM;3_FP5@.[5D$P=B#3?U@>UQZSR/W?;KDUO@P>W%Z&MJZ.[G?+]AOG4T OBA M1OI$VJP6-]M9>;-6X)NL_1+9[U C]$UV,:BM%CQSDOL TLR'*C[5ZWQNIW)H-(G8S"V4=,>OO736]#?EJ):/E@N]_'":^M542D$EC0''&%B M]UFT$O8 MMM%P<)-=)"4.;-RXHTFE:W"%E VC89(G:R7U)#MSDVF8,B[;3P.?CXW_+Y&; M%IA2;H14@.!" WL\1X KAH')D<04XY*CH$;4+B(31\4GE$+#X Z%^$:DX\0, M#0Z[0-52!F3]TB2+C3I(S!RF] MY&3$,?#8RSWB)IO;1+KU92ALQM,"_3__A MY)--?/%N)=UX=?U:-_^U?W]X=/F1-S_D%Q?+?+3!QAMCM-PMM.%Y10D#DD($ ML"$0<*8KH NL3)E+0PH6$@+,R_[$@<2>$W<(JFL9W(5Y_8,^,AV8"YWW]7IF M5U_L2PO,U_8 3AYYSYJ/N/=X]H]/GVB$R@Y?@%_V9F?-VW]+"_F(A'^/%PD+<=]NUR)E>PN',W+BFE2*2 )J@ N MC085+0N@L("*5C;XY('3@,*9"'%54;.!#K13E^0.:=9O4YA66V&._4I);I<6 MYRS)]=#)M"6Y0PR\A))<#P5YEN3ZK#2ZP.^#V-QMZEXX5=_'66]97_PMF,:* MYYR G"$&L"@P8!(2(!%CE$.2,P4CZ_SZ:,Y:[O=-;++O-?AVFSN*3AWY:-,S M.$VKH\"(\DD%H*7O^E$;#EJ4 U%0P4"%Y] M-&V=X-OU1B\_KQK %OGS?B-66^N77 YAI>J_/309A8L2F@_K3?V+G8W6JL=Z M@,_]VG)?XS<57 HC[+F<0AL'5;($HA0"*$:P$/8W.?(:7/\LW$_LO5J>,]DR MG>V.?*:I,9SFG?IYOA?[IL)\:)-N1$N.Y7.)34:^:8O*4I9;BB7EWD@U0FWA;: M"I<#T>S/AFP@]E>W@OQ\]VBQPWQLN,210'\]$B5%]3NG\0P0?CUB=N/U]7TX M(;#G>KM;4%7DFHL2$*H0P)(CP$4N "&BHKJ4.0U+P?81FOS$N=U- ]3IE!1B MG>-$CS+0#BA?1W=B.,X3R::$WW1DGA]N\T18+WC-T\\GO=QNA*1;_4E/G"IU@?AEN_=RST-Y5#ZT069HEOVCU^*#O MC%M[95_TSQ8>N)[R?*]_['ZUHOUS8;D@0I0%T S9V)W94)[EA( *2Z.,R1G1 M0<.O? E/'#OLV7!G_CTCP2[%6XE^#F4*U82YDRZM_#R9N5/SD3E&LIJ3A(>" M4.%358GYDIVW&+YZ;[1A^_JY.D<7LE2?3UO%Q_ MUN]AKWCG7[C^#\[<.=BV29Q .7QY'UX[HO/KN7 771\9]VA=^Z$]^Q/QWW6 MLI]RZYU4O\_=ZC;,Y%^C;\U+THI9M>-DG[DUNLC^,@-^$*L27;A(Y5G MW(HO1!W>CR\_'C[7I*XF=8M]DGHE-LMU'?0)10D5A@,*"058H1)4E;M]+TU> M84,H]QN]T$MA\GOUAE3P0)-N=0Q;8Q(A0V_(_>0+FF0R*,.(42;=Z\XVRV10 MK--A)L,?C-L'SZ!1WC^ZO?7.7""]VM/O4BY*4L(RA]J-^W+A+\H!LV=/((J< M"E;DN"J*D-TQB/K$)EG3B,=<#E.DUAIJ@C@@;N %QMH +K -#=4YLZ%4176 M:S>9*J/:[ [(5:)%KFITZA)F\J0!)@W<=9CJ_2*7R=09YD&U9. M;SYOLIJ;='%.E!(213]AM&>-B:+4%+G,14EG<02/(%J/0EEQ/H-/Y?D[4>A4[(>I$,X&&&2=OK%$^:82< MP"(OI4EMC2<4GL<2+T7LM<*.CT;FY39:+7=OA:S-N;[TDI*PO, <,"H(P#EE M@!>% 8+E5$-8$B6]@M=^$E/GWVJ"V9YB5$*\0R]^YC=.VC#K"Q0T/+'6*TNJ M9-HE@7D3:+T"7B3-^C\9B6W<;J&NX8,CJ'"I"B EI';+(QAPH@@P&!(BK=T) M8H+@BX]K3[S5M0C%1WJ!\,0G2O SKTC1PNSJ-P]YPA&$+SE/!1)\LO*\.,"7 M(EU _79\)!Y/]'9UCO_6%D.@7'#.H :8*P-PR36H5(5MT*@H5JA"!0N;6SA M;.K=R_53_5?Q]=N_7L YAB-T]BK,]:#B3. :@@5. MY"?\Z<[J-(+5<>Y!PA>(78+ ?-MK-K'NMC=[8./[-#U>.KJTWJ_FXW6[U M;KL@!#):Y 10 B' VE# *B4 XY1S27*.; @1-*HOCA$O\QDSS:]E(M,-]6V] MU:YKKR/;7(>H.0GS-Y%J]W,^$ZHRRA-UX&G7 Z9:U;;-7"VV=GZ[NS,?]7>]>M0+>\)12DH.%!(N\J$,5#G3 M@)2H8E#)@N(JK,3ER?J3E[ X:J[.8FLCR- 3S1-%>!YA8H4+/+.T4K6$4A:W M=_"?K);]=.V92]<[Q+JL5._Z4+)Q)-9(.R?B0*29@)4".9<%P,040'"%@%28 M4\BA)(B/'"720WKBV[I!A*:Q6O._44BOB_#[A:[I&FZWGGKR4+C\T\VQZ"/\ MW#,HKBC$8W[$M17"7,A7K1:_+8W^_75[8*YHA9"4!'!>%0Y0D@'!H 547FN M#5%5Y94A.U]XXEN&AI2? [B0>=B\QT@2>C?OJ%P_[@]+H]:R[J2H4_.32/6$ M0JI7Y.UN^CAOG(G]K7,0."\*6#N)BX_/X@+ZF-P;>._OT[:@.F_QWG+:\^L3 MB-OM;X<^+2,K@9E!0.<< ZP5!RS/,2@0*C@JB"S"JL92,C=U@J*WM=-MH*=_ M/YG&_/2A^+ZYI"_1]P3Q/*\F] RSUM)UIT[1GT3]_)&L?8B.G_'*-6W3W@4 MC4@\IGV'UM%V465)A_UP2F!>WIU? "\R=_D^FG1#C*@\/P/Z= M(_@.F'Q:DJ+ PD:<0N< 2ZD!9Q4$I2%(!E^WF%>!8=Y$X\A+,=9*I. +J;3SL2S4 (8>A$# M3L(5Z#NU)&+E>/B3U\NM?%AO'S='LRLUXYA3#3#D]@]2$%#! @("F13:(,1X MT&FQF\S$ 4N- 7*DZF-;(3KR],N4$/6D@\CLH"?]@G9A MG@Q\.@+RI(5W^,=J^TW+I5EJU8["D0QS+6 !2EQ8^RQS :J<4 "1R3&CA5(Y M\88]Z:,R]7GB T2-"-H6#'#1IE,W, #A;>D83 HUR09 X72N_9\<"C7Q'L" MB7+UPY$S@;Y^>UC_U/J3WGQ?2MV-$6HWZ5_U2IOE[JV5X/0W;77%(A>HS&E. M@22Y@_E@#(A<*4 HAS2'A<)^_?5IV9K8P)M>B^84X4X/6=5PDVVT7']>+?]# M*_MC4T2Z6]L?]R/36TP0$0&\G.A]^>WM\[^%0+_3!9A\O/BZV9=]W=1'CY;+ MA!.1DJHGU?RD-$S-.VTIJ2(O9C.E73T\57TQ'.J/]^_^L;*GG ?G(OYNG?AV M4955!9$K=G7H2!@)"2I:8<"ED(5$3-#":Q:O)[V)/>.16E:3BY[*YJN^87\V M@5+"'%7_C+9S3:55BW]6/;%ZXI+M"=04E) /$'H@3^^SRFSI^P"13K/Z(8]% M!IIBLUJN/F_WD](/UPR,X4+F)0)4NQD<"KLJ'D6!DAQ:IZ@(9&'#)WL(3>SR M]F0S2[>!+(N^C^E5E6?4ED !@>XM2O;P>.N*8*DBJ#XR\\9$5X2]B'*N?3[. M;#_JG5@^?&Q.,8?A41^$_*?X[.;/M67UGQZ_?7MP3>-$ZP)!PT"A!7.WJPQ4 M"ENOB3712%/"9!"L="#]B8W\0#?,H$.5Z&?G$ZHFS/P;1K*6D]-!<0=F3AIO M]ORD\PN1BDCD+D*IS^I%(E5S[EQBEXFM"W3 J9_<'P^R; M-8P:$O9?,I3?Y'F^QY$5C[LOZXT+POXU@_D-+VAM2O9'QLMLN=T^.NQ9UR]X M C K=MGO5NM?_NM_AF7^KP6\R5S06G_LM99UZ>:37Q4W[G+JFW;#1/5#/WR; MW]OR\UYCWD"8>VI5_ZE1?4WL)GM7:RYE45VW.,D*X\Z6G[FXK5NXRP*UGL_U M^8%3_?]F?_H?_VG_+_:/2FSU__A/_S]02P,$% @ ;X:=6@'+ 6@ M/! $ !0 !M960M,C R-# S,S%?<')E+GAM;.R]V7);29(F?-]/D7_-[>^5 ML2]M73W&E*A,VDBD1F163 MX\L7'NX>[A[_]C^_GX]^^I:FL^%D_)<_T3^3/_V4QF$2A^//?_G3[V?OP/SI M?_[[O_S+O_U_ /_GET_O?WH["1?G:3S_Z/G0T'/_C M7\L_WLW23\C>>+;X]B]_^C*??_W7GW_^XX\__OS=3T=_GDP__\P(X3]??OI/ MJX]_O_?Y/_CBT]1:^_/BMU7'X/R(Z ,./WS]UG\T[__RT\_+<4QG8S2 MIY1_*O_]_=/1K5>>ISC,;C:G?PZ3\Y_+)WY^,T%$(*V+OYW_^)K^\J?9\/SK M*%W^[,LTY;_\"?\2BDX)7[[P?RS_[N?K]WZ=IAF"9<'G>_S!ZL_+2[:@(7V? MIW%,2\8N7S&:A%L?&A6Q3J[^ MZY:"V8[NRV5WAI\=)*TXOL6#4TZ!T,:#E5E I(12RV/R;#>R;[[M-M4W%7HP M#3]-IC%-T6Y"P>L?1SL(L]&(/$Q38>3>#B.;W$' M'A"7;"H;HR$9]T^G+#@9)5@=50B.66OJ .+6:]>" V\?#MO+LA$PG$W=>#8L M@E\!VE(O@P\90G0>'27TECPSZ!=8Z46PQ!.IZNP.=]Z\%B1$^Y#82:(]H^)P M/!_.?[P;CM+QQ;E/TT%6VAJAT#<4W($PW(!SQ$/,AA+)O1>:[H2&NV]<"P6R M713L),$FM/\I?1X6(8SGQ^X<;9K6DBHT9RE(BNBE$;Q+&63(F1+KG""^ @)N MOW4M%*C64;"#))M PA%&\E,T80O!GZ+\TYO)Q7@^_?%F$M- )HWX91F(#@(] M'X^R248#VC,6LH^<)UX!&$\2L19.=.LXJ2?G)F!SYKX?113?, ^7*8J5);3$ M!&5-AF1U$1+NB,8P@BY2XEQ1SX*O 9A'7K\65$SK4*DAVR9 >/5:X+"M@V-7F;8$C#?X MY*"DY9$X!]2PDN%-#CR)#(A-(GE-4M*V'BRN7[Q>ZHJ\$%1L*="6 M,+'8&D^F'Z>3;\-Q2(/H&?4N$M R:!#>,;"!4OQ6)B&B9$:%>L"X\_;UT-%P M9K.::%N"R,?);.Y&_W?X=>$Z<>H)E\( 45Z"8"* L1Y#,8V_D58$P6M$KP^] M>SUX-)SPK"36GL%1K-[!-+D%W3Z8$$7B0)55:/>D ,^D!RH5;H,IN,QW2W7> M?-MZ &@XQ;FUZ'I6>3D8'7W\,AE?9F"B#R%8'B &A0&41=_8$Q$A"&9%IC)E MOYO_-ZZF^X53F3B+L6?VG*5Q,$;J4^;/A?)0&1BEM-1'@!*(6MS*DW84$ MFN<0'5,:-[>=U'_WC>NIO^$!AI.2>XLRB;"@3<7TR*NY0E<@33J MX&(VH(QED:@!GCD*19, GO,,P3KCH^?.D1H1X\-O7P\:S:<@*XBV"8@M!I/E$ M9 71-@&1/FZ?-D^@.](.^3U QRSACV>DK !4W1"[)"^(C^L:EQ$GKK MI>N5336?@]Q>D$W@X/3DS,$&<)9A+)RS!?22$,8\.*.R M$WS'LL\'7KH>#IK/-FXOR"9P<'B>II]QR_MU.OEC_N7-Y/RK&_\86.\9#4 MV^SD8E[:-TID/2"2)T42ND L"C1Y)H/S3@#"'"&M=8PI50#%4S2L!Y*&LY.5 MQ=P&:%!R4S4S<46^ Q( \E--[+V* $)3.W!E' M=C0-+<>C,\9:-;666.U M3KM53#WRXO5 T7"6LX9 F\+$LA%ER01/5D85#>YY%/UF% 7X;-"#BH%&EI+. ME7J\[KUZ/5PTG.*L(]2>D7& ',0%%R/W>:"C,9Q*!CF4SFO#]Z M>W!V^/;T#/_]<'A\=GKR[NCXSX2_NLW0>JW;F[ZB4I?W3ISM MV!!^,8//SGT=E/+]\[2HH"NXN4*@SRZ$7,Y/J<#(-=@(3@<#TCF>T9)X9I[R MX9%5OP#*ZCW+U9=&\]GE3ZZ7X3.D;&M,+A_[*7U+XXOT#I?;F\EX\=? MWES,YOBZZ>'W,+HH<=?!;);P_^.9^S[@FGB1V:U^ZZG%ONV3QS60V/\DK1@3@? M!,6E9!8#?EE*W96/&/6K5*;#,"FCE]+5!L>-U_?3Y=XE-+:5[?968S)WHRJP M.$VC43EB2.,T=:.#<3R(Y\/QHD&S'%0??O^:QK,T0+>1EGY]L)F604&,@#7, M0C*:F: \U>2I9?WTQW<)I@XTTH0!.OF:"@?CSTNAO<2)%H[3EN'KGX#L\I0F'2LES9V MO?F7-'U4< -C=5!)QR*P5/*G$HQT!CB+T7I%WE!^J;SAVTQ]'Z'',4!JA)-AT=W$WU-CZ(H+DB(GN8@?":UP=@A._T,U^G2PVM%]\TL M V1QM8Q_P2"\)'4,"=0NIH0(H4 (8[N&W MF\P;""O0.[T1;*,8E(C: K%E4H1A 3<5%8#9&+,(WKCX5+'!5AOP30+Z&=W3 M:1RZM7P;L"N';CI&LSC[F*:+LLQ?W&P8!B):IHA&DZ@=.IR)1W0X$>:!$V*= M0/#SVL[_@X3T--*G2[3L+O &3,I=)MX.1Q?S% ?42Z***;2*ETZA',%+(4"0 MR%$VPFKRU "7&KA9D=+3N)]](F<;H3<1'?XME?LA4CS A[K/JYD5)_E>6?B5 MU!(W0KARWAU=&8"%\K.48-Q"+#(7A!2N-JPVI;&G^4%=XJU3-;TH("YM-&>4 M9$\21&$\".<\F$04T. H#RY%EFO7!VU$8+\IV&[1LB4T-U=< YOK(\RMS/W] MYAGFF.;9$LB!H=6/*%*'@0@HKC7Q 1T(LB=Z^*?G/RX>.GP]_P,T=_/=Q#B?23[]M3O?3Z/% M OI@'$OK[S1]2>/9\-LJ%WM]AB&UHXIP,"QF$"Q1,%8B^++0GHB0DS65;<&& M)-9-KR7&K$,( &W';W>J^_4%]PG0/6NX:52_FTS1,1XO>WO#C\6=2V7@%&I]'!?? MC988B/]Q,9L7!5U)J$PMPU_,Y].AOY@[/TIGDX]N.:!*>RN30Z&4X@CARH J M@MHQG(840Z:-WS>73/Y0:B,.>TLW!-S<<%>904J=NE%83 M(H=I=E\D QIYL!Y9MD*5*_ PX/4*8P4N3#8Z:REU[1*(6K3WNY,TNCHZ!4#C MP%]GG3LEN(Z=?5.[3C:^EDVKPVDMB M[9>#]P?';PY/?SL\/#NMGD9[Y.D=)LW6X:=^BNS=<.S&8>A&'R?+*V:O$&FY M)8H8"DQX@H:)"S!.$8@N!8_8R4[4;A%:AZY=#5CI4I_/;JP[(8@TI-P\@%XU M8P2\B[AYN"9M)A=9!PUS;M(.X&?+DE]:MY7]>G;TXI9;R% M;%*IKC0)G/<4,$#+- I!$ZN],AXDI%_H[*+9!T&RBY@;P,H;-_M2-GG\S^%_ M7@R_85@S1OG,W[CI],=P_/FO;G21!A+C=)4=@41":7$O5V#@%@Q*>)V(XS:0 MVG6+:Q'6 I9V L!=GZBZ-IK(7AZ-OR$?D^F/TM!GO:->9P(T%^J3L."U%1!* MKX 046G^U#S@[2KKK]_?;W:C/F2VEFT#QN?T"X:89VEZ7IA8YD]F@X06F025 MP!NTR\(Z#U9;"40QGXPWS/OJ'MP#=/0;B-7'RX[A( M;]V2T2![ES03#'0HX8 .$IES";+E/@0J@[6USO8-MI5M9#!+7@$E>!4#VQMX"AZQVVM.2O+"D52C)O,FCI,@@?)7A;KJK- M$;E3:$AM[7;D!PEIP4VN@YF=Q=P 5MZN7GO5@;]B"%&?%4:"SGA0IARY>>J0 MD])?K:A35'+&9 IG*9H=$&;+DD0J9LI8DI&5;[:')=VIHID>[FT+(3%35@>6[P M=3?RY"9GMICG((- 5XV4H2"1 _$A$NTE.F^U/>3'J>GW,*H;[3\.L5U4T0"H M#D*87(SGLX_N1REL*T.70YA>(!WW6!S0J&BVN!ZIBZ%D)0C8Y!B@&*4RC@3J MJN=\UB>O&=CMA(B[FV1'ZFD >;>#STM^?EQE1X6./%ET"429>U M:Z*?):H9.]2=>U57,6T9IH'@ 2VGUB!+@8J0I66 607:I.0=$4SJVL.F;KR^ M&5.T%^=\(V$W8)&>D(C@/$=79G13M->"<0LNJX 1L=!:IZ@SK5TNMF,&H;-L M]EY05$D5#1B?&T-^Z M^3JZ?7Q:SN:";J) ]2#&11[.C3ZZ83P:OW%?AVC;!CS3E+AP$*F)($) 1A33 MP"0GBJ3@DZKM!SU"2M^YRTZ 4T/L#1B:@Q NSB]&;I[B.GV5@Z UBQK7 W/( M&9IG!]9*#]8C=49ZAU_4SR=M0F+?78C=H*U#-36 PD]I[H;C%"_'V=Y@]VW* MPS"<#V3B&/EJ!4GY$CV8#,9Y!3(J(E19=-4'R#U/5;\^54=8JZR,!N!U7U"# M*#'T9#0 L;&,118:C$>&E-/">",D4;5+!NY3T6^I0$?PV5'8#41TS\4J TVX M5D))()K$DF)-8(S295 ["5%JKF)M6_0<3?U":=\Y@MW5\AHZ[Y?S++ZD^3"@ MDWV+L=IM^+=?M?>>_"#?N;4:&(<(*!D.:U#LT@L \U\]-%);:O/%MM' M@_Z-&!@%?3)=O#,NPN'+P;&#Q#">45: -9Z"2"& "[C*LG7&^A2,SM6[:)\G MJ^^41&7,/)&2/ZUIXYKTBTDNP(6>,&$LMC5$"?%2"6[17IGJGT5/T5!@[7Y[Y M<3HI]S[$7W[\/BOM&U>E&0=A/ORV#*"O!C$F+F/F"C N+]5$)J/[:'&K3TX* M#,TST1U<_;@AENI>>UM]"&[D'H6MM/7H6PB>@;.=6^G$H\.YM\2F&"/L8HW6+J;+*I/$5F M1GMJ0 E%0*C2ML83?HM<*L5R\*1Z,7P'?/0;F>X9Q[T#H0$S^C;AF]''+BK& MKT=I-=G^X+R,.?ZOQ<\'EK UBLW7HZGG, M7>_HN==46UF5/<(3O?X[9;^KV3G'DW&1Z8 3*UP)SY26 83F&/\[Y2#@>E=< M"FH$?2: >>X=/8\&:05>5571@,6[O 8[+49X(R/+A4$H"L?B#:>F$XE_4[0QZFI.=Q(JW KJ*Z&@#=KVXX+K([&9<;,D[RK6D]5Z-Z!BJ3 M*!UG0(@K@YZ8QN!/9) \4?Q5I*+Z1KL>93W/*VD-E!VH M!Z*T!LN*ZFL"CM+AFCTVM ; M%><"LD@6A ]EC1(*G%IF0F+,R/JA]I,DK055_4\#U9H*;, Q_7T\O;--G(QO MCL+.3D3<+1($YDK?O]?@(X^00K;&>4&4K'V(\PQ):^'1_-/@L:8"VS&3=V]W MNR&_53?4E? <(XG32' ?'!$RTA^9152@F%**IO^.M2MQ98[3\-6#M2 M:P-V]#YGES=0E+[S3$5*)&4@I7Y2");!1$X!.60B":YHJATX/4E0OYGSKE#P M+-BV54DCP=!==E93Y2\]D@>GRP\(&R:K*[%1L"[8N=Y7EGQ%;:PH)7S)E+F.CFO R$V TYS%K 2+U?.= MZU'6;Q*^-S#NK*1&P;?.W+P!#U)0315ZRED#?LG!H4 A!A:<=%EJ7?MF@NTH M[3<9WQLXJRNQ4;=QE5Q 2,]\B $(4642071@>4X@!6.,)FZ=JIV1W)#$)LO5JR'F[LU8':JOG4T< MI1E2BK-W*.["%+K'']R\\/7C)#_.\<#150\ER;\"PE,%8JR/SCKGJ MGN66I#99F]X9:/>@SA9-ZZ/7V*$7X[@5UJ*SQ,NR- 1LN0XQ,:'1KW;(7NU+ M+=:GKDG706EQEELY<\0E1Q2M/@U\ M?>KZS1'M&9 =*:W=6&C5&?]P4.FYC83+(L@R$4T6KYYQD-YDDZ6.DM4N9-^< MRF:F5NPE%JJEKB;:)V]Y)F6*PLG7HK?9X?:KAXRGG<644-N8GH[WY*7R^FX8N;I9.\.*Y: M3>A30F<3DX$4(QIV$M'$D\"!2I&$=YP&5_L>A>>I:C)DZ0QU=974A#MXR5.I M0"Y"',=9N8Q0""8\.)+*&'=EP6N*3&2121+.2Q8[0MH-,IJ,.+J&UK9J: I+ M=];'C7E$ Q&4L524-C92;DP2$@,G@KZ'2CYH*AGQM:MMGZ>JR5!BST9L6R4U M ;SU13@(5'H?14+1,0("O0 P.6MPCL<0*7/>U[YF;WWJ^CUJWC,0.U): S'M M8 _A $FX+QD2FDA&I=B%9!VPT,WFO;E3EK>V2=X_; MSOJ%&\7M)DK<$;>'XSI1X^G%UZ^CA2C=Z%*41^,\F9Z[6[.8I;:9F>B!A8#1 M!T\*' H:,G$6D445H[43KVN2UF^G<&=([$(Q#;C(-RJJR[6'&/\.;)8R>XV! M+=$4;7R*X#/E8#4N(T&-5:+VEGV?BIXG!'>A[/O5[;M(O@'L7&6%%P/I(F>1 M2^'!,&++94UE,HA*$$T*GCJ=5 R587.+@)X+??> F.WE7?$(>_]C\W\[./[U M\/3H^/3LY,W_^NWD_=O#3Z>'__OWH[._=SM(?YWW[FNT_L8RJ#]L_XE+X'1, M.@AG0)4KVD00#'QR%JP+I8*(9QEK[QAK$;;[-9.KEYPM^HR8(8F:H %]!EQQ M-I8IKDZ")HXJAXZF(+4KS&]3T,S8_$I8N'_3Y-;R;F [O*)^*9$R.',R+G'( MP??A;!"B8])K#XDZC$6XRN"$<^"H]BK(%(6I7?'])$&-8&D+33\&FIW%W@"& M[O#P=G+NAN,!33H1CVM*TE#\0J? B&R 4.&2R^7VY]K3]1XDI!',[*[HNTC<."S_D,Y]F@Z,<327^W[+E/%RJ3-&NDQ((-P[[9A@/.3:.:R[1/0+ MF0J*??P>JRVDW !,#F)/9\%M:IC=6C$E% M/(L^@&36+ML,O$T<-WGK"?564E4[-[ V?9RLNM&'9$&4@Q)!!Y)S!HP&&H%5"1Y)3XVH7H3Q,2;]U)/6!5$'>#:#F MK)S'7TQ_++;LY>Z]8L1%[Z5%Y&=+21E-@AZCM;B%JXRL<2)DJ)VU>)28?BLK MZF.GCM0;@,]5T/$>E\(1?CD;B%BN$1 4O%0:1"*I!*MEK@TQ63*NLZ^]F=VG MHI&Q%A7#]^T$W !$[M?^W$^/?9J,1N\FTS_<- Z,XU9KB=(2#'$O,S)*K0>M M([$<7;U8_T9K(P?,@&\R XB M859Y'83WM9/5N]R5OL>QMQ75O^:UZ9OHHIGZJ?MB&B3+DA4H#.>I .&$ U,Z M@ B1Z"Q$9IFL/?#I/A6M3:SM#DX[:J 9)-V^N=9(ZY0O9ER5$="FS$4+B0"/ M62E#HA:B@P$.&UX:O,X_&RP+M@3,\IBP%.,48LJ\Y.)T\<$6RM$(35;U7I2H#K8V?[=#L]:;W M)F!_Z_J(1_+%"T[]/1&-X^6L@=41_6H"P2!832(N?L M K>-J UN(-E#LE$I M*KPVM+;-[8"-UH;>=K<$^L9 W'-@O;E6GY[,1V./R_7\W*-/SQ> _WJ'"0R MIU*Y^+'S< M@=Q^KZ?KR8_M5*=- /C6F>=B#UD-:D6^9O,/:?X%PU'/GC)Z\!D]75U![XEAO&IS0O7 V<2YRY$$M[$.X$ M+B OV5D(CBGG:&"A^N7&CU.S'M!>Q6E0)96T,^S^%D,K5J[7S,%YN2=JH)F. M7ED'-/KB(3,.+E(!VH6DT'3'P&N?$:U#UWJX>Q7'1M75U X"'RMH+ <USN?3H;^8EP*5L\G'A98&+B;'O0M A4*S[HTM,[LD&%^:DY3G M,MNDK:S=MO$8+>NA[U6<.E511Q.NX&-5*%(I+2(O(Q$C2D>C8$Q.&=#6&TLL M4Y'6#CUVJ@AZ%2>\-0R_"2'0D,'X2JI,3 ME\T+@NCK.5+97@55@51[$,3I[Q\^''SZ^\F[TZ-?CX_>';TY.#X[>//FY/?C MLZ/C7S^>O#]ZIN5M28]K/G@.J,R\Y0V'^,BH# MH[/7BMK P;@RH524FV=%$+'PFD7-7O1WF"7)V;^:X]^@;Z&6"*9DS1$+0/ MT;+S))<[S[W&<+12ZRP3!%,F)#'<:YUG#B2CGHF):;G\1PU<'!O MF$L5P3=L/!;K\I>#Q;BX#Q\/CT\/SHY.CK<)C!Y^4*5 : TJ*YF3ZXUB<67, M50G!JN2@G'W,KJME+^^:N0*;DQ@Z2R9!$$=QLRJ#%)65D- CS<)FE4S]P96[ M4+Q[YGG-M]^LL+_AQ$N=33#4 T&-V')$_C$(D098ZG>5,;7GCV\(\G]FKD] MXO-^5GM_JF[89+X_1$.T3:BV^L,Z)O$A*BJ9P/^6F*^C4P.VC_KL&H*/B&[<'!FS>_?_C]?1FS>W+V MV^&GXJ)\.OP-O92COQX>'>.WVX1DZSRUCB79F/YZ*>;G9DO=/*V_,7A?!D89 M 54Z3@5S 1PK5T=:$3V-DKM0^^AQ2U(K'+[>?-+_<8RE)9 MR !791GTQF0@6BJ>.IC+\"1-O2>D.\?4 Z>R];14K9:DBRSUZ=EBA/B66>K+ MOZZ7I7Z0GHI9ZE6U^<%HM #3S1]= B=)FJQ( LH@?A"4$M2M+7?:)6]E5EZY MVM>TK4?9KK9G=4NE&QV-\8$7BV<_E$2UEE$M9 9E+0J X_[M(J5@M!>4!:.3 MJSV :$W2^L]H5\;/7RN_WNIF@HB;]84K%<6CK/<8JP9*[IJL#I320&'^ MR?2S&P__:Z&<-Y/Q#+F)BV]6['Z\H;Q?+F;#<9K-WJ99F Z_KB:P/%4!Y4(( ML@Q-5K),$) T@\L>G4DJ4>P$?R5K[Z"=,M3O.+Z.@-T.!)H82?5[&29T.)L/ MS]T\S0;*"*=*NR*&) SI3QJ\=Q2BSLP9843]AM+;%/0[PJ\CS.T@Y"9 R!N[(,@A#@A>/ I92!DA"=JGV,O"F-_0[= MZPAHG2JJX4.?&T6RB['EVX09]Y]1O8#W(=KV4,:KHN6.9 4DEXQ39!$,I:7* MP'J#_TBE=>75V&$9[VGXDN+%""WJU4O>7$S+HEN(]QK;)#I&DRZE9=R!4$'B M5X9 C+&,2R645#^.69>V_I.A-;!RKU&@"\TTF_>X6TZ[M>%YY$'=%/UV:((> M+?FD6AK'D@?D&M5=RC2]R!IH"BQZ(0C+M4M6NBK]O8;XW3>4\"%@=/!V.+HH M@Q%N(U[+4N9E$>+*EZK7(, ZX8$2_&D07L=MTO=*:U9 M,_5PL>[6QNK)QW597MRAX=JQB#,Y:[0ONQG1N&4*QL!KSP'_%QS3WL;J%6O] M%AE?KZ>'Y[O=G*]Y$.;#;\/YCSM+R_K$'!4!.*YGC!G0O"F\@47S-\?%D42>0XB?\=SH,^-6"W=_'P_ECS!)+ MDV EM^.TQZC::PSA+0;S5!F6(W-1U'9X=B*XWT1O$\#N6LT-8/JFG)^]B&'V MV$T,U^PCBSJ4\I6TZ+DJ=3)6N0S1)A.,2R1T,,RH*@O])IM[Q'V?4&C64U[V M<&SM&=_Z\YI=)1UZOG>Z"Y(77-!(0,5L<9,F%#PKVW7.""IE9>2UO;+:O27X MM+)P[D9R(@OE+7)"YSVS:B*!J\B,Y F2* %HTG M]!1,)S;TESL+6?. M\^J3+W8DN?>ROP H4Q15^4Z %?[O/EI MBOJ^VKMS %942--[YZJ4[6V:XS+;L<[N\B'5"^T>I&X/E7:4*QZ$5T"90^^, M,PXFH8>4@\LZ9Y'JET_O8V#F)_<'QMEI.G2CV< YHYF1 53(I7I93C^?#!> M1AVG%U^_CG!?'F0BC>=*@!(E9VBE *\PO DA$,:HD*[ZS6D;DMC_]M4%V+K4 M4X\PQ+WA6F3'D_&[R22^&XZ',W01?\6O9P,F D]$6 HM"8%F"\4&"5H2@Q M3KBPSVQCS[ZDW\/%VI"I*],FNEJNV+G-!V*;>Q\7I_KXCPFJS,&B8+)QCD8F M,"+H:G_;'$ =7M#3\0:WO=0;V.&NN"BW3*Y.[6=IBH[_ /UY;[G%(&(QQSK+ M,K@B">*MRR+[ZZ=#CU*R%H0YOX^D80[M)OXDKG:Z-:D*AJ*1SE!S#0BW+ ML94'8U HE@:B=#0A5!\RWLY,YFZTQ]:3DKZ_6#YW MDAZJIOWPXPZQ^I8OZJ9U91LNNVYM$8SI:,N0.L/0(^:<@"?XK^[1OO%LSN^."^GZY/I]8&]D97JYF!7X35A$/Z6AI^_X)YZ@ ]UGQ.N"Y^FJSKA MV#^)_7"S/V ;6\,A9R$",7G2&$K Y)?#<$664-*9ZO+TE MJ?T8N[U!L;*N&LCR/++B'F,4MPVD4Y;[7UU9<]XY,%1K()X*YW.D7-<^&MN0 MQ'Z2TGNTAE5T4RWPKQ=Q+HUZBM%S[0DX4?ILI+=@C=' I6=E;$?6HO;Y\H.$ M]'NV4=5MJR?P!@S67296JV& U%LN*8?L2OK,4@^6(4.X'@S:7AVXKST!Z!%2 M^CW4V MRMA%ZP[.U[J;ACMVT-&)\2_72BO<>V4T"\6G*NTX52L6,,H:"CD85 M4Q+1%T\:6+2.*<-DJAXH=38%!]6Q: U=U% .9 I,:O3E O((@C*,,K(TH*51 ME%GNB6&5.;M-0:-)Q4TT?J^>=7L1-[ /'8SGPUC,("ZVZ_K;P^]A=($K[!V* M\$8R_X&Q/#\>?L#!]^%L0*S/WHDB@,A!),/!N:P@:ET&ARE.?>V4>X?L] O= M75 V:5/ES:+_V)VGMY-S-QP//,.H5UH*Q&8-0@D#AFL"&/:H&!SCF==VXY^C MJ>=NJ%; LQ:HM]1D \B\,]SD0RI!\X!EJ[FQI*QSE!#CY48:;8!R:C7U)+OJ MD_4?)*1%#&ZKZWN5EKL*O@'T7.T6Z(>G(_QR-DCEWE@2#>1R79MPY9(V[PQ$ MQX+U7F@M:U^X=9^*?@^1*NZA.PJX 8CL:,@/SLOLZH'F3D5/,R16FF5,M. 8 M1N,^ZR")*!6EM<=U5"&\$6=N2_34=>BV4&7#29"'9U)62(6L^> N)VON)2VR MX[ K$A"KU)9[0'';%2P;<$0(!)27@=L@K:U^^UK3,S;7FL^UV) (#\K9R"#1 M,B>,. '6Y%B.0+1@(AL6:QO3:L2_Z(F;FV!VTXF;W:B_!0=B03E^>!&[^:2( MEQBVA4PH")U1F$YFT%G9*'1D-E3/]=PDH.<-O1\0W/4#MM9( W#:7G#7;(_C MQY$;WP@$9?11"'1G8N(!77R)81O&?RA70331AEI;.WW3!1\]A]O;P^JNK>Q; MQPW@_!!=SB3OP6M*P09! L8&"2/2VL=.CQ'3 MLSGM'2=W#XZK**T!]#VN*:S(&"MXYD3FGVL/4!H^[1B M=^FAUE"WN[)ZKE#_X*;_2/,BE#3-D^FY&X>E\!9B7/%C<_24* [*\802"A(L M*=.134)?)]/@^9U2O =+UM=Y5[_%4,W@JQ/5-&#<;K"RK"IM%_:\6?8:\6XO^1;@LD(Y M]XI+21(8IDK5H<<]G+@(QF@5G"<;^,:KU^D^<4?_.E_6P0U12_M?P: M\$07V]M;-U^:/)Z5R")H<,:C&\V8 ><%@RQTHDY)GV7MJMM;!/0<]K23&]]* M(RW!:>5SZRB)5];BSLGC\BYPEZV$E-$3#T%&;FJ7@=TAH8&,]';*? P66TBV MY^3*K[AL%L, 45=L92;1G=**<@\8FF,P%A;-,8)"$,$+8113_(Y_\6 NY8%' M-Z+P;=0TJ2>S!FS!LT;T,1OZ_JK6R#B?F<8]. EE03B1P E+P22=+)5"VU#; M?.Q.=<^IDR8VL3WK_B6C??'/7].LW$/T,4V'DT@'D@@C*=H**JP!4>:A&DL" M.I%H_82D)JC:3=\UZ6_\3*XR]FI!?U<@-#%QX[IVZ6GN_5WN#[]_'4X7'U[R M/K#,)EDLCQ:FI%85[G;6!@C>L*(' /"V#O$'C)6\#JFNL; MHR7N3*(X_)ZF83A+'Z?#D ;:.Q4LM>"%+%=*E KLM+@H-5/OE1=1-N,5;<9: MX\>>C6X<'<+G%:RJ120U.UK9E%^G97:>D][*1!4:EA))Q:S !_1ORS&Q(]'X M6+WTNP,V&C^C;7NU[ J+5E;&-AOMLP;C4RK)"_SYF\EX47A^X49G:7K.!MRF M,O+ D8#&R6L&3G*,#)E5/"?E,JE=^M@#F_V.BW_A*Z]K6+6R\NHX MR4%X-@SEQHCB>+FUC3,EL_.RO#66_^OC3P'D_F?T_S M@TL)X^3B]/,L4>N=79)7"N2Z.FL A+LZ@Y>,7V4*%\OVCE]H.)->,5YN=T\H$X8+ M4QL*E!/N9$G%96T^RC&\9WD^F9^_ZWX?S+ ME\FHA$KX@XE&%Z79P&0&R>7@O5-1 M&=XE_!\F:SVPO[;3]+[UVX"_=3!:?&8UJ>.>' Z_ER_3@)/@;1G118,,(*26 MX(,)X*E-E.A 7*A]EK >9>L!][4>1G>@O8'*?/A9+]I?DQ OHEC5,> MSB^'$M_E.QBG?+8>DN4$!"$8^["L0 :KK&I)RS^Z*[B!]B&9'#*8N#!"*:.'2STP3@W1ULO@ M:A_Q]<;L>MV+K_4(_&5@K-I&MY];36[6$AR$^? ;VJG:%YP\]8XN[SI9F[5#:H(WA4H/7J93$9,:M-D%VTX]1G9,7?2'*)FCNL%!\6V"\Y'CEOA26 M9S0#FFG.7EI(TDIT*U$=WAH.B1JNJ+?>YM;*H>XQ\4)'F%1$9G>+90N8;+U. MOBXBG=.YF\XKW5>)F_W1;':1XMN+Z=6DEN59Y",5DY*0;*0"=&%*O[VF8+E2 M0%7F6A(NG*U_G^6F5+[0B24=XKU;13=Q%+*KV%'..0WGN'=?YQ28$BCM'" % M@JM:!12"*P>50CEK*7&I_M5P]=EXH8-(VC7_NT)EU_5RUK"_E F26PJWC,-H M7PB3P&6"=L/3E$D@1,2&Y_ELX"^U5]#4[H+9#28[^DN'XS8VF!O-A9=.HW A M).T@*>XPWK,!#.H";")1$$DS#[RQM7*/B7Y]K1<<<.\&AR9.,"J:A:>&?!4K MEB^M6';4"-Q)2ND:#@AO/-8QI>0#.L$X3V-<=P$;NVD MSYX3SJ,SR1_KJGQ21B0PE11EP$M9@Q"<@U%40HXR&<+0N*J]1U95.7PU:;LF M5F9_X'L9ONES\GD@R?.DA%14B7#C U6>[$M(4S:Q M''N V^M+;#XI&A-\<-X8X(YG]"$8^A"!>O A:C126GK;6NYF3=;Z78DO.&'3 M!70JNI_[J2?]E% 3PS!?34CKJJ3TF==T656Z"8>M%)92D4A0X&DJTV!D!F^$ M!XD U%KHK%WM_%?/A:75KEISB@I*J ;*$D=[D@QX*17$3 ENT$(2F6N;^5K$ MO_#RT?4Q>\^0]Z+^!L*0)>7XX<6EIH99AM)-D'40(!27Z+U)W!J1(^.T3SG6 M7O:W".@Y.=T/"!ZZ''8KC30 I^T%=\WV.'X>8IIMHYT <):?R,KW-\3&HKJP'$5>BDY"130X,'Q[T$$70" MPQ:-B9S9;(*E[93SOM_H!N;N3L6:< GVK/N7C/9GV^:ONGUO%H<*ZFD.V4/* MQ)?F>0ZEZ1@HC3KY+(R.S=S1O!6'C>\(E?&[MQD,.X/IGV.IK0H\8_9&.B&! M2().)\FD9#$-:!XUX5Q%4GWNPMZ8>Z$+; \(W_]BW )N+Z>HJM:\&)N=<"$; MR&7,GTA,@#7H7VN:$G%1*L)JCP[8%V\OM)#J-:W%'<#VJK?$V^._!VB)O-]DMS<]*9E5;=D,X M.8^^%EDJ]IL6X&^1>04G\N\1-P:14A#N5,91:B=,H'YS#-Y@0F>343P0D// M%Y-G[0R.KSKJ7%]\ ^FHM"I("+[H7] (CJ+5#AB^9^&,]6SO;3Q[X/O5IV^[ M6S@-&H&-4/Q/E_I]7GQ"1Q8"XR"T(T7_'*Q,$F2*5E&N>,BU[WQHAOD7NH/_ M4UF"+O'\JAV!VQG!YP57[M\C27A \3D0+I1+834#YAG+^)M _@2SZ_:$-QHKGY>:DQ[G6BDP'5IK/ F@%/90-+4&<6D#.+E6(%-.'_U M:?-78 (Z0_*K7O\;Q%*.J=)?JH"Q,CC3$%2[YAI]M MM%H['GB0UH+3FI2V50:&B0B$!*V<-TKSVK7GKZ75.E%;9C<3X*2T\%!OP3-+ M0#J68@S1X(_^N]6Z@U;K33#;7:OU)NIOP)N[W8')LN6TG"_39"2ZHIZ#HSP! M4X12DU*J?Y/(JVRUW@@$3[9:;Z*1!N#429ME*,X<(0:LY^7@!)T];YD'J5F, MW*7HK%(D2_Z,;[O&:QH_'.X< Y-N%-* #;T1,2Q$.%NQX21&M]1GH+F< M&@5&P> J!BJY)X$J$7/MZ[@?(:7QX\A]8:^FPGJ=SUL6T0:%\%<<_/+ M5<"ZXH@[1ZP7 8@N-\101\#YD!$XF9J0E45NUS!MZ[RK\9.N?=JWZJIIP,@M MQ%2R80MW1$MAK2P5?9*6T(WB2@E!@+4\DNQ]%'>WS#IQQR4!KV6>P\YQQU8: M:0E.JZ7FM-"R3$\1HJP&M#[@K/*07?!*TRBUJ)V$N4-" ][^=LI\#!9;2+9G M1WV1<2\G\64#6IG)K PEK@S)MQQ]P:#0!I,H@2O/67;&L[R.<_[ HQM1^#9J MFM2364,JYY=N&$^:._3WT>U"HTB\!H?^/V@F,U..!B_BABKG+?C!7:A\&YDU MI'*V(I\X(@@S#IP4&836&KQS$BA*ADFF";U[(]FS*F]9]"V@O2>NC MV>PBQ;<7T^'X\[*$>)E4?%@< YI3#H8S4+D,S;4A@LU) U66,!64MO7;8C8G ML_'3BLI(N@ODCM7: '(/1HO/K%*2]]@Y_%Z^3 /%?6;,>R!>E@G/B8%-&$Z& MQ'5@3J8.\GQK4=;XB4:W^.Q >=4@6;M2\?WAP>GAZ;%#V//*A. M3>$Z5%8J%'R?4-_71521,FW+-JU#+JE"G\%S*B#[%)-3/KE<>^30;0IVM43O MTVR6TN*9;],L3(>+P^&E-T*5#)I$#'6<=QCB4O1&4D#GQ$KTB8U@,M?N&7F" MG'[WQ!WT?M=^U!)YC_O8;#H??"K6=I$O%U+1F+(#I5@&840 +V@"(I$+):TP M:JWN GSJ#8S@=]?XN/7"OI%027V37679 @!6<;+VE@MF B2"7I?01H./4@*3 MBM&@$U5JK6*+=2#0Y_G!#LJZJ^XM)->SPC\,Q\/SB_,5X2PJB4_S-E_83<%13_-;R:R!6+<4Y)_E&=+4P?1C4E/\S MH*1$TT>B J>L@.1S!L SLVTY\$X'D_&[OHG M9_C5##WI4HEZ>8CJE3"&X<*R6H&(VH%G@8..-F="$C6I=A/5AB3VZWA6 ,7= M3$:'&NJ]ZCR59,#X\V)QWF#TW63Z*;G1X0P5=VG7DQ&"\%@NC\(83IB2JJ$8 MUX7,HDR29Z'O]/$\4H*^_CM[+G_I4O&3/6BA8725CN>OY>O+[3Z%F +N](%$ M"T+@4O5,)O#<&5KD2<*NX+KSRI[K;!K UBXZ:&#G?-BMN,Y>AYBSX<2#,&9:UVYM>(:D?@]@NW+#:NJA&5C=7C=G:7I>VH?'R[RF58ZI M2#UPEXNT% 5#D2-<(5;R9$40M0>%/$]5B_F^+4'P(,"J::0!C-WFY?(L+"K' MJ1<:K+01A,)_'/<6:%8IVB29H;4-UH.$M!@MUD'2[G+OM:7J83;NC(3YE$I] MU\UU0@=2A*@2%Q!TI" X1YDIQL$%;[TTT?+0+;*>I['%O;$+T%765G/&[ Y_ M9?S&Y&(\_X01S,K@4CT,X1UI4+4!TC24^64MK;Z,)--:>RW M/+C29_'(T7W8_E#;O6;:SY^)K5'-MP MU$V-!QV%<#@(:4&'*+449 MHHP9G0,,BKS3 B35R>03::W.7T_='XX&LY_#%! KAR#@6*D]$D87;JW M(TB2:1;<291N94SM0&[?X4 UX.U+915CA&[VP7<798KLZJ!]P>B;R?GY<+Y8 MB+ON@FL]O.8>N#DWW>R RJKD0](E?6K*N;XR+@>$R[/NZ=!E??%I^EK:K??HXO(F<(5R8@%1TW"!4JB%\$8+VO7&6U(8K\9X^8 NHWB7AHN$6AI8*S/ MW!$/WNA4YBU&,#$PD((F8GR92M8K,@N1_>:/V\3FQLI[8>A\-[F8#C+N"5$S MY"\P!D)J#=8F"Q8]F>2)R[3Z8(!-:>QW#D63V-Q8=3U7UJW+VT'&]UTQR)W@ M480(!!T59%!J<)XGB,8*FIU@\6[:\<$:NZU>OA;HU(L%W7Z4\H(,XB ';3(+ M"5"<%GT1)Z!4XH!AV20G>3"R+T.X%A;UB\5BIZK:'H*3N1MU#\'?QW%UAIWB MX?> 'STX+]\-N%(D!'2+O0TH22HB6&4X1F\Q4/2)T3DV^\3C8X2N!4[SNL%9 M18F;(]4ND3I.G\O@+B33;0G, M9J=[]L7CK88BFJUN.7CSYOW+VV^&G'2, MWQYN?ZJWP^C4.\<-!,TI"$8EV.+8!Z938)[XI*K?JK 9B3V/YVX7QEOIL%H&H;87?73\ MU\/3LP^'QV>GI93:C>.[X=B-P]"-%O6"LP\8.EP@M6Y^==OR9.P^E;5;!G#^ MXF;#':KGJKZ^CB?>G40J^>I'BUNQETW4H]$"JC=_=+D4$/#2NLAQ*?!4BD8# M&%:&"%'G:+""*5,[%[D>9;N< 12-'(QC^4]IY/Z&V\BREWQYLU/97:ZWE667 M;W 8[%(B0+)RPI%I!(N& +&SRPK3:U;9YS]YF_NUR_N "4W\_X=*Z*!+?UJ MB &$B.AV]$8'=Z+Z]%X@28M)0.E.2OI M)8-KA**_06RR1%)1_U;+1TCI!U1]N&D55-$ HA99?'QS$=1IFGX;!HSY2UO' M/>YF92KC[.%?K58IE3)34JXPUH[B:F(>+.4&C+1!^,B%%ZHR#&O2W_-N6P-0 M=Z>K]J7=!I#]83)./Y9K_]W%.%X.X8Z<)UK M5YX_3$G/(U9[0\:DNIH: -OOI[].OJ7IN$CES63Z=3)=:+)(]^!S0K&EV?7F M%*N0,,E[LITR*PC+FU1CHMJ>X-;D-FOE]@,3+M6< ,8_G Q M1O%^=:-?)M?KT&:;\N)*\"!P'2:FP$OOP' ?)9/+%@3AO+92 Y\#5 M-W;^QFKLF=/9P^*:1)ZA]_# MZ"(.QY]O'#GA*BM-Z:4W?3HOZ_C-9#8?1&W\8O&&Q6W'R%J9TI]!4N$]"T8P MN\Y%9CN2\4(J7K=$R+. [$9=#60&'F;WJDJIW-\PFI22J $QSC,9*21MT=I[ M;\$Q_$IQXK6CI3&G=C'BVL2]D$*?W=#9K3)-I;?1J:1H$ DLRQPE+'&'L,R5T2.)\>2BYVR_J%V/\!>2>=L+E#M0 M]0O&=\DC7#,M#<+/8"A@1-10!BR S5&"##S%R+61L7K_=0W"7TB\U2^^MU?U MKN.SSCJ#^37?MZ6P'"Z"+KW(+FONT(,*$O\I(YV$$1"8HEH&JJ*I74F\(8G] M#,-L!+HUU=> $2YBG/^X9N/=M^/A(K)D0<7,HP$J16D[41GWD23!R<2T(E18 M5;M8^#%:^AEXV1/>JBBDYR34/1[^>GQTVVF9#307=#'=7;&H0(3DP&L:(3IC MLXM&2';'S#V8:%KC5?V,I.PAF51;[(VAZ,ZQP,!A/,>"RQ ](U#@7\I %1!- M#0LYRTCS%@BZ\YI^!DPV@)Y=Q-WJQK;58XLDYZ4L06[ XG/DX5W*&4G$B$(GN#PB'TC8L#2Y^Q5AFU4A"2<*USNH @M .':"QA"G6_WHHG3B M\H3-P0_M8M]\:^(HPI4$H5J.+I1N-P-# K;:2MF:DW?Q1-"3V#^1:-:0\9 M]^;])G@X=,*^*"2#,(7H]085OWI-]2&(>VQ2R:&@JSL=(% WR;M:G;)T#+X M*JI@58JE#$D;GD7$,,WP=\@H?C]9_0AME>^VNS[.77HE'_C.[@V0A]#>J:OQ M6_Z>G_@7_[D;(&^R-,8DJ+ZV;A A0(B^#785-?B4JNX^+N@!$6/D$QLK6XGZ M(F+.B4@#A98;S4)#)*5!69,56>=)][X:=HR>B?OKG"7_(5G!D_@^ ]?XL;V\ MWO$0UGO*627+UAJ49J?$*&1WOP8VZC5Z5V/QPO6>L3Z$KHF;X8R.J;/D,--Z MQWW_<[VK&K,6PA:(HK44)6^ KH>43=SF9G1\G2F+V0YO MV_$Q?L=5:PWUA;IX1@^^K;M/=)S>[SOC0>=0TGU&8^X^&V'T%^3^7S!WI5GR\_\.?+#NOWFU:WVZK>P<^7G>@8D): MR['-ZR_OE:/8AEBIR;QW6?Q<_Q$R)IZ#R02.*:04_ M Y/<&J*]JCL[VC0<\L5)KPPD(UOU&C/$7!6D7(O@R-SQCGH'0X\1,BT IT;' M?K?8LT4U [P]9!X^SJ_MB^J,6).J%@26P-%3ZRQN"@&'5"DIF4K2O:]X/I'$ MB0/9\T&Q?YEX1 G- ("'CO)V-T0&47*@[DHJK=-# C2A@ C9:A-DD;[WS?;C M%$T\[W1,,.R7=_I)9D*1KA&BR@B*JK+HJ$G+0V_1OH&TP0=.HL3XR M7XXM@(DO@+Y<5/KMY]O.[C:0KJ[-OLV-[@*AM2UQ(7C+[D-AG3Z@>+G[G=/) M?B1Q+3OP;F)-\H8%L.;'FTQLTQ?+S3"+)+),GAF@E6O-KPNDPGXC,Z94F]C4 M9M%!:SRZ^+3)U1D9J?-%,S6VMG3_>?7I(^5%75#9GK+2XH]8*\B4FP]' C#D MP#Z]E#+14O"-EJD!@XA M8M 0JD HMEUBECY5J3IBY/[J$P*DCT@? HOPV?$_@^/P#=S()! M::)4 :I9-UYH_4&=$:S998@I>9]*[_'=CQ(R.^"<(N3CT#F!XS. S:^LIB_I MUEE\N3L%I)+72J,!(IW8630<78:"D'76(D3RF'N#YP@YT_0&FJG5ZR6V^2)P M>T -V? D F<)N%. \6 DRUA2FCS+<&,I-C<>?Z/K]\MR=Y'HX6^);LL$ MMAJ''A&,KP),R1)B>X8EBZ9((07KN^1#SZ!QFD9G,[/#WU70$P/ZT#ZV2B#% MFHC(@BV"[4YB38"Z2-!2H9,RF&P&C:W]!F2/4S%E&NU[H6 YBDCF5 I,I=9( M4H./CK4\:0>I37JN'B-JZ[P30P:&S*,4V%-&A^I_3V'8##RS#BK[Y>WS3<-N MK:7H(/)I8;7M.'1W48'01;6^I[+L/^P=[>+4*?1/T[]Q9F9T[XU2@C1:< 8I8F(5=K0&>;'*9HV()D.*WVMA""BLE6@/*M04]M3[)BU* HV\ Q7K6N]ZC;8_1,>[EP-@#L M)K*IAS,=X-BSRW9QZB*HZ*H(!DBFU*K'F2-_:8%X>TJ[K*@.FKUT=)5IKP)- M#JG.8ICML\R??_GI[>G/,'?_NL^SRX/T='IFV6S47>N1NP=L12JRP8(HKHV9 MM!QU.F=XMZ*D9"E%V[NN\S@E/5RG7Z_XNSZOS\-F"EY@R\N>*!B3/8=$E0#; M/#P=/9M=-)%]T1$VMT?&M$Y2![D_YNZ@9@>4U?EA^^+*[> MW=_,-C^'TDB)&($L>Q.&V0$<_U5(WN0:,0II>E>OCQ(T)_B<(N_E6,R? 9)> MTC5_V:NZVR>79X62G5FE$M,8DQZ:3!!C'_PN8#4@4S)50,\K>O84. MT3*G8.GI,CX*F1,9/K$M>G:YSE1ME/#MH]>MHA1!A50H@2^573 534M&LCYV MS*/"=E:6(9,YCJTQ)T"<*L'E".R3@'P6_QJ@)_YC$!EL0;CSY!B-)#(5V"\:68 M+J^[=Y:<\.7_:<+:%_<)G)M8X+\MKA:7GR]O@FX5=!;50I 9&?"6_6Y%!*)U MWJ]&_=@A/.F:1E(&(9CU3K$+4DD"IDF.) ME(,9%%%\2_"[BTX30'03_,G\FT&L\&]<+9IQ>XW7&ZT7HPM1I0Q"Y@BFM%8W MT3!PD8I7)%"Y0;K^"3'"/@W3OHON'4^>Q>&9(63K%%/(01L.DX)( 8R0;72< MR! 2FTKIV7]U@ZZ*GXB1.420YTGU"$1.8/'$D>/Z]AR55U]H=;5X]_[ZQ>(* MK_+BZEW;SIM7+U[?].'34J44"*J-?)*"%Q 4>L@1175*DS%#&D0-7&X^\#A% MHLMQV3L#M?(3?EISY\;X6B3+.P 9@F0UBPC!N0K"%5+%1&-$;[-SGX)IDYB= M\-*!N3. QGT+_/+V2IS0)C')C&M9J/6SR9"JDY!$Q&P5%D>]:_<'2)GV#?NX M&>_3^#T#V#3";VJ!MX6>C6_^TW*U6OZO%9CQ(W]R_?6BDH@./3OGON165_*0 M2D*0(@H*'."'84U5GU*0?0)]<\J&G@B(_5KM6-*9*?*>K\N/C7\OB/Z@56X" M?$<71)Y4(@$D1&MTG 1$R6J=*F9*KCW#[MT&Z GDS:F4-Q[N>LAF!K"[SRZV M^8M/;Y@6+*^N=OT)>2$X]G!2*(A"ZC;IH@)B\P^+J#'$BD:/6_<[3-N*5"8.\;:*^FT;%O<[7;\D#D;XP+QN@KI0Q I9U@A5M.X1-3A(SO&.= I: M%$5:[;EEC\9UQ]:84T;H/)1TY>;4J-ADO&_FYCY?[NXC:H')$H*F5D_/I*'5 M-:%EO['X:J0<,GGXV!IS\L([H*(7-V=GF9[C:O65W;N;)TC%D@P"6>4EQG7- M3>^55E=/2H>2@BB]0_UC]$S;!V5\"W0&]\=_ +;]H/V3\!/]\Q__!U!+ 0(4 M Q0 ( &^&G5@9I01_8 < .HE 7 " 0 !M960M M,C R-# Q,S%X97AX,S$Q+FAT;5!+ 0(4 Q0 ( &^&G5@"%*185P< (TE M 7 " 94' !M960M,C R-# Q,S%X97AX,S$R+FAT;5!+ M 0(4 Q0 ( &^&G5C A=LCW00 '\: 7 " 2$/ !M M960M,C R-# Q,S%X97AX,S(Q+FAT;5!+ 0(4 Q0 ( &^&G5B$'+FBHLX M $)""P 0 " 3,4 !M960M,C R-# S,S$N:'1M4$L! A0# M% @ ;X:=6)?V6HA-"P %&X ! ( ! ^, &UE9"TR M,#(T,#,S,2YX XML 57 med-20240331_htm.xml IDEA: XBRL DOCUMENT 0000910329 2024-01-01 2024-03-31 0000910329 2024-04-22 0000910329 2023-01-01 2023-03-31 0000910329 2024-03-31 0000910329 2023-12-31 0000910329 2022-12-31 0000910329 2023-03-31 0000910329 us-gaap:CommonStockMember 2023-12-31 0000910329 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000910329 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000910329 us-gaap:RetainedEarningsMember 2023-12-31 0000910329 us-gaap:TreasuryStockCommonMember 2023-12-31 0000910329 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0000910329 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0000910329 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0000910329 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0000910329 us-gaap:CommonStockMember 2024-03-31 0000910329 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0000910329 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0000910329 us-gaap:RetainedEarningsMember 2024-03-31 0000910329 us-gaap:TreasuryStockCommonMember 2024-03-31 0000910329 us-gaap:CommonStockMember 2022-12-31 0000910329 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000910329 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000910329 us-gaap:RetainedEarningsMember 2022-12-31 0000910329 us-gaap:TreasuryStockCommonMember 2022-12-31 0000910329 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0000910329 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0000910329 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0000910329 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-03-31 0000910329 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0000910329 us-gaap:CommonStockMember 2023-03-31 0000910329 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000910329 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0000910329 us-gaap:RetainedEarningsMember 2023-03-31 0000910329 us-gaap:TreasuryStockCommonMember 2023-03-31 0000910329 us-gaap:RestrictedStockMember 2024-01-01 2024-03-31 0000910329 us-gaap:RestrictedStockMember 2023-01-01 2023-03-31 0000910329 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-03-31 0000910329 us-gaap:RestrictedStockMember 2024-01-01 2024-03-31 0000910329 us-gaap:RestrictedStockMember 2023-12-31 0000910329 us-gaap:RestrictedStockMember 2022-12-31 0000910329 us-gaap:RestrictedStockMember 2023-01-01 2023-03-31 0000910329 us-gaap:RestrictedStockMember 2024-03-31 0000910329 us-gaap:RestrictedStockMember 2023-03-31 0000910329 srt:MinimumMember med:MarketAndPerformanceBasedShareMember 2024-01-01 2024-03-31 0000910329 srt:MaximumMember med:MarketAndPerformanceBasedShareMember 2024-01-01 2024-03-31 0000910329 med:MarketAndPerformanceBasedShareMember 2024-01-01 2024-03-31 0000910329 med:GrantedIn2022Member med:MarketAndPerformanceBasedShareMember 2023-01-01 2023-03-31 0000910329 med:MarketAndPerformanceBasedShareMember 2023-01-01 2023-03-31 0000910329 us-gaap:PerformanceSharesMember 2024-01-01 2024-03-31 0000910329 med:OptionsAndRestrictedStockMember 2024-01-01 2024-03-31 0000910329 med:OptionsAndRestrictedStockMember 2023-01-01 2023-03-31 0000910329 med:GrantedIn2024Member us-gaap:PerformanceSharesMember 2024-01-01 2024-03-31 0000910329 med:GrantedIn2023Member med:MarketAndPerformanceBasedShareMember 2024-01-01 2024-03-31 0000910329 med:GrantedIn2023Member med:MarketAndPerformanceBasedShareMember 2023-01-01 2023-03-31 0000910329 med:GrantedIn2022Member med:MarketAndPerformanceBasedShareMember 2024-01-01 2024-03-31 0000910329 med:GrantedIn2021Member us-gaap:PerformanceSharesMember 2024-01-01 2024-03-31 0000910329 med:GrantedIn2021Member us-gaap:PerformanceSharesMember 2023-01-01 2023-03-31 0000910329 med:GrantedIn2020Member us-gaap:PerformanceSharesMember 2024-01-01 2024-03-31 0000910329 med:GrantedIn2020Member us-gaap:PerformanceSharesMember 2023-01-01 2023-03-31 0000910329 med:MarketAndPerformanceBasedShareMember 2024-03-31 0000910329 srt:MinimumMember med:OperatingLeaseArrangementForRealEstateMember 2024-03-31 0000910329 srt:MaximumMember med:OperatingLeaseArrangementForRealEstateMember 2024-03-31 0000910329 srt:MinimumMember med:OperatingLeaseArrangementForEquipmentMember 2024-03-31 0000910329 us-gaap:CashAndCashEquivalentsMember 2024-03-31 0000910329 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2024-03-31 0000910329 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2024-03-31 0000910329 us-gaap:SecuritiesInvestmentMember us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2024-03-31 0000910329 us-gaap:FairValueInputsLevel1Member us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2024-03-31 0000910329 us-gaap:FairValueInputsLevel1Member us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember med:DebtSecuritiesGainsLossesMember 2024-03-31 0000910329 us-gaap:FairValueInputsLevel1Member us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember med:DebtSecuritiesAccruedInterestMember 2024-03-31 0000910329 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2024-03-31 0000910329 us-gaap:SecuritiesInvestmentMember us-gaap:FairValueInputsLevel1Member us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2024-03-31 0000910329 us-gaap:FairValueInputsLevel1Member 2024-03-31 0000910329 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member 2024-03-31 0000910329 us-gaap:SecuritiesInvestmentMember us-gaap:FairValueInputsLevel1Member 2024-03-31 0000910329 us-gaap:FairValueInputsLevel2Member us-gaap:MunicipalBondsMember 2024-03-31 0000910329 us-gaap:FairValueInputsLevel2Member us-gaap:MunicipalBondsMember med:DebtSecuritiesGainsLossesMember 2024-03-31 0000910329 us-gaap:FairValueInputsLevel2Member us-gaap:MunicipalBondsMember med:DebtSecuritiesAccruedInterestMember 2024-03-31 0000910329 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:MunicipalBondsMember 2024-03-31 0000910329 us-gaap:SecuritiesInvestmentMember us-gaap:FairValueInputsLevel2Member us-gaap:MunicipalBondsMember 2024-03-31 0000910329 us-gaap:SecuritiesInvestmentMember 2024-03-31 0000910329 us-gaap:CashAndCashEquivalentsMember 2023-12-31 0000910329 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2023-12-31 0000910329 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2023-12-31 0000910329 us-gaap:SecuritiesInvestmentMember us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2023-12-31 0000910329 us-gaap:FairValueInputsLevel1Member us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2023-12-31 0000910329 us-gaap:FairValueInputsLevel1Member us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember med:DebtSecuritiesGainsLossesMember 2023-12-31 0000910329 us-gaap:FairValueInputsLevel1Member us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember med:DebtSecuritiesAccruedInterestMember 2023-12-31 0000910329 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2023-12-31 0000910329 us-gaap:SecuritiesInvestmentMember us-gaap:FairValueInputsLevel1Member us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2023-12-31 0000910329 us-gaap:FairValueInputsLevel1Member 2023-12-31 0000910329 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member 2023-12-31 0000910329 us-gaap:SecuritiesInvestmentMember us-gaap:FairValueInputsLevel1Member 2023-12-31 0000910329 us-gaap:FairValueInputsLevel2Member us-gaap:MunicipalBondsMember 2023-12-31 0000910329 us-gaap:FairValueInputsLevel2Member us-gaap:MunicipalBondsMember med:DebtSecuritiesGainsLossesMember 2023-12-31 0000910329 us-gaap:FairValueInputsLevel2Member us-gaap:MunicipalBondsMember med:DebtSecuritiesAccruedInterestMember 2023-12-31 0000910329 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:MunicipalBondsMember 2023-12-31 0000910329 us-gaap:SecuritiesInvestmentMember us-gaap:FairValueInputsLevel2Member us-gaap:MunicipalBondsMember 2023-12-31 0000910329 us-gaap:SecuritiesInvestmentMember 2023-12-31 0000910329 med:LifeMDMember 2023-10-01 2023-12-31 0000910329 med:LifeMDMember us-gaap:CollaborativeArrangementMember 2023-01-01 2023-12-31 0000910329 med:LifeMDMember us-gaap:CollaborativeArrangementMember 2024-03-18 2024-03-18 0000910329 med:LifeMDMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2024-01-01 2024-03-31 0000910329 med:LifeMDMember srt:ScenarioForecastMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:SubsequentEventMember us-gaap:CollaborativeArrangementMember 2024-04-01 2024-06-30 0000910329 us-gaap:RevolvingCreditFacilityMember med:AmendedCreditAgreementMember 2021-04-13 0000910329 us-gaap:LetterOfCreditMember med:AmendedCreditAgreementMember 2021-04-13 0000910329 med:UncommittedIncrementalFacilityMember med:AmendedCreditAgreementMember 2021-04-13 0000910329 srt:MinimumMember med:AmendedCreditAgreementMember 2021-04-13 2021-04-13 0000910329 srt:MaximumMember med:AmendedCreditAgreementMember 2021-04-13 2021-04-13 0000910329 med:AmendedCreditAgreementMember med:SecuredOvernightFinancingRateSOFRMember 2024-01-01 2024-03-31 0000910329 med:AmendedCreditAgreementMember us-gaap:BaseRateMember 2024-01-01 2024-03-31 0000910329 med:AmendedCreditAgreementMember 2021-04-13 0000910329 med:AmendedCreditAgreementMember 2024-03-31 shares iso4217:USD iso4217:USD shares pure 0000910329 --12-31 2024 Q1 false 10-Q true 2024-03-31 false 001-31573 Medifast, Inc. DE 13-3714405 100 International Drive Baltimore MD 21202 410 581-8042 Common Stock, par value $0.001 per share MED NYSE Yes Yes Large Accelerated Filer false false false 10937245 174739000 348983000 47447000 102593000 127292000 246390000 119352000 192879000 7940000 53511000 1223000 -181000 2422000 -1000 3645000 -182000 11585000 53329000 3269000 13361000 8316000 39968000 0.76 3.68 0.76 3.67 10909000 10864000 10958000 10899000 0 1.65 8316000 39968000 15000 9000 -241000 0 -226000 9000 8090000 39977000 97471000 94440000 46273000 54591000 58957000 55601000 5471000 8727000 11412000 10670000 219584000 224029000 50986000 51467000 14536000 15645000 13648000 14650000 4005000 4117000 302759000 309908000 71229000 86415000 5958000 5885000 77187000 92300000 14611000 16127000 91798000 108427000 0.001 0.001 20000000 20000000 10937000 10937000 10896000 10896000 11000 11000 27963000 26573000 22000 248000 182965000 174649000 210961000 201481000 302759000 309908000 8316000 39968000 3261000 2974000 1108000 1369000 2171000 606000 -13000 0 9000 0 191000 0 112000 800000 2437000 0 -8318000 -21960000 742000 -6563000 -24000 887000 -15918000 -21897000 -3256000 -12603000 7282000 64059000 9169000 0 8235000 0 1841000 2115000 -2775000 -2115000 36000 105000 817000 3236000 710000 19163000 0 3602000 -1491000 -25896000 15000 9000 3031000 36057000 94440000 87691000 97471000 123748000 -100000 -46000 697000 18653000 10896000 11000 26573000 248000 174649000 0 201481000 8316000 8316000 59000 2171000 2171000 1000 36000 36000 19000 817000 817000 -226000 -226000 10937000 11000 27963000 22000 182965000 0 210961000 10928000 11000 21555000 24000 139852000 -6398000 155044000 39968000 39968000 69000 606000 606000 4000 105000 105000 30000 3236000 3236000 3602000 3602000 84000 10000000 -10000000 0 9000 9000 17994000 17994000 10887000 11000 19030000 33000 151826000 0 170900000 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The accompanying unaudited condensed consolidated financial statements of Medifast, Inc. and its wholly-owned subsidiaries (“Medifast,” the “Company,” “we,” “us,” or “our”) included herein have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim reporting and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Accordingly, certain information and notes that are normally required by GAAP have been condensed or omitted. However, in the opinion of management, all adjustments consisting of normal, recurring adjustments considered necessary for a fair presentation of the financial position and results of operations have been included and management believes the disclosures that are made are adequate to make the information presented not misleading. The condensed consolidated balance sheet at December 31, 2023 has been derived from the 2023 audited consolidated financial statements at that date included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (“2023 Form 10-K”).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations for the three months ended March 31, 2024 are not necessarily indicative of results that may be expected for the fiscal year ending December 31, 2024. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto, which are included in the 2023 Form 10-K.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Presentation of Financial Statements -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The unaudited condensed consolidated financial statements included herein include the accounts of the Company. All significant intercompany accounts and transactions have been eliminated.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting Pronouncements - Adopted in 2024</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update 2022-03—Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (“ASU 2023-03”) to (1) to clarify the guidance in Topic 820, Fair Value Measurement, when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security, (2) to amend a related illustrative example, and (3) to introduce new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value in accordance with Topic 820. For public business entities, the amendments in ASU 2022-03 are effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. Early adoption is permitted for both interim and annual financial statements that have not yet been issued or made available for issuance. The Company adopted the standard during the quarter ended March 31, 2024. The adoption of the standard had no material impact on the Company’s financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements - Pending Adoption</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update 2023-09—Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”) to enhance the transparency and decision usefulness of income tax disclosures, including jurisdictional information, by requiring consistent categories and greater disaggregation of information in the rate reconciliation and income taxes paid disclosures. ASU 2023-09 is effective for public business entities for annual periods beginning after December 15, 2024. Prospective application is required, though retrospective application is permitted. Entities are permitted to early adopt the standard. The Company did not early adopt for the 2024 reporting period. The Company is currently evaluating the impact of adopting ASU 2023-09 on its consolidated financial statements.</span></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The accompanying unaudited condensed consolidated financial statements of Medifast, Inc. and its wholly-owned subsidiaries (“Medifast,” the “Company,” “we,” “us,” or “our”) included herein have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim reporting and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Accordingly, certain information and notes that are normally required by GAAP have been condensed or omitted. However, in the opinion of management, all adjustments consisting of normal, recurring adjustments considered necessary for a fair presentation of the financial position and results of operations have been included and management believes the disclosures that are made are adequate to make the information presented not misleading. The condensed consolidated balance sheet at December 31, 2023 has been derived from the 2023 audited consolidated financial statements at that date included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (“2023 Form 10-K”).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations for the three months ended March 31, 2024 are not necessarily indicative of results that may be expected for the fiscal year ending December 31, 2024. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto, which are included in the 2023 Form 10-K.</span></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Presentation of Financial Statements -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The unaudited condensed consolidated financial statements included herein include the accounts of the Company. All significant intercompany accounts and transactions have been eliminated.</span></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting Pronouncements - Adopted in 2024</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update 2022-03—Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (“ASU 2023-03”) to (1) to clarify the guidance in Topic 820, Fair Value Measurement, when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security, (2) to amend a related illustrative example, and (3) to introduce new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value in accordance with Topic 820. For public business entities, the amendments in ASU 2022-03 are effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. Early adoption is permitted for both interim and annual financial statements that have not yet been issued or made available for issuance. The Company adopted the standard during the quarter ended March 31, 2024. The adoption of the standard had no material impact on the Company’s financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements - Pending Adoption</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update 2023-09—Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”) to enhance the transparency and decision usefulness of income tax disclosures, including jurisdictional information, by requiring consistent categories and greater disaggregation of information in the rate reconciliation and income taxes paid disclosures. ASU 2023-09 is effective for public business entities for annual periods beginning after December 15, 2024. Prospective application is required, though retrospective application is permitted. Entities are permitted to early adopt the standard. The Company did not early adopt for the 2024 reporting period. The Company is currently evaluating the impact of adopting ASU 2023-09 on its consolidated financial statements.</span></div> INVENTORIES<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consist principally of raw materials, non-food finished goods and packaged meal replacements held in the Company’s warehouses and outsourced distribution centers. Inventories are stated at the lower of cost or net realizable value, utilizing the first-in, first-out method. The cost of finished goods includes the cost of raw materials, packaging supplies, direct </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and indirect labor, and other indirect manufacturing costs. On a quarterly basis, management reviews inventories for unsalable or obsolete inventories.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Raw materials</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">6,343</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">7,944</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Packaging</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">1,673</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">1,962</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Non-food finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2,877</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">3,703</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Finished goods</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">36,769</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">43,248</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Reserve for obsolete inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(1,389)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(2,266)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">46,273</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">54,591</span></td></tr></table></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2023</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Raw materials</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">6,343</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">7,944</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Packaging</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">1,673</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">1,962</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Non-food finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2,877</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">3,703</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Finished goods</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">36,769</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">43,248</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Reserve for obsolete inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(1,389)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(2,266)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">46,273</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">54,591</span></td></tr></table></div> 6343000 7944000 1673000 1962000 2877000 3703000 36769000 43248000 1389000 2266000 46273000 54591000 EARNINGS PER SHARE<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share (“EPS”) computations are calculated utilizing the weighted average number of shares of the Company’s common stock outstanding during the periods presented. Diluted EPS is calculated utilizing the weighted average number of shares of the Company’s common stock outstanding adjusted for the effect of dilutive common stock equivalents.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted EPS (in thousands, except per share data):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:60.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.668%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,316 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,968 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Weighted average shares of common stock outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,909 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,864 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Effect of dilutive common stock equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Weighted average shares of common stock outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,958 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,899 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Earnings per share - basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.76 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Earnings per share - diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.76 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.67 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>The calculation of diluted EPS excluded 51 thousand and 13 thousand antidilutive restricted stock awards for the three months ended March 31, 2024 and 2023, respectively. <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted EPS (in thousands, except per share data):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:60.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.668%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,316 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,968 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Weighted average shares of common stock outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,909 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,864 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Effect of dilutive common stock equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Weighted average shares of common stock outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,958 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,899 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Earnings per share - basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.76 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Earnings per share - diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.76 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.67 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 8316000 39968000 10909000 10864000 49000 35000 10958000 10899000 0.76 3.68 0.76 3.67 51000 13000 SHARE-BASED COMPENSATION<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has issued non-qualified and incentive stock options to employees and non-employee directors. The fair value of these options was estimated on the date of grant using the Black-Scholes option pricing model, which required estimates of the expected term of the option, the risk-free interest rate, the expected volatility of the price of the Company’s common stock, and dividend yield. Options outstanding as of March 31, 2024 generally vested over a period of 3 years and expire 10 years from the date of grant. The exercise price of these options is $66.68. Due to the Company’s lack of option exercise history on the date of grant, the expected term was calculated using the simplified method defined as the midpoint between the vesting period and the contractual term of each option. The risk-free interest rate was based on the U.S. Treasury yield curve in effect on the date of grant that most closely corresponds to the expected term of the option. The expected volatility was based on the historical volatility of the Company’s common stock over the period of time equivalent to the expected term for each award. The </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">dividend yield was computed as the annualized dividend rate at the grant date divided by the strike price of the stock option. For the three months ended March 31, 2024 and 2023, the Company did not grant stock options. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of our stock option activity (in thousands, except per share data):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.056%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Awards</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Weighted-Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Awards</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Outstanding at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62.20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54.98 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27.68 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27.18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26.52 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Outstanding at end of the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66.68 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Exercisable at end of the period</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66.68 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.65 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2024, the weighted-average remaining contractual life for both the outstanding stock options and exercisable stock options was 3.9 years with an aggregate intrinsic value of $0. There was no unrecognized compensation on the awards for the period ended March 31, 2024. For the three months ended March 31, 2024 and 2023, the Company received $36 thousand and $105 thousand in cash proceeds from the exercise of stock options, respectively. The total intrinsic value for stock options exercised during the three months ended March 31, 2024 and 2023 was $15 thousand and $328 thousand, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Stock</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has issued restricted stock to employees and non-employee directors generally with vesting terms up to 3 years after the date of grant. The fair value of the restricted stock is equal to the market price of the Company’s common stock on the date of grant. Expense for restricted stock is amortized ratably over the vesting period.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our restricted stock activity (in thousands, except per share data):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.617%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Shares</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Weighted-Average Grant Date Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Shares</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Weighted-Average Grant Date Fair Value</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Outstanding at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127.87 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187.94 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35.75 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102.83 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139.19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163.81 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">190.76 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Outstanding at end of the period</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">242 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64.55 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">138.33 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company withheld approximately 11 thousand shares and 9 thousand shares of the Company’s common stock to cover minimum tax liability withholding obligations upon the vesting of shares of restricted stock for the three months ended March 31, 2024 and 2023, respectively. The total fair value of restricted stock awards vested during the three months ended March 31, 2024 and 2023 was $1.3 million and $2.4 million, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market and Performance-based Share Awards</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has issued market and performance-based share awards in 2022 and 2023 and performance-based share awards in 2020, 2021, and 2024 to certain key executives who were granted deferred shares and may earn between 0% and 250% of the target number depending upon both the Company’s total stockholder return (“TSR”), for those with market conditions, and the Company’s performance against predetermined performance goals over a three-year performance period after the date of grant. Market and performance-based share awards that are tied to the Company’s TSR are valued using the Monte Carlo method and are recognized ratably as expense over the award’s performance period. The fair value of the performance-based share awards </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is equal to the market price of the Company’s common stock on the date of grant adjusted by expected level of achievement over the performance period. Expense for performance-based share awards is amortized ratably over the performance period. In the event that management determines that the Company will not reach the lower threshold of the predetermined performance goals established in the grant agreement, any previously recognized expense is reversed in the period in which such a determination is made. Management determined that the market and performance-based share awards granted in 2022 would not reach the lower threshold of the predetermined performance goal resulting in a $1.4 million decrease in the Company’s share-based compensation expense for the three months ended March 31, 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company withheld approximately 8 thousand shares and 21 thousand shares of the Company’s common stock to cover minimum tax liability withholding obligations upon the vesting of shares of market and performance-based share awards for the years ended March 31, 2024 and 2023, respectively. The total fair value of performance-based share awards issued during the three months ended March 31, 2024 was $1.3 million and the total fair value of market and performance-based share awards issued during the three months ended March 31, 2023 was $5.3 million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense is recorded in selling, general, and administrative expense in the accompanying Condensed Consolidated Statements of Income. The total expense during the three months ended March 31, 2024 and 2023 are as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Shares</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Share-Based Compensation Expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Shares</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Share-Based Compensation Expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options and restricted stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">264 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">1,600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">134 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">1,226 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Performance-based share awards granted in 2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">117 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">77 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Market and performance-based share awards granted in 2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">47 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">482 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">47 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">79 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Market and performance-based share awards granted in 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(1,388)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Performance-based share awards granted in 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">640 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Performance-based share awards granted in 2020</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">49 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">466 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2,171 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">225 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">606 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The total income tax expense recognized in the accompanying Condensed Consolidated Statements of Income for restricted stock awards was $0.4 million for the three months ended March 31, 2024 and a benefit of $0.1 million for the three months ended March 31, 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was $8.8 million of total unrecognized compensation cost related to restricted stock awards as of March 31, 2024, which is expected to be recognized over a weighted-average period of 2.3 years. There was $7.5 million of unrecognized compensation costs related to the 131 thousand performance-based shares and 71 thousand market and performance-based shares presented in the table above as of March 31, 2024, which is expected to be recognized over a weighted-average period of 2.1 years.</span></div> P3Y P10Y 66.68 0 0 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of our stock option activity (in thousands, except per share data):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.056%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Awards</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Weighted-Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Awards</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Outstanding at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62.20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54.98 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27.68 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27.18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26.52 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Outstanding at end of the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66.68 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Exercisable at end of the period</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66.68 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.65 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 25000 62.20 33000 54.98 1000 27.68 4000 27.18 2000 26.52 0 0 22000 66.68 29000 58.65 22000 66.68 29000 58.65 P3Y10M24D P3Y10M24D 0 0 0 36000 105000 15000 328000 P3Y <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our restricted stock activity (in thousands, except per share data):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.617%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Shares</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Weighted-Average Grant Date Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Shares</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Weighted-Average Grant Date Fair Value</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Outstanding at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127.87 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187.94 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35.75 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102.83 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139.19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163.81 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">190.76 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Outstanding at end of the period</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">242 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64.55 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">138.33 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 114000 127.87 60000 187.94 162000 35.75 67000 102.83 34000 139.19 22000 163.81 0 0 0 190.76 242000 64.55 105000 138.33 11000 9000 1300000 2400000 0 2.50 P3Y -1400000 8000 21000 1300000 5300000 The total expense during the three months ended March 31, 2024 and 2023 are as follows (in thousands):<div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Shares</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Share-Based Compensation Expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Shares</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Share-Based Compensation Expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options and restricted stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">264 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">1,600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">134 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">1,226 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Performance-based share awards granted in 2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">117 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">77 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Market and performance-based share awards granted in 2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">47 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">482 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">47 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">79 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Market and performance-based share awards granted in 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">24 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(1,388)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Performance-based share awards granted in 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">640 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Performance-based share awards granted in 2020</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">49 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">466 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2,171 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">225 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">606 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 264000 1600000 134000 1226000 117000 77000 47000 482000 47000 79000 24000 0 25000 -1388000 14000 12000 15000 640000 0 0 4000 49000 466000 2171000 225000 606000 -400000 100000 8800000 P2Y3M18D 7500000 131000 71000 P2Y1M6D LEASES<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Leases</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating leases for office and warehouse space and certain equipment. In certain of the Company’s lease agreements, the rental payments are adjusted periodically based on defined terms within the lease. The Company did not have any finance leases as of March 31, 2024 and 2023, respectively, or for the three-month periods then ended, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our leases relating to office and warehouse space have lease terms of 65 months to 102 months. Our leases relating to equipment have lease terms of 36 months, with certain of them having automatic renewal clauses.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s warehouse agreements also contain non-lease components, in the form of payments towards variable logistics services and labor charges, which the Company is obligated to pay based on the services consumed by it. Such amounts are not included in the measurement of the lease liability but are recognized as expenses when they are incurred.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The operating lease expense was $1.2 million and $1.5 million for the three months ended March 31, 2024 and 2023, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to the Company’s operating leases was as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.129%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Cash paid for amounts included in the measurements of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Operating cash flow used in operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,563 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,804 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Right-of-use assets obtained in exchange for lease obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Operating leases</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2024, the weighted average remaining lease term was 3 years, 7 months and the weighted average discount rate was 2.30%.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the maturity of the Company’s operating lease liabilities as of March 31, 2024 (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.794%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.006%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2024 (excluding the three months ended March 31, 2024)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,749 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,462 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,783 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,553 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,618 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">240 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,405 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(836)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,569 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> P65M P102M P36M 1200000 1500000 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to the Company’s operating leases was as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.129%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Three months ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Cash paid for amounts included in the measurements of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Operating cash flow used in operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,563 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,804 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Right-of-use assets obtained in exchange for lease obligations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Operating leases</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1563000 1804000 0 0 P3Y7M 0.0230 <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the maturity of the Company’s operating lease liabilities as of March 31, 2024 (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.794%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.006%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2024 (excluding the three months ended March 31, 2024)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,749 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,462 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,783 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,553 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,618 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">240 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,405 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(836)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,569 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 4749000 6462000 4783000 2553000 2618000 240000 21405000 836000 20569000 ACCUMULATED OTHER COMPREHENSIVE INCOME<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the components of accumulated other comprehensive income, net of tax where applicable (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.274%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">December 31, 2023</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Foreign currency translation</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(33)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(48)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Unrealized gains on investments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">55</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">296</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accumulated other comprehensive income</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">22</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">248</span></td></tr></table></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the components of accumulated other comprehensive income, net of tax where applicable (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.274%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">December 31, 2023</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Foreign currency translation</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(33)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(48)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Unrealized gains on investments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">55</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">296</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accumulated other comprehensive income</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">22</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">248</span></td></tr></table></div> -33000 -48000 55000 296000 22000 248000 INVESTMENTS<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain financial assets and liabilities are accounted for at fair value, which is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The following fair value hierarchy prioritizes the inputs used to measure fair value:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 – Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an on-going basis.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 – Pricing inputs are other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date. Level 2 includes those financial instruments that are valued using models or other valuation methodologies.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 – Pricing inputs include significant inputs that are generally less observable from objective sources. These inputs may be used with internally developed methodologies that result in management’s best estimate of fair value from the perspective of a market participant.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the Company’s cash and financial assets that are measured at fair value on a recurring basis for each of the hierarchy levels (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.605%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Unrealized Gains (Losses)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Accrued Interest</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Estimated </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Cash &amp; Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Investment<br/>Securities</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Cash and cash equivalents, excluding money market accounts</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">92,291</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">92,291</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">92,291</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">—</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Level 1:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Money market accounts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">5,180</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">5,180</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">5,180</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">—</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Government &amp; agency securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">15,454</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(14)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">64</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">15,504</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">15,504</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">10,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2,587</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">12,587</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">12,587</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">30,634</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2,573</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">64</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">33,271</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">5,180</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">28,091</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Level 2:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate bonds</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">30,412</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">182</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">272</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">30,866</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">30,866</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">153,337</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2,755</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">336</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">156,428</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">97,471</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">58,957</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.606%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Accrued<br/>Interest</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Estimated<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Cash &amp; Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Investment<br/>Securities</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Cash and cash equivalents, excluding money market accounts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">88,778</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">88,778</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">88,778</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">—</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Level 1:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Money market accounts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">5,662</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">5,662</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">5,662</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">—</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Government &amp; agency securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">15,282</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">126</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">40</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">15,448</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">15,448</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">10,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">150</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">10,150</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">10,150</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">30,944</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">276</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">40</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">31,260</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">5,662</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">25,598</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Level 2:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">29,440</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">293</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">270</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">30,003</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">30,003</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">149,162</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">569</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">310</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">150,041</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">94,440</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">55,601</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had $9 thousand of realized gains for the three months ended March 31, 2024 and no realized gains or losses for the three months ended March 31, 2023</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2023, the Company entered into an agreement to purchase common stock of LifeMD, Inc (Nasdaq: LFMD), a leading provider of virtual primary care, and made a $10 million payment to LifeMD for the purchase of the shares. The securities are subject to a registration rights agreement which stipulates that the registration of the securities is to be made as soon as practicable, but not later than 90 days, following written demand by the Company. Written demand has been made, and the securities registration remained in process as of March 31, 2024. In addition, the shares are subject to a 180-day lock-up period from the closing date of the agreement, December 11, 2023. The fair value of the investment is recorded within the </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investment securities of the consolidated balance sheet. The gains related to the Company’s LifeMD investment for the three months ended March 31, 2024 and 2023 are summarized in the table below (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.762%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">March 31, 2023</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Net gains recognized during the period on equity securities</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2,437 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Less: Net gains recognized on equity securities sold</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Unrealized gains recognized during the reporting period on equity securities still held at the reporting date</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2,437 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company concurrently entered into an agreement in which LifeMD would provide services to stand-up the collaboration between LifeMD and the Company. The agreement stipulated an initial milestone payment of $5 million due upon execution of the agreement for these services. The services under the initial milestone were completed prior to December 31, 2023, and this amount was included in the Company’s selling, general, and administrative expenses on the consolidated statement of income for the quarter ended December 31, 2023. The Company made a second milestone payment under the agreement of $2.5 million on March 18, 2024. Of the total $2.5 million second milestone payment, $1.3 million was recognized within selling, general, and administrative expenses for services performed by LifeMD for the quarter ended March 31, 2024, with the remaining $1.2 million expected to be recognized in the second quarter. The final milestone payment of $2.5 million is expected to be made in the second quarter of 2024, with the expense being recognized in the consolidated statement of income as the services are rendered.</span></div> <div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the Company’s cash and financial assets that are measured at fair value on a recurring basis for each of the hierarchy levels (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.605%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Unrealized Gains (Losses)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Accrued Interest</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Estimated </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Cash &amp; Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Investment<br/>Securities</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Cash and cash equivalents, excluding money market accounts</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">92,291</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">92,291</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">92,291</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">—</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Level 1:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Money market accounts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">5,180</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">5,180</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">5,180</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">—</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Government &amp; agency securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">15,454</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(14)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">64</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">15,504</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">15,504</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">10,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2,587</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">12,587</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">12,587</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">30,634</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2,573</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">64</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">33,271</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">5,180</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">28,091</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Level 2:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate bonds</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">30,412</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">182</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">272</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">30,866</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">30,866</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">153,337</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2,755</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">336</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">156,428</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">97,471</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">58,957</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.606%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Accrued<br/>Interest</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Estimated<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Cash &amp; Cash<br/>Equivalents</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Investment<br/>Securities</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Cash and cash equivalents, excluding money market accounts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">88,778</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">88,778</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">88,778</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">—</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Level 1:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Money market accounts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">5,662</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">5,662</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">5,662</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">—</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Government &amp; agency securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">15,282</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">126</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">40</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">15,448</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">15,448</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">10,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">150</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">10,150</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">10,150</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">30,944</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">276</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">40</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">31,260</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">5,662</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">25,598</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Level 2:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">29,440</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">293</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">270</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">30,003</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">30,003</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">149,162</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">569</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">310</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">150,041</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">94,440</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">55,601</span></td></tr></table></div> 92291000 92291000 92291000 5180000 5180000 5180000 0 15454000 14000 64000 15504000 0 15504000 10000000 2587000 0 12587000 0 12587000 30634000 2573000 64000 33271000 5180000 28091000 30412000 182000 272000 30866000 0 30866000 153337000 2755000 336000 156428000 97471000 58957000 88778000 88778000 88778000 5662000 5662000 5662000 0 15282000 126000 40000 15448000 0 15448000 10000000 150000 0 10150000 0 10150000 30944000 276000 40000 31260000 5662000 25598000 29440000 293000 270000 30003000 0 30003000 149162000 569000 310000 150041000 94440000 55601000 9000 0 10000000 The gains related to the Company’s LifeMD investment for the three months ended March 31, 2024 and 2023 are summarized in the table below (in thousands):<div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.762%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">March 31, 2023</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Net gains recognized during the period on equity securities</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2,437 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Less: Net gains recognized on equity securities sold</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Unrealized gains recognized during the reporting period on equity securities still held at the reporting date</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2,437 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div> 2437000 0 0 0 2437000 0 5000000 2500000 2500000 1300000 1200000 2500000 DEBT<div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Agreement</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 13, 2021, the Company and certain of its subsidiaries (collectively, the “Guarantors”) entered into a credit agreement (the “Credit Agreement”) among the Company, the Guarantors, the lenders party thereto and Citibank, N.A., in its capacity as administrative agent. On May 31, 2022, the Credit Agreement was amended to increase the borrowing capacity and convert the interest rate to be based on Secured Overnight Financing Rate (“SOFR”), from London Inter-Bank Offered Rate (LIBOR) (the “Amended Credit Agreement”). The Amended Credit Agreement provides for a </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$225.0 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> senior secured revolving credit facility with a </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$20.0 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> letter of credit sublimit. The Amended Credit Agreement also provides for an uncommitted incremental facility that permits the Company, subject to certain conditions, to increase the senior secured revolving credit facility by up to </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$100.0 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Amended Credit Agreement matures on April 13, 2026.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s obligations under the Amended Credit Agreement are guaranteed by the Guarantors. The obligations of the Company and the Guarantors are secured by first-priority liens on substantially all of the assets of the Company and the Guarantors, subject to certain exceptions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Amended Credit Agreement, the Company will pay to the administrative agent for the account of each revolving lender a commitment fee on a quarterly basis based on amounts committed but unused under the revolving facility from 0.20% to 0.40% per annum depending on the Company’s Total Net Leverage Ratio (as defined in the Amended Credit Agreement). The Company is also obligated to pay the administrative agent customary fees for credit facilities of this size and type.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revolving borrowings under the Amended Credit Agreement bear interest at a rate per annum equal to (i) the Term SOFR Rate for the interest period plus the Applicable Rate (as defined in the Amended Credit Agreement) based on the Company’s Total Net Leverage Ratio or (ii) the Alternate Base Rate (as defined in the Amended Credit Agreement) as in effect from time to time plus the Applicable Rate based on the Company’s Total Net Leverage Ratio. As of March 31, 2024, the Applicable Rate for Term SOFR Loans is 1.25% per annum and the Applicable Rate for ABR Loans is 0.25% per annum. SOFR based loans also include a Credit Spread Adjustment based on the duration of the borrowing.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Credit Agreement contains affirmative and negative covenants customarily applicable to senior secured credit facilities, including covenants that, among other things, limit or restrict the ability of the Company and its subsidiaries, subject to negotiated exceptions, to incur additional indebtedness and additional liens on their assets, engage in mergers or acquisitions or dispose of assets, pay dividends or make other distributions, voluntarily prepay other indebtedness, enter into transactions with affiliated persons, make investments and change the nature of their businesses. The Amended Credit Agreement also contains customary events of default, subject to thresholds and grace periods, including, among others, payment default, covenant default, cross default to other material indebtedness and judgment default. In addition, the Amended Credit </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agreement requires the Company to maintain a Total Net Leverage Ratio of no more than 2.75 to 1.00 and an Interest Coverage Ratio of at least 3.50 to 1.00.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had no borrowings outstanding under the Amended Credit Agreement, inclusive of the credit facility and letter of credit sublimit, as of March 31, 2024 and was in compliance with all covenants.</span></div> 225000000 20000000 100000000 0.0020 0.0040 0.0125 0.0025 2.75 3.50 0